No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, 2wipC, 1.0000, 0.00, 1.000, 292, 291, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
2, 2wxvC, 0.9983, 0.25, 1.000, 299, 291, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
3, 2bkzC, 0.9983, 0.26, 1.000, 298, 291, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
4, 2c4gC, 0.9975, 0.31, 1.000, 300, 291, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
5, 1vywC, 0.9973, 0.32, 1.000, 299, 291, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
6, 2wihC, 0.9968, 0.35, 1.000, 299, 291, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
7, 2wpaC, 0.9953, 0.43, 1.000, 299, 291, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
8, 3f5xC, 0.9950, 0.47, 1.000, 298, 291, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
9, 2bpmC, 0.9950, 0.45, 1.000, 299, 291, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
10, 2i40C, 0.9948, 0.46, 1.000, 296, 291, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
11, 1fvvC, 0.9948, 0.46, 1.000, 298, 291, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
12, 5if1C, 0.9945, 0.48, 1.000, 296, 291, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
13, 2v22A, 0.9940, 0.50, 1.000, 296, 291, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
14, 2uueA, 0.9937, 0.51, 1.000, 296, 291, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
15, 2c5oA, 0.9934, 0.53, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
16, 1ol1A, 0.9932, 0.52, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
17, 1ol2A, 0.9931, 0.53, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
18, 2whbA, 0.9930, 0.54, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
19, 2wevA, 0.9928, 0.55, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
20, 2c5xA, 0.9926, 0.56, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
21, 2bkzA, 0.9926, 0.79, 1.000, 302, 291, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
22, 2c5oC, 0.9925, 0.56, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
23, 1finA, 0.9925, 0.61, 1.000, 298, 291, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
24, 1urcA, 0.9924, 0.57, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
25, 2c5nA, 0.9923, 0.57, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
26, 3f5xA, 0.9921, 0.45, 1.000, 297, 290, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
27, 2x1nA, 0.9915, 0.61, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
28, 2wipA, 0.9913, 0.83, 1.000, 297, 291, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
29, 2uueC, 0.9909, 0.63, 1.000, 296, 291, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
30, 1okwA, 0.9906, 0.63, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
31, 2v22C, 0.9904, 0.65, 1.000, 296, 291, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
32, 1vywA, 0.9904, 0.85, 1.000, 302, 291, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
33, 2whbC, 0.9903, 0.64, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
34, 2c5vA, 0.9901, 0.68, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
35, 1finC, 0.9899, 0.68, 1.000, 298, 291, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
36, 2wxvA, 0.9898, 0.85, 1.000, 302, 291, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
37, 2x1nC, 0.9896, 0.68, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
38, 2wihA, 0.9896, 0.87, 1.000, 302, 291, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
39, 2c4gA, 0.9895, 0.83, 1.000, 301, 291, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
40, 2bpmA, 0.9895, 0.86, 1.000, 302, 291, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
41, 2c5vC, 0.9890, 0.71, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
42, 1fvvA, 0.9889, 0.80, 1.000, 298, 291, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
43, 2wpaA, 0.9888, 0.90, 1.000, 302, 291, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
44, 1urcC, 0.9888, 0.76, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
45, 1ol1C, 0.9886, 0.72, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
46, 1okwC, 0.9886, 0.71, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
47, 5if1A, 0.9884, 0.87, 1.000, 298, 291, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
48, 2wfyC, 0.9884, 0.71, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
49, 2c5xC, 0.9883, 0.73, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
50, 2c5nC, 0.9879, 0.78, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
51, 2wfyA, 0.9874, 0.63, 1.000, 295, 290, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
52, 1okvA, 0.9870, 0.63, 1.000, 295, 290, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
53, 4fx3C, 0.9858, 0.90, 1.000, 298, 291, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
54, 2wevC, 0.9855, 0.85, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
55, 1ol2C, 0.9851, 0.85, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
56, 3ej1A, 0.9848, 0.45, 0.997, 295, 288, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
57, 3eocA, 0.9847, 0.45, 0.997, 295, 288, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
58, 3eocC, 0.9841, 0.48, 0.997, 293, 288, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
59, 4fx3A, 0.9837, 0.96, 1.000, 298, 291, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
60, 3ej1C, 0.9837, 0.50, 1.000, 294, 288, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
61, 1okvC, 0.9835, 0.89, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
62, 5lqeC, 0.9802, 0.80, 0.983, 296, 289, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
63, 4cfwC, 0.9796, 0.80, 0.983, 297, 289, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
64, 4cfmA, 0.9796, 0.80, 0.983, 296, 289, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
65, 1h1qA, 0.9795, 0.80, 0.983, 296, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
66, 2cjmC, 0.9792, 0.80, 0.983, 294, 289, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
67, 1h1rA, 0.9792, 0.81, 0.983, 296, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
68, 5nevC, 0.9791, 0.83, 0.983, 296, 289, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
69, 1e9hA, 0.9790, 0.82, 0.983, 295, 289, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
70, 1jstC, 0.9788, 0.82, 0.983, 297, 289, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
71, 1pkdA, 0.9786, 0.83, 0.983, 296, 289, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
72, 1h1qC, 0.9786, 0.82, 0.983, 296, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
73, 1pkdC, 0.9785, 0.83, 0.983, 296, 289, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
74, 5cyiC, 0.9784, 0.83, 0.983, 296, 289, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
75, 1e9hC, 0.9784, 0.83, 0.983, 296, 289, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
76, 2uzeA, 0.9782, 0.84, 0.983, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
77, 2wmbA, 0.9781, 0.84, 0.983, 296, 289, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
78, 1gy3C, 0.9778, 0.85, 0.983, 295, 289, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
79, 2uzlC, 0.9777, 0.86, 0.983, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
80, 2uzlA, 0.9777, 0.86, 0.983, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
81, 1h1sA, 0.9777, 0.85, 0.983, 296, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
82, 3eidA, 0.9776, 0.46, 1.000, 292, 286, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
83, 2uzeC, 0.9776, 0.87, 0.983, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
84, 1h26A, 0.9776, 0.86, 0.983, 296, 289, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
85, 1h1sC, 0.9773, 0.86, 0.983, 296, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
86, 1oiyC, 0.9769, 0.87, 0.983, 296, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
87, 1h27A, 0.9769, 0.87, 0.983, 296, 289, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
88, 1h1rC, 0.9769, 0.86, 0.983, 296, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
89, 3ddpA, 0.9768, 0.88, 0.983, 297, 289, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
90, 1h28A, 0.9766, 0.87, 0.983, 296, 289, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
91, 2iw8A, 0.9765, 0.88, 0.965, 297, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
92, 1gy3A, 0.9765, 0.88, 0.983, 295, 289, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
93, 5cyiA, 0.9762, 0.97, 0.983, 298, 289, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
94, 1h28C, 0.9762, 0.89, 0.983, 296, 289, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
95, 2uzdC, 0.9761, 0.90, 0.983, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
96, 2c6tC, 0.9759, 0.90, 0.983, 295, 289, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
97, 1p5eA, 0.9759, 0.90, 0.983, 296, 289, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
98, 2uzbA, 0.9757, 0.91, 0.983, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
99, 2g9xA, 0.9756, 0.90, 0.979, 298, 289, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
100, 1oi9A, 0.9756, 0.82, 0.983, 295, 288, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
101, 2cciA, 0.9752, 0.92, 0.983, 296, 289, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
102, 2wmaA, 0.9750, 0.95, 0.983, 296, 289, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
103, 4cfvA, 0.9749, 0.96, 0.979, 300, 289, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
104, 4eooC, 0.9748, 0.92, 0.979, 297, 289, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
105, 1qmzC, 0.9747, 0.93, 0.983, 296, 289, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
106, 1qmzA, 0.9747, 0.93, 0.983, 296, 289, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
107, 5nevA, 0.9745, 0.85, 0.983, 295, 288, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
108, 2i40A, 0.9745, 0.45, 1.000, 291, 285, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
109, 4eopC, 0.9743, 0.93, 0.979, 296, 289, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
110, 1jstA, 0.9740, 0.94, 0.983, 297, 289, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
111, 5lqeA, 0.9737, 0.87, 0.983, 295, 288, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
112, 3tnwC, 0.9736, 0.78, 0.983, 291, 287, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
113, 4bcnC, 0.9735, 0.78, 0.983, 295, 287, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
114, 3dogA, 0.9734, 0.88, 0.976, 297, 288, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
115, 4bcpA, 0.9733, 1.04, 0.979, 298, 289, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
116, 4bcnA, 0.9732, 0.79, 0.983, 296, 287, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
117, 4cfnC, 0.9731, 0.80, 0.983, 296, 287, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
118, 1p5eC, 0.9730, 0.98, 0.983, 296, 289, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
119, 4eolC, 0.9729, 0.97, 0.972, 299, 289, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
120, 4cfwA, 0.9727, 1.10, 0.983, 299, 289, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
121, 4bcoA, 0.9727, 1.04, 0.979, 298, 289, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
122, 4bcmC, 0.9726, 0.80, 0.983, 294, 287, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
123, 4cfxA, 0.9725, 1.09, 0.983, 298, 289, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
124, 4eosC, 0.9724, 0.98, 0.983, 296, 289, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
125, 3qhrC, 0.9723, 1.08, 0.983, 297, 289, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
126, 4cfxC, 0.9722, 1.06, 0.983, 298, 289, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
127, 3eidC, 0.9722, 0.54, 1.000, 290, 285, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
128, 3qhrA, 0.9720, 1.08, 0.983, 297, 289, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
129, 4eoiC, 0.9719, 0.98, 0.976, 296, 289, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
130, 4eokC, 0.9717, 1.01, 0.972, 299, 289, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
131, 2cciC, 0.9717, 1.01, 0.983, 296, 289, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
132, 4ii5C, 0.9716, 1.09, 0.983, 295, 289, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
133, 4ii5A, 0.9715, 1.09, 0.983, 295, 289, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
134, 4i3zA, 0.9715, 1.09, 0.983, 295, 289, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
135, 4cfuA, 0.9715, 0.83, 0.976, 299, 287, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
136, 4i3zC, 0.9714, 1.09, 0.983, 295, 289, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
137, 3bhvA, 0.9714, 0.84, 0.976, 297, 287, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
138, 2cchA, 0.9714, 1.11, 0.983, 296, 289, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
139, 2iw6C, 0.9712, 0.91, 0.979, 295, 288, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
140, 4eonC, 0.9710, 1.00, 0.972, 298, 289, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
141, 3bhuA, 0.9710, 0.85, 0.979, 297, 287, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
142, 5lmkA, 0.9709, 0.86, 0.979, 296, 287, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
143, 4eomA, 0.9709, 0.86, 0.962, 296, 287, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
144, 3bhtA, 0.9709, 0.85, 0.979, 297, 287, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
145, 2cchC, 0.9709, 1.14, 0.983, 296, 289, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
146, 3qhwA, 0.9706, 1.12, 0.983, 297, 289, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
147, 2uzdA, 0.9706, 1.02, 0.983, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
148, 3qhwC, 0.9705, 1.12, 0.983, 297, 289, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
149, 2c6tA, 0.9702, 1.03, 0.983, 295, 289, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
150, 3ddqA, 0.9696, 0.88, 0.979, 296, 287, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
151, 3ddpC, 0.9693, 1.10, 0.979, 298, 289, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
152, 4eonA, 0.9692, 1.19, 0.972, 299, 289, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
153, 4bcmA, 0.9690, 0.81, 0.983, 295, 286, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
154, 1oiyA, 0.9690, 0.81, 0.983, 293, 286, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
155, 4cfnA, 0.9689, 0.82, 0.983, 296, 286, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
156, 3tnwA, 0.9688, 0.81, 0.983, 295, 286, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
157, 3my5A, 0.9684, 0.82, 0.976, 296, 286, CDK2/CYCLINA IN COMPLEX WITH DRB
158, 1oguA, 0.9684, 0.83, 0.976, 296, 286, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
159, 4eoqA, 0.9680, 0.84, 0.976, 295, 286, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
160, 1oi9C, 0.9680, 1.06, 0.983, 296, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
161, 1h25A, 0.9680, 0.83, 0.983, 293, 286, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
162, 1oiuA, 0.9679, 0.84, 0.976, 296, 286, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
163, 1h24A, 0.9679, 0.84, 0.983, 293, 286, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
164, 1h24C, 0.9676, 0.85, 0.983, 293, 286, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
165, 2uzbC, 0.9670, 0.87, 0.983, 292, 286, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
166, 4eooA, 0.9666, 0.78, 0.972, 294, 285, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
167, 4eopA, 0.9659, 1.02, 0.979, 297, 287, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
168, 2iw6A, 0.9653, 0.82, 0.979, 292, 285, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
169, 2iw9A, 0.9652, 0.83, 0.972, 293, 285, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
170, 1h1pA, 0.9651, 1.13, 0.983, 296, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
171, 4eosA, 0.9650, 0.93, 0.983, 296, 286, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
172, 4eorA, 0.9631, 0.88, 0.975, 293, 285, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
173, 5uq2A, 0.9630, 1.39, 0.983, 296, 290, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
174, 4eojA, 0.9628, 0.88, 0.968, 295, 285, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
175, 4eoiA, 0.9625, 0.91, 0.975, 294, 285, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
176, 1h1pC, 0.9615, 1.20, 0.983, 296, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
177, 1h27C, 0.9597, 0.87, 0.982, 291, 284, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
178, 4eolA, 0.9595, 1.05, 0.969, 294, 286, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
179, 4bckA, 0.9579, 1.31, 0.983, 298, 289, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
180, 4eokA, 0.9563, 1.04, 0.972, 293, 285, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
181, 4bckC, 0.9553, 1.19, 0.983, 293, 287, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
182, 1fq1B, 0.9550, 1.41, 0.983, 295, 289, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
183, 4bcqC, 0.9549, 1.19, 0.983, 292, 287, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
184, 4bcqA, 0.9511, 1.37, 0.983, 292, 288, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
185, 5l2wA, 0.9480, 1.23, 0.982, 297, 283, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
186, 2cjmA, 0.9461, 0.89, 0.982, 285, 280, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
187, 1w98A, 0.9459, 1.27, 0.982, 297, 283, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
188, 1f5qA, 0.9445, 1.95, 0.997, 296, 291, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
189, 2jgzA, 0.9422, 1.11, 0.982, 288, 281, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
190, 5uq1A, 0.9420, 1.26, 0.979, 288, 282, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
191, 5uq1C, 0.9387, 1.37, 0.975, 289, 283, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
192, 4nstC, 0.9289, 1.88, 0.413, 317, 288, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
193, 4cxaA, 0.9288, 1.80, 0.411, 329, 287, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
194, 1unlA, 0.9271, 1.73, 0.583, 292, 283, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
195, 1jsuA, 0.9268, 1.87, 0.936, 285, 281, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
196, 5acbD, 0.9256, 1.80, 0.418, 319, 287, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
197, 4nstA, 0.9254, 1.94, 0.413, 322, 288, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
198, 6b3eA, 0.9253, 1.92, 0.410, 309, 288, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
199, 5acbC, 0.9244, 1.92, 0.417, 324, 288, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
200, 1ungA, 0.9227, 1.85, 0.583, 288, 283, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
201, 4un0C, 0.9226, 1.90, 0.418, 308, 287, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
202, 4krcA, 0.9226, 1.76, 0.567, 297, 284, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
203, 6b3eC, 0.9220, 1.95, 0.413, 307, 288, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
204, 5efqC, 0.9220, 2.00, 0.420, 325, 288, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
205, 4imyC, 0.9220, 2.03, 0.406, 310, 288, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
206, 3o0gA, 0.9220, 1.70, 0.587, 289, 281, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
207, 4imyA, 0.9218, 2.03, 0.406, 314, 288, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
208, 4imyE, 0.9216, 1.98, 0.408, 313, 287, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
209, 3miaA, 0.9213, 2.07, 0.403, 324, 288, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
210, 5efqA, 0.9209, 2.05, 0.420, 321, 288, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
211, 4krdA, 0.9202, 1.58, 0.569, 294, 281, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
212, 1f5qC, 0.9199, 1.95, 0.958, 288, 283, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
213, 3mi9A, 0.9191, 2.10, 0.403, 328, 288, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
214, 4bchA, 0.9190, 2.05, 0.406, 308, 288, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
215, 3lq5A, 0.9185, 2.02, 0.404, 307, 287, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
216, 4cxaC, 0.9175, 1.91, 0.418, 330, 285, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
217, 4or5F, 0.9174, 2.12, 0.403, 324, 288, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
218, 4bcgA, 0.9167, 2.03, 0.404, 312, 287, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
219, 4ec8A, 0.9162, 2.06, 0.406, 325, 288, STRUCTURE OF FULL LENGTH CDK9 IN COMPLEX WITH CYCLINT AND DRB
220, 3my1A, 0.9162, 2.02, 0.401, 314, 287, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
221, 1h25C, 0.9161, 0.86, 0.982, 278, 271, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
222, 1unlB, 0.9151, 1.93, 0.572, 292, 283, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
223, 4ec9A, 0.9147, 2.01, 0.406, 306, 286, CRYSTAL STRUCTURE OF FULL-LENGTH CDK9 IN COMPLEX WITH CYCLIN T
224, 4or5A, 0.9143, 2.15, 0.403, 319, 288, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
225, 4yc3A, 0.9134, 1.93, 0.644, 295, 281, CDK1/CYCLINB1/CKS2 APO
226, 4bciA, 0.9128, 1.98, 0.407, 308, 285, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
227, 4bcfA, 0.9124, 2.05, 0.409, 307, 286, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
228, 4bcjA, 0.9122, 2.11, 0.404, 309, 287, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
229, 3tn8A, 0.9100, 2.06, 0.411, 304, 285, CDK9/CYCLIN T IN COMPLEX WITH CAN508
230, 5xs2A, 0.9092, 2.12, 0.380, 366, 287, CDK8-CYCC IN COMPLEX WITH COMPOUND 17:3-CHLORO-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
231, 4ogrE, 0.9086, 2.22, 0.406, 310, 288, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
232, 5l1zA, 0.9077, 2.23, 0.403, 310, 288, TAR COMPLEX WITH HIV-1 TAT-AFF4-P-TEFB
233, 4ogrA, 0.9063, 2.24, 0.406, 314, 288, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
234, 5hq0A, 0.9060, 2.14, 0.668, 292, 283, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
235, 4y72A, 0.9060, 2.14, 0.668, 292, 283, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
236, 4eojC, 0.9058, 1.30, 0.949, 282, 272, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
237, 3tniA, 0.9057, 2.04, 0.406, 297, 283, STRUCTURE OF CDK9/CYCLIN T F241L
238, 2pk9A, 0.9055, 1.65, 0.567, 287, 277, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
239, 1h4lB, 0.9039, 1.53, 0.584, 278, 274, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
240, 1h4lA, 0.9026, 1.55, 0.584, 278, 274, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
241, 4ogrI, 0.9024, 2.31, 0.403, 318, 288, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
242, 2pmiC, 0.9017, 1.66, 0.569, 285, 276, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
243, 4ez7A, 0.9015, 2.10, 0.957, 302, 280, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
244, 5a14A, 0.9014, 1.92, 0.975, 284, 276, HUMAN CDK2 WITH TYPE II INHIBITOR
245, 1j1bA, 0.9008, 2.02, 0.320, 354, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
246, 3blrA, 0.9005, 2.06, 0.404, 300, 282, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
247, 1j1cA, 0.9005, 2.02, 0.320, 354, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
248, 3pxzA, 0.8995, 2.28, 0.971, 302, 280, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
249, 1j1cB, 0.8995, 2.05, 0.320, 364, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
250, 3i4bB, 0.8994, 2.04, 0.320, 347, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
251, 3blqA, 0.8994, 1.81, 0.406, 295, 278, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
252, 1j1bB, 0.8988, 2.05, 0.320, 364, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
253, 5lqfA, 0.8983, 1.82, 0.653, 287, 277, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
254, 3pxfA, 0.8983, 2.27, 0.971, 302, 280, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
255, 3i4bA, 0.8982, 2.07, 0.320, 359, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
256, 2gphA, 0.8975, 2.09, 0.363, 345, 281, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
257, 1q41B, 0.8974, 2.07, 0.320, 343, 281, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
258, 4acgB, 0.8969, 2.07, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
259, 4ic7A, 0.8966, 2.06, 0.389, 355, 280, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
260, 5hbjA, 0.8964, 1.86, 0.367, 342, 278, CDK8-CYCC IN COMPLEX WITH 8-[2-AMINO-3-CHLORO-5-(1-METHYL-1H-INDAZOL- 5-YL)-PYRIDIN-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
261, 4achB, 0.8961, 2.09, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
262, 4acgA, 0.8961, 2.10, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
263, 1unhB, 0.8961, 1.52, 0.588, 276, 272, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
264, 4nm0A, 0.8958, 2.09, 0.320, 356, 281, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
265, 4crlA, 0.8958, 2.00, 0.375, 339, 280, CRYSTAL STRUCTURE OF HUMAN CDK8-CYCLIN C IN COMPLEX WITH CORTISTATIN A
266, 4nu1A, 0.8953, 2.25, 0.319, 356, 282, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N-TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
267, 4b7tA, 0.8950, 2.11, 0.320, 350, 281, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND LEUCETTINE L4
268, 4acdB, 0.8950, 2.11, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
269, 4accA, 0.8950, 2.10, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
270, 4achA, 0.8948, 2.12, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
271, 4acdA, 0.8947, 2.11, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
272, 4accB, 0.8946, 2.11, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
273, 1unhA, 0.8946, 1.55, 0.588, 276, 272, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
274, 1h8fB, 0.8945, 2.10, 0.320, 350, 281, GLYCOGEN SYNTHASE KINASE 3 BETA.
275, 5f94A, 0.8942, 2.12, 0.320, 346, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
276, 1h8fA, 0.8942, 2.11, 0.320, 352, 281, GLYCOGEN SYNTHASE KINASE 3 BETA.
277, 5f94B, 0.8941, 2.12, 0.320, 349, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
278, 4nm3A, 0.8938, 2.16, 0.320, 357, 281, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N- TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
279, 3pupB, 0.8937, 2.08, 0.321, 347, 280, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
280, 2jldA, 0.8937, 2.08, 0.321, 349, 280, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
281, 3pupA, 0.8936, 2.08, 0.321, 346, 280, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
282, 5lqfD, 0.8935, 1.88, 0.652, 285, 276, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
283, 4nm5A, 0.8935, 2.17, 0.324, 361, 281, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
284, 2g9xC, 0.8935, 0.93, 0.974, 274, 265, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
285, 5hbeA, 0.8932, 2.14, 0.363, 344, 281, CDK8-CYCC IN COMPLEX WITH 8-[3-CHLORO-5-(1-METHYL-22-DIOXO-2 3- DIHYDRO-1H-2L6-BENZO[C]ISOTHIAZOL-5-YL)-PYRIDIN- 4-YL]-1-OXA-38- DIAZA-SPIRO[4.5]DECAN-2-ONE
286, 3zu7A, 0.8932, 2.22, 0.359, 344, 281, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
287, 4ptcA, 0.8931, 2.13, 0.320, 342, 281, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
288, 3zuvC, 0.8931, 2.06, 0.369, 357, 279, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
289, 1r0eB, 0.8931, 2.11, 0.320, 344, 281, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
290, 5idpA, 0.8929, 2.05, 0.357, 342, 280, CDK8-CYCC IN COMPLEX WITH (3-AMINO-1H-INDAZOL-5-YL)-[(S)-2-(4-FLUORO- PHENYL)-PIPERIDIN-1-YL]-METHANONE
291, 2jldB, 0.8929, 2.08, 0.321, 349, 280, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
292, 4iz5B, 0.8928, 2.07, 0.361, 347, 280, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
293, 4iz5A, 0.8928, 2.06, 0.361, 347, 280, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
294, 5kpkB, 0.8927, 2.08, 0.321, 344, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
295, 4iz5D, 0.8927, 2.07, 0.361, 347, 280, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
296, 4iz5C, 0.8927, 2.07, 0.361, 347, 280, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
297, 3m1sB, 0.8927, 2.09, 0.321, 349, 280, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
298, 5icpA, 0.8925, 2.15, 0.363, 343, 281, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (5-METHYL-IMIDAZO[51-B][134]THIADIAZOL-2-YL)-METHANONE
299, 5hlnA, 0.8924, 2.08, 0.321, 346, 280, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
300, 1o9uA, 0.8924, 2.09, 0.321, 349, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
301, 4pteB, 0.8923, 2.16, 0.320, 347, 281, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
302, 4eoqC, 0.8923, 0.98, 0.977, 275, 265, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
303, 1r0eA, 0.8923, 2.13, 0.320, 344, 281, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
304, 5ceiA, 0.8922, 2.14, 0.356, 345, 281, CRYSTAL STRUCTURE OF CDK8:CYCLIN C COMPLEX WITH COMPOUND 22
305, 3m1sA, 0.8921, 2.06, 0.323, 348, 279, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
306, 3erkA, 0.8921, 2.19, 0.367, 350, 281, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
307, 2o5kA, 0.8921, 2.17, 0.320, 350, 281, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
308, 5nhlA, 0.8920, 2.24, 0.367, 345, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
309, 4ptcB, 0.8920, 2.15, 0.320, 347, 281, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
310, 4nm7A, 0.8920, 2.20, 0.324, 355, 281, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
311, 1ykrA, 0.8920, 2.53, 0.982, 298, 285, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
312, 4qteA, 0.8918, 2.26, 0.363, 348, 281, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
313, 4eomC, 0.8918, 0.99, 0.966, 275, 265, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
314, 1uv5A, 0.8918, 2.15, 0.320, 348, 281, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
315, 5nhvA, 0.8917, 2.25, 0.370, 345, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
316, 3zuvA, 0.8917, 2.21, 0.371, 357, 280, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
317, 2pmiA, 0.8917, 1.78, 0.566, 284, 274, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
318, 5i5zA, 0.8916, 2.11, 0.361, 345, 280, CDK8-CYCC IN COMPLEX WITH 8-(1-METHYL-22-DIOXO-23-DIHYDRO-1H-2L6- BENZO[C]ISOTHIAZOL-5-YL)-[16]NAPHTHYRIDINE-2-CARBOXYLIC ACID METHYLAMIDE
319, 4ic7D, 0.8915, 2.13, 0.389, 353, 280, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
320, 5v60A, 0.8914, 2.24, 0.364, 347, 280, PHOSPHO-ERK2 BOUND TO AMP-PCP
321, 3sd0B, 0.8914, 2.18, 0.320, 349, 281, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
322, 5nhpA, 0.8913, 2.26, 0.367, 338, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
323, 5v61A, 0.8911, 2.11, 0.366, 348, 279, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
324, 3zdiA, 0.8910, 2.14, 0.321, 348, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND INHIBITOR 7D
325, 2erkA, 0.8910, 2.21, 0.368, 351, 280, PHOSPHORYLATED MAP KINASE ERK2
326, 5ke0A, 0.8909, 2.26, 0.367, 340, 281, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
327, 4pteA, 0.8909, 2.06, 0.326, 341, 279, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
328, 5u6iA, 0.8906, 2.14, 0.368, 339, 280, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
329, 5hd7A, 0.8906, 2.26, 0.363, 347, 281, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
330, 3zrkB, 0.8906, 2.20, 0.324, 348, 281, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
331, 4f7sA, 0.8905, 2.16, 0.356, 339, 281, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
332, 3sayB, 0.8904, 2.13, 0.321, 347, 280, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
333, 5kpkA, 0.8901, 2.12, 0.321, 346, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
334, 5hlnB, 0.8901, 2.13, 0.321, 346, 280, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
335, 2ojjA, 0.8901, 2.29, 0.367, 344, 281, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
336, 3sd0A, 0.8900, 2.19, 0.320, 350, 281, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
337, 5nhoA, 0.8899, 2.27, 0.367, 343, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
338, 5nhhA, 0.8899, 2.28, 0.367, 348, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
339, 4cfuC, 0.8898, 0.85, 0.981, 272, 263, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
340, 3blhA, 0.8898, 1.74, 0.415, 291, 275, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
341, 1q5kA, 0.8898, 2.04, 0.327, 345, 278, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
342, 5v62A, 0.8897, 2.13, 0.366, 349, 279, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
343, 3bhvC, 0.8896, 0.85, 0.981, 271, 263, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
344, 1pyxA, 0.8896, 1.98, 0.329, 343, 277, GSK-3 BETA COMPLEXED WITH AMP-PNP
345, 2z7lA, 0.8895, 2.28, 0.370, 329, 281, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
346, 4qtbA, 0.8894, 2.27, 0.370, 351, 281, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
347, 3sayA, 0.8893, 2.05, 0.324, 347, 278, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
348, 2ojiA, 0.8893, 2.28, 0.363, 344, 281, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
349, 5xqxA, 0.8892, 1.81, 0.384, 340, 276, HUMAN CDK8-CYCC IN COMPLEX WITH COMPOUND 4: N-METHYL-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
350, 5uq3A, 0.8892, 1.53, 0.963, 270, 269, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1-P27 TERNARY COMPLEX
351, 6g93A, 0.8890, 2.13, 0.366, 343, 279, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
352, 4qyyA, 0.8890, 2.29, 0.367, 337, 281, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
353, 4h3qA, 0.8890, 2.27, 0.359, 352, 281, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
354, 3bhtC, 0.8890, 0.87, 0.981, 270, 263, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
355, 2ojgA, 0.8890, 2.31, 0.367, 337, 281, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
356, 5bnjA, 0.8889, 2.12, 0.358, 343, 279, CDK8/CYCC IN COMPLEX WITH 8-{3-CHLORO-5-[4-(1-METHYL-1H-PYRAZOL-4-YL)- PHENYL]-PYRIDIN- 4-YL}-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
357, 6g9aA, 0.8888, 2.13, 0.366, 341, 279, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
358, 1oguC, 0.8888, 0.88, 0.981, 272, 263, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
359, 1golA, 0.8888, 2.27, 0.356, 357, 281, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
360, 5kpmA, 0.8887, 2.14, 0.321, 344, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
361, 4erkA, 0.8887, 2.27, 0.359, 350, 281, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
362, 3zrlB, 0.8887, 2.25, 0.320, 347, 281, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
363, 4bcpC, 0.8886, 0.88, 0.981, 267, 263, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
364, 1erkA, 0.8886, 2.27, 0.367, 357, 281, STRUCTURE OF SIGNAL-REGULATED KINASE
365, 4iz7A, 0.8884, 2.08, 0.363, 344, 278, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
366, 3bhuC, 0.8884, 0.88, 0.981, 271, 263, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
367, 6gdqA, 0.8883, 2.26, 0.364, 339, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
368, 5hd4A, 0.8882, 2.30, 0.367, 347, 281, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
369, 5f95A, 0.8882, 2.05, 0.327, 345, 278, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
370, 3zrmB, 0.8882, 2.26, 0.320, 347, 281, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
371, 6g97A, 0.8881, 2.13, 0.366, 344, 279, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
372, 5hnbA, 0.8881, 2.17, 0.361, 342, 280, CDK8-CYCC IN COMPLEX WITH [6-HYDROXY-3-(3-METHYL-BENZYL)-1H-INDAZOL-5- YL]-((S)-3-HYDROXY-PYRROLIDIN-1-YL)-METHANONE
373, 5airA, 0.8881, 2.01, 0.331, 353, 278, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
374, 4qtbB, 0.8881, 2.30, 0.370, 348, 281, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
375, 5byzA, 0.8879, 2.15, 0.391, 348, 279, ERK5 IN COMPLEX WITH SMALL MOLECULE
376, 4s2zA, 0.8879, 2.29, 0.359, 346, 281, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
377, 4fv3A, 0.8878, 2.28, 0.364, 346, 280, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
378, 4xrlA, 0.8877, 2.24, 0.371, 337, 280, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
379, 4j71A, 0.8877, 2.17, 0.321, 347, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
380, 4kd1A, 0.8876, 2.61, 0.982, 298, 285, CDK2 IN COMPLEX WITH DINACICLIB
381, 4izaA, 0.8876, 2.30, 0.359, 346, 281, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
382, 3f88A, 0.8876, 2.06, 0.327, 340, 278, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
383, 3pxqA, 0.8874, 2.08, 0.993, 298, 275, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
384, 4nifB, 0.8873, 2.14, 0.369, 349, 279, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
385, 5nguA, 0.8872, 2.26, 0.371, 339, 280, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
386, 5byyA, 0.8872, 1.95, 0.388, 338, 276, ERK5 IN COMPLEX WITH SMALL MOLECULE
387, 4fmqA, 0.8872, 2.25, 0.361, 350, 280, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
388, 5nhjA, 0.8871, 2.31, 0.367, 345, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
389, 4zsjA, 0.8871, 2.10, 0.391, 344, 279, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
390, 6g9hA, 0.8869, 2.27, 0.364, 343, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
391, 4nifE, 0.8869, 2.15, 0.369, 348, 279, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
392, 3q3bA, 0.8869, 2.04, 0.325, 344, 277, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
393, 3f88B, 0.8868, 2.10, 0.324, 340, 278, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
394, 4fv2A, 0.8867, 2.30, 0.368, 344, 280, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
395, 2b53A, 0.8867, 2.36, 0.925, 294, 280, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
396, 5umoA, 0.8866, 2.29, 0.359, 347, 281, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
397, 3nizA, 0.8866, 2.10, 0.594, 288, 276, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
398, 1pmeA, 0.8866, 2.25, 0.368, 333, 280, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
399, 4s34A, 0.8865, 2.30, 0.363, 343, 281, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
400, 5nhfA, 0.8863, 2.28, 0.371, 339, 280, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
401, 3q3bB, 0.8859, 1.98, 0.330, 341, 276, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
402, 4s33A, 0.8857, 2.34, 0.367, 347, 281, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
403, 2b54A, 0.8857, 2.72, 0.968, 298, 284, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
404, 6g9mA, 0.8856, 2.30, 0.364, 341, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
405, 6b8jA, 0.8856, 2.33, 0.325, 344, 280, CO-STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE BETA WITH A SELECTIVE (5-IMIDAZOL-2-YL-4-PHENYLPYRIMIDIN-2-YL)[2-(2-PYRIDYLAMINO) ETHYL]AMINE INHIBITOR
406, 4s30A, 0.8854, 2.32, 0.363, 342, 281, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
407, 3zrkA, 0.8854, 2.14, 0.319, 345, 279, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
408, 1pyxB, 0.8854, 1.92, 0.331, 338, 275, GSK-3 BETA COMPLEXED WITH AMP-PNP
409, 4qnyB, 0.8852, 2.29, 0.313, 339, 281, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
410, 4zsgA, 0.8851, 2.14, 0.384, 347, 279, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
411, 4gt3A, 0.8851, 2.29, 0.371, 347, 280, ATP-BOUND FORM OF THE ERK2 KINASE
412, 4bcoC, 0.8851, 0.89, 0.981, 269, 262, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
413, 4g6oA, 0.8850, 2.26, 0.366, 339, 279, CRYSTAL STRUCTURE OF THE ERK2
414, 2zoqA, 0.8850, 2.33, 0.370, 351, 281, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
415, 4j71B, 0.8848, 2.19, 0.321, 347, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
416, 4e7wA, 0.8848, 2.33, 0.357, 359, 280, STRUCTURE OF GSK3 FROM USTILAGO MAYDIS
417, 1buhA, 0.8848, 2.24, 0.946, 287, 276, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
418, 5kpmB, 0.8847, 2.18, 0.321, 345, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
419, 4g6lA, 0.8847, 2.02, 0.361, 336, 277, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
420, 4fv1A, 0.8846, 2.33, 0.368, 342, 280, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
421, 4s31A, 0.8844, 2.34, 0.359, 347, 281, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
422, 4fuxA, 0.8843, 2.28, 0.364, 342, 280, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
423, 3r63A, 0.8841, 2.34, 0.359, 347, 281, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
424, 6g9dA, 0.8840, 2.31, 0.368, 345, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
425, 4eorC, 0.8840, 1.01, 0.939, 270, 263, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
426, 5oy4A, 0.8839, 2.23, 0.321, 349, 280, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
427, 1tvoA, 0.8839, 2.34, 0.363, 350, 281, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
428, 6g91A, 0.8838, 2.31, 0.368, 344, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
429, 4zzmA, 0.8838, 2.30, 0.371, 344, 280, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
430, 3zrlA, 0.8838, 2.17, 0.319, 345, 279, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
431, 2ow3B, 0.8837, 2.25, 0.325, 351, 280, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
432, 3zrmA, 0.8836, 2.17, 0.319, 344, 279, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
433, 3r83A, 0.8836, 2.47, 0.940, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
434, 1q3wB, 0.8836, 2.02, 0.330, 341, 276, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
435, 4s32A, 0.8835, 2.36, 0.367, 346, 281, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
436, 3qqlA, 0.8835, 2.45, 0.940, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR L3
437, 6gn1A, 0.8834, 2.10, 0.321, 339, 277, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
438, 6g8xA, 0.8834, 2.32, 0.368, 338, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
439, 5airB, 0.8833, 2.17, 0.326, 361, 279, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
440, 4zzoA, 0.8832, 2.30, 0.371, 339, 280, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
441, 4zznA, 0.8832, 2.30, 0.371, 338, 280, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
442, 4zslA, 0.8832, 2.12, 0.392, 341, 278, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
443, 2zoqB, 0.8832, 2.37, 0.370, 351, 281, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
444, 2ow3A, 0.8832, 2.25, 0.329, 346, 280, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
445, 6ge0A, 0.8831, 2.29, 0.369, 343, 279, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
446, 5nzzG, 0.8831, 2.22, 0.375, 342, 277, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
447, 4g6nA, 0.8831, 2.31, 0.368, 341, 280, CRYSTAL STRUCTURE OF THE ERK2
448, 4fv7A, 0.8831, 2.14, 0.367, 342, 278, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
449, 4xozA, 0.8830, 2.28, 0.361, 341, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
450, 3anrA, 0.8830, 1.74, 0.335, 342, 272, HUMAN DYRK1A/HARMINE COMPLEX
451, 1xo2B, 0.8830, 1.97, 0.482, 289, 278, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
452, 5lcjA, 0.8829, 2.31, 0.364, 345, 280, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
453, 5oy4B, 0.8828, 2.24, 0.321, 353, 280, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
454, 4j1rC, 0.8828, 2.25, 0.321, 344, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
455, 4gcjA, 0.8828, 2.27, 0.982, 304, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
456, 6gn1B, 0.8827, 2.11, 0.321, 339, 277, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
457, 4j1rA, 0.8827, 2.25, 0.321, 343, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
458, 6g9nA, 0.8826, 2.35, 0.361, 344, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
459, 4j1rD, 0.8826, 2.25, 0.321, 345, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
460, 3du8A, 0.8826, 1.99, 0.331, 336, 275, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
461, 5o7iA, 0.8823, 2.14, 0.385, 340, 278, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
462, 4xj0A, 0.8823, 2.26, 0.366, 345, 279, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
463, 3pj8A, 0.8823, 2.33, 0.989, 288, 279, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
464, 5aneA, 0.8822, 2.49, 0.982, 294, 281, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
465, 3r8pA, 0.8822, 2.45, 0.940, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
466, 1q3wA, 0.8821, 2.12, 0.325, 344, 277, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
467, 6g92A, 0.8820, 2.34, 0.368, 343, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
468, 4xneA, 0.8820, 2.26, 0.362, 344, 279, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
469, 3eb0A, 0.8820, 2.03, 0.348, 311, 276, CRYSTAL STRUCTURE OF CGD4_240 FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH INDIRUBIN E804
470, 3anqA, 0.8820, 1.75, 0.338, 342, 272, HUMAN DYRK1A/INHIBITOR COMPLEX
471, 4qnyA, 0.8819, 2.29, 0.314, 333, 280, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
472, 3anrB, 0.8819, 1.76, 0.331, 342, 272, HUMAN DYRK1A/HARMINE COMPLEX
473, 3du8B, 0.8818, 2.01, 0.331, 339, 275, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
474, 4gvaA, 0.8817, 2.30, 0.364, 345, 280, ADP-BOUND FORM OF THE ERK2 KINASE
475, 3anqB, 0.8816, 1.77, 0.338, 343, 272, HUMAN DYRK1A/INHIBITOR COMPLEX
476, 5nzzE, 0.8815, 2.24, 0.375, 343, 277, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
477, 4qp1A, 0.8815, 2.26, 0.358, 342, 279, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
478, 3gb2A, 0.8815, 2.09, 0.332, 340, 277, GSK3BETA INHIBITOR COMPLEX
479, 1pw2A, 0.8814, 2.53, 0.979, 294, 281, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
480, 6g9kA, 0.8813, 2.31, 0.369, 343, 279, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
481, 3anrC, 0.8811, 1.79, 0.342, 337, 272, HUMAN DYRK1A/HARMINE COMPLEX
482, 2iw9C, 0.8811, 0.90, 0.977, 268, 261, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
483, 5anjA, 0.8809, 2.67, 0.979, 291, 283, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
484, 1i09B, 0.8809, 2.02, 0.330, 341, 276, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
485, 1v0oA, 0.8808, 1.91, 0.624, 276, 271, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
486, 5aikA, 0.8807, 1.77, 0.331, 344, 272, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
487, 4xrjA, 0.8807, 2.27, 0.362, 344, 279, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
488, 4mygA, 0.8806, 2.15, 0.384, 335, 276, MAPK13 ACTIVE FORM
489, 5nzzF, 0.8805, 2.20, 0.373, 341, 276, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
490, 4gsbA, 0.8805, 2.28, 0.373, 343, 279, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
491, 3anqC, 0.8805, 1.78, 0.331, 340, 272, HUMAN DYRK1A/INHIBITOR COMPLEX
492, 5aikC, 0.8804, 1.77, 0.331, 342, 272, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
493, 1q3dB, 0.8804, 2.14, 0.330, 339, 276, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
494, 1wzyA, 0.8802, 2.36, 0.370, 350, 281, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
495, 5a3xA, 0.8801, 1.80, 0.338, 342, 272, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
496, 2f49A, 0.8801, 2.08, 0.382, 335, 275, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
497, 5aikB, 0.8800, 1.76, 0.324, 342, 272, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
498, 3eb0C, 0.8800, 2.07, 0.344, 310, 276, CRYSTAL STRUCTURE OF CGD4_240 FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH INDIRUBIN E804
499, 5idnA, 0.8799, 1.91, 0.383, 336, 274, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (3-METHYL-1H-PYRAZOLO[34-B]PYRIDIN-5-YL)-METHANONE
500, 4xp2A, 0.8799, 2.30, 0.366, 337, 279, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
501, 4lynA, 0.8799, 2.43, 0.996, 287, 280, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
502, 4afjB, 0.8799, 2.18, 0.325, 346, 277, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
503, 2clxA, 0.8797, 2.48, 0.979, 293, 280, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
504, 1hckA, 0.8797, 2.54, 0.979, 294, 281, HUMAN CYCLIN-DEPENDENT KINASE 2
505, 5fgkA, 0.8795, 1.82, 0.374, 331, 273, CDK8-CYCC IN COMPLEX WITH 8-[3-(3-AMINO-1H-INDAZOL-6-YL)-5-CHLORO- PYRIDINE-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
506, 3qyzA, 0.8795, 2.37, 0.371, 339, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
507, 3qywA, 0.8795, 2.34, 0.364, 340, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
508, 5lckA, 0.8793, 2.32, 0.362, 345, 279, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
509, 3f7zB, 0.8793, 2.10, 0.322, 339, 276, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
510, 5a3xB, 0.8792, 1.80, 0.331, 340, 272, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
511, 4qpaB, 0.8792, 2.36, 0.357, 345, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
512, 3qtwA, 0.8792, 2.51, 0.943, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
513, 2exmA, 0.8792, 2.77, 0.982, 298, 284, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
514, 4j1rB, 0.8790, 2.18, 0.327, 346, 278, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
515, 3rm6A, 0.8790, 2.38, 0.943, 293, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
516, 3qxoA, 0.8788, 2.61, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
517, 1q4lA, 0.8788, 2.00, 0.328, 342, 274, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
518, 2b9iA, 0.8787, 2.17, 0.380, 338, 276, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
519, 5hvyA, 0.8786, 2.35, 0.378, 335, 278, CDK8/CYCC IN COMPLEX WITH COMPOUND 20
520, 3r71A, 0.8786, 2.57, 0.979, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
521, 6g9jA, 0.8785, 2.31, 0.367, 347, 278, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
522, 5aikD, 0.8785, 1.75, 0.332, 342, 271, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
523, 3rpoA, 0.8785, 2.55, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
524, 3r7yA, 0.8785, 2.57, 0.982, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
525, 1q41A, 0.8784, 2.00, 0.332, 339, 274, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
526, 1hclA, 0.8784, 2.58, 0.982, 294, 281, HUMAN CYCLIN-DEPENDENT KINASE 2
527, 5a4eD, 0.8783, 1.78, 0.336, 331, 271, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
528, 3r1qA, 0.8783, 2.53, 0.936, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
529, 3qx2A, 0.8783, 2.56, 0.979, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
530, 1h26C, 0.8782, 0.88, 0.981, 267, 260, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
531, 6gdmA, 0.8781, 2.23, 0.372, 341, 277, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
532, 5a3xD, 0.8781, 1.78, 0.336, 331, 271, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
533, 2y9qA, 0.8781, 2.37, 0.362, 349, 279, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
534, 5osjA, 0.8780, 2.58, 0.972, 292, 281, CDK2(WT) WITH COVALENT ADDUCT AT C177
535, 4afjA, 0.8780, 2.10, 0.326, 342, 276, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
536, 5a3xC, 0.8779, 1.83, 0.331, 333, 272, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
537, 4qp1B, 0.8778, 2.38, 0.364, 343, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
538, 5hlpA, 0.8776, 2.11, 0.330, 337, 276, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
539, 2fysA, 0.8776, 2.29, 0.369, 348, 279, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
540, 5a4tA, 0.8774, 1.75, 0.328, 341, 271, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
541, 4xp3A, 0.8774, 2.41, 0.371, 339, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
542, 4fv0A, 0.8774, 2.28, 0.363, 341, 278, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
543, 1q3dA, 0.8774, 2.07, 0.331, 339, 275, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
544, 1pxjA, 0.8774, 2.57, 0.979, 294, 281, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
545, 1pxoA, 0.8773, 2.54, 0.982, 294, 281, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
546, 3r28A, 0.8772, 2.54, 0.936, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
547, 3qzhA, 0.8771, 2.60, 0.936, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
548, 3py1A, 0.8771, 2.43, 0.982, 302, 280, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
549, 2a0cX, 0.8771, 2.63, 0.975, 294, 282, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
550, 4cfmC, 0.8770, 0.83, 0.981, 266, 259, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
551, 2fa2A, 0.8770, 2.11, 0.382, 333, 275, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
552, 4f6wA, 0.8769, 1.77, 0.375, 330, 272, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 1 (N-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-4-[2-({[3-TERT-BUTYL- 1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]CARBAMOYL}AMINO)ETHYL]PIPERAZINE- 1-CARBOXAMIDE)
553, 5a54A, 0.8767, 1.81, 0.339, 341, 271, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
554, 3r6xA, 0.8767, 2.53, 0.940, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
555, 5hbhA, 0.8766, 1.95, 0.371, 336, 275, CDK8-CYCC IN COMPLEX WITH 5-{5-CHLORO-4-[1-(2-METHOXY-ETHYL)-18- DIAZA-SPIRO[4.5]DEC-8-YL]-PYRIDIN-3-YL}-1-METHYL-13-DIHYDRO- BENZO[C]ISOTHIAZOLE 22-DIOXIDE
556, 5a4tB, 0.8766, 1.79, 0.328, 339, 271, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
557, 4nctD, 0.8765, 1.77, 0.332, 331, 271, HUMAN DYRK1A IN COMPLEX WITH PKC412
558, 4cfvC, 0.8765, 0.84, 0.981, 264, 259, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
559, 3anrD, 0.8765, 1.74, 0.337, 340, 270, HUMAN DYRK1A/HARMINE COMPLEX
560, 5a54D, 0.8764, 1.76, 0.337, 334, 270, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
561, 5a4qA, 0.8764, 1.81, 0.339, 341, 271, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
562, 5a4lA, 0.8764, 1.79, 0.332, 341, 271, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
563, 3raiA, 0.8764, 2.56, 0.940, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
564, 3my5C, 0.8764, 0.85, 0.981, 266, 259, CDK2/CYCLINA IN COMPLEX WITH DRB
565, 3anqD, 0.8764, 1.74, 0.337, 334, 270, HUMAN DYRK1A/INHIBITOR COMPLEX
566, 5a4qB, 0.8763, 1.79, 0.328, 335, 271, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
567, 3qwkA, 0.8763, 2.53, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
568, 3pxrA, 0.8763, 2.65, 0.975, 294, 282, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
569, 3o71A, 0.8763, 2.24, 0.371, 340, 278, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
570, 3lfnA, 0.8763, 2.20, 0.996, 285, 276, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
571, 1pxiA, 0.8763, 2.60, 0.979, 294, 281, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
572, 1gngA, 0.8763, 2.37, 0.325, 348, 280, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
573, 6dcgA, 0.8762, 2.25, 0.370, 326, 276, DISCOVERY OF MK-8353: AN ORALLY BIOAVAILABLE DUAL MECHANISM ERK INHIBITOR FOR ONCOLOGY 
574, 5a4tD, 0.8762, 1.73, 0.333, 332, 270, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
575, 5a4lB, 0.8762, 1.81, 0.336, 339, 271, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
576, 4erwA, 0.8762, 2.55, 0.964, 292, 279, CDK2 IN COMPLEX WITH STAUROSPORINE
577, 3qzfA, 0.8761, 2.61, 0.975, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
578, 3juhA, 0.8761, 2.37, 0.301, 334, 279, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
579, 5a4qD, 0.8760, 1.76, 0.337, 334, 270, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
580, 5a4lD, 0.8760, 1.75, 0.333, 334, 270, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
581, 4un0D, 0.8760, 1.62, 0.428, 276, 269, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
582, 3royA, 0.8760, 2.65, 0.936, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
583, 3r7vA, 0.8760, 2.52, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
584, 3qziA, 0.8760, 2.62, 0.936, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
585, 3qx4A, 0.8760, 2.56, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
586, 2wo6A, 0.8760, 1.87, 0.331, 344, 272, HUMAN DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A IN COMPLEX WITH A CONSENSUS SUBSTRATE PEPTIDE
587, 2jd5B, 0.8760, 2.04, 0.312, 360, 276, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
588, 2f49B, 0.8760, 2.12, 0.382, 337, 275, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
589, 1q5kB, 0.8760, 2.11, 0.335, 344, 275, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
590, 1oirA, 0.8760, 2.27, 0.956, 286, 275, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
591, 3r73A, 0.8759, 2.55, 0.940, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
592, 2ds1A, 0.8759, 2.41, 0.942, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
593, 1wccA, 0.8759, 2.17, 0.996, 283, 276, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
594, 5kplB, 0.8758, 2.10, 0.327, 339, 275, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
595, 4nctA, 0.8758, 1.81, 0.339, 341, 271, HUMAN DYRK1A IN COMPLEX WITH PKC412
596, 3py3A, 0.8757, 2.02, 0.369, 355, 274, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
597, 1q99B, 0.8757, 2.05, 0.312, 364, 276, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
598, 5a54B, 0.8756, 1.82, 0.332, 339, 271, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
599, 5a4eA, 0.8755, 1.82, 0.339, 341, 271, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
600, 4iq6B, 0.8755, 1.98, 0.333, 332, 273, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
601, 4h3pA, 0.8755, 2.32, 0.368, 342, 277, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
602, 3tiyA, 0.8755, 2.57, 0.964, 293, 281, CDK2 IN COMPLEX WITH NSC 35676
603, 3r7eA, 0.8755, 2.65, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
604, 4qp8B, 0.8754, 2.03, 0.374, 337, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
605, 4ptgA, 0.8754, 2.01, 0.337, 333, 273, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
606, 3qwjA, 0.8754, 2.65, 0.975, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
607, 3r1sA, 0.8753, 2.57, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
608, 2b9hA, 0.8753, 2.16, 0.382, 337, 275, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
609, 3rk9A, 0.8752, 2.66, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
610, 2b9jA, 0.8752, 2.17, 0.382, 337, 275, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
611, 3rm7A, 0.8751, 2.64, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
612, 2c5yA, 0.8751, 2.45, 0.978, 290, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
613, 1q97B, 0.8751, 2.06, 0.312, 361, 276, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
614, 3rk5A, 0.8750, 2.61, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
615, 2wmbC, 0.8750, 0.88, 0.981, 266, 259, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
616, 3rniA, 0.8749, 2.49, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
617, 4ianA, 0.8748, 1.90, 0.308, 321, 273, CRYSTAL STRUCTURE OF APO HUMAN PRPF4B KINASE DOMAIN
618, 6ft7B, 0.8747, 2.35, 0.274, 356, 277, CRYSTAL STRUCTURE OF CLK3 IN COMPLEX WITH COMPOUND 8A 
619, 3tnhA, 0.8747, 1.88, 0.417, 288, 271, CDK9/CYCLIN T IN COMPLEX WITH CAN508
620, 3qqfA, 0.8747, 2.65, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR L1
621, 4iz7C, 0.8746, 2.17, 0.364, 340, 275, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
622, 3r1yA, 0.8746, 2.69, 0.936, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
623, 6fyrA, 0.8745, 2.30, 0.274, 355, 277, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CPD-2 AT 1.42A 
624, 4au8B, 0.8745, 1.78, 0.593, 277, 270, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
625, 1q8zB, 0.8744, 2.07, 0.312, 364, 276, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
626, 4mygB, 0.8743, 2.01, 0.387, 335, 274, MAPK13 ACTIVE FORM
627, 3rkbA, 0.8743, 2.67, 0.979, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
628, 3dogC, 0.8743, 0.90, 0.973, 267, 259, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
629, 6ft7A, 0.8742, 2.38, 0.274, 356, 277, CRYSTAL STRUCTURE OF CLK3 IN COMPLEX WITH COMPOUND 8A 
630, 4ifcA, 0.8741, 1.91, 0.308, 327, 273, CRYSTAL STRUCTURE OF ADP-BOUND HUMAN PRPF4B KINASE DOMAIN
631, 3rk7A, 0.8741, 2.67, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
632, 3h30A, 0.8741, 2.32, 0.299, 333, 278, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
633, 2xmyA, 0.8741, 2.76, 0.968, 295, 283, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
634, 5osmA, 0.8740, 2.39, 0.942, 292, 277, CDK2(F80C C177A) WITH COVALENT ADDUCT AT C80
635, 4ifcB, 0.8740, 1.92, 0.308, 329, 273, CRYSTAL STRUCTURE OF ADP-BOUND HUMAN PRPF4B KINASE DOMAIN
636, 3f7zA, 0.8740, 2.02, 0.322, 339, 273, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
637, 2eu9A, 0.8740, 2.31, 0.274, 345, 277, CRYSTAL STRUCTURE OF CLK3
638, 3r9dA, 0.8739, 2.58, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
639, 2xnbA, 0.8739, 2.68, 0.982, 296, 282, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
640, 4iirB, 0.8738, 1.92, 0.308, 327, 273, CRYSTAL STRUCTURE OF AMPPNP-BOUND HUMAN PRPF4B KINASE DOMAIN
641, 2f2cB, 0.8737, 1.76, 0.493, 280, 270, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
642, 3qrtA, 0.8736, 2.60, 0.926, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
643, 1b38A, 0.8736, 2.41, 0.949, 290, 277, HUMAN CYCLIN-DEPENDENT KINASE 2
644, 5m4cA, 0.8735, 2.33, 0.300, 329, 277, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
645, 4nctB, 0.8735, 1.88, 0.336, 333, 271, HUMAN DYRK1A IN COMPLEX WITH PKC412
646, 3sa0A, 0.8734, 2.44, 0.369, 354, 279, COMPLEX OF ERK2 WITH NORATHYRIOL
647, 1q8yB, 0.8734, 2.08, 0.312, 357, 276, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
648, 4xp0A, 0.8733, 2.31, 0.375, 336, 277, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
649, 3juhB, 0.8733, 2.42, 0.305, 334, 279, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
650, 4au8A, 0.8731, 1.68, 0.582, 276, 268, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
651, 2fa2B, 0.8731, 2.18, 0.382, 332, 275, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
652, 3qu0A, 0.8730, 2.70, 0.975, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
653, 3ns9A, 0.8730, 2.38, 0.975, 289, 276, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
654, 3lfqA, 0.8729, 2.36, 0.957, 289, 276, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
655, 5nqcA, 0.8728, 2.33, 0.299, 331, 278, CK2ALPHA IN COMPLEX WITH NMR154
656, 4ez3A, 0.8726, 2.53, 0.975, 294, 280, CDK2 IN COMPLEX WITH NSC 134199
657, 4rj3A, 0.8725, 2.38, 0.953, 287, 276, CDK2 WITH EGFR INHIBITOR COMPOUND 8
658, 3lfsA, 0.8725, 2.44, 0.953, 290, 277, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
659, 1jwhA, 0.8724, 2.31, 0.296, 336, 277, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
660, 5kplA, 0.8723, 2.05, 0.333, 339, 273, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
661, 4zxtA, 0.8722, 2.46, 0.369, 348, 279, COMPLEX OF ERK2 WITH CATECHOL
662, 1h01A, 0.8722, 2.34, 0.956, 286, 275, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
663, 1aq1A, 0.8722, 1.83, 0.970, 277, 269, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
664, 5a4tC, 0.8720, 1.82, 0.333, 332, 270, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
665, 4f7nA, 0.8720, 1.95, 0.375, 334, 272, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 11 (1- [3-TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(5- HYDROXYPENTYL)UREA)
666, 2vtoA, 0.8720, 2.17, 0.967, 283, 274, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
667, 2jd5A, 0.8720, 2.03, 0.314, 353, 274, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
668, 1pxpA, 0.8720, 2.69, 0.972, 294, 282, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
669, 6cpwA, 0.8719, 2.32, 0.370, 328, 276, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
670, 4ylkA, 0.8719, 1.94, 0.320, 341, 272, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-CHLORO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLONE-6-CARBOXYLIC ACID INHIBITOR 5S
671, 4qp7A, 0.8719, 2.17, 0.372, 337, 274, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
672, 4fkuA, 0.8719, 2.61, 0.979, 293, 280, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
673, 3uliA, 0.8719, 2.30, 0.960, 286, 277, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
674, 3rgfA, 0.8719, 2.07, 0.380, 321, 274, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC
675, 2b52A, 0.8719, 2.15, 0.985, 283, 274, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
676, 1oiuC, 0.8719, 0.88, 0.981, 265, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
677, 4nctC, 0.8718, 1.82, 0.337, 339, 270, HUMAN DYRK1A IN COMPLEX WITH PKC412
678, 4n0sA, 0.8718, 2.40, 0.371, 348, 278, COMPLEX OF ERK2 WITH CAFFEIC ACID
679, 4mq1B, 0.8718, 1.85, 0.339, 340, 271, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
680, 4iirA, 0.8718, 1.95, 0.308, 325, 273, CRYSTAL STRUCTURE OF AMPPNP-BOUND HUMAN PRPF4B KINASE DOMAIN
681, 4qp4A, 0.8717, 2.17, 0.372, 337, 274, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
682, 4ijpB, 0.8717, 1.95, 0.308, 333, 273, CRYSTAL STRUCTURE OF HUMAN PRPF4B KINASE DOMAIN IN COMPLEX WITH 4-{5- [(2-CHLORO-PYRIDIN-4-YLMETHYL)-CARBAMOYL]-THIOPHEN-2-YL}- BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMINE
683, 3ql8A, 0.8717, 2.69, 0.965, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
684, 4yllA, 0.8716, 1.93, 0.320, 340, 272, CRYSTAL STRUCTURE OF DYRK1AA IN COMPLEX WITH 10-BROMO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLONE-6-CARBOXYLIC ACID INHIBITOR 5T
685, 2vtmA, 0.8716, 2.47, 0.953, 290, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
686, 1gngB, 0.8716, 2.40, 0.325, 355, 280, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
687, 5a4eB, 0.8715, 2.05, 0.336, 322, 271, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
688, 3qtzA, 0.8715, 2.66, 0.975, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
689, 2r3fA, 0.8715, 2.44, 0.953, 290, 277, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
690, 3qtqA, 0.8714, 2.63, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
691, 5m4fA, 0.8713, 2.33, 0.300, 330, 277, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
692, 1h0vA, 0.8713, 2.50, 0.953, 288, 278, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
693, 5jq5A, 0.8712, 2.30, 0.953, 287, 274, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
694, 4ek4A, 0.8712, 2.40, 0.953, 287, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
695, 3ddqC, 0.8712, 0.90, 0.973, 266, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
696, 2vx3B, 0.8712, 1.88, 0.328, 340, 271, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
697, 4qp9A, 0.8711, 2.11, 0.374, 335, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
698, 3c9wB, 0.8711, 2.04, 0.373, 336, 271, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
699, 3c9wA, 0.8711, 2.04, 0.373, 336, 271, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
700, 4f6uA, 0.8710, 2.05, 0.381, 334, 273, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 5 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-[3-(MORPHOLIN-4-YL) PROPYL]UREA)
701, 4b99A, 0.8710, 2.21, 0.396, 335, 273, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
702, 3rpvA, 0.8710, 2.65, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
703, 2vtlA, 0.8710, 2.46, 0.953, 290, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
704, 4mq1D, 0.8709, 1.82, 0.337, 336, 270, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
705, 2wo6B, 0.8709, 1.89, 0.332, 339, 271, HUMAN DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A IN COMPLEX WITH A CONSENSUS SUBSTRATE PEPTIDE
706, 5a4lC, 0.8708, 1.88, 0.337, 332, 270, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
707, 3wblA, 0.8708, 2.24, 0.996, 283, 275, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
708, 1q97A, 0.8708, 1.99, 0.311, 351, 273, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
709, 3qxpA, 0.8707, 2.39, 0.935, 294, 278, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
710, 1h07A, 0.8707, 2.34, 0.960, 285, 275, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
711, 5lmkC, 0.8706, 0.91, 0.981, 265, 258, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
712, 5a4qC, 0.8706, 1.84, 0.337, 332, 270, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
713, 4yljB, 0.8706, 1.94, 0.327, 347, 272, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
714, 4ek5A, 0.8706, 2.43, 0.953, 289, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
715, 3ti1A, 0.8706, 2.72, 0.947, 294, 282, CDK2 IN COMPLEX WITH SUNITINIB
716, 1q8zA, 0.8706, 2.10, 0.309, 354, 275, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
717, 5oo0A, 0.8705, 2.47, 0.975, 288, 277, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
718, 5a54C, 0.8705, 1.88, 0.341, 332, 270, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
719, 4mq1A, 0.8705, 1.88, 0.336, 345, 271, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
720, 4fklA, 0.8705, 2.46, 0.953, 290, 277, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
721, 1q99A, 0.8705, 2.10, 0.309, 354, 275, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
722, 5wp1A, 0.8704, 2.39, 0.363, 340, 278, COMPLEX OF ERK2 WITH 5;7-DIHYDROXYCHROMONE 
723, 2c6lA, 0.8704, 2.54, 0.968, 291, 278, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
724, 4yu2D, 0.8703, 1.94, 0.331, 346, 272, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
725, 4ek3A, 0.8703, 2.43, 0.953, 287, 276, CRYSTAL STRUCTURE OF APO CDK2
726, 3qruA, 0.8703, 2.59, 0.929, 295, 282, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
727, 2vx3D, 0.8703, 1.88, 0.332, 342, 271, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
728, 2uzoA, 0.8703, 2.53, 0.946, 290, 279, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
729, 1v0oB, 0.8703, 1.94, 0.628, 274, 269, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
730, 1gz8A, 0.8703, 2.47, 0.953, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
731, 4ijpA, 0.8702, 1.98, 0.304, 330, 273, CRYSTAL STRUCTURE OF HUMAN PRPF4B KINASE DOMAIN IN COMPLEX WITH 4-{5- [(2-CHLORO-PYRIDIN-4-YLMETHYL)-CARBAMOYL]-THIOPHEN-2-YL}- BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMINE
732, 4ianB, 0.8702, 1.98, 0.308, 319, 273, CRYSTAL STRUCTURE OF APO HUMAN PRPF4B KINASE DOMAIN
733, 3qqkA, 0.8701, 2.57, 0.968, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR L4
734, 2vx3A, 0.8701, 1.95, 0.327, 346, 272, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
735, 2r3rA, 0.8701, 2.47, 0.953, 290, 277, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
736, 1ungB, 0.8701, 1.54, 0.581, 268, 265, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
737, 4mq2B, 0.8700, 1.90, 0.336, 338, 271, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
738, 2c69A, 0.8700, 2.59, 0.964, 292, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
739, 5hlpB, 0.8699, 2.09, 0.330, 335, 273, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
740, 4yljD, 0.8699, 1.94, 0.327, 347, 272, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
741, 3rjcA, 0.8698, 2.60, 0.950, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR L4-12
742, 2vtsA, 0.8698, 2.18, 0.985, 282, 273, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
743, 5ievA, 0.8697, 2.21, 0.993, 284, 275, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
744, 4yu2B, 0.8697, 1.95, 0.331, 347, 272, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
745, 3r8zA, 0.8697, 2.56, 0.986, 290, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
746, 2c68A, 0.8697, 2.58, 0.950, 290, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
747, 1b39A, 0.8697, 2.46, 0.949, 290, 277, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
748, 3teiA, 0.8696, 2.23, 0.369, 339, 274, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
749, 3qtxA, 0.8696, 2.70, 0.954, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
750, 3nszA, 0.8696, 2.20, 0.295, 327, 275, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
751, 3iggA, 0.8696, 2.50, 0.949, 290, 277, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
752, 2c6kA, 0.8696, 2.60, 0.982, 292, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
753, 1q8yA, 0.8696, 2.07, 0.307, 351, 274, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
754, 4yu2A, 0.8695, 2.02, 0.330, 348, 273, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
755, 2gmxA, 0.8695, 2.20, 0.355, 357, 276, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
756, 1y8yA, 0.8695, 2.56, 0.953, 292, 279, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
757, 5ooiB, 0.8694, 2.40, 0.303, 325, 277, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
758, 5iexA, 0.8694, 2.34, 0.989, 285, 277, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
759, 2no3A, 0.8694, 2.39, 0.356, 357, 278, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
760, 2r3oA, 0.8692, 2.43, 0.953, 289, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
761, 2r3hA, 0.8692, 2.42, 0.953, 289, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
762, 1ckpA, 0.8692, 2.03, 0.967, 279, 272, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
763, 4qtaA, 0.8691, 1.99, 0.370, 335, 270, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
764, 2v0dA, 0.8691, 2.59, 0.964, 292, 279, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
765, 4n4sA, 0.8690, 2.22, 0.372, 342, 277, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
766, 2iw8C, 0.8690, 0.95, 0.969, 265, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
767, 2b9fA, 0.8690, 2.28, 0.382, 337, 275, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
768, 4fkvA, 0.8689, 2.17, 0.996, 282, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
769, 2a4lA, 0.8689, 2.31, 0.963, 286, 273, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
770, 6fykB, 0.8688, 2.43, 0.272, 349, 276, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
771, 2c6oA, 0.8688, 2.58, 0.946, 290, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
772, 4md9P, 0.8687, 2.41, 0.296, 328, 277, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
773, 3r8uA, 0.8687, 2.67, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
774, 4yu2C, 0.8686, 1.98, 0.331, 346, 272, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
775, 3w8lA, 0.8686, 2.28, 0.301, 326, 276, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
776, 3r9hA, 0.8686, 2.77, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
777, 5ieyA, 0.8685, 2.41, 0.993, 286, 277, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
778, 4mq1C, 0.8685, 1.87, 0.341, 328, 270, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
779, 4yljC, 0.8684, 1.97, 0.327, 346, 272, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
780, 4mq2D, 0.8684, 1.91, 0.332, 329, 271, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
781, 1y91A, 0.8684, 2.12, 0.971, 286, 273, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
782, 1q4lB, 0.8684, 2.08, 0.324, 337, 272, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
783, 1cm8B, 0.8684, 2.26, 0.370, 327, 273, PHOSPHORYLATED MAP KINASE P38-GAMMA
784, 1cm8A, 0.8684, 2.26, 0.370, 327, 273, PHOSPHORYLATED MAP KINASE P38-GAMMA
785, 2w17A, 0.8683, 2.07, 0.971, 278, 272, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
786, 2vx3C, 0.8683, 1.93, 0.328, 338, 271, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
787, 2zjwA, 0.8682, 2.29, 0.301, 332, 276, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
788, 3fwqB, 0.8681, 2.47, 0.294, 334, 279, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
789, 2vtpA, 0.8681, 2.20, 0.967, 281, 273, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
790, 1pxlA, 0.8681, 2.44, 0.978, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
791, 4azeB, 0.8679, 1.99, 0.331, 345, 272, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
792, 3tizA, 0.8679, 2.64, 0.929, 293, 281, CDK2 IN COMPLEX WITH NSC 111848
793, 3h30B, 0.8679, 2.40, 0.299, 333, 278, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
794, 3qqjA, 0.8678, 2.68, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR L2
795, 2c6mA, 0.8678, 2.62, 0.964, 290, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
796, 2c6iA, 0.8678, 2.63, 0.961, 292, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
797, 1pf8A, 0.8678, 2.53, 0.986, 298, 280, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
798, 4qp3A, 0.8677, 2.17, 0.363, 339, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
799, 4azeA, 0.8677, 1.99, 0.331, 348, 272, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
800, 2oxyA, 0.8677, 2.40, 0.300, 327, 277, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
801, 4f7lA, 0.8676, 1.81, 0.378, 328, 270, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 2 (TERT- BUTYL [3-({[3-TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5- YL]CARBAMOYL}AMINO)PROPYL]CARBAMATE)
802, 2vtrA, 0.8676, 2.50, 0.957, 290, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
803, 5ooiA, 0.8675, 2.43, 0.303, 329, 277, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
804, 5b0xA, 0.8675, 2.41, 0.300, 329, 277, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
805, 4mq2A, 0.8675, 1.98, 0.331, 343, 272, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
806, 4azeC, 0.8675, 1.99, 0.331, 348, 272, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
807, 3kxhA, 0.8675, 2.40, 0.300, 326, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
808, 2wmaC, 0.8675, 0.99, 0.973, 265, 258, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
809, 2w1hA, 0.8675, 2.31, 0.996, 283, 276, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
810, 1howA, 0.8675, 2.19, 0.316, 346, 275, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
811, 6fypA, 0.8674, 2.34, 0.279, 348, 276, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CX-4945 AT 2.29A 
812, 3s00A, 0.8674, 2.76, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR L4-14
813, 5k5nA, 0.8673, 2.06, 0.331, 331, 272, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
814, 4mq2C, 0.8673, 1.94, 0.336, 339, 271, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
815, 5n1vB, 0.8670, 2.44, 0.300, 331, 277, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
816, 3qqgA, 0.8670, 2.73, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR L2-5
817, 1j91B, 0.8670, 2.39, 0.300, 327, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
818, 5n1vA, 0.8669, 2.44, 0.300, 331, 277, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
819, 3s2pA, 0.8669, 2.06, 0.967, 279, 272, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
820, 2r3pA, 0.8668, 2.47, 0.953, 289, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
821, 2r3gA, 0.8668, 2.37, 0.960, 287, 274, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
822, 5k4jA, 0.8667, 2.15, 0.971, 282, 273, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
823, 4fkiA, 0.8667, 2.21, 0.971, 287, 273, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
824, 4md9K, 0.8666, 2.41, 0.296, 328, 277, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
825, 4dglC, 0.8666, 2.40, 0.292, 334, 277, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
826, 3qtuA, 0.8666, 2.74, 0.908, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
827, 3ofmA, 0.8666, 2.44, 0.300, 325, 277, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
828, 2oxyB, 0.8666, 2.41, 0.300, 327, 277, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
829, 5csvA, 0.8665, 2.28, 0.305, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
830, 4yljA, 0.8665, 1.99, 0.327, 346, 272, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
831, 4o6eA, 0.8664, 2.07, 0.374, 328, 270, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
832, 3s0oA, 0.8664, 2.70, 0.925, 293, 281, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
833, 3r8lA, 0.8664, 2.74, 0.933, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR L3-4
834, 1e1vA, 0.8664, 2.54, 0.978, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
835, 4md9G, 0.8663, 2.31, 0.297, 329, 276, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
836, 6fyiA, 0.8662, 2.34, 0.273, 336, 275, X-RAY STRUCTURE OF CLK2-KD(130-496)/TG003 AT 2.6A 
837, 3wikA, 0.8662, 2.39, 0.296, 334, 277, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
838, 3fwqA, 0.8662, 2.50, 0.294, 334, 279, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
839, 2eufB, 0.8662, 1.81, 0.500, 282, 268, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
840, 1pjkA, 0.8662, 2.32, 0.301, 331, 276, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
841, 6fykA, 0.8661, 2.47, 0.272, 349, 276, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
842, 4md9E, 0.8661, 2.31, 0.297, 329, 276, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
843, 5xvuA, 0.8660, 2.24, 0.302, 321, 275, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
844, 4md8G, 0.8660, 2.46, 0.296, 332, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
845, 4f70A, 0.8660, 1.91, 0.378, 327, 270, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 4 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-[2-(MORPHOLIN-4-YL) ETHYL]UREA)
846, 1w8cA, 0.8660, 2.53, 0.953, 290, 277, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
847, 1h0wA, 0.8660, 2.26, 0.960, 283, 275, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
848, 6fylA, 0.8659, 2.31, 0.273, 340, 275, X-RAY STRUCTURE OF CLK2-KD(136-496)/CX-4945 AT 1.95A 
849, 4fuyA, 0.8659, 2.24, 0.377, 329, 273, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
850, 3fz1A, 0.8659, 2.22, 0.967, 284, 274, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
851, 1j91A, 0.8659, 2.45, 0.300, 327, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
852, 5cspA, 0.8658, 2.28, 0.305, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
853, 4qp2B, 0.8658, 2.17, 0.368, 329, 272, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
854, 5nzzH, 0.8657, 2.19, 0.379, 335, 272, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
855, 5g6vB, 0.8657, 2.18, 0.524, 302, 273, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INHIBITOR
856, 4qp6A, 0.8657, 2.20, 0.363, 339, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
857, 4qp2A, 0.8657, 2.21, 0.363, 336, 273, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
858, 4md8E, 0.8657, 2.46, 0.296, 332, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
859, 4grbA, 0.8657, 2.26, 0.298, 327, 275, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
860, 5cu4A, 0.8656, 2.34, 0.301, 327, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
861, 4f7jA, 0.8656, 1.96, 0.381, 326, 270, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 3 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(2-HYDROXYETHYL) UREA)
862, 3vuiA, 0.8656, 2.19, 0.358, 355, 274, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
863, 1ds5B, 0.8656, 2.44, 0.300, 328, 277, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
864, 5oulA, 0.8655, 2.39, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
865, 5oniA, 0.8655, 2.37, 0.297, 334, 276, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
866, 3vuhA, 0.8655, 2.19, 0.358, 355, 274, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
867, 4h3pD, 0.8654, 2.26, 0.370, 338, 273, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
868, 3vugA, 0.8654, 2.19, 0.358, 356, 274, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
869, 3q9wA, 0.8654, 2.29, 0.305, 328, 275, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
870, 3c13A, 0.8654, 2.29, 0.305, 328, 275, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
871, 3axwA, 0.8654, 2.46, 0.300, 329, 277, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
872, 5unpB, 0.8653, 2.44, 0.276, 347, 275, STRUCTURE OF CDC2-LIKE KINASE 2 (CLK2) IN COMPLEX WITH COMPOUND T-025 [N2-METHYL-N4-(PYRIMIDIN-2-YLMETHYL)-5-(QUINOLIN-6-YL)-7H-PYRROLO[2; 3-D]PYRIMIDINE-2;4-DIAMINE] 
873, 5unpA, 0.8653, 2.44, 0.276, 347, 275, STRUCTURE OF CDC2-LIKE KINASE 2 (CLK2) IN COMPLEX WITH COMPOUND T-025 [N2-METHYL-N4-(PYRIMIDIN-2-YLMETHYL)-5-(QUINOLIN-6-YL)-7H-PYRROLO[2; 3-D]PYRIMIDINE-2;4-DIAMINE] 
874, 3unkA, 0.8653, 2.84, 0.972, 295, 283, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
875, 5xvuB, 0.8652, 2.26, 0.302, 321, 275, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
876, 4md9L, 0.8652, 2.48, 0.296, 328, 277, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
877, 2r3iA, 0.8652, 2.49, 0.953, 289, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
878, 1jsvA, 0.8652, 2.41, 0.960, 287, 274, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
879, 5ct0A, 0.8651, 2.25, 0.298, 326, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
880, 3q9yA, 0.8651, 2.34, 0.301, 327, 276, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
881, 4md9F, 0.8650, 2.32, 0.297, 327, 276, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
882, 3vudA, 0.8650, 2.19, 0.358, 355, 274, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
883, 3owlA, 0.8650, 2.46, 0.300, 330, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
884, 3mtlA, 0.8650, 1.88, 0.500, 294, 270, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INDIRUBIN E804
885, 2fysB, 0.8650, 2.38, 0.370, 338, 276, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
886, 1na7A, 0.8650, 2.32, 0.301, 326, 276, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
887, 5mmrA, 0.8649, 2.26, 0.298, 326, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
888, 4rllA, 0.8649, 2.35, 0.301, 329, 276, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
889, 4ib5C, 0.8649, 2.48, 0.300, 332, 277, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
890, 3bqcA, 0.8649, 2.30, 0.305, 328, 275, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
891, 6fykC, 0.8648, 2.45, 0.273, 349, 275, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
892, 5xvuC, 0.8648, 2.27, 0.302, 321, 275, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
893, 5motA, 0.8648, 2.30, 0.305, 328, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
894, 5mhqA, 0.8648, 2.41, 0.956, 291, 275, CCT068127 IN COMPLEX WITH CDK2
895, 5clpB, 0.8648, 2.33, 0.301, 327, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
896, 4xj0B, 0.8648, 2.27, 0.372, 338, 274, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
897, 4izaC, 0.8648, 2.08, 0.365, 335, 271, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
898, 1e1xA, 0.8648, 2.55, 0.953, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
899, 5oslA, 0.8647, 2.35, 0.301, 328, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 7
900, 3qzgA, 0.8647, 2.75, 0.936, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
901, 2no3B, 0.8647, 2.50, 0.356, 357, 278, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
902, 4md8H, 0.8645, 2.47, 0.296, 331, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
903, 4md7H, 0.8645, 2.41, 0.304, 330, 276, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
904, 2r64A, 0.8645, 2.10, 0.967, 279, 272, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
905, 2h96A, 0.8645, 2.53, 0.356, 358, 278, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
906, 1pxnA, 0.8645, 2.78, 0.972, 294, 282, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
907, 4fkgA, 0.8644, 2.20, 0.971, 286, 272, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
908, 3sqqA, 0.8644, 2.29, 0.982, 288, 275, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
909, 5mp8A, 0.8643, 2.21, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
910, 5g6vA, 0.8643, 2.27, 0.526, 308, 274, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INHIBITOR
911, 4md7G, 0.8643, 2.42, 0.304, 332, 276, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
912, 3vukA, 0.8643, 2.19, 0.358, 355, 274, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
913, 2vv9A, 0.8643, 2.12, 0.960, 279, 272, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
914, 5t1hA, 0.8642, 2.48, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2
915, 5oueA, 0.8642, 2.38, 0.301, 328, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
916, 3amyA, 0.8642, 2.16, 0.297, 318, 273, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
917, 5cx9A, 0.8641, 2.37, 0.301, 328, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
918, 4md7E, 0.8641, 2.46, 0.300, 332, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
919, 3r7iA, 0.8641, 2.39, 0.964, 282, 275, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
920, 1lr4A, 0.8641, 2.45, 0.300, 327, 277, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
921, 5modA, 0.8640, 2.28, 0.298, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
922, 4nh1B, 0.8640, 2.47, 0.300, 332, 277, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
923, 3u87A, 0.8640, 2.48, 0.300, 329, 277, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
924, 3owjA, 0.8640, 2.40, 0.301, 328, 276, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
925, 1ds5C, 0.8640, 2.46, 0.300, 328, 277, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
926, 5cvhA, 0.8639, 2.33, 0.298, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA
927, 5cu2A, 0.8639, 2.36, 0.301, 328, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
928, 4md8F, 0.8639, 2.48, 0.296, 332, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
929, 4fkwA, 0.8639, 2.09, 0.996, 280, 272, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
930, 2w06A, 0.8639, 2.30, 0.967, 282, 274, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
931, 1pxkA, 0.8639, 2.56, 0.953, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
932, 5otzA, 0.8638, 2.36, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
933, 5cu0A, 0.8638, 2.28, 0.298, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
934, 5ctpB, 0.8638, 2.38, 0.301, 327, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
935, 5cquA, 0.8638, 2.36, 0.301, 328, 276, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
936, 4nh1A, 0.8638, 2.47, 0.300, 330, 277, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
937, 2uznA, 0.8638, 2.22, 0.971, 279, 272, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
938, 5h8bA, 0.8637, 2.49, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
939, 2bhhA, 0.8637, 1.74, 0.974, 274, 267, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
940, 5m56B, 0.8636, 2.50, 0.303, 328, 277, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
941, 3wowA, 0.8636, 2.32, 0.297, 334, 276, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
942, 3r8vA, 0.8636, 2.83, 0.975, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
943, 3qqhA, 0.8636, 2.79, 0.975, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR L2-2
944, 6gmdB, 0.8635, 2.29, 0.298, 326, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
945, 3v3vA, 0.8635, 2.18, 0.363, 351, 273, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
946, 1lp4A, 0.8635, 2.45, 0.300, 327, 277, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
947, 5mmfA, 0.8634, 2.28, 0.298, 326, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
948, 4anmA, 0.8634, 2.46, 0.300, 328, 277, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
949, 1fvtA, 0.8634, 2.15, 0.967, 282, 273, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
950, 5os8A, 0.8633, 2.37, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
951, 5os7A, 0.8633, 2.29, 0.298, 326, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
952, 3le6A, 0.8633, 2.35, 0.949, 283, 272, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
953, 2qc6A, 0.8633, 2.46, 0.300, 326, 277, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
954, 2pvrA, 0.8633, 2.38, 0.301, 328, 276, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
955, 3pe2A, 0.8632, 2.38, 0.301, 327, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
956, 1dawA, 0.8632, 2.45, 0.300, 327, 277, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
957, 5oquA, 0.8631, 2.27, 0.299, 324, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
958, 5mo8A, 0.8631, 2.30, 0.298, 325, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
959, 3wilA, 0.8631, 2.36, 0.301, 331, 276, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
960, 5larA, 0.8629, 2.38, 0.367, 350, 278, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
961, 3w55A, 0.8629, 2.19, 0.368, 335, 272, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
962, 1dayA, 0.8629, 2.44, 0.300, 327, 277, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
963, 5x8iB, 0.8628, 2.32, 0.277, 327, 274, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
964, 5owlB, 0.8628, 2.49, 0.300, 332, 277, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
965, 5n9kA, 0.8628, 2.38, 0.301, 329, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
966, 5moeA, 0.8628, 2.26, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
967, 3rpsA, 0.8628, 2.28, 0.298, 334, 275, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
968, 3mb6A, 0.8628, 2.38, 0.305, 329, 275, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
969, 1ds5A, 0.8628, 2.47, 0.300, 328, 277, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
970, 5t31B, 0.8627, 2.23, 0.337, 333, 273, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
971, 4md9M, 0.8627, 2.39, 0.293, 331, 276, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
972, 4looA, 0.8627, 2.27, 0.376, 349, 274, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
973, 5x8iA, 0.8626, 2.32, 0.277, 328, 274, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
974, 5otlB, 0.8626, 2.31, 0.298, 326, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 29
975, 5mpjA, 0.8626, 2.35, 0.298, 326, 275, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
976, 5mohA, 0.8626, 2.25, 0.303, 326, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
977, 5mo7A, 0.8626, 2.32, 0.298, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
978, 4ux9B, 0.8626, 2.11, 0.362, 327, 271, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
979, 4qp3B, 0.8626, 2.22, 0.379, 331, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
980, 4md7F, 0.8626, 2.48, 0.300, 332, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
981, 3pzhA, 0.8626, 2.47, 0.300, 327, 277, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
982, 3owkA, 0.8626, 2.52, 0.300, 330, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
983, 5orkA, 0.8625, 2.27, 0.299, 324, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
984, 4dgoA, 0.8625, 2.47, 0.300, 325, 277, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
985, 3pvgA, 0.8625, 2.47, 0.300, 326, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
986, 4ubaB, 0.8624, 2.37, 0.297, 333, 276, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
987, 3ig7A, 0.8624, 2.07, 0.967, 278, 271, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
988, 1zoeA, 0.8624, 2.47, 0.300, 325, 277, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
989, 1lpuA, 0.8623, 2.47, 0.300, 327, 277, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
990, 1h00A, 0.8623, 2.16, 0.985, 278, 272, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
991, 5h8eA, 0.8622, 2.50, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
992, 3pwdA, 0.8622, 2.49, 0.300, 327, 277, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
993, 3pe1A, 0.8622, 2.39, 0.301, 327, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
994, 5ts8A, 0.8621, 2.37, 0.304, 332, 276, Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 56-DIBROMOBENZOTRIAZOLE
995, 5mo5A, 0.8621, 2.25, 0.299, 326, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
996, 5lxdB, 0.8621, 2.16, 0.304, 385, 273, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
997, 5lxdA, 0.8621, 2.16, 0.304, 385, 273, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
998, 4qp6B, 0.8621, 2.23, 0.379, 334, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
999, 4f6sA, 0.8621, 2.09, 0.380, 328, 271, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 7 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]UREA)
1000, 3oz6A, 0.8621, 2.53, 0.368, 343, 277, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
1001, 1ds5D, 0.8621, 2.48, 0.300, 328, 277, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1002, 1di8A, 0.8621, 2.22, 1.000, 283, 273, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
1003, 5oniB, 0.8620, 2.35, 0.297, 334, 276, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1004, 5n9nA, 0.8620, 2.40, 0.301, 329, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
1005, 5mowA, 0.8620, 2.28, 0.299, 328, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1006, 5mo7B, 0.8620, 2.27, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1007, 3kxnA, 0.8620, 2.46, 0.300, 327, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
1008, 3at2A, 0.8620, 2.37, 0.297, 334, 276, CRYSTAL STRUCTURE OF CK2ALPHA
1009, 1m2pA, 0.8620, 2.48, 0.300, 325, 277, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
1010, 4fbxA, 0.8619, 2.29, 0.302, 333, 275, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
1011, 1pxmA, 0.8619, 2.67, 0.946, 290, 278, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
1012, 5ot5A, 0.8618, 2.33, 0.298, 326, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
1013, 5movA, 0.8618, 2.29, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
1014, 2r3mA, 0.8618, 2.03, 0.970, 278, 270, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1015, 3o17A, 0.8617, 2.41, 0.361, 357, 277, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
1016, 3e3bX, 0.8617, 2.37, 0.301, 334, 276, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
1017, 2r3qA, 0.8617, 2.40, 0.963, 286, 273, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1018, 1om1A, 0.8617, 2.49, 0.300, 325, 277, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
1019, 5yf9X, 0.8616, 2.31, 0.302, 319, 275, CRYSTAL STRUCTURE OF CK2A2 FORM-2 
1020, 5owhA, 0.8616, 2.28, 0.298, 334, 275, HIGH SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3-AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1021, 1h08A, 0.8616, 2.43, 0.993, 283, 274, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1022, 5orjA, 0.8615, 2.30, 0.299, 325, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
1023, 3q9xB, 0.8615, 2.45, 0.304, 330, 276, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1024, 3ngaA, 0.8615, 2.51, 0.300, 331, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1025, 1w0xC, 0.8615, 2.26, 0.982, 280, 273, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
1026, 5orhB, 0.8614, 2.27, 0.299, 325, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
1027, 3nr9C, 0.8614, 2.47, 0.273, 347, 275, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
1028, 2w05A, 0.8614, 2.06, 0.970, 276, 269, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
1029, 2oxxA, 0.8614, 2.49, 0.300, 325, 277, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1030, 6fyvA, 0.8613, 2.32, 0.266, 329, 274, X-RAY STRUCTURE OF CLK4-KD(146-480)/CX-4945 AT 2.46A 
1031, 5y9mA, 0.8613, 2.30, 0.298, 320, 275, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
1032, 5cu3A, 0.8613, 2.29, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1033, 4fkjA, 0.8613, 2.13, 0.974, 278, 271, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
1034, 3u87B, 0.8613, 2.52, 0.300, 329, 277, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1035, 3r9oA, 0.8613, 2.34, 0.989, 282, 274, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
1036, 1m2rA, 0.8613, 2.53, 0.300, 327, 277, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
1037, 1ke6A, 0.8613, 2.25, 0.967, 280, 273, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
1038, 5y9mX, 0.8612, 2.31, 0.298, 319, 275, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
1039, 5cqwA, 0.8612, 2.52, 0.300, 331, 277, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1040, 4fkqA, 0.8612, 2.29, 0.964, 283, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1041, 3r0tA, 0.8612, 2.41, 0.301, 327, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
1042, 3pxyA, 0.8612, 2.82, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR JWS648
1043, 5n9lA, 0.8611, 2.40, 0.301, 329, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
1044, 5cu0B, 0.8611, 2.33, 0.295, 325, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1045, 4qp8A, 0.8611, 2.13, 0.373, 335, 271, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
1046, 4dgnA, 0.8611, 2.49, 0.300, 325, 277, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
1047, 5othA, 0.8610, 2.34, 0.298, 326, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
1048, 5k5nB, 0.8610, 2.14, 0.333, 334, 270, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
1049, 5h8gA, 0.8610, 2.21, 0.300, 324, 273, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
1050, 3r7uA, 0.8610, 2.32, 0.967, 282, 274, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
1051, 5mmrB, 0.8609, 2.27, 0.296, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
1052, 5cvfA, 0.8609, 2.30, 0.303, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
1053, 5cu6A, 0.8609, 2.45, 0.301, 327, 276, CRYSTAL STRUCTURE OF CK2ALPHA
1054, 2pvnA, 0.8609, 2.48, 0.296, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1055, 2oxdA, 0.8609, 2.47, 0.300, 325, 277, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
1056, 5oumA, 0.8608, 2.33, 0.298, 326, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
1057, 5otoA, 0.8608, 2.33, 0.298, 327, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
1058, 4ux9A, 0.8608, 2.24, 0.360, 343, 272, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1059, 4jqeA, 0.8608, 2.55, 0.278, 369, 277, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
1060, 4ek6A, 0.8608, 2.09, 0.978, 278, 270, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
1061, 3kxgA, 0.8608, 2.49, 0.300, 326, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
1062, 1zohA, 0.8608, 2.50, 0.300, 326, 277, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
1063, 4qpaA, 0.8607, 2.28, 0.375, 331, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
1064, 3qa0B, 0.8607, 2.47, 0.304, 330, 276, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1065, 3q04A, 0.8607, 2.39, 0.301, 328, 276, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
1066, 1jamA, 0.8607, 2.50, 0.300, 327, 277, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
1067, 5yf9B, 0.8606, 2.34, 0.298, 319, 275, CRYSTAL STRUCTURE OF CK2A2 FORM-2 
1068, 5otyA, 0.8606, 2.43, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
1069, 5myvB, 0.8606, 2.11, 0.293, 349, 273, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1070, 4dgmA, 0.8606, 2.50, 0.300, 326, 277, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
1071, 3ngaB, 0.8606, 2.53, 0.300, 331, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1072, 2vtaA, 0.8606, 2.14, 0.974, 278, 271, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1073, 1ke7A, 0.8606, 2.25, 0.967, 281, 273, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
1074, 1jowB, 0.8606, 1.78, 0.494, 277, 267, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
1075, 6gmdA, 0.8605, 2.28, 0.296, 325, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
1076, 5os7B, 0.8605, 2.28, 0.296, 325, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
1077, 5lxcB, 0.8604, 2.23, 0.300, 385, 273, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 5372 (COMPOUND 1)
1078, 3u9cA, 0.8604, 2.48, 0.304, 331, 276, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1079, 3nr9A, 0.8604, 2.47, 0.273, 341, 275, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
1080, 6eiiB, 0.8603, 2.29, 0.299, 326, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
1081, 4ub7A, 0.8603, 2.35, 0.293, 334, 276, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
1082, 4md9H, 0.8603, 2.40, 0.297, 328, 276, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1083, 5ot6A, 0.8602, 2.36, 0.298, 327, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
1084, 4ek8A, 0.8602, 2.27, 0.971, 280, 272, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1085, 5otrA, 0.8601, 2.43, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 14
1086, 5mo6A, 0.8601, 2.30, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1087, 5lxcA, 0.8601, 2.09, 0.303, 383, 271, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 5372 (COMPOUND 1)
1088, 3rawA, 0.8601, 2.53, 0.279, 351, 276, CRYSTAL STRUCTURE OF HUMAN CDC-LIKE KINASE 3 ISOFORM IN COMPLEX WITH LEUCETTINE L41
1089, 3fl5A, 0.8601, 2.50, 0.300, 324, 277, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
1090, 2vtiA, 0.8601, 2.31, 0.982, 280, 273, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1091, 5oquB, 0.8600, 2.31, 0.299, 324, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
1092, 5m4uA, 0.8600, 2.44, 0.304, 332, 276, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1093, 5otdA, 0.8599, 2.34, 0.298, 327, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
1094, 3qa0A, 0.8599, 2.55, 0.300, 330, 277, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1095, 3py0A, 0.8599, 2.80, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR SU9516
1096, 5m56A, 0.8598, 2.55, 0.303, 331, 277, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1097, 5m4iA, 0.8598, 2.36, 0.293, 331, 276, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1098, 5aniA, 0.8598, 2.25, 0.963, 280, 272, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1099, 2vthA, 0.8598, 2.15, 0.974, 278, 271, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
1100, 4ux9C, 0.8597, 2.08, 0.363, 333, 270, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1101, 3u4uA, 0.8597, 2.34, 0.298, 327, 275, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
1102, 3kxmA, 0.8597, 2.51, 0.300, 326, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
1103, 6ehkA, 0.8596, 2.47, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712 AND COMPOUND 37
1104, 5omyA, 0.8596, 2.43, 0.301, 332, 276, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1105, 5mo6B, 0.8596, 2.30, 0.296, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1106, 5kwhA, 0.8596, 2.55, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2
1107, 5buiA, 0.8596, 2.24, 0.368, 338, 272, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
1108, 4fkrA, 0.8596, 2.34, 0.978, 282, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1109, 3od6X, 0.8596, 2.36, 0.373, 344, 276, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
1110, 6eiiA, 0.8595, 2.32, 0.299, 326, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
1111, 5modB, 0.8595, 2.31, 0.296, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1112, 2f9gA, 0.8595, 2.15, 0.385, 332, 270, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
1113, 1ke8A, 0.8595, 2.23, 0.982, 282, 273, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
1114, 5owlA, 0.8594, 2.55, 0.300, 331, 277, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1115, 2pvmA, 0.8594, 2.52, 0.296, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1116, 1zogA, 0.8594, 2.50, 0.300, 325, 277, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
1117, 1dm2A, 0.8594, 1.82, 0.966, 274, 267, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
1118, 5oueB, 0.8593, 2.31, 0.296, 326, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
1119, 5mo5B, 0.8593, 2.31, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1120, 5mmfB, 0.8592, 2.31, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
1121, 5jq8A, 0.8592, 2.18, 0.967, 278, 270, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
1122, 5cu3B, 0.8592, 2.33, 0.299, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1123, 3ezvA, 0.8592, 2.09, 0.963, 277, 270, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
1124, 2j9mA, 0.8592, 1.86, 0.966, 275, 268, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
1125, 5mo8B, 0.8591, 2.33, 0.299, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1126, 3rawB, 0.8591, 2.50, 0.275, 349, 276, CRYSTAL STRUCTURE OF HUMAN CDC-LIKE KINASE 3 ISOFORM IN COMPLEX WITH LEUCETTINE L41
1127, 5oumB, 0.8589, 2.31, 0.296, 326, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
1128, 3u9cB, 0.8589, 2.48, 0.304, 331, 276, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1129, 3be9A, 0.8589, 2.52, 0.296, 327, 277, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
1130, 2h96B, 0.8589, 2.40, 0.355, 357, 276, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
1131, 5myvC, 0.8588, 2.14, 0.289, 348, 273, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1132, 5ct0B, 0.8588, 2.31, 0.296, 326, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
1133, 5orhA, 0.8587, 2.32, 0.296, 324, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
1134, 5cshA, 0.8587, 2.32, 0.299, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
1135, 5cqwB, 0.8587, 2.55, 0.300, 331, 277, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1136, 4yc6E, 0.8587, 2.61, 0.663, 285, 273, CDK1/CKS1
1137, 4fktA, 0.8587, 2.28, 0.971, 278, 272, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1138, 4qp4B, 0.8586, 2.23, 0.371, 335, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
1139, 2pvhA, 0.8586, 2.53, 0.296, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1140, 3mb7A, 0.8585, 2.47, 0.301, 330, 276, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
1141, 5ku8A, 0.8584, 2.52, 0.301, 328, 276, CRYSTAL STRUCTURE OF CK2
1142, 5h8bB, 0.8584, 2.56, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1143, 4qp7B, 0.8584, 2.17, 0.373, 335, 271, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
1144, 4kwpA, 0.8584, 2.43, 0.301, 329, 276, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
1145, 3rzbA, 0.8584, 2.31, 0.982, 282, 273, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
1146, 1vyzA, 0.8584, 2.16, 0.978, 279, 270, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
1147, 5cx9B, 0.8583, 2.32, 0.296, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
1148, 5cvgA, 0.8583, 2.24, 0.305, 326, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
1149, 5ctpA, 0.8583, 2.32, 0.296, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1150, 2g01A, 0.8583, 2.40, 0.355, 355, 276, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
1151, 1g5sA, 0.8583, 1.85, 0.985, 275, 267, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
1152, 5ouuB, 0.8582, 2.35, 0.296, 325, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
1153, 5h8eB, 0.8582, 2.57, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1154, 4fksA, 0.8582, 2.10, 0.974, 275, 270, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1155, 3q9xA, 0.8582, 2.57, 0.300, 330, 277, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1156, 2pvjA, 0.8582, 2.54, 0.296, 326, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1157, 4ubaA, 0.8581, 2.42, 0.297, 333, 276, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1158, 4gubA, 0.8581, 2.46, 0.301, 329, 276, CASEIN KINASE II BOUND TO INHIBITOR
1159, 3rpsB, 0.8581, 2.44, 0.297, 334, 276, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
1160, 3i60A, 0.8581, 1.98, 0.376, 335, 266, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
1161, 3e3pA, 0.8581, 2.39, 0.337, 337, 276, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1162, 4ib5B, 0.8580, 2.58, 0.292, 329, 277, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1163, 4fkpA, 0.8580, 2.28, 0.971, 279, 272, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1164, 5t1hB, 0.8579, 2.57, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2
1165, 5mpjB, 0.8579, 2.35, 0.299, 324, 274, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
1166, 4rlkA, 0.8579, 2.54, 0.300, 327, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
1167, 4bzdA, 0.8579, 2.04, 0.963, 277, 270, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
1168, 5orjB, 0.8578, 2.35, 0.296, 324, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
1169, 2pvkA, 0.8578, 2.54, 0.296, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1170, 5cvhB, 0.8577, 2.35, 0.299, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA
1171, 3warA, 0.8577, 2.53, 0.296, 334, 277, CRYSTAL STRUCTURE OF HUMAN CK2A
1172, 1ke5A, 0.8577, 2.30, 0.982, 281, 273, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
1173, 5j1wB, 0.8576, 2.45, 0.277, 337, 274, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1174, 5cu2B, 0.8576, 2.33, 0.296, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
1175, 2wu7A, 0.8576, 2.51, 0.272, 348, 276, CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH V25
1176, 5t31A, 0.8575, 2.19, 0.332, 334, 271, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
1177, 5mowB, 0.8575, 2.35, 0.299, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1178, 4xoyA, 0.8575, 2.45, 0.364, 326, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1179, 1ke9A, 0.8575, 2.18, 0.971, 281, 272, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
1180, 5mxxA, 0.8574, 2.18, 0.293, 361, 273, CRYSTAL STRUCTURE OF HUMAN SR PROTEIN KINASE 1 (SRPK1) IN COMPLEX WITH COMPOUND 1
1181, 3q9zB, 0.8574, 2.51, 0.304, 332, 276, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1182, 3nr9B, 0.8573, 2.48, 0.274, 347, 274, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
1183, 3at3A, 0.8573, 2.47, 0.301, 332, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
1184, 2vtqA, 0.8573, 1.96, 0.974, 274, 267, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1185, 4ptgB, 0.8572, 2.04, 0.332, 332, 268, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
1186, 3e3pB, 0.8571, 2.51, 0.329, 337, 277, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1187, 2r3kA, 0.8571, 2.12, 0.970, 277, 270, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1188, 5k4iA, 0.8570, 2.02, 0.373, 336, 268, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
1189, 2wu6A, 0.8570, 2.47, 0.279, 350, 276, CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH DKI
1190, 6fyoA, 0.8569, 2.50, 0.281, 331, 274, X-RAY STRUCTURE OF CLK1-KD(148-484)/CPD-2 AT 2.32A 
1191, 5f95B, 0.8569, 2.10, 0.331, 338, 269, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
1192, 4yc6G, 0.8569, 2.60, 0.615, 285, 273, CDK1/CKS1
1193, 2pvlA, 0.8569, 2.56, 0.296, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1194, 1m2qA, 0.8569, 2.60, 0.300, 327, 277, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
1195, 5kwhB, 0.8567, 2.59, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2
1196, 3w8lB, 0.8567, 2.48, 0.301, 326, 276, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
1197, 5orkB, 0.8565, 2.32, 0.297, 323, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
1198, 5moeB, 0.8564, 2.30, 0.293, 323, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1199, 4mwhA, 0.8564, 2.60, 0.278, 371, 277, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1200, 4ewqA, 0.8564, 2.45, 0.366, 346, 273, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
1201, 4fi1A, 0.8563, 2.61, 0.278, 371, 277, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1202, 3unjA, 0.8563, 2.79, 0.926, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
1203, 3qtrA, 0.8563, 2.33, 0.960, 282, 273, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
1204, 2btsA, 0.8563, 1.88, 0.970, 274, 267, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
1205, 2qkrA, 0.8562, 1.95, 0.568, 273, 266, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
1206, 5otiA, 0.8561, 2.49, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 27
1207, 1f0qA, 0.8561, 2.59, 0.296, 329, 277, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
1208, 3o2mB, 0.8560, 2.34, 0.361, 358, 274, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
1209, 2x7gA, 0.8559, 2.21, 0.289, 344, 273, STRUCTURE OF HUMAN SERINE-ARGININE-RICH PROTEIN-SPECIFIC KINASE 2 (SRPK2) BOUND TO PURVALANOL B
1210, 4lfiA, 0.8558, 2.61, 0.278, 370, 277, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1211, 3o2mA, 0.8558, 2.44, 0.359, 358, 276, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
1212, 3at4A, 0.8558, 2.49, 0.301, 331, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
1213, 1z57A, 0.8558, 2.51, 0.281, 333, 274, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH 10Z-HYMENIALDISINE
1214, 5ku8B, 0.8557, 2.60, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2
1215, 4yc6A, 0.8557, 2.63, 0.663, 285, 273, CDK1/CKS1
1216, 5anoA, 0.8556, 2.17, 0.978, 277, 270, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1217, 4yc6C, 0.8556, 2.62, 0.663, 285, 273, CDK1/CKS1
1218, 6ft8A, 0.8555, 2.52, 0.281, 338, 274, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 8G 
1219, 5j1vB, 0.8555, 2.49, 0.281, 337, 274, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1220, 2vtnA, 0.8555, 1.93, 0.970, 274, 267, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1221, 6ft9B, 0.8554, 2.49, 0.277, 337, 274, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1222, 5ot6B, 0.8554, 2.36, 0.299, 326, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
1223, 4aguC, 0.8554, 2.03, 0.390, 278, 267, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1224, 4n4sB, 0.8553, 2.14, 0.368, 337, 272, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
1225, 4lfiB, 0.8553, 2.60, 0.278, 371, 277, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1226, 5othB, 0.8552, 2.40, 0.299, 324, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
1227, 5cs6A, 0.8552, 2.55, 0.298, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1228, 2vu3A, 0.8552, 1.94, 0.993, 285, 267, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1229, 2gmxB, 0.8552, 2.40, 0.355, 357, 276, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
1230, 4acmA, 0.8551, 2.04, 0.970, 277, 269, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
1231, 2pk9C, 0.8550, 1.59, 0.575, 266, 261, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
1232, 1giiA, 0.8550, 2.28, 0.971, 279, 272, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1233, 2r3jA, 0.8549, 2.16, 0.970, 278, 270, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1234, 6g33C, 0.8547, 2.48, 0.285, 336, 274, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1235, 5oyfA, 0.8547, 2.51, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 31
1236, 5j1wA, 0.8547, 2.47, 0.281, 338, 274, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1237, 3o0gB, 0.8547, 1.58, 0.590, 264, 261, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
1238, 3begA, 0.8547, 2.21, 0.289, 348, 273, CRYSTAL STRUCTURE OF SR PROTEIN KINASE 1 COMPLEXED TO ITS SUBSTRATE ASF/SF2
1239, 2vtjA, 0.8547, 2.05, 0.978, 276, 269, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1240, 2b55A, 0.8547, 2.04, 0.996, 276, 268, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
1241, 5ot5B, 0.8546, 2.39, 0.299, 325, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
1242, 5oszA, 0.8546, 2.52, 0.297, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 23
1243, 5ci6B, 0.8546, 2.14, 0.353, 350, 269, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
1244, 3o17B, 0.8545, 2.53, 0.361, 357, 277, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
1245, 3l1sB, 0.8544, 1.98, 0.331, 330, 266, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1246, 1jwhB, 0.8544, 2.46, 0.297, 335, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
1247, 3l1sA, 0.8543, 1.99, 0.331, 336, 266, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1248, 5otdB, 0.8542, 2.38, 0.299, 324, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
1249, 5mp8B, 0.8542, 2.28, 0.298, 323, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1250, 6ehuA, 0.8541, 2.52, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1251, 5ouuA, 0.8541, 2.31, 0.298, 324, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
1252, 4fv6A, 0.8541, 1.92, 0.374, 332, 265, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
1253, 4ib5A, 0.8538, 2.57, 0.304, 331, 276, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1254, 4aa4A, 0.8538, 2.43, 0.381, 347, 273, P38ALPHA MAP KINASE BOUND TO CMPD 22
1255, 3nieA, 0.8538, 2.68, 0.395, 369, 276, CRYSTAL STRUCTURE OF PF11_0147
1256, 1gihA, 0.8535, 2.10, 0.989, 276, 269, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1257, 5otqA, 0.8534, 2.54, 0.297, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 33
1258, 3sw4A, 0.8534, 2.22, 0.970, 279, 271, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1259, 6ft9A, 0.8532, 2.59, 0.280, 336, 275, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1260, 5cshB, 0.8530, 2.29, 0.303, 323, 271, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
1261, 2r7iA, 0.8530, 2.53, 0.297, 322, 276, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1262, 5otoB, 0.8528, 2.39, 0.299, 324, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
1263, 3q9zA, 0.8528, 2.62, 0.300, 332, 277, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1264, 1wbpA, 0.8528, 2.27, 0.289, 350, 273, SRPK1 BOUND TO 9MER DOCKING MOTIF PEPTIDE
1265, 4fv8A, 0.8527, 1.95, 0.377, 333, 265, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
1266, 4wuaA, 0.8525, 2.27, 0.289, 344, 273, CRYSTAL STRUCTURE OF HUMAN SRPK1 COMPLEXED TO AN INHIBITOR SRPIN340
1267, 3rpyA, 0.8525, 2.08, 0.959, 277, 269, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
1268, 2vttA, 0.8525, 1.85, 0.989, 272, 265, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1269, 3rmfA, 0.8524, 2.14, 0.970, 278, 270, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
1270, 2r7iC, 0.8524, 2.48, 0.298, 321, 275, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1271, 2r3nA, 0.8524, 2.05, 0.963, 275, 268, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1272, 3qtsA, 0.8523, 2.35, 0.967, 282, 273, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
1273, 4nj3A, 0.8522, 2.05, 0.993, 277, 268, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
1274, 3nwwA, 0.8522, 2.17, 0.375, 339, 269, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
1275, 5j1vA, 0.8521, 2.61, 0.280, 338, 275, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1276, 5ci6A, 0.8521, 2.20, 0.357, 335, 269, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
1277, 2btrA, 0.8521, 2.01, 0.996, 275, 267, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
1278, 5xv7A, 0.8517, 2.29, 0.289, 350, 273, SRPK1 IN COMPLEX WITH ALECTINIB
1279, 2duvA, 0.8517, 1.81, 0.989, 272, 265, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
1280, 5andA, 0.8515, 2.11, 0.963, 273, 268, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1281, 3rahA, 0.8514, 2.35, 0.967, 282, 273, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
1282, 5my8A, 0.8513, 2.29, 0.289, 355, 273, CRYSTAL STRUCTURE OF SRPK1 IN COMPLEX WITH SPHINX31
1283, 1wakA, 0.8513, 2.30, 0.293, 353, 273, X-RAY STRUCTURE OF SRPK1
1284, 1r78A, 0.8513, 1.92, 0.989, 273, 266, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
1285, 1urwA, 0.8512, 2.07, 0.981, 274, 268, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
1286, 4f9aC, 0.8511, 2.48, 0.259, 317, 274, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
1287, 3r8mA, 0.8511, 2.59, 0.971, 286, 276, CDK2 IN COMPLEX WITH INHIBITOR L3-3
1288, 3bx5A, 0.8511, 2.20, 0.379, 338, 269, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
1289, 1v0bA, 0.8511, 2.90, 0.607, 286, 275, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
1290, 4i5hA, 0.8510, 2.12, 0.376, 335, 266, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
1291, 3rp9A, 0.8509, 2.74, 0.397, 350, 277, CRYSTAL STRUCTURE OF THE APO MAPK FROM TOXOPLASMA GONDII 25.M01780 OR TGME49_007820
1292, 3mvlA, 0.8509, 2.10, 0.381, 339, 268, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
1293, 1v0pA, 0.8509, 2.54, 0.616, 277, 271, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
1294, 3s1hA, 0.8508, 2.09, 0.963, 277, 269, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
1295, 3ezrA, 0.8508, 1.90, 0.970, 273, 266, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
1296, 2r3lA, 0.8507, 2.03, 0.970, 275, 268, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1297, 5ztnA, 0.8506, 2.19, 0.310, 395, 271, THE CRYSTAL STRUCTURE OF HUMAN DYRK2 IN COMPLEX WITH CURCUMIN 
1298, 5clpA, 0.8506, 2.35, 0.303, 322, 271, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
1299, 1p2aA, 0.8506, 1.94, 0.970, 271, 267, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
1300, 4aacA, 0.8505, 2.37, 0.384, 350, 271, P38ALPHA MAP KINASE BOUND TO CMPD 29
1301, 3rprA, 0.8505, 2.37, 0.967, 282, 273, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
1302, 5ztnB, 0.8503, 2.18, 0.306, 395, 271, THE CRYSTAL STRUCTURE OF HUMAN DYRK2 IN COMPLEX WITH CURCUMIN 
1303, 5fp6A, 0.8503, 2.33, 0.971, 278, 272, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
1304, 3dt1A, 0.8503, 2.54, 0.377, 356, 273, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
1305, 4fv4A, 0.8502, 2.10, 0.377, 329, 265, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
1306, 2bheA, 0.8502, 1.96, 0.966, 274, 267, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
1307, 2r7iB, 0.8501, 2.48, 0.299, 322, 274, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1308, 6g33B, 0.8499, 2.62, 0.276, 337, 275, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1309, 5ankA, 0.8499, 2.03, 0.974, 273, 266, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1310, 4f9aA, 0.8499, 2.46, 0.259, 315, 274, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
1311, 3rakA, 0.8498, 2.12, 0.974, 277, 269, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
1312, 4jr7A, 0.8495, 2.62, 0.280, 367, 275, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1313, 3r9nA, 0.8495, 2.49, 0.967, 282, 274, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
1314, 1oitA, 0.8495, 1.95, 0.974, 273, 265, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1315, 4azfA, 0.8494, 2.19, 0.303, 404, 271, HUMAN DYRK2 IN COMPLEX WITH LEUCETTINE L41
1316, 3sw7A, 0.8494, 2.16, 0.959, 278, 270, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1317, 3lltA, 0.8494, 2.34, 0.256, 341, 270, CRYSTAL STRUCTURE OF PF14_0431 KINASE DOMAIN.
1318, 3hl7A, 0.8494, 2.09, 0.378, 336, 267, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
1319, 3ralA, 0.8492, 2.16, 0.974, 277, 269, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
1320, 3kvwA, 0.8492, 2.20, 0.310, 403, 271, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2) IN COMPLEX WITH AN INDIRUBIN LIGAND
1321, 2r7iD, 0.8492, 2.49, 0.299, 322, 274, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1322, 2g01B, 0.8490, 2.60, 0.357, 356, 277, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
1323, 6ehuB, 0.8489, 2.60, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1324, 3k2lA, 0.8489, 2.27, 0.306, 402, 271, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2)
1325, 5lw1H, 0.8488, 2.30, 0.343, 355, 271, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1326, 4dglD, 0.8488, 2.68, 0.300, 328, 277, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1327, 5y86A, 0.8487, 2.36, 0.301, 391, 272, CRYSTAL STRUCTURE OF KINASE 
1328, 5lw1B, 0.8487, 2.31, 0.343, 355, 271, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1329, 5ax3A, 0.8487, 2.10, 0.376, 329, 266, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
1330, 3nieB, 0.8487, 2.69, 0.396, 367, 275, CRYSTAL STRUCTURE OF PF11_0147
1331, 3n9xB, 0.8487, 2.79, 0.404, 374, 277, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
1332, 4fkoA, 0.8484, 2.26, 0.956, 291, 271, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1333, 4f9bA, 0.8483, 2.48, 0.259, 318, 274, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
1334, 1v1kA, 0.8483, 2.12, 0.981, 277, 269, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1335, 5xyyA, 0.8482, 2.61, 0.381, 350, 273, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
1336, 4iq6A, 0.8482, 2.02, 0.336, 324, 265, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
1337, 4aguA, 0.8482, 2.13, 0.391, 277, 266, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1338, 2i6lA, 0.8482, 2.43, 0.328, 292, 271, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1339, 2vagA, 0.8480, 2.53, 0.279, 330, 272, CRYSTAL STRUCTURE OF DI-PHOSPHORYLATED HUMAN CLK1 IN COMPLEX WITH A NOVEL SUBSTITUTED INDOLE INHIBITOR
1340, 4f9bC, 0.8479, 2.51, 0.263, 316, 274, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
1341, 4bghA, 0.8479, 2.11, 0.989, 275, 268, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
1342, 3e7oA, 0.8477, 2.47, 0.341, 342, 273, CRYSTAL STRUCTURE OF JNK2
1343, 6ft9C, 0.8476, 2.60, 0.277, 337, 274, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1344, 2ozaB, 0.8476, 2.42, 0.373, 340, 271, STRUCTURE OF P38ALPHA COMPLEX
1345, 3ds6D, 0.8469, 2.55, 0.374, 349, 273, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1346, 5m44A, 0.8467, 2.56, 0.296, 329, 274, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1347, 6gihA, 0.8466, 2.49, 0.304, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
1348, 5lw1E, 0.8466, 2.33, 0.343, 355, 271, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1349, 1pyeA, 0.8465, 1.86, 0.977, 266, 262, CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
1350, 6eq9A, 0.8464, 2.38, 0.358, 350, 271, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AMP-PCP 
1351, 3hllA, 0.8464, 2.10, 0.368, 337, 266, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
1352, 3gfeA, 0.8464, 2.59, 0.377, 352, 273, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
1353, 4f99A, 0.8462, 2.52, 0.259, 312, 274, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
1354, 1oukA, 0.8462, 2.67, 0.374, 348, 273, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
1355, 4f9wA, 0.8461, 2.08, 0.376, 336, 266, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1356, 4eh2A, 0.8461, 2.13, 0.368, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
1357, 3i5zA, 0.8461, 2.01, 0.376, 331, 263, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
1358, 1ob3A, 0.8461, 2.57, 0.616, 277, 271, STRUCTURE OF P. FALCIPARUM PFPK5
1359, 3gc9B, 0.8460, 2.31, 0.364, 339, 269, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1360, 5otlA, 0.8459, 2.35, 0.300, 320, 270, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 29
1361, 1ouyA, 0.8459, 2.65, 0.381, 350, 273, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
1362, 4fa2A, 0.8458, 2.15, 0.376, 339, 266, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
1363, 4aa5A, 0.8458, 2.53, 0.391, 340, 271, P38ALPHA MAP KINASE BOUND TO CMPD 33
1364, 2fvdA, 0.8457, 1.90, 0.981, 284, 265, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
1365, 5myvA, 0.8456, 2.37, 0.289, 352, 273, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1366, 4zthA, 0.8456, 2.16, 0.376, 339, 266, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
1367, 3v6rA, 0.8456, 2.50, 0.352, 349, 273, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1368, 3kf7A, 0.8456, 2.09, 0.368, 337, 266, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND
1369, 3gc8B, 0.8456, 2.39, 0.368, 346, 269, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1370, 5bveA, 0.8455, 1.89, 0.374, 330, 262, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1371, 2zazA, 0.8455, 2.64, 0.377, 345, 273, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
1372, 1wbwA, 0.8453, 2.66, 0.381, 351, 273, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1373, 4f9yA, 0.8452, 2.13, 0.378, 339, 267, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1374, 4fv9A, 0.8451, 1.97, 0.376, 331, 263, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
1375, 2rg6A, 0.8451, 2.27, 0.383, 335, 269, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J
1376, 4kinB, 0.8450, 2.47, 0.376, 341, 271, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1377, 4fv5A, 0.8450, 2.01, 0.373, 330, 263, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
1378, 3s3iA, 0.8449, 2.60, 0.377, 349, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1379, 3rocA, 0.8449, 2.12, 0.372, 337, 266, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
1380, 3v6sA, 0.8447, 2.50, 0.355, 349, 273, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1381, 3itzA, 0.8447, 2.60, 0.374, 357, 273, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
1382, 3d7zA, 0.8447, 2.61, 0.379, 348, 272, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
1383, 2zb1A, 0.8447, 2.49, 0.369, 345, 271, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
1384, 3mvlB, 0.8446, 2.20, 0.381, 339, 268, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
1385, 3mptA, 0.8446, 2.59, 0.364, 347, 272, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
1386, 5bvdA, 0.8445, 1.91, 0.374, 330, 262, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1387, 4lopD, 0.8444, 2.50, 0.368, 351, 272, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1388, 1m7qA, 0.8444, 2.66, 0.374, 348, 273, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1389, 5myvD, 0.8443, 2.41, 0.286, 351, 273, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1390, 2zb0A, 0.8443, 2.61, 0.381, 349, 273, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
1391, 3flsA, 0.8442, 2.58, 0.369, 343, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
1392, 2lgcA, 0.8442, 2.32, 0.381, 359, 268, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
1393, 3ocgA, 0.8441, 2.14, 0.372, 336, 266, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
1394, 4kipA, 0.8440, 2.30, 0.369, 337, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
1395, 2balA, 0.8440, 2.22, 0.371, 337, 267, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
1396, 1ywrA, 0.8440, 2.23, 0.381, 338, 268, CRYSTAL STRUCTURE ANALYSIS OF INACTIVE P38 KINASE DOMAIN IN COMPLEX WITH A MONOCYCLIC PYRAZOLONE INHIBITOR
1397, 3ds6A, 0.8439, 2.53, 0.359, 343, 273, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1398, 4d1xA, 0.8438, 2.08, 0.974, 274, 266, CDK2 IN COMPLEX WITH LUCIFERIN
1399, 3obgA, 0.8438, 2.09, 0.376, 332, 266, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1400, 3n9xA, 0.8438, 2.70, 0.411, 374, 275, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
1401, 4aguB, 0.8437, 2.17, 0.392, 276, 265, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1402, 1di9A, 0.8437, 2.61, 0.381, 348, 273, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
1403, 5bujA, 0.8436, 1.97, 0.373, 331, 263, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
1404, 3rinA, 0.8436, 2.62, 0.381, 349, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1405, 3e92A, 0.8436, 2.53, 0.376, 348, 271, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1406, 3bv2A, 0.8436, 2.21, 0.376, 337, 266, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
1407, 1r3cA, 0.8434, 2.63, 0.374, 349, 273, THE STRUCTURE OF P38ALPHA C162S MUTANT
1408, 6emhB, 0.8433, 2.34, 0.354, 344, 271, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1409, 5awmA, 0.8433, 2.35, 0.343, 345, 271, THE CRYSTAL STRUCTURE OF JNK FROM DROSOPHILA MELANOGASTER REVEALS AN EVOLUTIONARILY CONSERVED TOPOLOGY WITH THAT OF MAMMALIAN JNK PROTEINS.
1410, 4eh6A, 0.8433, 2.14, 0.370, 335, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F5 AND RL87
1411, 1i09A, 0.8433, 2.08, 0.336, 338, 265, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
1412, 4kinC, 0.8432, 2.37, 0.378, 338, 270, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1413, 4lopB, 0.8431, 2.35, 0.356, 350, 270, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1414, 3gc8A, 0.8431, 2.43, 0.362, 347, 268, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1415, 3mvmB, 0.8430, 2.29, 0.384, 332, 268, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
1416, 2ghmA, 0.8430, 2.27, 0.378, 336, 267, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
1417, 1w84A, 0.8428, 2.63, 0.374, 351, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1418, 3mpaA, 0.8427, 2.01, 0.367, 331, 264, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1419, 3fmhA, 0.8427, 2.57, 0.369, 347, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1420, 3u8wA, 0.8426, 2.62, 0.374, 349, 273, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
1421, 3mh0A, 0.8425, 2.19, 0.375, 332, 267, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1422, 2rg5A, 0.8424, 2.30, 0.384, 333, 268, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B
1423, 6emhA, 0.8423, 2.36, 0.354, 344, 271, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1424, 4lopA, 0.8423, 2.52, 0.368, 351, 272, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1425, 3flyA, 0.8423, 2.56, 0.369, 347, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1426, 4eh7A, 0.8422, 2.22, 0.372, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
1427, 4eh3A, 0.8422, 2.22, 0.368, 339, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F2 AND RL87
1428, 1ua2C, 0.8422, 2.01, 0.445, 286, 263, CRYSTAL STRUCTURE OF HUMAN CDK7
1429, 5n66A, 0.8421, 2.14, 0.366, 332, 265, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9J
1430, 3zyaA, 0.8421, 2.27, 0.367, 346, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
1431, 4o2zA, 0.8420, 2.35, 0.337, 363, 267, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
1432, 3gc9A, 0.8420, 2.21, 0.361, 335, 266, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1433, 3flqA, 0.8420, 2.71, 0.381, 345, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
1434, 3fklA, 0.8420, 2.33, 0.381, 344, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
1435, 1ua2B, 0.8420, 2.04, 0.449, 286, 263, CRYSTAL STRUCTURE OF HUMAN CDK7
1436, 4eh8A, 0.8419, 2.16, 0.370, 336, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F7 AND RL87
1437, 3oz6B, 0.8418, 2.84, 0.378, 341, 275, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
1438, 2gtnA, 0.8418, 2.15, 0.374, 337, 265, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
1439, 4loqB, 0.8417, 2.34, 0.356, 351, 270, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1440, 6g33A, 0.8416, 2.59, 0.279, 335, 272, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1441, 4loqD, 0.8414, 2.35, 0.356, 351, 270, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1442, 4ehvA, 0.8414, 2.29, 0.376, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
1443, 1gijA, 0.8414, 2.07, 0.970, 273, 266, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1444, 5bueA, 0.8412, 2.01, 0.373, 329, 263, ERK2 COMPLEXED WITH N-BENZYLPYRIDONE TETRAHYDROAZAINDAZOLE
1445, 4kipB, 0.8412, 2.30, 0.386, 338, 267, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
1446, 1oveA, 0.8412, 2.65, 0.374, 349, 273, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
1447, 3ds6C, 0.8411, 2.52, 0.377, 349, 273, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1448, 1zzlA, 0.8411, 2.70, 0.374, 351, 273, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
1449, 1bl6A, 0.8411, 2.76, 0.369, 351, 274, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
1450, 1zyjA, 0.8409, 2.19, 0.372, 331, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A
1451, 1w82A, 0.8409, 2.64, 0.376, 351, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1452, 1ua2D, 0.8408, 2.04, 0.445, 286, 263, CRYSTAL STRUCTURE OF HUMAN CDK7
1453, 5d1jA, 0.8407, 1.73, 0.992, 265, 260, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(11-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]- 4-PIPERIDINECARBOXAMIDE (BMS-387032)
1454, 3flzA, 0.8407, 2.58, 0.369, 347, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
1455, 4loqA, 0.8406, 2.34, 0.356, 352, 270, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1456, 3mvmA, 0.8406, 2.39, 0.383, 335, 269, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
1457, 3hv3A, 0.8406, 2.22, 0.365, 335, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL49
1458, 3bv3A, 0.8406, 2.25, 0.372, 338, 266, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
1459, 1yw2A, 0.8406, 2.12, 0.374, 341, 265, MUTATED MUS MUSCULUS P38 KINASE (MP38)
1460, 3hp5A, 0.8405, 2.16, 0.370, 330, 265, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIMIDOPYRIDAZINONE COMPOUND
1461, 3mh2A, 0.8404, 2.02, 0.367, 330, 264, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1462, 3hp2A, 0.8403, 2.18, 0.374, 341, 265, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
1463, 3fmkA, 0.8403, 2.59, 0.373, 346, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1464, 3flwA, 0.8402, 2.55, 0.370, 345, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
1465, 3queA, 0.8399, 2.18, 0.374, 343, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH SKEPINONE-L
1466, 4kiqC, 0.8398, 2.33, 0.369, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1467, 1w7hA, 0.8398, 2.65, 0.370, 351, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1468, 3gcqA, 0.8397, 2.24, 0.365, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL45
1469, 1oiqA, 0.8397, 1.85, 0.973, 264, 261, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1470, 3nnuA, 0.8396, 2.66, 0.376, 348, 271, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
1471, 3fknA, 0.8396, 2.56, 0.363, 346, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
1472, 3nnwA, 0.8395, 2.66, 0.376, 349, 271, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
1473, 3nnvA, 0.8395, 2.62, 0.376, 348, 271, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
1474, 4kiqB, 0.8394, 2.34, 0.369, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1475, 3fmmA, 0.8394, 2.61, 0.362, 346, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
1476, 1wboA, 0.8392, 2.71, 0.377, 351, 273, FRAGMENT BASED P38 INHIBITORS
1477, 3gp0A, 0.8390, 2.13, 0.360, 333, 264, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
1478, 5etcA, 0.8389, 2.71, 0.370, 355, 273, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
1479, 3iphA, 0.8389, 2.50, 0.368, 345, 269, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
1480, 3ds6B, 0.8388, 2.55, 0.374, 343, 273, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1481, 1a9uA, 0.8388, 2.63, 0.355, 351, 273, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
1482, 3fmjA, 0.8387, 2.69, 0.371, 344, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
1483, 3o8uA, 0.8386, 2.20, 0.374, 332, 265, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1484, 4ynoA, 0.8385, 2.54, 0.385, 342, 270, CRYSTAL STRUCTURE OF MAPK13 AT INACTIVE FORM
1485, 3fmnA, 0.8385, 2.58, 0.367, 341, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO2530
1486, 3lhjA, 0.8384, 2.21, 0.376, 341, 266, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
1487, 1bmkA, 0.8384, 2.79, 0.369, 351, 274, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
1488, 5cs6B, 0.8383, 2.24, 0.308, 316, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1489, 1yqjA, 0.8383, 2.67, 0.355, 356, 273, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
1490, 4kiqD, 0.8382, 2.36, 0.369, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1491, 3mw1A, 0.8381, 2.66, 0.375, 342, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1492, 3gc0A, 0.8381, 2.40, 0.539, 278, 267, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
1493, 2ghlA, 0.8381, 2.22, 0.374, 334, 265, MUTANT MUS MUSCULUS P38 KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-874743
1494, 1bl7A, 0.8380, 2.70, 0.359, 351, 273, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
1495, 4kinD, 0.8379, 2.48, 0.374, 339, 270, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1496, 4r3cA, 0.8378, 2.05, 0.373, 335, 263, CRYSTAL STRUCTURE OF P38 ALPHA MAP KINASE IN COMPLEX WITH A NOVEL ISOFORM SELECTIVE DRUG CANDIDATE
1497, 3uvqA, 0.8378, 2.08, 0.373, 333, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOSUBERONE DERIVATIVE
1498, 2yixA, 0.8378, 2.65, 0.379, 351, 272, TRIAZOLOPYRIDINE INHIBITORS OF P38
1499, 4ic8B, 0.8375, 2.55, 0.365, 336, 271, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1500, 3p7bA, 0.8375, 2.27, 0.376, 332, 266, P38 INHIBITOR-BOUND
1501, 4lopC, 0.8374, 2.20, 0.370, 341, 265, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1502, 3o8pA, 0.8372, 2.20, 0.362, 336, 265, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1503, 3fmlA, 0.8372, 2.64, 0.362, 342, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6224
1504, 5j1wC, 0.8370, 2.39, 0.287, 316, 268, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1505, 3o8tA, 0.8370, 2.29, 0.372, 332, 266, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG-MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1506, 4w4yA, 0.8369, 2.66, 0.352, 350, 273, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1507, 3hrbA, 0.8369, 2.75, 0.381, 344, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1508, 2puuA, 0.8369, 2.19, 0.370, 330, 265, CRYSTAL STRUCTURE OF P38 COMPLEX WITH 1-(5-TERT-BUTYL-2-P- TOLYL-2H-PYRAZOL-3-YL)-3-[4-(6-MORPHOLIN-4-YLMETHYL- PYRIDIN-3-YL)NAPHTHALEN-1-YL]UREA
1509, 1wbvA, 0.8369, 2.67, 0.373, 351, 271, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1510, 5bvfA, 0.8368, 1.86, 0.371, 327, 259, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1511, 3gc7A, 0.8367, 2.70, 0.370, 349, 273, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1512, 2i0hA, 0.8367, 2.71, 0.370, 349, 273, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH AN ARYLPYRIDAZINONE
1513, 1wbtA, 0.8367, 2.69, 0.376, 351, 271, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1514, 3p5kA, 0.8366, 2.28, 0.376, 332, 266, P38 INHIBITOR-BOUND
1515, 3newA, 0.8366, 2.20, 0.370, 334, 265, P38-ALPHA COMPLEXED WITH COMPOUND 10
1516, 3mh3A, 0.8366, 2.20, 0.362, 334, 265, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1517, 1zz2A, 0.8366, 2.37, 0.381, 337, 268, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
1518, 4eh4A, 0.8365, 2.23, 0.375, 337, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F3 AND RL87
1519, 3qudA, 0.8365, 2.30, 0.372, 345, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO-BENZOPHENONE
1520, 4kinA, 0.8362, 2.52, 0.379, 338, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1521, 3p79A, 0.8362, 2.28, 0.376, 332, 266, P38 INHIBITOR-BOUND
1522, 3p78A, 0.8362, 2.28, 0.376, 332, 266, P38 INHIBITOR-BOUND
1523, 1p38A, 0.8362, 2.73, 0.359, 351, 273, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
1524, 1ua2A, 0.8360, 2.11, 0.445, 286, 263, CRYSTAL STRUCTURE OF HUMAN CDK7
1525, 5angA, 0.8359, 1.96, 0.962, 268, 262, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1526, 4y5hA, 0.8359, 2.59, 0.358, 349, 271, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1527, 4y46A, 0.8359, 2.58, 0.358, 340, 271, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1528, 1wbsA, 0.8357, 2.72, 0.376, 351, 271, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1529, 4w4xA, 0.8356, 2.66, 0.352, 342, 273, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1530, 4w4vA, 0.8356, 2.73, 0.358, 342, 274, JNK2/3 IN COMPLEX WITH 3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1531, 4kiqA, 0.8356, 2.37, 0.373, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1532, 3oc1A, 0.8355, 2.21, 0.370, 330, 265, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1533, 3mh1A, 0.8355, 2.22, 0.366, 337, 265, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1534, 2gfsA, 0.8354, 2.63, 0.359, 344, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3201195
1535, 3p7cA, 0.8353, 2.22, 0.377, 332, 265, P38 INHIBITOR-BOUND
1536, 3fkoA, 0.8351, 2.59, 0.372, 343, 269, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
1537, 4qtdA, 0.8350, 2.54, 0.348, 355, 270, STRUCTURE OF HUMAN JNK1 IN COMPLEX WITH SCH772984 AND THE AMPPNP- HYDROLYSED TRIPHOSPHATE REVEALING THE SECOND TYPE-I BINDING MODE
1538, 3e93A, 0.8350, 2.68, 0.378, 346, 270, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1539, 1w83A, 0.8350, 2.75, 0.376, 351, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1540, 5mz3A, 0.8349, 2.74, 0.376, 350, 271, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
1541, 3kq7A, 0.8349, 2.68, 0.376, 348, 271, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
1542, 1r39A, 0.8349, 2.63, 0.358, 345, 271, THE STRUCTURE OF P38ALPHA
1543, 4yr8A, 0.8347, 2.26, 0.351, 320, 265, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1544, 3hv4A, 0.8346, 2.43, 0.378, 339, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
1545, 3hv6A, 0.8345, 2.20, 0.375, 331, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH RL39
1546, 3fsfA, 0.8345, 2.71, 0.365, 340, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 3-(26- DICHLORO-PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]- 1-METHYL-34-DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
1547, 4kkeA, 0.8344, 2.61, 0.358, 354, 271, THE CRYSTAL STRUCTURE OF AMP-BOUND JNK3
1548, 4l8mA, 0.8343, 2.26, 0.375, 339, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOXEPINONE
1549, 3uvpA, 0.8342, 2.35, 0.367, 334, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZAMIDE SUBSTITUTED BENZOSUBERONE
1550, 3objA, 0.8342, 2.36, 0.375, 332, 267, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1551, 5o8uA, 0.8341, 2.17, 0.364, 331, 264, COVALENT INHIBITOR 4B BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S252C
1552, 5ekoA, 0.8341, 2.51, 0.375, 341, 269, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1553, 4ux9D, 0.8341, 2.77, 0.350, 344, 274, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1554, 4awiA, 0.8339, 2.49, 0.351, 352, 268, HUMAN JNK1ALPHA KINASE WITH 4-PHENYL-7-AZAINDOLE IKK2 INHIBITOR.
1555, 4dljA, 0.8338, 2.16, 0.365, 336, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL163
1556, 3fskA, 0.8337, 2.56, 0.362, 342, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6257
1557, 4kkgA, 0.8336, 2.57, 0.359, 353, 270, CRYSTAL STRUCTURE OF APO AND AMP-BOUND JNK3
1558, 3gcuA, 0.8336, 2.45, 0.378, 339, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
1559, 3tg1A, 0.8333, 2.16, 0.367, 334, 264, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH A MAPK DOCKING PARTNER
1560, 1wbnA, 0.8331, 2.72, 0.376, 351, 271, FRAGMENT BASED P38 INHIBITORS
1561, 4kkhA, 0.8330, 2.64, 0.358, 351, 271, THE CRYSTAL STRUCTURE OF INHIBITOR-BOUND JNK3
1562, 4ditA, 0.8330, 2.08, 0.337, 328, 261, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
1563, 4w4wA, 0.8329, 2.64, 0.358, 349, 271, JNK2/3 IN COMPLEX WITH N-(2-METHYLPYRIDIN-4-YL)-3-{4- [(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL-1-YL}BENZAMIDE
1564, 4dliA, 0.8329, 2.26, 0.371, 334, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH RL87
1565, 2onlB, 0.8329, 2.47, 0.377, 339, 268, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1566, 3hvcA, 0.8327, 1.99, 0.381, 327, 260, CRYSTAL STRUCTURE OF HUMAN P38ALPHA MAP KINASE
1567, 3hv5A, 0.8324, 2.47, 0.378, 339, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
1568, 3pg1A, 0.8322, 2.11, 0.333, 341, 264, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR (1.95 ANGS RESOLUTION)
1569, 3hegA, 0.8322, 2.31, 0.368, 333, 266, P38 IN COMPLEX WITH SORAFENIB
1570, 3gbzA, 0.8321, 2.36, 0.545, 274, 266, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
1571, 3c5uA, 0.8319, 2.26, 0.368, 338, 266, P38 ALPHA MAP KINASE COMPLEXED WITH A BENZOTHIAZOLE BASED INHIBITOR
1572, 1lewA, 0.8319, 2.44, 0.381, 341, 268, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
1573, 4tyhB, 0.8318, 2.33, 0.377, 335, 265, TERNARY COMPLEX OF P38 AND MK2 WITH A P38 INHIBITOR
1574, 4eh9A, 0.8317, 2.28, 0.376, 334, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F11 AND RL87
1575, 1wfcA, 0.8317, 2.67, 0.357, 340, 269, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
1576, 4eymA, 0.8316, 2.48, 0.381, 340, 268, MAPK13 COMPLEX WITH INHIBITOR
1577, 6f5eB, 0.8315, 2.27, 0.362, 346, 265, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1578, 5lenB, 0.8315, 2.27, 0.362, 346, 265, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX WITH JNK1A1 AND JIP1 PEPTIDE
1579, 4yr8E, 0.8314, 2.36, 0.350, 317, 266, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1580, 5etiA, 0.8313, 2.76, 0.368, 355, 272, STRUCTURE OF DEAD KINASE MAPK14
1581, 2onlA, 0.8312, 2.40, 0.378, 338, 267, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1582, 5fp5A, 0.8311, 1.89, 0.985, 264, 260, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 4-FLUOROBENZOIC ACID (AT222) IN AN ALTERNATE BINDING SITE.
1583, 2okrA, 0.8310, 2.49, 0.377, 339, 268, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1584, 1lezA, 0.8310, 2.49, 0.383, 343, 269, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
1585, 3cgoA, 0.8308, 2.54, 0.362, 332, 268, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1586, 5mtxA, 0.8307, 2.24, 0.366, 331, 265, DIBENZOOXEPINONE INHIBITOR 12B IN COMPLEX WITH P38 MAPK
1587, 3flnC, 0.8307, 2.58, 0.371, 343, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
1588, 6emhC, 0.8306, 2.39, 0.358, 334, 268, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1589, 4eyjA, 0.8306, 2.35, 0.383, 338, 266, MAPK13 COMPLEX WITH INHIBITOR
1590, 2gtmA, 0.8306, 2.15, 0.378, 341, 262, MUTATED MOUSE P38 MAP KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-892579
1591, 5o90A, 0.8305, 2.23, 0.382, 330, 262, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
1592, 4f9cA, 0.8305, 2.69, 0.262, 306, 271, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND XL413
1593, 4ka3A, 0.8303, 2.40, 0.367, 340, 267, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
1594, 3lfbA, 0.8301, 2.35, 0.376, 333, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL98
1595, 3l8xA, 0.8299, 2.17, 0.379, 326, 261, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-PYRIMIDINE BASED INHIBITOR
1596, 3cgfA, 0.8299, 2.53, 0.362, 346, 268, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1597, 5n68A, 0.8298, 2.10, 0.372, 328, 261, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9M
1598, 3v6rB, 0.8298, 2.46, 0.354, 346, 268, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1599, 2wajA, 0.8298, 2.53, 0.361, 348, 269, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-34- DIHYDROISOQUINOLINE INHIBITOR
1600, 1kv1A, 0.8297, 2.20, 0.378, 331, 262, P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1
1601, 3nnxA, 0.8295, 2.14, 0.387, 336, 261, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
1602, 3mgyA, 0.8293, 2.26, 0.375, 329, 264, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1603, 2p33A, 0.8293, 2.55, 0.362, 332, 268, SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1604, 3ctqA, 0.8292, 2.39, 0.376, 336, 266, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
1605, 3pzeA, 0.8291, 2.44, 0.350, 347, 266, JNK1 IN COMPLEX WITH INHIBITOR
1606, 2y8oA, 0.8291, 2.39, 0.378, 339, 267, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A MAPK DOCKING PEPTIDE
1607, 2zdtA, 0.8290, 2.58, 0.362, 342, 268, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1608, 2qd9A, 0.8289, 2.22, 0.373, 330, 263, P38 ALPHA MAP KINASE INHIBITOR BASED ON HETEROBICYCLIC SCAFFOLDS
1609, 1jnkA, 0.8288, 2.56, 0.362, 346, 268, THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
1610, 3k3iA, 0.8286, 2.21, 0.378, 332, 262, P38ALPHA BOUND TO NOVEL DGF-OUT COMPOUND PF-00215955
1611, 4h3bA, 0.8285, 2.27, 0.374, 351, 265, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1612, 4h3bC, 0.8284, 2.27, 0.374, 351, 265, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1613, 3ptgA, 0.8284, 2.29, 0.374, 340, 265, DESIGN AND SYNTHESIS OF A NOVEL ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR
1614, 3p7aA, 0.8283, 2.40, 0.376, 332, 266, P38 INHIBITOR-BOUND
1615, 3hecA, 0.8283, 2.35, 0.370, 329, 265, P38 IN COMPLEX WITH IMATINIB
1616, 5mtyA, 0.8282, 2.26, 0.367, 328, 264, DIBENZOSUBERONE INHIBITOR 8E IN COMPLEX WITH P38 MAPK
1617, 5xyxA, 0.8281, 2.56, 0.372, 337, 266, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
1618, 3lffA, 0.8281, 2.35, 0.370, 335, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL166
1619, 5uojA, 0.8280, 2.45, 0.360, 343, 267, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTROMS RESOLUTION
1620, 4h36A, 0.8280, 2.27, 0.374, 353, 265, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH ATF2 PEPTIDE
1621, 3npcA, 0.8280, 2.29, 0.360, 357, 264, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1622, 3gi3A, 0.8279, 2.38, 0.370, 330, 265, CRYSTAL STRUCTURE OF A N-PHENYL-N -NAPHTHYLUREA ANALOG IN COMPLEX WITH P38 MAP KINASE
1623, 4u79A, 0.8278, 2.46, 0.360, 337, 267, CRYSTAL STRUCTURE OF HUMAN JNK3 IN COMPLEX WITH A BENZENESULFONAMIDE INHIBITOR.
1624, 1pmuA, 0.8278, 2.51, 0.357, 342, 269, THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR
1625, 3hv7A, 0.8277, 2.31, 0.380, 330, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL38
1626, 3fc1X, 0.8277, 2.24, 0.369, 330, 263, CRYSTAL STRUCTURE OF P38 KINASE BOUND TO PYRIMIDO-PYRIDAZINONE INHIBITOR
1627, 5j1vC, 0.8273, 2.48, 0.293, 314, 266, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1628, 3d83A, 0.8272, 2.72, 0.379, 347, 269, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
1629, 4e73A, 0.8271, 2.21, 0.346, 318, 263, CRYSTAL STRUCTURE OF JNK1BETA-JIP IN COMPLEX WITH AN AZAQUINOLONE INHBITOR
1630, 1oz1A, 0.8270, 2.75, 0.383, 344, 269, P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
1631, 3g90X, 0.8268, 2.58, 0.362, 345, 268, JNK-3 BOUND TO (Z)-5-FLUORO-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL) METHYL)-3-(HYDROXYIMINO)INDOLIN-2-ONE
1632, 5eknA, 0.8267, 2.31, 0.375, 336, 264, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1633, 4loqC, 0.8267, 2.21, 0.370, 337, 262, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1634, 3npcB, 0.8267, 2.20, 0.363, 356, 262, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1635, 2okrD, 0.8266, 2.42, 0.376, 339, 266, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1636, 5etaB, 0.8262, 2.17, 0.374, 335, 262, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
1637, 4g1wA, 0.8262, 2.20, 0.350, 322, 263, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 7-FLUORO-3- [4-(2-HYDROXY-ETHANESULFONYL)-BENZYL]-4-OXO-1-PHENYL-14-DIHYDRO- QUINOLINE-2-CARBOXYLIC ACID METHYL ESTER
1638, 1ukiA, 0.8262, 2.28, 0.362, 328, 265, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1639, 4x21A, 0.8261, 2.35, 0.364, 336, 264, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1640, 3g9nA, 0.8261, 2.64, 0.361, 346, 269, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-PHENYLINDOLIN-2-ONE
1641, 3hv4B, 0.8260, 2.46, 0.380, 338, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
1642, 1pmnA, 0.8260, 2.73, 0.361, 344, 269, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE- PYRIMIDINE INHIBITOR
1643, 6cnhA, 0.8258, 2.09, 0.296, 321, 260, HUMAN PRPF4B IN COMPLEX WITH REBASTINIB
1644, 4ic8A, 0.8258, 2.62, 0.384, 325, 268, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1645, 2o0uA, 0.8257, 2.54, 0.363, 331, 267, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1- PIPERIDINYL)PROPANOYL]-4567-TETRAHYDROTHIENO[23-C]PYRIDIN-2-YL}- 1-NAPHTHALENECARBOXAMIDE
1646, 3iw6A, 0.8256, 2.39, 0.376, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZYLPIPERAZIN- PYRROL
1647, 3ha8A, 0.8256, 2.27, 0.364, 342, 264, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/COMPOUND 14B
1648, 5etaA, 0.8254, 2.28, 0.369, 336, 263, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
1649, 4d1zA, 0.8254, 1.82, 0.984, 258, 257, CDK2 IN COMPLEX WITH A LUCIFERIN DERIVATE
1650, 5n67A, 0.8251, 2.16, 0.377, 327, 260, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9L
1651, 3hv5B, 0.8251, 2.48, 0.380, 339, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
1652, 5tbeA, 0.8249, 2.18, 0.378, 332, 262, HUMAN P38ALPHA MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 2
1653, 3p4kA, 0.8249, 2.39, 0.380, 338, 266, THE THIRD CONFORMATION OF P38A MAP KINASE OBSERVED IN PHOSPHORYLATED P38A AND IN SOLUTION
1654, 2xs0A, 0.8249, 2.23, 0.346, 346, 263, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1655, 3gcuB, 0.8248, 2.48, 0.380, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
1656, 4bgqA, 0.8246, 2.23, 0.378, 276, 262, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
1657, 4a9yA, 0.8246, 2.32, 0.380, 334, 263, P38ALPHA MAP KINASE BOUND TO CMPD 8
1658, 2bakA, 0.8246, 2.32, 0.380, 334, 263, P38ALPHA MAP KINASE BOUND TO MPAQ
1659, 3s4qA, 0.8243, 2.30, 0.375, 326, 261, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-TRIAZINE BASED INHIBITOR
1660, 4whzA, 0.8240, 2.65, 0.362, 342, 268, DESIGN AND SYNTHESIS OF HIGHLY POTENT AND ISOFORM SELECTIVE JNK3 INHIBITORS: SAR STUDIES ON AMINOPYRAZOLE DERIVATIVES
1661, 3iw7A, 0.8239, 2.42, 0.376, 335, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH AN IMIDAZO-PYRIDINE
1662, 3da6A, 0.8238, 2.48, 0.363, 328, 267, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-METHYL- 4-(3-(2-(METHYLAMINO)PYRIMIDIN-4-YL)PYRIDIN-2-YLOXY) NAPHTHALEN-1-YL)-1H-BENZO[D]IMIDAZOL-2-AMINE
1663, 3gcvA, 0.8237, 2.31, 0.376, 338, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL62
1664, 3e7oB, 0.8237, 2.16, 0.349, 326, 261, CRYSTAL STRUCTURE OF JNK2
1665, 5tcoA, 0.8236, 2.23, 0.366, 327, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 1
1666, 3ttiA, 0.8236, 2.65, 0.362, 341, 268, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-930 AN ORALLY ACTIVE ANTI-FIBROTIC JNK INHIBITOR
1667, 1jvpP, 0.8234, 2.30, 0.954, 268, 261, CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) IN COMPLEX WITH PKF049-365
1668, 3lfeA, 0.8232, 2.42, 0.376, 334, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL116
1669, 3eljA, 0.8232, 2.59, 0.352, 347, 267, JNK1 COMPLEXED WITH A BIS-ANILINO-PYRROLOPYRIMIDINE INHIBITOR.
1670, 5n65A, 0.8230, 2.31, 0.367, 333, 264, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9H
1671, 6ekdA, 0.8226, 2.18, 0.368, 325, 261, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1672, 5etfA, 0.8226, 2.45, 0.376, 338, 266, STRUCTURE OF DEAD KINASE MAPK14 WITH BOUND THE KIM DOMAIN OF MKK6
1673, 3lfcA, 0.8226, 2.44, 0.372, 334, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL99
1674, 3k3jA, 0.8225, 2.24, 0.368, 329, 261, P38ALPHA BOUND TO NOVEL DFG-OUT COMPOUND PF-00416121
1675, 1ianA, 0.8225, 2.12, 0.378, 328, 259, HUMAN P38 MAP KINASE INHIBITOR COMPLEX
1676, 5o8vA, 0.8223, 2.17, 0.375, 328, 259, COVALENT INHIBITOR 4A BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S251C
1677, 3fl4A, 0.8222, 2.56, 0.375, 339, 264, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO5634
1678, 2o2uA, 0.8220, 2.34, 0.364, 319, 264, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-CYANO-4567- TETRAHYDRO-1-BENZOTHIEN-2-YL)-2-FLUOROBENZAMIDE
1679, 4hysA, 0.8219, 2.12, 0.352, 321, 261, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 4-(4- INDAZOL-1-YL-PYRIMIDIN-2-YLAMINO)-CYCLOHEXAN
1680, 3v6sB, 0.8219, 2.27, 0.361, 340, 263, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1681, 3pg3A, 0.8219, 2.45, 0.368, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL182
1682, 3g9lX, 0.8215, 2.53, 0.361, 336, 266, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-STYRYLINDOLIN-2-ONE
1683, 6emhD, 0.8212, 2.39, 0.357, 331, 266, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1684, 4eh5A, 0.8211, 2.16, 0.375, 329, 259, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F4 AND RL87
1685, 3rtpA, 0.8209, 2.27, 0.363, 331, 262, DESIGN AND SYNTHESIS OF BRAIN PENETRANT SELECTIVE JNK INHIBITORS WITH IMPROVED PHARMACOKINETIC PROPERTIES FOR THE PREVENTION OF NEURODEGENERATION
1686, 3fi4A, 0.8208, 2.60, 0.383, 339, 264, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO4499
1687, 5n64A, 0.8207, 2.22, 0.369, 329, 260, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9G
1688, 3ttjA, 0.8207, 2.50, 0.361, 333, 266, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-359 A JNK INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
1689, 5n63A, 0.8204, 2.24, 0.378, 325, 259, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9C
1690, 3zduA, 0.8204, 2.79, 0.344, 297, 270, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
1691, 2ewaA, 0.8202, 2.14, 0.382, 330, 259, DUAL BINDING MODE OF PYRIDINYLIMIDAZOLE TO MAP KINASE P38
1692, 4x21B, 0.8200, 2.33, 0.364, 336, 264, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1693, 3oy1A, 0.8200, 2.48, 0.364, 329, 264, HIGHLY SELECTIVE C-JUN N-TERMINAL KINASE (JNK) 2 AND 3 INHIBITORS WITH IN VITRO CNS-LIKE PHARMACOKINETIC PROPERTIES
1694, 3oefX, 0.8200, 2.45, 0.375, 334, 264, CRYSTAL STRUCTURE OF Y323F INACTIVE MUTANT OF P38ALPHA MAP KINASE
1695, 6eq9B, 0.8199, 2.29, 0.365, 332, 263, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AMP-PCP 
1696, 4l7fA, 0.8199, 2.50, 0.356, 354, 264, CO-CRYSTAL STRUCTURE OF JNK1 AND AX13587
1697, 1pmvA, 0.8198, 2.66, 0.362, 347, 268, THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR
1698, 2zduA, 0.8197, 2.43, 0.364, 330, 264, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1699, 3vulA, 0.8195, 2.35, 0.357, 344, 263, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
1700, 3iw5A, 0.8194, 2.48, 0.365, 336, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH AN INDOLE DERIVATIVE
1701, 4izyA, 0.8190, 2.16, 0.352, 322, 261, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 4-{4-[4-(4- METHANESULFONYL-PIPERIDIN-1-YL)-INDOL-1-YL]-PYRIMIDIN-2-YLAMINO}- CYCLOHEXAN
1702, 2ok1A, 0.8189, 2.54, 0.362, 333, 265, CRYSTAL STRUCTURE OF JNK3 BOUND TO N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1703, 4z9lA, 0.8185, 2.47, 0.362, 333, 265, THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR
1704, 4hyuA, 0.8185, 2.18, 0.352, 322, 261, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 4-{4-[4-(3- METHANESULFONYL-PROPOXY)-INDAZOL-1-YL]-PYRIMIDIN-2-YLAMINO}- CYCLOHEXAN
1705, 3hubA, 0.8185, 2.37, 0.366, 335, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH SCIOS-469
1706, 1v0pB, 0.8185, 1.92, 0.589, 258, 253, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
1707, 3lfaA, 0.8182, 2.41, 0.360, 333, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH DASATINIB
1708, 1blxA, 0.8182, 2.91, 0.468, 305, 269, P19INK4D/CDK6 COMPLEX
1709, 4tthB, 0.8181, 1.64, 0.524, 256, 252, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
1710, 4h39A, 0.8180, 2.30, 0.365, 340, 263, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH JIP1 PEPTIDE
1711, 4pniA, 0.8179, 2.18, 0.255, 492, 259, BOVINE G PROTEIN-COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH GSK2163632A
1712, 3uvrA, 0.8178, 2.55, 0.377, 331, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH KM064
1713, 6anlA, 0.8176, 2.53, 0.368, 338, 266, STRUCTURE-BASED DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZO[12-B]PYRIDAZINE-BASED P38 MAP KINASE INHIBITORS
1714, 3zsiA, 0.8176, 2.22, 0.378, 326, 259, X-RAY STRUCTURE OF P38ALPHA BOUND TO VX-745
1715, 1g3nE, 0.8175, 2.67, 0.479, 293, 265, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
1716, 1v0bB, 0.8170, 2.13, 0.584, 261, 257, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
1717, 4geoA, 0.8167, 2.35, 0.372, 326, 261, P38A MAP KINASE DEF-POCKET PENTA MUTANT (M194A L195A H228A I229A Y258A)
1718, 1g3nA, 0.8167, 2.68, 0.479, 293, 265, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
1719, 3zshA, 0.8165, 2.42, 0.367, 331, 264, X-RAY STRUCTURE OF P38ALPHA BOUND TO SCIO-469
1720, 4e6cA, 0.8164, 2.32, 0.374, 330, 262, P38A-PERIFOSINE COMPLEX
1721, 3hucA, 0.8164, 2.56, 0.365, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL40
1722, 3uibA, 0.8163, 2.24, 0.342, 309, 257, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR IN COMPLEX WITH SB203580
1723, 3vumA, 0.8160, 2.29, 0.360, 347, 261, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M7 IN MAP KINASE JNK1
1724, 4fr4A, 0.8158, 2.15, 0.236, 350, 258, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1725, 3fv8A, 0.8157, 2.25, 0.369, 331, 260, JNK3 BOUND TO PIPERAZINE AMIDE INHIBITOR SR2774.
1726, 2yiwA, 0.8157, 2.10, 0.379, 325, 256, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE
1727, 1kv2A, 0.8157, 1.99, 0.380, 325, 255, HUMAN P38 MAP KINASE IN COMPLEX WITH BIRB 796
1728, 3l8sA, 0.8156, 2.50, 0.366, 334, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH CP-547632
1729, 1ukhA, 0.8155, 2.12, 0.351, 321, 259, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1730, 2excX, 0.8153, 2.43, 0.364, 335, 264, INHIBITOR COMPLEX OF JNK3
1731, 4fr4F, 0.8150, 2.16, 0.240, 346, 258, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1732, 3fi2A, 0.8150, 2.53, 0.367, 326, 264, CRYSTAL STRUCTURE OF JNK3 WITH AMINO-PYRAZOLE INHIBITOR SR- 3451
1733, 4fr4C, 0.8149, 2.12, 0.233, 344, 258, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1734, 4fr4D, 0.8147, 2.17, 0.240, 346, 258, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1735, 3oxiA, 0.8145, 2.36, 0.366, 322, 262, DESIGN AND SYNTHESIS OF DISUBSTITUTED THIOPHENE AND THIAZOLE BASED INHIBITORS OF JNK FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
1736, 3iw8A, 0.8142, 2.57, 0.368, 334, 266, STRUCTURE OF INACTIVE HUMAN P38 MAP KINASE IN COMPLEX WITH A THIAZOLE-UREA
1737, 3gcsA, 0.8138, 2.46, 0.377, 331, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH SORAFENIB
1738, 4fr4E, 0.8136, 2.14, 0.236, 342, 258, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1739, 1ob3B, 0.8136, 2.08, 0.571, 258, 254, STRUCTURE OF P. FALCIPARUM PFPK5
1740, 4fr4B, 0.8134, 2.14, 0.233, 350, 258, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1741, 3kvxA, 0.8134, 2.31, 0.369, 327, 260, JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR SR-3562
1742, 2hy81, 0.8134, 2.15, 0.301, 293, 256, PAK1 COMPLEX WITH ST2001
1743, 2yisA, 0.8131, 2.12, 0.379, 325, 256, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE.
1744, 2b1pA, 0.8129, 2.51, 0.357, 331, 263, INHIBITOR COMPLEX OF JNK3
1745, 4yr8C, 0.8128, 2.33, 0.352, 318, 261, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1746, 4wboA, 0.8128, 2.33, 0.255, 497, 259, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1747, 4e5bA, 0.8126, 2.24, 0.375, 324, 259, STRUCTURE OF P38A MAP KINASE WITHOUT BOG
1748, 4aa0A, 0.8121, 2.31, 0.378, 328, 259, P38ALPHA MAP KINASE BOUND TO CMPD 2
1749, 3lfdA, 0.8121, 2.62, 0.368, 331, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL113
1750, 4e6aA, 0.8120, 2.38, 0.372, 324, 261, P38A-PIA23 COMPLEX
1751, 4wboD, 0.8119, 2.37, 0.255, 491, 259, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1752, 2baqA, 0.8118, 2.26, 0.393, 329, 257, P38ALPHA BOUND TO RO3201195
1753, 3coiA, 0.8117, 2.88, 0.385, 344, 270, CRYSTAL STRUCTURE OF P38DELTA KINASE
1754, 4wboC, 0.8115, 2.35, 0.252, 481, 258, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1755, 4bbmA, 0.8105, 3.38, 0.395, 314, 276, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
1756, 2acxA, 0.8104, 2.32, 0.266, 495, 259, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
1757, 3odzX, 0.8103, 2.71, 0.367, 335, 264, CRYSTAL STRUCTURE OF P38ALPHA Y323R ACTIVE MUTANT
1758, 3q53A, 0.8095, 2.15, 0.298, 291, 255, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
1759, 3c51A, 0.8095, 2.26, 0.249, 487, 257, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 3.55A
1760, 2fsmX, 0.8089, 2.34, 0.373, 326, 260, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-B
1761, 4wboB, 0.8088, 2.37, 0.260, 495, 258, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1762, 5wjjA, 0.8085, 2.57, 0.364, 338, 264, STRUCTURE-BASED DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZO[12-B]PYRIDAZINE-BASED P38 MAP KINASE INHIBITORS
1763, 2npqA, 0.8085, 2.35, 0.369, 326, 260, A NOVEL LIPID BINDING SITE IN THE P38 ALPHA MAP KINASE
1764, 3iw4C, 0.8081, 2.30, 0.261, 332, 257, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1765, 4yhjB, 0.8080, 2.49, 0.259, 490, 259, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
1766, 3t8oA, 0.8080, 2.41, 0.255, 493, 259, RHODOPSIN KINASE (GRK1) L166K MUTANT AT 2.5A RESOLUTION
1767, 2xrwA, 0.8074, 2.36, 0.353, 348, 258, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1768, 2fslX, 0.8073, 2.48, 0.368, 332, 261, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-A
1769, 2r9sB, 0.8069, 2.38, 0.363, 325, 259, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1770, 4e5aX, 0.8068, 2.37, 0.375, 332, 259, THE W197A MUTANT OF P38A MAP KINASE
1771, 1yhwA, 0.8066, 2.24, 0.285, 293, 256, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
1772, 3gcpA, 0.8065, 2.60, 0.370, 337, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH SB203580
1773, 1yhvA, 0.8065, 2.25, 0.285, 293, 256, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
1774, 2jedB, 0.8064, 2.36, 0.280, 320, 257, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1775, 3zsgA, 0.8063, 2.70, 0.365, 337, 266, X-RAY STRUCTURE OF P38ALPHA BOUND TO TAK-715
1776, 3zs5A, 0.8063, 2.72, 0.365, 340, 266, STRUCTURAL BASIS FOR KINASE SELECTIVITY OF THREE CLINICAL P38ALPHA INHIBITORS
1777, 3ocbA, 0.8061, 2.33, 0.273, 315, 256, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1778, 3g33C, 0.8061, 2.91, 0.472, 291, 265, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
1779, 5izjA, 0.8060, 2.18, 0.267, 328, 255, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
1780, 2acxB, 0.8060, 2.29, 0.272, 492, 257, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
1781, 4yhjA, 0.8056, 2.42, 0.260, 501, 258, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
1782, 2fstX, 0.8055, 2.34, 0.375, 324, 259, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327L) ACTIVATING MUTANT
1783, 3fi3A, 0.8054, 2.60, 0.363, 328, 262, CRYSTAL STRUCTURE OF JNK3 WITH INDAZOLE INHIBITOR SR-3737
1784, 5izjB, 0.8053, 2.15, 0.267, 325, 255, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
1785, 5dfpA, 0.8053, 2.19, 0.302, 292, 255, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
1786, 4eqcA, 0.8053, 2.22, 0.302, 296, 255, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
1787, 3c50A, 0.8053, 2.39, 0.252, 499, 258, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
1788, 3iw4B, 0.8052, 2.32, 0.261, 325, 257, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1789, 4dawA, 0.8048, 2.25, 0.302, 293, 255, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
1790, 2r9sA, 0.8047, 2.44, 0.363, 325, 259, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1791, 3g33A, 0.8044, 2.91, 0.472, 291, 265, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
1792, 4e8aA, 0.8042, 2.39, 0.371, 327, 259, THE CRYSTAL STRUCTURE OF P38A MAP KINASE IN COMPLEX WITH PIA24
1793, 5veeA, 0.8040, 2.31, 0.267, 289, 255, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
1794, 3c4xA, 0.8039, 2.33, 0.249, 496, 257, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
1795, 3q52A, 0.8038, 2.23, 0.298, 292, 255, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
1796, 3fxzA, 0.8038, 2.24, 0.286, 292, 255, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
1797, 3cqwA, 0.8033, 2.26, 0.275, 318, 255, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1798, 3c4wB, 0.8033, 2.35, 0.249, 518, 257, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
1799, 3c4wA, 0.8031, 2.34, 0.249, 494, 257, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
1800, 3ocbB, 0.8030, 2.30, 0.278, 319, 255, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1801, 3iw4A, 0.8030, 2.38, 0.261, 330, 257, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1802, 3c50B, 0.8030, 2.44, 0.252, 496, 258, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
1803, 3c4yA, 0.8029, 2.38, 0.255, 478, 259, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
1804, 3qc9D, 0.8025, 2.44, 0.252, 486, 258, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
1805, 3qc9C, 0.8025, 2.44, 0.252, 482, 258, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
1806, 3qc9B, 0.8025, 2.44, 0.252, 481, 258, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
1807, 3qc9A, 0.8025, 2.44, 0.252, 486, 258, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
1808, 6c0tA, 0.8022, 2.40, 0.226, 334, 257, CRYSTAL STRUCTURE OF CGMP-DEPENDENT PROTEIN KINASE IALPHA (PKG IALPHA) CATALYTIC DOMAIN BOUND WITH N46 
1809, 2y7jA, 0.8022, 2.23, 0.285, 284, 253, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1810, 2jedA, 0.8021, 2.36, 0.281, 324, 256, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1811, 4l9iB, 0.8020, 2.35, 0.253, 493, 257, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
1812, 4ekkA, 0.8020, 2.31, 0.278, 318, 255, AKT1 WITH AMP-PNP
1813, 3c4zA, 0.8020, 2.39, 0.249, 493, 257, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 1.84A
1814, 2fsoX, 0.8020, 2.34, 0.376, 325, 258, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A) ACTIVATING MUTANT
1815, 4aaaA, 0.8017, 2.97, 0.398, 295, 269, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
1816, 5deyA, 0.8015, 2.32, 0.281, 295, 256, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
1817, 1u5qA, 0.8014, 2.34, 0.272, 308, 257, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1818, 3ow4A, 0.8013, 2.30, 0.275, 317, 255, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1819, 3nyoB, 0.8012, 2.47, 0.272, 553, 257, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
1820, 5ml5A, 0.8009, 2.56, 0.368, 326, 261, HUMAN P38ALPHA MAPK IN COMPLEX WITH IMIDAZOLYL PYRIDINE INHIBITOR 11B
1821, 2jdoA, 0.8009, 2.32, 0.275, 314, 255, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1822, 5dewA, 0.8008, 2.32, 0.281, 295, 256, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
1823, 1u5rA, 0.8008, 2.35, 0.272, 308, 257, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1824, 3nyoA, 0.8005, 2.49, 0.272, 553, 257, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
1825, 3fy0A, 0.8005, 2.31, 0.286, 292, 255, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
1826, 2x39A, 0.8004, 2.33, 0.278, 316, 255, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
1827, 2biyA, 0.8004, 2.36, 0.270, 287, 256, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
1828, 3c4xB, 0.8003, 2.35, 0.246, 475, 256, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
1829, 2y7jC, 0.8003, 2.29, 0.285, 284, 253, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1830, 2gcdA, 0.8003, 2.37, 0.272, 308, 257, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1831, 4wnkA, 0.8001, 2.30, 0.262, 499, 256, CRYSTAL STRUCTURE OF BOVINE G PROTEIN COUPLED-RECEPTOR KINASE 5 IN COMPLEX WITH CCG215022
1832, 3mvhA, 0.8000, 2.25, 0.280, 311, 254, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1833, 2i6lB, 0.8000, 2.80, 0.323, 269, 260, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1834, 2bajA, 0.8000, 2.54, 0.389, 337, 257, P38ALPHA BOUND TO PYRAZOLOUREA
1835, 5lcpA, 0.7998, 2.35, 0.267, 350, 255, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH FASUDIL (M77)
1836, 3nynB, 0.7997, 2.29, 0.275, 553, 255, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
1837, 5lcuA, 0.7996, 2.36, 0.267, 350, 255, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A S-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 01)
1838, 4nttB, 0.7996, 2.34, 0.263, 339, 255, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
1839, 2ou7A, 0.7996, 2.35, 0.246, 292, 256, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1840, 6ccyA, 0.7992, 2.31, 0.275, 325, 255, CRYSTAL STRUCTURE OF AKT1 IN COMPLEX WITH A SELECTIVE INHIBITOR 
1841, 4nusA, 0.7991, 2.59, 0.286, 301, 259, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
1842, 2owbA, 0.7990, 2.36, 0.246, 294, 256, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1843, 4j53A, 0.7989, 2.36, 0.246, 293, 256, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
1844, 5m71A, 0.7988, 2.37, 0.267, 350, 255, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH AN (R)-METHYL SUBSTITUED FASUDIL-DERIVATIVE. 
1845, 2gcdB, 0.7988, 2.39, 0.272, 308, 257, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1846, 3nynA, 0.7987, 2.30, 0.278, 553, 255, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
1847, 1stcE, 0.7987, 2.34, 0.263, 334, 255, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
1848, 4c57B, 0.7984, 2.39, 0.253, 308, 257, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
1849, 2v5qB, 0.7983, 2.38, 0.242, 285, 256, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
1850, 4c57A, 0.7980, 2.40, 0.253, 310, 257, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
1851, 3mv5A, 0.7979, 2.34, 0.275, 315, 255, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1852, 4q9zB, 0.7978, 2.44, 0.277, 308, 256, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1853, 4nw5A, 0.7978, 2.31, 0.293, 302, 256, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
1854, 3a8xA, 0.7978, 2.29, 0.275, 334, 255, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1855, 5l2sA, 0.7977, 2.24, 0.492, 263, 254, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND ABEMACICLIB.
1856, 4nw6A, 0.7977, 2.32, 0.293, 302, 256, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
1857, 4b6lA, 0.7977, 2.44, 0.265, 281, 257, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
1858, 1u5qB, 0.7977, 2.40, 0.272, 308, 257, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1859, 2yacA, 0.7976, 2.38, 0.246, 290, 256, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
1860, 3thbA, 0.7975, 2.36, 0.246, 287, 256, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
1861, 5f9eB, 0.7974, 2.43, 0.277, 293, 256, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1862, 3o7lD, 0.7974, 2.31, 0.263, 333, 255, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
1863, 5lcrA, 0.7973, 2.28, 0.268, 350, 254, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH OPEN-CHAIN FASUDIL-DERIVATIVE (LIGAND 04)
1864, 2v5qA, 0.7973, 2.55, 0.253, 285, 257, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
1865, 1u5rB, 0.7973, 2.42, 0.272, 308, 257, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1866, 3pvwA, 0.7972, 2.51, 0.252, 613, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
1867, 4uakA, 0.7971, 2.79, 0.251, 404, 263, MRCK BETA IN COMPLEX WITH ADP
1868, 4tnbA, 0.7970, 2.36, 0.273, 529, 256, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH SANGIVAMYCIN
1869, 3kb7A, 0.7969, 2.40, 0.246, 289, 256, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1870, 5o0eA, 0.7967, 2.34, 0.268, 349, 254, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND FASUDIL 
1871, 3rcjA, 0.7967, 2.37, 0.275, 281, 255, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
1872, 1bx6A, 0.7967, 2.39, 0.263, 337, 255, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1873, 5uvcA, 0.7966, 2.53, 0.252, 457, 258, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
1874, 2xh5A, 0.7966, 2.30, 0.276, 316, 254, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
1875, 3nuxA, 0.7965, 2.27, 0.488, 261, 254, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1876, 3fc2A, 0.7965, 2.39, 0.246, 293, 256, PLK1 IN COMPLEX WITH BI6727
1877, 2uw9A, 0.7965, 2.40, 0.275, 316, 255, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1878, 5ok3A, 0.7964, 2.35, 0.268, 349, 254, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP241 AND FASUDIL 
1879, 4ra4A, 0.7964, 2.37, 0.263, 317, 255, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1880, 4q9zA, 0.7963, 2.42, 0.282, 331, 255, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1881, 4nttA, 0.7963, 2.37, 0.255, 339, 255, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
1882, 4a4lA, 0.7963, 2.39, 0.246, 290, 256, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
1883, 3c4yB, 0.7963, 2.39, 0.254, 466, 256, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
1884, 5ta6A, 0.7961, 2.40, 0.246, 294, 256, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
1885, 4ra5A, 0.7961, 2.44, 0.282, 332, 255, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1886, 3ow4B, 0.7960, 2.33, 0.280, 317, 254, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1887, 3iecA, 0.7960, 2.23, 0.313, 311, 252, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1888, 5mrdA, 0.7959, 2.49, 0.273, 283, 256, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
1889, 4j52A, 0.7959, 2.41, 0.246, 293, 256, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
1890, 3iecC, 0.7958, 2.26, 0.313, 311, 252, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1891, 6c9dB, 0.7957, 2.60, 0.316, 422, 256, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
1892, 5lvmA, 0.7957, 2.49, 0.273, 283, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
1893, 5f9eA, 0.7954, 2.51, 0.281, 334, 256, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1894, 3pvuA, 0.7954, 2.55, 0.244, 609, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
1895, 5m6yA, 0.7953, 2.31, 0.268, 350, 254, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A METHYLISOQUINOLINE FASUDIL-DERIVATIVE 
1896, 5lvlA, 0.7953, 2.43, 0.271, 285, 255, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
1897, 4a4oA, 0.7953, 2.42, 0.246, 290, 256, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
1898, 2bujA, 0.7953, 2.43, 0.242, 291, 256, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
1899, 1h1wA, 0.7953, 2.44, 0.267, 284, 255, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
1900, 4l9iA, 0.7952, 2.49, 0.253, 504, 257, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
1901, 4eklA, 0.7952, 2.39, 0.275, 329, 255, AKT1 WITH GDC0068
1902, 4ekkB, 0.7952, 2.31, 0.280, 318, 254, AKT1 WITH AMP-PNP
1903, 3qklA, 0.7952, 2.42, 0.275, 317, 255, SPIROCHROMANE AKT INHIBITORS
1904, 2i0eA, 0.7952, 2.38, 0.250, 326, 256, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1905, 5uuuA, 0.7951, 2.56, 0.252, 414, 258, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
1906, 3rwqA, 0.7951, 2.45, 0.267, 283, 255, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1907, 2rkuA, 0.7951, 2.41, 0.246, 294, 256, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
1908, 3a8xB, 0.7950, 2.06, 0.282, 329, 252, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1909, 5lctA, 0.7949, 2.43, 0.267, 350, 255, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A R-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 02)
1910, 2y7jB, 0.7949, 2.43, 0.280, 281, 254, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1911, 5xvfA, 0.7948, 2.40, 0.268, 289, 254, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH062
1912, 4gv1A, 0.7948, 2.34, 0.276, 329, 254, PKB ALPHA IN COMPLEX WITH AZD5363
1913, 1zysA, 0.7947, 2.58, 0.265, 271, 257, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
1914, 1uvrA, 0.7947, 2.42, 0.267, 284, 255, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
1915, 3hrfA, 0.7946, 2.46, 0.271, 284, 255, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
1916, 3hrcA, 0.7946, 2.53, 0.273, 279, 256, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
1917, 3cquA, 0.7946, 2.42, 0.275, 318, 255, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1918, 4rqvA, 0.7945, 2.45, 0.267, 288, 255, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
1919, 5ntjA, 0.7944, 2.30, 0.268, 346, 254, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUND RKP032 
1920, 5m6vA, 0.7944, 2.34, 0.268, 350, 254, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A DOUBLE METHYLATED FASUDIL-DERIVATIVE 
1921, 2welA, 0.7944, 2.43, 0.294, 304, 255, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
1922, 3pfqA, 0.7942, 2.37, 0.247, 520, 255, CRYSTAL STRUCTURE AND ALLOSTERIC ACTIVATION OF PROTEIN KINASE C BETA II
1923, 1cmkE, 0.7942, 2.41, 0.267, 348, 255, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
1924, 5lvoA, 0.7941, 2.52, 0.273, 285, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
1925, 4tndA, 0.7940, 2.47, 0.268, 529, 257, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH AMP-PNP
1926, 1ctpE, 0.7940, 2.42, 0.263, 332, 255, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
1927, 5lvnA, 0.7939, 2.53, 0.273, 283, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
1928, 4xx9A, 0.7939, 2.52, 0.273, 288, 256, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
1929, 5m75A, 0.7938, 2.35, 0.268, 350, 254, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A (S)-METHYL SUBSTITUED FASUDIL-DERIVATIVE 
1930, 4rqkA, 0.7938, 2.45, 0.267, 285, 255, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
1931, 3iecD, 0.7938, 2.31, 0.313, 311, 252, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1932, 3iecB, 0.7938, 2.27, 0.313, 313, 252, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1933, 2ydiA, 0.7938, 2.73, 0.264, 279, 258, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
1934, 1ql6A, 0.7938, 2.44, 0.283, 281, 254, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
1935, 4c35A, 0.7937, 2.40, 0.268, 337, 254, PKA-S6K1 CHIMERA WITH COMPOUND 1 (NU1085) BOUND
1936, 4c2vA, 0.7937, 2.20, 0.298, 270, 252, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
1937, 2f57A, 0.7937, 2.46, 0.255, 297, 255, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
1938, 4ct1A, 0.7936, 2.52, 0.277, 283, 256, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
1939, 4a06A, 0.7936, 2.38, 0.268, 282, 254, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
1940, 2jdrA, 0.7936, 2.34, 0.280, 316, 254, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
1941, 5vedA, 0.7935, 2.43, 0.268, 289, 254, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1942, 4yzbA, 0.7935, 2.40, 0.281, 466, 253, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
1943, 4rrvA, 0.7935, 2.53, 0.273, 283, 256, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND PIFTIDE
1944, 3l9mA, 0.7935, 2.38, 0.268, 338, 254, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1945, 3d5uA, 0.7935, 2.40, 0.258, 288, 256, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
1946, 3a8wB, 0.7935, 2.23, 0.273, 327, 253, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1947, 2x8dA, 0.7934, 2.61, 0.268, 279, 257, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
1948, 4ra5B, 0.7932, 2.42, 0.282, 310, 255, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1949, 5ta8A, 0.7931, 2.47, 0.250, 294, 256, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
1950, 5l2tA, 0.7931, 2.18, 0.496, 261, 252, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND RIBOCICLIB.
1951, 3krwA, 0.7930, 2.61, 0.264, 618, 258, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
1952, 4w8eA, 0.7929, 2.40, 0.276, 290, 254, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
1953, 1okyA, 0.7929, 2.34, 0.273, 281, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1954, 5ackA, 0.7928, 2.50, 0.267, 286, 255, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
1955, 2f57B, 0.7928, 2.40, 0.272, 299, 254, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
1956, 5oteA, 0.7926, 2.79, 0.255, 407, 263, MRCK BETA IN COMPLEX WITH BDP-00008900
1957, 4ysmA, 0.7925, 2.39, 0.276, 475, 254, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
1958, 4qmwA, 0.7925, 2.41, 0.252, 286, 254, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
1959, 5nw8A, 0.7924, 2.31, 0.269, 337, 253, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP032 AND FASUDIL 
1960, 3otuA, 0.7924, 2.52, 0.276, 276, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
1961, 1smhA, 0.7924, 2.38, 0.264, 348, 254, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
1962, 2pmlX, 0.7923, 2.62, 0.209, 340, 258, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP ANALOGUE
1963, 2bcjA, 0.7923, 2.56, 0.245, 624, 257, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
1964, 1szmA, 0.7923, 2.38, 0.264, 317, 254, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
1965, 5otfA, 0.7922, 2.80, 0.255, 411, 263, MRCK BETA IN COMPLEX WITH BDP-00009066
1966, 6c9dA, 0.7921, 2.66, 0.312, 425, 256, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
1967, 4rerA, 0.7921, 2.23, 0.302, 458, 252, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX BOUND TO AMP AND CYCLODEXTRIN
1968, 4figB, 0.7920, 2.40, 0.268, 292, 254, CATALYTIC DOMAIN OF HUMAN PAK4
1969, 4figA, 0.7920, 2.40, 0.268, 292, 254, CATALYTIC DOMAIN OF HUMAN PAK4
1970, 1phkA, 0.7920, 2.46, 0.283, 277, 254, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
1971, 4ntsB, 0.7919, 2.40, 0.255, 341, 255, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1972, 2x4zA, 0.7919, 2.46, 0.256, 290, 254, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
1973, 5vibA, 0.7918, 2.36, 0.264, 308, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
1974, 4o0rA, 0.7918, 2.53, 0.281, 293, 256, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1975, 4aw2A, 0.7918, 2.77, 0.256, 398, 262, CRYSTAL STRUCTURE OF CDC42 BINDING PROTEIN KINASE ALPHA (MRCK ALPHA)
1976, 3l9lA, 0.7918, 2.40, 0.272, 338, 254, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1977, 1zrzA, 0.7918, 2.40, 0.275, 310, 255, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
1978, 1rejA, 0.7918, 2.40, 0.264, 333, 254, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
1979, 4ysmB, 0.7917, 2.60, 0.289, 475, 256, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
1980, 2pmnX, 0.7916, 2.68, 0.208, 340, 259, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP-SITE INHIBITOR
1981, 3qkkA, 0.7915, 2.46, 0.275, 326, 255, SPIROCHROMANE AKT INHIBITORS
1982, 3ag9B, 0.7914, 2.40, 0.264, 317, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
1983, 4qfgA, 0.7913, 2.26, 0.298, 365, 252, STRUCTURE OF AMPK IN COMPLEX WITH STAUROSPORINE INHIBITOR AND IN THE ABSENCE OF A SYNTHETIC ACTIVATOR
1984, 2w99B, 0.7913, 3.15, 0.474, 291, 266, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1985, 4xbrA, 0.7912, 2.42, 0.268, 315, 254, IN CELLULO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA
1986, 4qmzA, 0.7912, 2.44, 0.276, 286, 254, MST3 IN COMPLEX WITH SUNITINIB
1987, 2uw7A, 0.7912, 2.44, 0.260, 335, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1988, 3a7iA, 0.7911, 2.42, 0.276, 286, 254, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
1989, 2jdvA, 0.7911, 2.45, 0.260, 334, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
1990, 3krxA, 0.7910, 2.63, 0.264, 618, 258, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
1991, 4o0tA, 0.7909, 2.56, 0.281, 292, 256, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1992, 4a07A, 0.7909, 2.43, 0.268, 282, 254, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
1993, 3ztxA, 0.7909, 2.38, 0.289, 269, 253, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
1994, 3d5wA, 0.7909, 2.39, 0.264, 284, 254, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
1995, 1xh5A, 0.7909, 2.36, 0.253, 335, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1996, 5n1dA, 0.7908, 2.40, 0.268, 348, 254, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-METHYL-1-(5-PYRIDIN-3-YLOXYFURAN-2-YL) METHANAMINE
1997, 4o0vA, 0.7908, 2.47, 0.268, 290, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1998, 3a8wA, 0.7908, 2.07, 0.279, 326, 251, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1999, 1xhaA, 0.7908, 2.40, 0.264, 348, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2000, 4qmxA, 0.7907, 2.43, 0.252, 287, 254, MST3 IN COMPLEX WITH SARACATINIB
2001, 4fieB, 0.7907, 2.43, 0.268, 300, 254, FULL-LENGTH HUMAN PAK4
2002, 4fieA, 0.7907, 2.43, 0.268, 300, 254, FULL-LENGTH HUMAN PAK4
2003, 3db6A, 0.7907, 2.44, 0.254, 287, 256, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
2004, 1xh8A, 0.7907, 2.39, 0.264, 337, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2005, 3pscA, 0.7906, 2.45, 0.246, 614, 256, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
2006, 4hyiA, 0.7905, 2.49, 0.267, 269, 255, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
2007, 5uplA, 0.7904, 2.44, 0.268, 290, 254, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTEFACE - 2 PEPTIDE: PAK4FL CDC42 - UNREFINED
2008, 5bmsA, 0.7904, 2.49, 0.268, 290, 254, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2009, 4b8mA, 0.7904, 2.30, 0.290, 270, 252, AURORA B KINASE IN COMPLEX WITH VX-680
2010, 2uztA, 0.7904, 2.49, 0.263, 336, 255, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
2011, 4yzbB, 0.7903, 2.45, 0.278, 464, 252, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
2012, 2bfxA, 0.7903, 2.38, 0.292, 269, 253, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
2013, 1j3hA, 0.7903, 2.38, 0.260, 329, 254, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2014, 4o0yA, 0.7902, 2.48, 0.268, 290, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2015, 4c34A, 0.7902, 2.35, 0.269, 336, 253, PKA-S6K1 CHIMERA WITH STAUROSPORINE BOUND
2016, 2vrxA, 0.7902, 2.37, 0.292, 268, 253, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
2017, 1svhA, 0.7902, 2.36, 0.253, 335, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
2018, 5l2iA, 0.7901, 2.32, 0.484, 260, 252, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND PALBOCICLIB.
2019, 5kbqA, 0.7901, 2.48, 0.282, 289, 255, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
2020, 2vo0A, 0.7901, 2.47, 0.260, 340, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
2021, 2pmoX, 0.7901, 2.67, 0.202, 340, 258, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH HYMENIALDISINE
2022, 4ks8A, 0.7900, 2.51, 0.291, 286, 254, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
2023, 3orxC, 0.7900, 2.47, 0.273, 283, 256, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2024, 3l9mB, 0.7900, 2.44, 0.268, 336, 254, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
2025, 2vgoA, 0.7900, 2.30, 0.290, 268, 252, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
2026, 1bkxA, 0.7900, 2.34, 0.253, 337, 253, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
2027, 5m0uA, 0.7899, 2.33, 0.257, 346, 253, APOSTRUCTURE STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) FROM CHO CELLS WITH A PEPTIDIC INHIBITOR FRAGMENT 
2028, 4qmlA, 0.7899, 2.45, 0.276, 280, 254, MST3 IN COMPLEX WITH AMP-PNP
2029, 3orxA, 0.7899, 2.47, 0.273, 283, 256, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2030, 3kk8A, 0.7899, 2.67, 0.300, 283, 257, CAMKII SUBSTRATE COMPLEX A
2031, 5dykA, 0.7898, 2.43, 0.254, 809, 256, CRYSTAL STRUCTURE OF PF3D7_1436600
2032, 4jdiA, 0.7898, 2.39, 0.269, 289, 253, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
2033, 3orxD, 0.7898, 2.48, 0.273, 282, 256, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2034, 4ks7A, 0.7897, 2.47, 0.276, 286, 254, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
2035, 2vgpA, 0.7897, 2.30, 0.290, 265, 252, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
2036, 1ia8A, 0.7897, 2.60, 0.267, 272, 255, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
2037, 4o0xA, 0.7896, 2.49, 0.268, 290, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2038, 1uu7A, 0.7896, 2.39, 0.269, 280, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
2039, 4fifB, 0.7894, 2.46, 0.268, 292, 254, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
2040, 4fifA, 0.7894, 2.46, 0.268, 293, 254, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
2041, 2uw6A, 0.7894, 2.43, 0.261, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2042, 5isoC, 0.7893, 2.35, 0.285, 429, 253, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2043, 4jdhA, 0.7892, 2.40, 0.269, 289, 253, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
2044, 4crsA, 0.7892, 2.45, 0.280, 331, 254, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
2045, 3orxB, 0.7892, 2.44, 0.271, 280, 255, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2046, 1j3hB, 0.7891, 2.41, 0.260, 327, 254, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2047, 4qmmA, 0.7890, 2.44, 0.272, 288, 254, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
2048, 2y7jD, 0.7890, 2.39, 0.262, 281, 252, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2049, 4c2wA, 0.7889, 2.41, 0.292, 268, 253, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
2050, 1rekA, 0.7889, 2.42, 0.268, 336, 254, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
2051, 5lcqA, 0.7888, 2.37, 0.257, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH LONG-CHAIN FASUDIL-DERIVATIVE (LIGAND 05)
2052, 5he2A, 0.7888, 2.50, 0.250, 628, 256, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
2053, 2ywpA, 0.7888, 2.56, 0.267, 269, 255, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
2054, 2uw0A, 0.7888, 2.44, 0.261, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
2055, 2uvyA, 0.7888, 2.44, 0.261, 333, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
2056, 4qmnA, 0.7887, 2.47, 0.276, 283, 254, MST3 IN COMPLEX WITH BOSUTINIB
2057, 3e5aA, 0.7887, 2.43, 0.298, 264, 252, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
2058, 2jdtA, 0.7887, 2.46, 0.260, 334, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
2059, 2bfxB, 0.7887, 2.45, 0.269, 275, 253, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
2060, 4qmyA, 0.7886, 2.45, 0.276, 287, 254, MST3 IN COMPLEX WITH STAUROSPORINE
2061, 4qmtA, 0.7886, 2.48, 0.272, 284, 254, MST3 IN COMPLEX WITH HESPERADIN
2062, 4qmsA, 0.7886, 2.44, 0.276, 283, 254, MST3 IN COMPLEX WITH DASATINIB
2063, 2uw4A, 0.7886, 2.47, 0.260, 334, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2064, 2i0eB, 0.7886, 2.44, 0.250, 300, 256, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
2065, 6b2eA, 0.7885, 2.32, 0.286, 442, 252, STRUCTURE OF FULL LENGTH HUMAN AMPK (A2B2G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4. 
2066, 5he0A, 0.7885, 2.51, 0.262, 621, 256, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
2067, 4pnkA, 0.7885, 2.48, 0.250, 625, 256, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
2068, 6aywB, 0.7884, 2.60, 0.294, 293, 255, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2069, 4qnaA, 0.7884, 2.46, 0.276, 284, 254, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
2070, 2bfyA, 0.7884, 2.42, 0.289, 270, 253, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2071, 1o6kA, 0.7884, 2.40, 0.280, 317, 254, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
2072, 5h9bA, 0.7883, 2.49, 0.324, 269, 253, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
2073, 4ntsA, 0.7883, 2.49, 0.247, 341, 255, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
2074, 4aw0A, 0.7883, 2.59, 0.275, 283, 255, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
2075, 3l9lB, 0.7883, 2.39, 0.257, 337, 253, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
2076, 1zltA, 0.7883, 2.48, 0.268, 272, 254, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
2077, 1xh9A, 0.7883, 2.40, 0.257, 336, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2078, 5m0bA, 0.7882, 2.38, 0.257, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A SHORT-CHAINED N-(2-AMINOETHYL)ISOQUINOLINE-5-SULFONAMIDE) FASUDIL-DERIVATIVE (LIGAND 03) 
2079, 3qkmA, 0.7882, 2.41, 0.276, 329, 254, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
2080, 2uvxA, 0.7882, 2.49, 0.260, 335, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
2081, 1ym7D, 0.7882, 2.45, 0.246, 599, 256, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
2082, 1ym7A, 0.7882, 2.45, 0.246, 608, 256, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
2083, 3agmA, 0.7881, 2.46, 0.268, 337, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
2084, 2vnwA, 0.7881, 2.45, 0.261, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
2085, 2ojfE, 0.7881, 2.51, 0.263, 336, 255, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
2086, 1ym7C, 0.7881, 2.45, 0.246, 607, 256, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
2087, 4qmuA, 0.7880, 2.47, 0.252, 286, 254, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
2088, 2e9oA, 0.7880, 2.48, 0.268, 269, 254, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
2089, 1ym7B, 0.7880, 2.45, 0.246, 608, 256, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
2090, 5li9A, 0.7879, 2.38, 0.273, 329, 253, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
2091, 2xckA, 0.7879, 2.36, 0.267, 275, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2092, 4c2vB, 0.7878, 2.45, 0.289, 280, 253, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
2093, 2vo3A, 0.7878, 2.45, 0.261, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
2094, 4b8mB, 0.7877, 2.39, 0.286, 279, 252, AURORA B KINASE IN COMPLEX WITH VX-680
2095, 3v8sD, 0.7877, 2.82, 0.264, 397, 261, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2096, 1o6lA, 0.7877, 2.41, 0.280, 316, 254, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
2097, 4otdA, 0.7876, 2.46, 0.283, 334, 254, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
2098, 4c2wB, 0.7876, 2.37, 0.286, 277, 252, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
2099, 3e87B, 0.7876, 2.43, 0.276, 321, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2100, 3e87A, 0.7876, 2.43, 0.276, 321, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2101, 3cikA, 0.7876, 2.52, 0.246, 619, 256, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
2102, 5li1A, 0.7875, 2.45, 0.283, 331, 254, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
2103, 5he1A, 0.7875, 2.52, 0.258, 618, 256, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
2104, 4axaA, 0.7875, 2.52, 0.260, 335, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1S)-2-AMINO-1-( 4-CHLOROPHENYL)-1-(4-(1H-PYRAZOL-4-YL)PHENYL)ETHAN-1-OL
2105, 3dneA, 0.7875, 2.41, 0.253, 336, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2106, 2uw3A, 0.7875, 2.46, 0.261, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
2107, 1xjdA, 0.7875, 2.34, 0.287, 280, 251, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
2108, 1q8wA, 0.7875, 2.37, 0.265, 334, 253, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
2109, 1omwA, 0.7875, 2.58, 0.245, 614, 257, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
2110, 4z84A, 0.7874, 2.42, 0.253, 335, 253, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 34A
2111, 4ez5A, 0.7874, 2.28, 0.494, 258, 251, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
2112, 3tv7D, 0.7874, 2.77, 0.258, 397, 260, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
2113, 2q0nA, 0.7874, 2.48, 0.272, 293, 254, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
2114, 6c0uA, 0.7873, 2.50, 0.267, 338, 255, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CALPHA SUBUNIT BOUND WITH N46 
2115, 4yr8F, 0.7873, 2.36, 0.369, 300, 252, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
2116, 2vd5A, 0.7873, 2.62, 0.271, 390, 258, STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII
2117, 2ghgA, 0.7873, 2.56, 0.267, 269, 255, H-CHK1 COMPLEXED WITH A431994
2118, 2aypA, 0.7873, 2.43, 0.268, 268, 254, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
2119, 2f7xE, 0.7872, 2.51, 0.263, 336, 255, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
2120, 1q61A, 0.7872, 2.43, 0.253, 335, 253, PKA TRIPLE MUTANT MODEL OF PKB
2121, 5dzcA, 0.7871, 2.54, 0.262, 816, 256, CRYSTAL STRUCTURE OF PVX_084705 IN COMPLEX WITH AMP-PNP
2122, 4w8dA, 0.7871, 2.47, 0.272, 289, 254, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
2123, 4cfhA, 0.7871, 2.32, 0.298, 401, 252, STRUCTURE OF AN ACTIVE FORM OF MAMMALIAN AMPK
2124, 3pwyA, 0.7871, 2.43, 0.274, 281, 252, CRYSTAL STRUCTURE OF AN EXTENDER (SPD28345)-MODIFIED HUMAN PDK1 COMPLEX 2
2125, 3j4rE, 0.7871, 2.41, 0.255, 325, 255, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
2126, 3j4rD, 0.7871, 2.41, 0.255, 325, 255, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
2127, 3j4qE, 0.7871, 2.41, 0.255, 325, 255, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
2128, 3j4qD, 0.7871, 2.41, 0.255, 325, 255, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
2129, 5t5tA, 0.7870, 2.38, 0.298, 368, 252, AMPK BOUND TO ALLOSTERIC ACTIVATOR
2130, 3ztxB, 0.7870, 2.53, 0.289, 272, 253, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
2131, 3l9nA, 0.7870, 2.45, 0.268, 332, 254, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
2132, 2cgxA, 0.7870, 2.49, 0.272, 265, 254, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
2133, 5upkB, 0.7869, 2.52, 0.268, 288, 254, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTERFACE - 3 PEPTIDE: PAK4CAT PAK4-N45 CDC42
2134, 4ie9A, 0.7869, 2.50, 0.264, 335, 254, BOVINE PKA C-ALPHA IN COMPLEX WITH 3-PYRIDYLMETHYL-5-METHYL-1H- PYRAZOLE-3-CARBOXYLATE
2135, 2vrxB, 0.7869, 2.52, 0.292, 274, 253, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
2136, 2oh0E, 0.7869, 2.51, 0.263, 336, 255, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
2137, 5ukmA, 0.7868, 2.54, 0.250, 621, 256, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
2138, 4z83E, 0.7868, 2.50, 0.264, 335, 254, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 47A
2139, 4fijA, 0.7868, 2.44, 0.277, 291, 253, CATALYTIC DOMAIN OF HUMAN PAK4
2140, 3v8sB, 0.7868, 2.82, 0.264, 397, 261, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2141, 3mfuA, 0.7868, 2.80, 0.305, 302, 256, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
2142, 3e88A, 0.7868, 2.44, 0.280, 319, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2143, 3ckxA, 0.7868, 2.30, 0.270, 276, 252, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
2144, 2vnyA, 0.7868, 2.47, 0.261, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
2145, 2f7zE, 0.7868, 2.48, 0.252, 336, 254, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
2146, 2brbA, 0.7868, 2.65, 0.271, 272, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2147, 5k3yA, 0.7867, 2.43, 0.289, 267, 253, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
2148, 4o27B, 0.7867, 2.57, 0.267, 281, 255, CRYSTAL STRUCTURE OF MST3-MO25 COMPLEX WITH WIF MOTIF
2149, 4ij9A, 0.7867, 2.43, 0.253, 335, 253, BOVINE PKA C-ALPHA IN COMPLEX WITH 2-[[5-(4-PYRIDYL)-1H-124-TRIAZOL- 3-YL]SULFANYL]-1-(2-THIOPHENYL)ETHANONE
2150, 4i6fA, 0.7867, 2.58, 0.240, 285, 258, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2151, 3e88B, 0.7867, 2.44, 0.280, 319, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2152, 2hxqA, 0.7867, 2.63, 0.267, 272, 255, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
2153, 3dbeA, 0.7866, 2.36, 0.257, 284, 253, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 557
2154, 5dh3B, 0.7865, 2.46, 0.275, 283, 255, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
2155, 4qmvA, 0.7865, 2.47, 0.272, 288, 254, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
2156, 2vgpB, 0.7865, 2.40, 0.266, 277, 252, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
2157, 2vgoB, 0.7865, 2.34, 0.267, 277, 251, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
2158, 2uzuE, 0.7865, 2.52, 0.263, 336, 255, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
2159, 3tv7B, 0.7864, 2.81, 0.264, 397, 261, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
2160, 3d0eB, 0.7864, 2.47, 0.280, 322, 254, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
2161, 2xchA, 0.7864, 2.36, 0.275, 278, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2162, 2f7eE, 0.7864, 2.53, 0.263, 336, 255, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
2163, 5f0aA, 0.7863, 2.44, 0.263, 811, 255, CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND 1-TERT-BUTYL-3-(3- CHLOROPHENOXY)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE INHIBITOR
2164, 3d0eA, 0.7863, 2.47, 0.276, 322, 254, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
2165, 3ambA, 0.7863, 2.50, 0.272, 340, 254, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
2166, 3a7gB, 0.7863, 2.41, 0.276, 290, 254, HUMAN MST3 KINASE
2167, 5x3fB, 0.7862, 2.52, 0.247, 348, 255, CRYSTAL STRUCTURE OF THE YGJG-PROTEIN A-ZPA963-PKA CATALYTIC DOMAIN
2168, 4uj2A, 0.7862, 2.52, 0.268, 335, 254, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
2169, 4rewA, 0.7862, 2.45, 0.300, 411, 253, CRYSTAL STRUCTURE OF THE NON-PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX
2170, 4ualA, 0.7861, 2.89, 0.252, 403, 262, MRCK BETA IN COMPLEX WITH BDP00005290
2171, 4ct2A, 0.7861, 2.19, 0.280, 277, 250, HUMAN PDK1-PKCZETA KINASE CHIMERA
2172, 4ae6A, 0.7861, 2.48, 0.259, 319, 255, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
2173, 3kk9A, 0.7861, 2.49, 0.304, 275, 253, CAMKII SUBSTRATE COMPLEX B
2174, 3e8dB, 0.7861, 2.46, 0.280, 317, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2175, 3e8dA, 0.7861, 2.46, 0.280, 315, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2176, 3a7hB, 0.7861, 2.41, 0.276, 290, 254, HUMAN MST3 KINASE IN COMPLEX WITH ATP
2177, 2vo6A, 0.7861, 2.49, 0.261, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
2178, 2e9uA, 0.7861, 2.61, 0.267, 269, 255, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
2179, 2cgvA, 0.7861, 2.44, 0.273, 264, 253, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
2180, 6b1uA, 0.7860, 2.37, 0.286, 441, 252, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
2181, 2wtkC, 0.7860, 2.69, 0.253, 285, 257, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
2182, 2gnlA, 0.7860, 2.52, 0.276, 338, 254, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
2183, 1xh6A, 0.7860, 2.43, 0.253, 331, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2184, 4u8zA, 0.7859, 2.46, 0.272, 289, 254, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
2185, 4otgA, 0.7859, 2.38, 0.281, 322, 253, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
2186, 4i6bA, 0.7859, 2.61, 0.240, 285, 258, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2187, 3nayB, 0.7859, 2.34, 0.279, 278, 251, PDK1 IN COMPLEX WITH INHIBITOR MP6
2188, 2gnjA, 0.7859, 2.45, 0.265, 335, 253, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
2189, 1fotA, 0.7859, 2.45, 0.236, 299, 254, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
2190, 5vhbA, 0.7858, 2.46, 0.265, 325, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITOR
2191, 5vefA, 0.7858, 2.46, 0.269, 289, 253, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
2192, 4o22A, 0.7858, 2.35, 0.254, 336, 252, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
2193, 4i6hA, 0.7858, 2.59, 0.240, 285, 258, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2194, 2hxlA, 0.7858, 2.53, 0.272, 272, 254, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
2195, 2e9nA, 0.7858, 2.52, 0.268, 269, 254, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
2196, 1re8A, 0.7858, 2.48, 0.264, 337, 254, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
2197, 5vloB, 0.7857, 2.63, 0.294, 293, 255, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2198, 4i5pA, 0.7857, 2.60, 0.240, 284, 258, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2199, 2uw5A, 0.7857, 2.50, 0.261, 333, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2200, 2uvzA, 0.7857, 2.48, 0.261, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
2201, 4qmoA, 0.7856, 2.46, 0.272, 288, 254, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
2202, 4jdkA, 0.7856, 2.40, 0.270, 288, 252, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
2203, 2c1bA, 0.7856, 2.46, 0.253, 335, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
2204, 6e4uA, 0.7855, 2.39, 0.298, 365, 252, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
2205, 4fiiA, 0.7855, 2.47, 0.269, 291, 253, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
2206, 4fihA, 0.7855, 2.47, 0.269, 291, 253, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
2207, 3amaA, 0.7855, 2.46, 0.261, 342, 253, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
2208, 2uzwE, 0.7855, 2.48, 0.252, 336, 254, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
2209, 1sveA, 0.7855, 2.43, 0.253, 341, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
2210, 6aywA, 0.7854, 2.48, 0.295, 293, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2211, 5lvpB, 0.7854, 2.39, 0.279, 276, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2212, 3tkuB, 0.7854, 2.91, 0.248, 395, 262, MRCK BETA IN COMPLEX WITH FASUDIL
2213, 2c1aA, 0.7854, 2.51, 0.264, 335, 254, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
2214, 2br1A, 0.7854, 2.65, 0.271, 272, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2215, 1xh4A, 0.7854, 2.40, 0.254, 334, 252, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2216, 6babD, 0.7853, 2.64, 0.294, 291, 255, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2217, 3c0iA, 0.7853, 2.87, 0.301, 298, 256, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
2218, 3aglB, 0.7853, 2.43, 0.269, 335, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
2219, 2uzvA, 0.7853, 2.46, 0.264, 336, 254, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
2220, 1svgA, 0.7853, 2.43, 0.253, 338, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
2221, 1q62A, 0.7853, 2.48, 0.249, 336, 253, PKA DOUBLE MUTANT MODEL OF PKB
2222, 5o5mA, 0.7852, 2.42, 0.269, 336, 253, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND RKP117 
2223, 4ujbA, 0.7852, 2.52, 0.268, 344, 254, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
2224, 3mfsA, 0.7852, 2.83, 0.305, 303, 256, CASK-4M CAM KINASE DOMAIN AMPPNP
2225, 5vloA, 0.7851, 2.49, 0.295, 290, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2226, 5ho7A, 0.7851, 2.38, 0.275, 280, 251, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2227, 3ag9A, 0.7851, 2.49, 0.260, 323, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
2228, 5ezvA, 0.7850, 2.40, 0.286, 441, 252, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
2229, 4yxrA, 0.7850, 2.46, 0.253, 334, 253, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
2230, 4xw4A, 0.7850, 2.37, 0.254, 334, 252, X-RAY STRUCTURE OF PKAC WITH AMPPNP SP20 CALCIUM IONS
2231, 4c0tA, 0.7850, 2.71, 0.236, 290, 258, CANDIDA ALBICANS PKH KINASE DOMAIN
2232, 3sc1A, 0.7850, 2.37, 0.275, 278, 251, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
2233, 3dndA, 0.7850, 2.44, 0.253, 334, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2234, 4qfsA, 0.7849, 2.41, 0.298, 361, 252, STRUCTURE OF AMPK IN COMPLEX WITH BR2-A769662CORE ACTIVATOR AND STAUROSPORINE INHIBITOR
2235, 2gdoA, 0.7849, 2.44, 0.269, 269, 253, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
2236, 1xh7A, 0.7849, 2.48, 0.265, 337, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2237, 6c2yA, 0.7848, 2.45, 0.264, 617, 254, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257142 
2238, 3tkuA, 0.7848, 2.98, 0.255, 395, 263, MRCK BETA IN COMPLEX WITH FASUDIL
2239, 1vebA, 0.7848, 2.51, 0.264, 338, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
2240, 5uzkA, 0.7847, 2.46, 0.257, 335, 253, CRYSTAL STRUCTURE OF PKA BOUND TO AN PYRROLO PYRIDINE INHIBITOR
2241, 4ujaA, 0.7847, 2.47, 0.257, 336, 253, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
2242, 4aw1A, 0.7847, 2.47, 0.270, 283, 252, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
2243, 2vo7A, 0.7847, 2.47, 0.253, 335, 253, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
2244, 2cguA, 0.7847, 2.46, 0.273, 263, 253, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
2245, 4qfrA, 0.7846, 2.40, 0.298, 361, 252, STRUCTURE OF AMPK IN COMPLEX WITH CL-A769662 ACTIVATOR AND STAUROSPORINE INHIBITOR
2246, 4jdjA, 0.7846, 2.42, 0.270, 288, 252, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
2247, 3oogA, 0.7846, 2.47, 0.257, 333, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
2248, 2gnfA, 0.7846, 2.51, 0.280, 339, 254, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
2249, 1ydsE, 0.7846, 2.45, 0.253, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
2250, 6e4wA, 0.7845, 2.42, 0.298, 361, 252, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
2251, 5lvpA, 0.7845, 2.34, 0.283, 275, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2252, 4yxsA, 0.7845, 2.53, 0.264, 335, 254, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2253, 3zo2A, 0.7845, 2.47, 0.265, 340, 253, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2254, 3pooA, 0.7845, 2.38, 0.258, 331, 252, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2255, 2qvsE, 0.7845, 2.51, 0.259, 323, 255, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
2256, 4zy4A, 0.7844, 2.30, 0.283, 288, 251, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
2257, 4qmqA, 0.7844, 2.47, 0.272, 289, 254, MST3 IN COMPLEX WITH CP-673451
2258, 3a7jA, 0.7844, 2.58, 0.252, 286, 254, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
2259, 1ydrE, 0.7844, 2.51, 0.264, 334, 254, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
2260, 5n23A, 0.7843, 2.50, 0.273, 333, 253, PROTEIN KINASE A MUTANTS AS SURROGATE MODEL FOR AURORA B WITH AT9283 INHIBITOR
2261, 3x2wA, 0.7843, 2.38, 0.254, 336, 252, MICHAELIS COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2262, 5fg8A, 0.7842, 2.55, 0.320, 269, 253, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2263, 4uj1A, 0.7842, 2.53, 0.268, 335, 254, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
2264, 2gnhA, 0.7842, 2.51, 0.280, 338, 254, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
2265, 6e4tA, 0.7841, 2.42, 0.298, 361, 252, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
2266, 5lvpC, 0.7841, 2.41, 0.279, 275, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2267, 5k3yB, 0.7841, 2.36, 0.267, 277, 251, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
2268, 3zo4A, 0.7841, 2.48, 0.253, 335, 253, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2269, 2brnA, 0.7841, 2.59, 0.264, 268, 254, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2270, 5ufuA, 0.7840, 2.42, 0.298, 368, 252, STRUCTURE OF AMPK BOUND TO ACTIVATOR
2271, 3x2uA, 0.7840, 2.42, 0.254, 336, 252, MICHAELIS-LIKE INITIAL COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT.
2272, 2vn9B, 0.7840, 2.58, 0.290, 301, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
2273, 5ig1A, 0.7839, 2.71, 0.282, 300, 255, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
2274, 4qmpA, 0.7838, 2.50, 0.272, 289, 254, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
2275, 3zo3A, 0.7838, 2.49, 0.265, 337, 253, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2276, 3owpA, 0.7838, 2.49, 0.257, 334, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2277, 3ovvA, 0.7838, 2.50, 0.257, 335, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2278, 2xikA, 0.7838, 2.52, 0.277, 288, 253, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
2279, 2gngA, 0.7838, 2.51, 0.280, 338, 254, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
2280, 2bfyB, 0.7838, 2.45, 0.270, 278, 252, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2281, 5lvpD, 0.7837, 2.40, 0.279, 276, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2282, 5isoA, 0.7837, 2.44, 0.281, 453, 253, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2283, 4zhxA, 0.7837, 2.41, 0.286, 408, 252, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
2284, 5he3A, 0.7836, 2.60, 0.246, 623, 256, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
2285, 3c0hB, 0.7836, 2.83, 0.297, 300, 256, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
2286, 2gu8A, 0.7836, 2.38, 0.254, 335, 252, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
2287, 4uj9A, 0.7835, 2.49, 0.257, 339, 253, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
2288, 4mk0A, 0.7835, 2.58, 0.250, 631, 256, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH A A RATIONALLY DESIGNED PAROXETINE DERIVATIVE
2289, 3mfrA, 0.7835, 2.83, 0.305, 302, 256, CASK-4M CAM KINASE DOMAIN NATIVE
2290, 2w9zB, 0.7835, 3.23, 0.475, 287, 265, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
2291, 2vn9A, 0.7835, 2.59, 0.290, 301, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
2292, 2erzE, 0.7835, 2.53, 0.264, 334, 254, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
2293, 5bx6A, 0.7834, 2.54, 0.268, 343, 254, PKA IN COMPLEX WITH A HALOGENATED PHTHALAZINONE FRAGMENT COMPOUND.
2294, 4hptE, 0.7834, 2.47, 0.253, 335, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING COMPLETE PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
2295, 2uw8A, 0.7834, 2.51, 0.261, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
2296, 3vqhA, 0.7833, 2.49, 0.257, 344, 253, BROMINE SAD PARTIALLY RESOLVES MULTIPLE BINDING MODES FOR PKA INHIBITOR H-89
2297, 5kq5A, 0.7832, 2.43, 0.298, 362, 252, AMPK BOUND TO ALLOSTERIC ACTIVATOR
2298, 5eykB, 0.7832, 2.44, 0.270, 275, 252, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
2299, 4qo9B, 0.7831, 2.59, 0.252, 285, 254, MST3 IN COMPLEX WITH DANUSERTIB
2300, 4xw5A, 0.7830, 2.52, 0.265, 334, 253, X-RAY STRUCTURE OF PKAC WITH ATP CP20 CALCIUM IONS
2301, 2gfcA, 0.7830, 2.48, 0.253, 335, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2302, 4iebA, 0.7829, 2.41, 0.295, 472, 251, CRYSTAL STRUCTURE OF A GLY128MET MUTANT OF THE TOXOPLASMA CDPK TGME49_101440
2303, 3p0mA, 0.7829, 2.48, 0.257, 335, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2304, 3e8eI, 0.7829, 2.46, 0.253, 345, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2305, 2c3kA, 0.7829, 2.46, 0.274, 262, 252, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
2306, 2broA, 0.7828, 2.72, 0.267, 272, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2307, 5bx7A, 0.7827, 2.49, 0.257, 343, 253, PKA IN COMPLEX WITH A BENZOTHIOPHENE FRAGMENT COMPOUND.
2308, 4l67A, 0.7827, 2.62, 0.272, 289, 254, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
2309, 3zo1A, 0.7827, 2.50, 0.265, 339, 253, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2310, 3v5wA, 0.7827, 2.62, 0.246, 623, 256, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
2311, 2gniA, 0.7827, 2.47, 0.269, 338, 253, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
2312, 2f2uB, 0.7827, 2.88, 0.261, 383, 261, CRYSTAL STRUCTURE OF THE RHO-KINASE KINASE DOMAIN
2313, 5dh3A, 0.7826, 2.54, 0.275, 287, 255, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
2314, 3o7lB, 0.7826, 2.46, 0.245, 326, 253, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
2315, 3nayA, 0.7826, 2.39, 0.275, 278, 251, PDK1 IN COMPLEX WITH INHIBITOR MP6
2316, 5wngD, 0.7825, 2.88, 0.258, 396, 260, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2317, 5m0cA, 0.7825, 2.50, 0.257, 336, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE FASUDIL-FRAGMENT ISOQUINOLINE-5-SULFONAMIDE 
2318, 3hkoA, 0.7825, 2.76, 0.266, 319, 256, CRYSTAL STRUCTURE OF A CDPK KINASE DOMAIN FROM CRYPTOSPORIDIUM PARVUM CGD7_40
2319, 3c0hA, 0.7825, 2.89, 0.297, 300, 256, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
2320, 1ydtE, 0.7825, 2.48, 0.253, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
2321, 5wg4A, 0.7824, 2.52, 0.256, 621, 254, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257284
2322, 4ewhB, 0.7823, 2.48, 0.252, 273, 254, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
2323, 4bbmB, 0.7823, 3.10, 0.408, 292, 260, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
2324, 3mftA, 0.7823, 3.02, 0.298, 302, 258, CASK-4M CAM KINASE DOMAIN MN2+
2325, 2e9vA, 0.7823, 2.55, 0.268, 268, 254, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
2326, 4ewhA, 0.7822, 2.48, 0.252, 274, 254, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
2327, 3e8cD, 0.7822, 2.54, 0.264, 344, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2328, 1q8uA, 0.7822, 2.54, 0.264, 341, 254, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
2329, 5uklA, 0.7821, 2.54, 0.247, 630, 255, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
2330, 3nx8A, 0.7821, 2.55, 0.268, 333, 254, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
2331, 3e8cF, 0.7821, 2.54, 0.264, 341, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2332, 1jluE, 0.7821, 2.49, 0.253, 337, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
2333, 5j5xA, 0.7820, 2.50, 0.257, 340, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1416
2334, 4iakA, 0.7820, 2.42, 0.254, 334, 252, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2335, 3e8cE, 0.7820, 2.54, 0.264, 336, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2336, 3e8cC, 0.7820, 2.55, 0.264, 341, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2337, 3e8cB, 0.7820, 2.54, 0.264, 344, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2338, 3e8cA, 0.7820, 2.55, 0.264, 341, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2339, 2cgwA, 0.7820, 2.44, 0.270, 262, 252, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
2340, 1q8tA, 0.7820, 2.49, 0.253, 338, 253, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
2341, 1jbpE, 0.7820, 2.48, 0.253, 339, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
2342, 4ae9A, 0.7819, 2.49, 0.264, 321, 254, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
2343, 3tacA, 0.7819, 2.76, 0.289, 324, 256, CRYSTAL STRUCTURE OF THE LIPRIN-ALPHA/CASK COMPLEX
2344, 3rwpA, 0.7819, 2.42, 0.272, 277, 250, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
2345, 3iopA, 0.7819, 2.39, 0.272, 275, 250, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
2346, 5jznB, 0.7818, 2.20, 0.296, 266, 247, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
2347, 5hngA, 0.7818, 2.44, 0.271, 280, 251, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2348, 4xbuA, 0.7818, 2.64, 0.268, 292, 254, IN VITRO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA PEPTIDE
2349, 4auaA, 0.7818, 2.19, 0.498, 256, 249, LIGANDED X-RAY CRYSTAL STRUCTURE OF CYCLIN DEPENDENT KINASE 6 (CDK6)
2350, 3tnqB, 0.7818, 2.53, 0.265, 331, 253, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2351, 3oxtA, 0.7818, 2.34, 0.263, 335, 251, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2352, 2cdzA, 0.7818, 2.52, 0.270, 289, 252, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
2353, 4c37A, 0.7817, 2.52, 0.269, 335, 253, PKA-S6K1 CHIMERA WITH COMPOUND 21A (CCT196539) BOUND
2354, 4c38A, 0.7816, 2.52, 0.269, 334, 253, PKA-S6K1 CHIMERA WITH COMPOUND 21E (CCT239066) BOUND
2355, 3lijA, 0.7816, 2.25, 0.325, 465, 249, CRYSTAL STRUCTURE OF FULL LENGTH CPCDPK3 (CGD5_820) IN COMPLEX WITH CA2+ AND AMPPNP
2356, 5i0bA, 0.7815, 2.41, 0.271, 288, 251, STRUCTURE OF PAK4
2357, 5ezrA, 0.7815, 2.60, 0.262, 803, 256, CRYSTAL STRUCTURE OF PVX_084705 BOUND TO COMPOUND
2358, 3nusA, 0.7815, 2.30, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
2359, 3mvjE, 0.7815, 2.53, 0.268, 334, 254, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2360, 2c30A, 0.7815, 2.73, 0.259, 289, 255, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
2361, 5oq5A, 0.7814, 2.46, 0.270, 265, 252, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
2362, 4iayA, 0.7814, 2.46, 0.254, 333, 252, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2363, 4fsnA, 0.7814, 2.48, 0.271, 270, 251, CRYSTAL STRUCTURE OF THE CHK1
2364, 5n3qA, 0.7813, 2.53, 0.269, 336, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINOBENZAMIDE
2365, 3idbA, 0.7813, 2.51, 0.253, 341, 253, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
2366, 1okzA, 0.7813, 2.29, 0.273, 276, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
2367, 4wbbB, 0.7812, 2.53, 0.265, 334, 253, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
2368, 3nuuA, 0.7812, 2.30, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
2369, 5n3rA, 0.7811, 2.50, 0.273, 336, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(CARBAMOYLAMINO)-4- METHYLSULFANYLBUTANOIC ACID
2370, 5hvuA, 0.7811, 2.82, 0.266, 394, 259, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH A PYRIDINE THIAZOLE PIPERIDINE INHIBITOR
2371, 4iazA, 0.7811, 2.47, 0.254, 334, 252, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH BA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2372, 4appA, 0.7811, 2.54, 0.257, 291, 253, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
2373, 3nuyA, 0.7811, 2.31, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
2374, 3h9oA, 0.7811, 2.41, 0.272, 275, 250, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
2375, 2qurA, 0.7811, 2.48, 0.253, 338, 253, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
2376, 6fd3A, 0.7810, 2.55, 0.308, 296, 253, THIOPHOSPHORYLATED PAK3 KINASE DOMAIN
2377, 5vi9A, 0.7810, 2.63, 0.257, 306, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
2378, 5n3gA, 0.7810, 2.51, 0.273, 337, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (R)-14-OXAZEPAN-6-OL
2379, 5n1fA, 0.7810, 2.52, 0.269, 337, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-QUINOLIN-5-YLPYRIDINE-3-CARBOXAMIDE
2380, 2hz4A, 0.7810, 2.52, 0.226, 262, 252, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
2381, 5n3pA, 0.7809, 2.52, 0.269, 336, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 1H-INDOL-5-OL
2382, 4qyeA, 0.7809, 2.50, 0.271, 271, 251, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
2383, 2e9vB, 0.7809, 2.56, 0.268, 268, 254, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
2384, 5n3jA, 0.7808, 2.53, 0.269, 337, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-NITROBENZOIC ACID
2385, 4rvkA, 0.7808, 2.38, 0.272, 264, 250, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
2386, 4cfeC, 0.7808, 2.44, 0.286, 403, 252, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2387, 1q24A, 0.7808, 2.53, 0.249, 335, 253, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
2388, 3ow3A, 0.7807, 2.42, 0.254, 334, 252, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
2389, 1eh4B, 0.7807, 2.55, 0.180, 293, 256, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
2390, 5n3nA, 0.7806, 2.52, 0.269, 337, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE [(2R)-24-DIHYDROXY-4-OXOBUTYL]- TRIMETHYLAZANIUM
2391, 5ho8A, 0.7806, 2.30, 0.273, 278, 249, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2392, 5dylA, 0.7806, 2.44, 0.261, 802, 253, CRYSTAL STRUCTURE OF PVX_084705
2393, 4rz7A, 0.7806, 2.36, 0.261, 801, 253, CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND PCI32765
2394, 4iafA, 0.7806, 2.48, 0.254, 333, 252, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2395, 4dh5A, 0.7806, 2.47, 0.254, 333, 252, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ADP PHOSPHATE AND IP20
2396, 3q5iA, 0.7806, 2.30, 0.301, 470, 249, CRYSTAL STRUCTURE OF PBANKA_031420
2397, 3orzB, 0.7806, 2.49, 0.275, 278, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2398, 3nunA, 0.7806, 2.34, 0.273, 278, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
2399, 3e8eP, 0.7806, 2.51, 0.253, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2400, 1sykB, 0.7806, 2.55, 0.252, 323, 254, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
2401, 1sykA, 0.7806, 2.55, 0.252, 348, 254, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
2402, 5wg3A, 0.7805, 2.54, 0.252, 618, 254, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG258748
2403, 5n1hA, 0.7805, 2.53, 0.269, 337, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL 4-(AMINOMETHYL)BENZOATE
2404, 3x2vA, 0.7805, 2.45, 0.254, 331, 252, MICHAELIS-LIKE COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2405, 3orzD, 0.7805, 2.49, 0.275, 278, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2406, 3bhhB, 0.7805, 2.73, 0.318, 289, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2407, 5n1gA, 0.7804, 2.52, 0.269, 337, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-(2-AMINO-13-THIAZOL-4-YL)-1- OXASPIRO[4.5]DECAN-2-ONE
2408, 4j96B, 0.7804, 2.81, 0.235, 305, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
2409, 1uu8A, 0.7804, 2.30, 0.277, 277, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
2410, 2bdwB, 0.7803, 2.69, 0.297, 309, 256, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
2411, 5n3tA, 0.7802, 2.53, 0.269, 337, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 5-CHLOROTHIOPHENE-2-SULFONAMIDE
2412, 4l6qA, 0.7802, 2.85, 0.255, 388, 259, ROCK2 IN COMPLEX WITH BENZOXABOROLE
2413, 3qd3A, 0.7802, 2.34, 0.273, 278, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
2414, 3kkvA, 0.7802, 2.52, 0.265, 335, 253, STRUCTURE OF PKA WITH A PROTEIN KINASE B-SELECTIVE INHIBITOR.
2415, 2v7oA, 0.7802, 2.68, 0.302, 305, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
2416, 1nvsA, 0.7802, 2.39, 0.272, 264, 250, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
2417, 5ui0B, 0.7801, 2.81, 0.231, 304, 255, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
2418, 2jdsA, 0.7801, 2.48, 0.254, 334, 252, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
2419, 5wneD, 0.7800, 2.90, 0.258, 396, 260, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2420, 3c0gB, 0.7800, 2.87, 0.294, 320, 255, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
2421, 1nvrA, 0.7800, 2.40, 0.272, 264, 250, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
2422, 4qyfA, 0.7799, 2.40, 0.272, 269, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
2423, 4dg2E, 0.7799, 2.53, 0.265, 347, 253, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
2424, 3qcqA, 0.7799, 2.35, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
2425, 3odyX, 0.7799, 2.82, 0.373, 321, 255, CRYSTAL STRUCTURE OF P38ALPHA Y323Q ACTIVE MUTANT
2426, 2brmA, 0.7799, 2.56, 0.261, 263, 253, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2427, 5n3kA, 0.7798, 2.53, 0.269, 337, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE O-GUANIDINO-L-HOMOSERINE
2428, 4c33A, 0.7798, 2.48, 0.258, 335, 252, PKA-S6K1 CHIMERA APO
2429, 3nupA, 0.7798, 2.21, 0.492, 252, 248, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
2430, 3c0gA, 0.7798, 2.88, 0.294, 309, 255, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
2431, 5izfA, 0.7797, 2.58, 0.268, 336, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1408
2432, 4iacA, 0.7797, 2.44, 0.254, 333, 252, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION AMP-PCP AND PSEUDO-SUBSTRATE PEPTIDE SP20
2433, 4cffA, 0.7797, 2.46, 0.286, 424, 252, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
2434, 3fjqE, 0.7797, 2.54, 0.253, 334, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
2435, 2vd5B, 0.7797, 2.66, 0.273, 380, 256, STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII
2436, 1nvqA, 0.7797, 2.40, 0.272, 264, 250, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
2437, 5n3iA, 0.7796, 2.54, 0.273, 337, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL (2S)-2-AMINO-3-PHENYLPROPANOATE
2438, 4njdA, 0.7796, 2.66, 0.268, 290, 254, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
2439, 4l6qB, 0.7796, 2.90, 0.273, 388, 260, ROCK2 IN COMPLEX WITH BENZOXABOROLE
2440, 3qcxA, 0.7796, 2.35, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
2441, 6babB, 0.7795, 2.64, 0.300, 285, 253, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2442, 5m0lA, 0.7795, 2.53, 0.257, 338, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE METHYLATED FASUDIL-DERIVED FRAGMENT N-METHYLISOQUINOLINE-5- SULFONAMIDE (LIGAND 02) 
2443, 3qcsA, 0.7795, 2.36, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
2444, 3f3zA, 0.7795, 2.54, 0.262, 271, 252, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
2445, 6b16A, 0.7794, 2.28, 0.285, 285, 249, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
2446, 5n3hA, 0.7793, 2.55, 0.269, 337, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE PYRIDINE-3-CARBOXAMIDE
2447, 5jznA, 0.7793, 2.23, 0.287, 268, 247, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
2448, 4ft9A, 0.7793, 2.41, 0.272, 270, 250, CRYSTAL STRUCTURE OF THE CHK1
2449, 4cffC, 0.7793, 2.47, 0.286, 422, 252, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
2450, 3dlsA, 0.7793, 2.50, 0.258, 285, 252, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2451, 1fmoE, 0.7793, 2.53, 0.253, 336, 253, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
2452, 5n3sA, 0.7792, 2.56, 0.269, 337, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-HYDROXYBENZAMIDE
2453, 5n3lA, 0.7792, 2.55, 0.269, 337, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-[(1R)-2-AMINO-1-HYDROXYETHYL]BENZENE-1 2-DIOL
2454, 4o21A, 0.7792, 2.50, 0.254, 333, 252, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
2455, 4dfzE, 0.7792, 2.47, 0.254, 347, 252, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
2456, 1apmE, 0.7792, 2.53, 0.253, 338, 253, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
2457, 5n3oA, 0.7791, 2.44, 0.270, 335, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-(13-OXAZOL-5-YL)ANILINE
2458, 4j7bA, 0.7791, 2.33, 0.269, 284, 249, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
2459, 4ib3A, 0.7791, 2.49, 0.254, 336, 252, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH ADP PHOSPHORYLATED PEPTIDE PSP20 AND NO METAL
2460, 3hx4A, 0.7791, 2.40, 0.285, 467, 249, CRYSTAL STRUCTURE OF CDPK1 OF TOXOPLASMA GONDII TGME49_101440 IN PRESENCE OF CALCIUM
2461, 3eqrB, 0.7791, 2.37, 0.251, 271, 251, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
2462, 2qhmA, 0.7791, 2.41, 0.272, 268, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2A
2463, 5oorA, 0.7790, 2.34, 0.269, 273, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
2464, 3qfvB, 0.7790, 2.99, 0.248, 396, 262, MRCK BETA IN COMPLEX WITH TPCA-1
2465, 3e8eE, 0.7790, 2.51, 0.253, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2466, 2etkA, 0.7790, 2.81, 0.266, 400, 259, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
2467, 4xliB, 0.7789, 2.49, 0.226, 264, 252, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
2468, 3tkiA, 0.7789, 2.52, 0.271, 272, 251, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
2469, 3qfvA, 0.7789, 2.99, 0.248, 395, 262, MRCK BETA IN COMPLEX WITH TPCA-1
2470, 3qamE, 0.7789, 2.55, 0.249, 348, 253, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
2471, 3e8eA, 0.7789, 2.54, 0.253, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2472, 2wtkB, 0.7789, 2.69, 0.242, 311, 256, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
2473, 1atpE, 0.7788, 2.54, 0.253, 334, 253, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
2474, 3gu5A, 0.7787, 2.48, 0.262, 280, 252, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
2475, 3e8eB, 0.7787, 2.53, 0.253, 337, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2476, 4j98B, 0.7786, 2.56, 0.242, 304, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
2477, 3twjA, 0.7786, 2.89, 0.269, 396, 260, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
2478, 3ionA, 0.7786, 2.41, 0.273, 274, 249, PDK1 IN COMPLEX WITH COMPOUND 8H
2479, 4xw6A, 0.7785, 2.52, 0.254, 334, 252, X-RAY STRUCTURE OF PKAC WITH ADP FREE PHOSPHATE ION CP20 MAGNESIUM IONS
2480, 4ftiA, 0.7785, 2.54, 0.271, 270, 251, CRYSTAL STRUCTURE OF THE CHK1
2481, 2z8cA, 0.7785, 2.72, 0.197, 297, 254, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
2482, 4cfeA, 0.7784, 2.48, 0.286, 425, 252, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2483, 4dh8A, 0.7783, 2.52, 0.254, 333, 252, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20
2484, 4c36A, 0.7783, 2.49, 0.258, 335, 252, PKA-S6K1 CHIMERA WITH COMPOUND 15E (CCT147581) BOUND
2485, 3w2qA, 0.7783, 2.76, 0.198, 307, 257, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
2486, 2c3jA, 0.7783, 2.40, 0.268, 257, 250, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
2487, 1uu3A, 0.7783, 2.40, 0.273, 276, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
2488, 1rdqE, 0.7783, 2.46, 0.250, 340, 252, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
2489, 6b1uC, 0.7782, 2.50, 0.282, 459, 252, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
2490, 5fetA, 0.7782, 2.48, 0.257, 802, 253, CRYSTAL STRUCTURE OF PVX_084705 IN PRESENCE OF COMPOUND 2
2491, 4zy6A, 0.7782, 2.24, 0.286, 284, 248, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2492, 4rvmA, 0.7782, 2.42, 0.272, 264, 250, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
2493, 4qo9A, 0.7782, 2.57, 0.277, 280, 253, MST3 IN COMPLEX WITH DANUSERTIB
2494, 4hyhA, 0.7782, 2.38, 0.272, 263, 250, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
2495, 5jzjA, 0.7781, 2.23, 0.285, 271, 246, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
2496, 3bhhA, 0.7781, 2.77, 0.322, 289, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2497, 3ue4B, 0.7780, 2.63, 0.217, 268, 253, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
2498, 3qcyA, 0.7780, 2.31, 0.274, 275, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
2499, 4dfxE, 0.7779, 2.49, 0.254, 347, 252, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
2500, 3orzC, 0.7779, 2.50, 0.272, 276, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2501, 3orzA, 0.7779, 2.51, 0.272, 276, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2502, 2cpkE, 0.7779, 2.52, 0.254, 333, 252, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
2503, 3orxE, 0.7778, 2.38, 0.276, 274, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2504, 2r7bA, 0.7778, 2.39, 0.273, 274, 249, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
2505, 2hogA, 0.7778, 2.43, 0.272, 272, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
2506, 2f2uA, 0.7778, 2.97, 0.261, 386, 261, CRYSTAL STRUCTURE OF THE RHO-KINASE KINASE DOMAIN
2507, 2eb2A, 0.7778, 2.73, 0.195, 305, 256, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
2508, 1uu9A, 0.7778, 2.38, 0.273, 276, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
2509, 2qhnA, 0.7777, 2.43, 0.272, 268, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1A
2510, 2hy0A, 0.7777, 2.44, 0.272, 272, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
2511, 5n3mA, 0.7776, 2.56, 0.269, 337, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE D-ARGININE
2512, 5ezvC, 0.7776, 2.51, 0.282, 440, 252, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
2513, 4wb5A, 0.7776, 2.54, 0.258, 335, 252, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2514, 4j7bD, 0.7776, 2.34, 0.270, 281, 248, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
2515, 4ftuA, 0.7776, 2.50, 0.272, 270, 250, CRYSTAL STRUCTURE OF THE CHK1
2516, 3e8eL, 0.7776, 2.53, 0.253, 336, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2517, 2f4jA, 0.7776, 2.68, 0.228, 287, 254, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
2518, 5u7qB, 0.7775, 2.95, 0.250, 385, 260, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2519, 5kksA, 0.7775, 2.82, 0.267, 395, 258, ROCK 1 BOUND TO AZAINDOLE THIOZOLE INHIBITOR
2520, 2etrA, 0.7775, 2.92, 0.262, 400, 260, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
2521, 5xdkA, 0.7774, 2.75, 0.199, 307, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
2522, 5oopA, 0.7774, 2.38, 0.264, 261, 250, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
2523, 4ib1A, 0.7774, 2.53, 0.254, 335, 252, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH K+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2524, 3ndmD, 0.7774, 2.81, 0.255, 396, 259, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
2525, 4rvlA, 0.7773, 2.38, 0.273, 258, 249, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 7: 3-(2- HYDROXYPHENYL)-9H-PYRROLO[23-B:54-C ]DIPYRIDINE-6-CARBONITRILE
2526, 4dc2A, 0.7773, 2.44, 0.281, 328, 253, STRUCTURE OF PKC IN COMPLEX WITH A SUBSTRATE PEPTIDE FROM PAR-3
2527, 3mvjB, 0.7773, 2.59, 0.260, 320, 254, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2528, 2pe2A, 0.7773, 2.43, 0.273, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
2529, 2pe0A, 0.7773, 2.42, 0.273, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
2530, 1jksA, 0.7773, 2.50, 0.262, 280, 252, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2531, 1jkkA, 0.7773, 2.50, 0.262, 277, 252, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
2532, 4x6rA, 0.7772, 2.57, 0.265, 347, 253, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
2533, 3qalE, 0.7772, 2.58, 0.249, 339, 253, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
2534, 3gu4A, 0.7771, 2.50, 0.262, 280, 252, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
2535, 2esmA, 0.7771, 2.82, 0.266, 400, 259, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO FASUDIL
2536, 1ig1A, 0.7771, 2.51, 0.262, 280, 252, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
2537, 4ft5A, 0.7769, 2.51, 0.272, 265, 250, CRYSTAL STRUCTURE OF THE CHK1
2538, 4fsrA, 0.7769, 2.44, 0.272, 269, 250, CRYSTAL STRUCTURE OF THE CHK1
2539, 4dg0E, 0.7769, 2.52, 0.254, 338, 252, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
2540, 5ui0A, 0.7768, 2.65, 0.237, 301, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
2541, 3nlbA, 0.7768, 2.53, 0.271, 261, 251, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
2542, 1jklA, 0.7768, 2.51, 0.262, 280, 252, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
2543, 5wg5A, 0.7767, 2.52, 0.253, 617, 253, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224061
2544, 5uyjA, 0.7767, 2.46, 0.284, 281, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2545, 2c3lA, 0.7767, 2.48, 0.272, 265, 250, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
2546, 6bl8B, 0.7766, 2.75, 0.220, 268, 254, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
2547, 5hkmA, 0.7766, 2.32, 0.274, 272, 248, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2548, 3orxG, 0.7766, 2.35, 0.277, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2549, 3orxF, 0.7766, 2.35, 0.277, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2550, 4twpB, 0.7765, 2.62, 0.225, 271, 253, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
2551, 4ib0A, 0.7765, 2.54, 0.254, 334, 252, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH NA+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2552, 4iadA, 0.7765, 2.54, 0.254, 334, 252, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2553, 4hpuE, 0.7765, 2.53, 0.254, 336, 252, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING PARTIAL PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
2554, 3pvbA, 0.7765, 2.55, 0.254, 341, 252, CRYSTAL STRUCTURE OF (73-244)RIA:C HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
2555, 3fhiA, 0.7765, 2.58, 0.253, 336, 253, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
2556, 5ukkA, 0.7764, 2.68, 0.258, 613, 256, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
2557, 5g1xA, 0.7764, 2.31, 0.294, 262, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH N-MYC
2558, 5e8xA, 0.7764, 2.69, 0.217, 304, 253, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
2559, 3orxH, 0.7764, 2.35, 0.277, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2560, 3ha6A, 0.7764, 2.34, 0.298, 263, 248, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
2561, 3dfcB, 0.7764, 2.50, 0.262, 280, 252, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
2562, 3comA, 0.7764, 2.48, 0.281, 264, 253, CRYSTAL STRUCTURE OF MST1 KINASE
2563, 1z5mA, 0.7764, 2.44, 0.273, 275, 249, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
2564, 5lxmA, 0.7763, 2.28, 0.306, 266, 248, CRYSTAL STRUCTURE OF AURORA-A BOUND TO A HYDROCARBON-STAPLED PROTEOMIMETIC OF TPX2
2565, 4r3pA, 0.7763, 2.86, 0.198, 310, 258, CRYSTAL STRUCTURES OF EGFR IN COMPLEX WITH MIG6
2566, 4j96A, 0.7763, 2.86, 0.235, 302, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
2567, 4iaiA, 0.7763, 2.53, 0.254, 333, 252, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH CA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2568, 4i23A, 0.7763, 2.72, 0.196, 304, 255, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
2569, 5cziA, 0.7762, 2.82, 0.198, 310, 257, EGFR L858R MUTANT IN COMPLEX WITH A SHC PEPTIDE SUBSTRATE
2570, 3gu7A, 0.7762, 2.52, 0.262, 280, 252, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
2571, 3d5xA, 0.7762, 2.31, 0.257, 279, 249, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
2572, 5ugbA, 0.7761, 2.62, 0.201, 307, 254, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
2573, 4j97D, 0.7761, 2.60, 0.242, 285, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2574, 4ae6B, 0.7761, 2.64, 0.260, 321, 254, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
2575, 4dh7A, 0.7760, 2.56, 0.254, 333, 252, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20 
2576, 3a7gA, 0.7760, 2.66, 0.276, 289, 254, HUMAN MST3 KINASE
2577, 5wnhD, 0.7759, 2.97, 0.262, 397, 260, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2578, 4zy5A, 0.7759, 2.29, 0.286, 283, 248, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
2579, 4wb7A, 0.7759, 2.55, 0.258, 402, 252, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2580, 4qygB, 0.7759, 2.45, 0.272, 264, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
2581, 4ft7A, 0.7759, 2.42, 0.273, 270, 249, CRYSTAL STRUCTURE OF THE CHK1
2582, 3ot3A, 0.7759, 2.43, 0.273, 259, 249, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
2583, 3lcdA, 0.7759, 2.49, 0.214, 290, 252, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
2584, 3dlsD, 0.7759, 2.44, 0.252, 284, 250, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2585, 3dgkA, 0.7759, 2.52, 0.262, 278, 252, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
2586, 1m52B, 0.7759, 2.44, 0.219, 272, 251, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
2587, 5op7A, 0.7758, 2.34, 0.265, 261, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
2588, 4zhxC, 0.7758, 2.54, 0.282, 452, 252, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
2589, 4qyhB, 0.7758, 2.45, 0.272, 264, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
2590, 2wtkE, 0.7758, 2.75, 0.242, 308, 256, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
2591, 2r0uA, 0.7758, 2.46, 0.272, 269, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 54
2592, 2qcsA, 0.7758, 2.55, 0.254, 335, 252, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
2593, 5eykA, 0.7757, 2.40, 0.297, 263, 249, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
2594, 4j97A, 0.7757, 2.60, 0.242, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2595, 4pf4A, 0.7756, 2.53, 0.262, 278, 252, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
2596, 4fszA, 0.7756, 2.53, 0.272, 268, 250, CRYSTAL STRUCTURE OF THE CHK1
2597, 3mvjA, 0.7756, 2.59, 0.257, 334, 253, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2598, 3gu6A, 0.7756, 2.53, 0.262, 280, 252, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
2599, 2x7fB, 0.7756, 2.26, 0.254, 288, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2600, 2w4jA, 0.7756, 2.54, 0.262, 276, 252, X-RAY STRUCTURE OF A DAP-KINASE 2-277
2601, 5u7qC, 0.7755, 2.86, 0.274, 390, 259, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2602, 4yuqA, 0.7755, 2.47, 0.285, 462, 249, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
2603, 4xeyA, 0.7755, 2.44, 0.219, 269, 251, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
2604, 4j98A, 0.7755, 2.73, 0.241, 304, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
2605, 4dh3A, 0.7755, 2.55, 0.254, 333, 252, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ATP AND IP20
2606, 3w2oA, 0.7755, 2.83, 0.198, 305, 257, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
2607, 4x6qC, 0.7754, 2.53, 0.254, 334, 252, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
2608, 4wb7B, 0.7754, 2.56, 0.258, 402, 252, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2609, 2x7fC, 0.7754, 2.12, 0.252, 285, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2610, 2phkA, 0.7754, 2.61, 0.285, 277, 253, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
2611, 1eh4A, 0.7754, 2.61, 0.184, 293, 256, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
2612, 3comB, 0.7753, 2.57, 0.271, 279, 255, CRYSTAL STRUCTURE OF MST1 KINASE
2613, 3cblA, 0.7753, 2.65, 0.233, 356, 253, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
2614, 2xynC, 0.7753, 2.39, 0.224, 262, 250, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
2615, 4qygA, 0.7752, 2.49, 0.272, 264, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
2616, 3tnpF, 0.7752, 2.53, 0.254, 334, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2617, 3tnpC, 0.7752, 2.53, 0.254, 334, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2618, 3up2A, 0.7750, 2.42, 0.296, 266, 250, AURORA A IN COMPLEX WITH RPM1686
2619, 3a7hA, 0.7750, 2.69, 0.260, 289, 254, HUMAN MST3 KINASE IN COMPLEX WITH ATP
2620, 1cdkB, 0.7750, 2.49, 0.258, 342, 252, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2621, 5ootA, 0.7749, 2.32, 0.266, 260, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
2622, 4j99B, 0.7749, 2.68, 0.245, 291, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2623, 4j97C, 0.7749, 2.61, 0.242, 283, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2624, 4j95B, 0.7749, 2.62, 0.242, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
2625, 3uztA, 0.7749, 2.41, 0.269, 586, 249, STRUCTURE OF THE C13.18 RNA APTAMER IN COMPLEX WITH G PROTEIN-COUPLED RECEPTOR KINASE 2
2626, 2etkB, 0.7749, 2.77, 0.265, 398, 257, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
2627, 5czhA, 0.7748, 2.84, 0.198, 311, 257, EGFR L858R MUTANT IN COMPLEX WITH AN OPTIMAL PEPTIDE SUBSTRATE
2628, 4j97B, 0.7748, 2.73, 0.241, 283, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2629, 4yveA, 0.7747, 2.84, 0.267, 390, 258, ROCK 1 BOUND TO METHOXYPHENYL THIAZOLE INHIBITOR
2630, 4dg3E, 0.7747, 2.57, 0.254, 335, 252, CRYSTAL STRUCTURE OF R336A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED TURN MOTIF.
2631, 3gu8A, 0.7747, 2.53, 0.262, 278, 252, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
2632, 5vioA, 0.7746, 2.73, 0.278, 271, 252, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
2633, 5jr7A, 0.7746, 2.59, 0.265, 335, 253, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
2634, 3ndmB, 0.7746, 2.85, 0.255, 396, 259, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
2635, 3eqrA, 0.7746, 2.53, 0.251, 270, 251, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
2636, 3a7fA, 0.7746, 2.46, 0.272, 283, 250, HUMAN MST3 KINASE
2637, 5wnfD, 0.7745, 2.91, 0.263, 396, 259, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2638, 4wb8A, 0.7745, 2.58, 0.258, 334, 252, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT) EXON 1 DELETION
2639, 4b4lA, 0.7745, 2.77, 0.251, 299, 255, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
2640, 3uodA, 0.7745, 2.34, 0.297, 266, 249, AURORA A IN COMPLEX WITH RPM1693
2641, 3gniB, 0.7745, 2.60, 0.246, 304, 252, STRUCTURE OF STRAD AND MO25
2642, 3d9vA, 0.7745, 2.86, 0.266, 400, 259, CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI- METHYLATED VARIANT OF FASUDIL
2643, 2v7aB, 0.7745, 2.62, 0.229, 268, 253, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
2644, 2pe1A, 0.7745, 2.46, 0.273, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
2645, 1rqqB, 0.7745, 2.86, 0.204, 294, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
2646, 5xvaA, 0.7744, 2.45, 0.276, 292, 250, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH216
2647, 5bmlA, 0.7744, 2.80, 0.266, 393, 256, ROCK 1 BOUND TO A PYRIDINE THIAZOLE INHIBITOR
2648, 4fzaB, 0.7744, 2.72, 0.256, 281, 254, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
2649, 1m52A, 0.7744, 2.47, 0.223, 271, 251, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
2650, 5opvA, 0.7743, 2.38, 0.266, 261, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
2651, 5em8A, 0.7743, 2.69, 0.197, 303, 254, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
2652, 2e9pA, 0.7743, 2.80, 0.268, 269, 254, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
2653, 4dh1A, 0.7742, 2.56, 0.254, 333, 252, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH LOW MG2+ ATP AND IP20
2654, 3bwjA, 0.7742, 2.58, 0.254, 338, 252, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
2655, 5vioD, 0.7741, 2.64, 0.282, 271, 252, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
2656, 4qyhA, 0.7741, 2.51, 0.272, 264, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
2657, 3qd4A, 0.7741, 2.34, 0.271, 276, 247, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
2658, 4ft3A, 0.7740, 2.34, 0.274, 269, 248, CRYSTAL STRUCTURE OF THE CHK1
2659, 3jvrA, 0.7740, 2.33, 0.271, 258, 247, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
2660, 3ehaA, 0.7740, 2.49, 0.263, 279, 251, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
2661, 3bu6A, 0.7740, 2.81, 0.201, 294, 254, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
2662, 2gs6A, 0.7740, 2.66, 0.197, 311, 254, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
2663, 2gqgB, 0.7740, 2.66, 0.226, 276, 252, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
2664, 5kktB, 0.7739, 2.95, 0.273, 394, 260, ROCK 1 BOUND TO AZAINDOLE THIOZOLE PIPERAZINE INHIBITOR
2665, 3soaA, 0.7739, 2.77, 0.286, 436, 255, FULL-LENGTH HUMAN CAMKII
2666, 3c4eB, 0.7739, 2.39, 0.265, 273, 249, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2667, 1l3rE, 0.7739, 2.36, 0.256, 338, 250, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
2668, 5g15A, 0.7738, 2.48, 0.284, 265, 250, STRUCTURE AURORA A (122-403) BOUND TO ACTIVATING MONOBODY MB1 AND AMPPCP
2669, 4xh0A, 0.7738, 2.72, 0.180, 350, 256, STRUCTURE OF C. GLABRATA HRR25 BOUND TO ADP (SO4 CONDITION)
2670, 4hnfB, 0.7738, 2.67, 0.187, 290, 256, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
2671, 3w2pA, 0.7738, 2.81, 0.198, 308, 257, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
2672, 3utoB, 0.7738, 2.90, 0.237, 566, 257, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
2673, 2v7aA, 0.7738, 2.61, 0.226, 269, 252, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
2674, 5w4wB, 0.7737, 2.73, 0.176, 291, 256, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2675, 5auyA, 0.7737, 2.49, 0.263, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
2676, 4kikB, 0.7737, 3.01, 0.273, 648, 260, HUMAN IKB KINASE BETA
2677, 3c4eA, 0.7737, 2.39, 0.265, 273, 249, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2678, 5vilA, 0.7736, 2.75, 0.274, 271, 252, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
2679, 1u59A, 0.7736, 2.69, 0.224, 282, 255, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2680, 5vjaC, 0.7735, 2.45, 0.255, 265, 251, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2681, 5kktA, 0.7735, 2.73, 0.270, 389, 256, ROCK 1 BOUND TO AZAINDOLE THIOZOLE PIPERAZINE INHIBITOR
2682, 5jzjB, 0.7735, 2.07, 0.296, 261, 243, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
2683, 4yuqB, 0.7735, 2.44, 0.286, 462, 248, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
2684, 4tksA, 0.7735, 2.76, 0.196, 307, 255, NATIVE-SAD PHASING FOR HUMAN EGFR KINASE DOMAIN.
2685, 2etrB, 0.7735, 2.79, 0.265, 398, 257, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
2686, 5uy6A, 0.7734, 2.45, 0.289, 282, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2687, 5av3A, 0.7734, 2.52, 0.263, 275, 251, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
2688, 5n7pA, 0.7733, 2.55, 0.258, 350, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINO-5-(PYRROLIDIN-1-YL)-1H-PYRAZOLE- 4-CARBONITRILE
2689, 5jr7C, 0.7733, 2.61, 0.265, 335, 253, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
2690, 5flfB, 0.7733, 2.71, 0.242, 292, 252, DISEASE LINKED MUTATION IN FGFR
2691, 5eg3A, 0.7733, 2.76, 0.235, 301, 255, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
2692, 4yvcA, 0.7733, 2.78, 0.257, 388, 257, ROCK 1 BOUND TO THIAZOLE INHIBITOR
2693, 5xgnA, 0.7732, 2.66, 0.206, 302, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
2694, 4yo4A, 0.7732, 2.57, 0.262, 280, 252, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
2695, 2xuuA, 0.7732, 2.68, 0.252, 301, 254, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
2696, 5vioC, 0.7731, 2.73, 0.278, 271, 252, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
2697, 5oktA, 0.7731, 2.71, 0.187, 285, 256, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
2698, 5n32A, 0.7731, 2.65, 0.257, 345, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-CHLOROBENZYL CARBAMIMIDOTHIOATE
2699, 4btkA, 0.7731, 2.71, 0.191, 287, 257, TTBK1 IN COMPLEX WITH INHIBITOR
2700, 3utoA, 0.7731, 2.92, 0.237, 559, 257, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
2701, 5xvgA, 0.7730, 2.67, 0.273, 292, 253, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH226
2702, 4j99C, 0.7730, 2.75, 0.245, 291, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2703, 4ft0A, 0.7730, 2.40, 0.274, 266, 248, CRYSTAL STRUCTURE OF THE CHK1
2704, 4fsyA, 0.7730, 2.53, 0.277, 267, 249, CRYSTAL STRUCTURE OF THE CHK1
2705, 4deaA, 0.7730, 2.34, 0.297, 266, 249, AURORA A IN COMPLEX WITH YL1-038-18
2706, 3v8sC, 0.7730, 2.77, 0.272, 395, 257, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2707, 3ue4A, 0.7730, 2.53, 0.219, 270, 251, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
2708, 3dlsF, 0.7730, 2.21, 0.255, 281, 247, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2709, 3dlsC, 0.7730, 2.44, 0.261, 281, 249, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2710, 2ivsA, 0.7730, 2.67, 0.238, 284, 252, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
2711, 2g2hB, 0.7730, 2.74, 0.213, 272, 253, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2712, 1szmB, 0.7730, 2.79, 0.240, 320, 254, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2713, 6fckA, 0.7729, 2.79, 0.263, 269, 255, CHK1 KINASE IN COMPLEX WITH COMPOUND 13
2714, 5w4wA, 0.7729, 2.74, 0.176, 291, 256, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2715, 5vcwB, 0.7729, 2.26, 0.279, 285, 247, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PELITINIB
2716, 4fzfB, 0.7729, 2.83, 0.255, 279, 255, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH DKI
2717, 3dlsE, 0.7729, 2.24, 0.262, 282, 248, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2718, 5vjaB, 0.7728, 2.46, 0.259, 266, 251, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2719, 5u7rA, 0.7728, 2.85, 0.261, 387, 257, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2720, 5av2A, 0.7728, 2.53, 0.263, 275, 251, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2721, 4yc8B, 0.7728, 2.51, 0.220, 264, 250, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
2722, 4fttA, 0.7728, 2.42, 0.274, 266, 248, CRYSTAL STRUCTURE OF THE CHK1
2723, 3v8sA, 0.7728, 2.78, 0.272, 395, 257, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2724, 3uzpA, 0.7728, 2.71, 0.195, 292, 256, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
2725, 3f5uA, 0.7728, 2.52, 0.259, 279, 251, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
2726, 2gs2A, 0.7728, 2.72, 0.197, 305, 254, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
2727, 5wneA, 0.7727, 2.88, 0.264, 384, 258, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2728, 5vjaA, 0.7727, 2.55, 0.246, 266, 252, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2729, 5auvA, 0.7727, 2.52, 0.263, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
2730, 3qd0A, 0.7727, 2.37, 0.271, 274, 247, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
2731, 6brcA, 0.7726, 2.41, 0.286, 265, 248, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
2732, 5op5A, 0.7726, 2.30, 0.267, 259, 247, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
2733, 5av1A, 0.7726, 2.52, 0.263, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
2734, 2wmvA, 0.7726, 2.27, 0.272, 251, 246, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2735, 5vilC, 0.7725, 2.77, 0.274, 271, 252, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
2736, 5flfA, 0.7725, 2.69, 0.242, 296, 252, DISEASE LINKED MUTATION IN FGFR
2737, 4u45A, 0.7725, 2.51, 0.259, 289, 251, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
2738, 3f5gA, 0.7725, 2.53, 0.263, 279, 251, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
2739, 2j0iA, 0.7725, 2.59, 0.274, 289, 252, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
2740, 5u7rB, 0.7724, 2.86, 0.261, 387, 257, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2741, 5n37A, 0.7724, 2.69, 0.269, 347, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-(13-BENZODIOXOL-5-YLMETHYL) CYCLOPENTANAMINE
2742, 5hibA, 0.7724, 2.72, 0.189, 314, 254, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2743, 4ypdA, 0.7724, 2.59, 0.262, 281, 252, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
2744, 3zh8C, 0.7724, 2.66, 0.283, 312, 254, A NOVEL SMALL MOLECULE APKC INHIBITOR
2745, 2yexA, 0.7724, 2.79, 0.263, 269, 255, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2746, 2pvyD, 0.7724, 2.72, 0.238, 283, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
2747, 1kobA, 0.7724, 2.95, 0.237, 352, 257, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2748, 5flfC, 0.7723, 2.80, 0.237, 283, 253, DISEASE LINKED MUTATION IN FGFR
2749, 5c1qB, 0.7723, 2.42, 0.269, 273, 249, SERINE/THREONINE-PROTEIN KINASE PIM-1
2750, 3kxxA, 0.7723, 2.78, 0.240, 305, 254, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
2751, 2esmB, 0.7723, 2.79, 0.265, 398, 257, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO FASUDIL
2752, 2bvaB, 0.7723, 2.26, 0.258, 274, 248, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
2753, 5kksB, 0.7722, 2.97, 0.277, 395, 260, ROCK 1 BOUND TO AZAINDOLE THIOZOLE INHIBITOR
2754, 1xwsA, 0.7722, 2.40, 0.265, 273, 249, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
2755, 4xliA, 0.7721, 2.30, 0.223, 264, 247, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
2756, 4ll5A, 0.7721, 2.42, 0.265, 268, 249, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
2757, 4ftcA, 0.7721, 2.42, 0.274, 266, 248, CRYSTAL STRUCTURE OF THE CHK1
2758, 3vbtA, 0.7721, 2.32, 0.258, 267, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2759, 2j5eA, 0.7721, 2.88, 0.202, 309, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
2760, 6cd6D, 0.7720, 2.37, 0.262, 267, 248, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
2761, 6cd6C, 0.7720, 2.51, 0.269, 265, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
2762, 5av0A, 0.7720, 2.53, 0.263, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
2763, 4zogB, 0.7720, 2.71, 0.222, 268, 252, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
2764, 4u44A, 0.7720, 2.42, 0.256, 286, 250, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
2765, 4ae9B, 0.7720, 2.84, 0.248, 321, 254, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
2766, 3uo5A, 0.7720, 2.38, 0.297, 267, 249, AURORA A IN COMPLEX WITH YL1-038-31
2767, 3c4eC, 0.7720, 2.40, 0.261, 272, 249, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2768, 2zm3B, 0.7720, 2.66, 0.201, 296, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2769, 2oi4X, 0.7720, 2.27, 0.266, 275, 248, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
2770, 1cdkA, 0.7720, 2.64, 0.257, 342, 253, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2771, 6fekA, 0.7719, 2.70, 0.238, 294, 252, ONCOGENIC POINT MUTATION OF RET RECEPTOR TYROSINE KINASE
2772, 5u7rC, 0.7719, 2.85, 0.257, 387, 257, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2773, 5telA, 0.7719, 2.46, 0.265, 273, 249, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2774, 5n1kA, 0.7719, 2.53, 0.255, 341, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-AMINO-1-(4-FLUOROPHENYL)ETHANOL
2775, 5n1eA, 0.7719, 2.56, 0.258, 347, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-(13-BENZODIOXOL-5-YL)-2-PIPERIDIN-1- YLACETAMIDE
2776, 5auxA, 0.7719, 2.53, 0.263, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
2777, 4tw9B, 0.7719, 2.72, 0.191, 289, 256, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
2778, 3bu5A, 0.7719, 2.77, 0.198, 291, 253, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
2779, 2w1cA, 0.7719, 2.39, 0.302, 261, 248, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2780, 2r2pA, 0.7719, 2.54, 0.206, 283, 252, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
2781, 2j2iB, 0.7719, 2.29, 0.266, 273, 248, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
2782, 2hz4C, 0.7719, 2.46, 0.221, 259, 249, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
2783, 1kobB, 0.7719, 2.96, 0.237, 352, 257, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2784, 1koaA, 0.7719, 2.89, 0.234, 447, 256, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
2785, 5wngA, 0.7718, 2.89, 0.264, 395, 258, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2786, 5n50A, 0.7718, 2.41, 0.261, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 2-(4-CHLOROPHENYL) SULFANYLACETOHYDRAZIDE
2787, 5ig1B, 0.7718, 2.85, 0.276, 304, 254, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
2788, 5flfD, 0.7718, 2.70, 0.242, 290, 252, DISEASE LINKED MUTATION IN FGFR
2789, 4twcB, 0.7718, 2.71, 0.191, 292, 256, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
2790, 3zh8A, 0.7718, 2.68, 0.283, 318, 254, A NOVEL SMALL MOLECULE APKC INHIBITOR
2791, 3b2tA, 0.7718, 2.82, 0.240, 288, 254, STRUCTURE OF PHOSPHOTRANSFERASE
2792, 2xynA, 0.7718, 2.47, 0.216, 264, 250, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
2793, 2g2iA, 0.7718, 2.45, 0.232, 271, 250, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2794, 6aydA, 0.7717, 2.42, 0.265, 272, 249, PIM1 COMPLEXED WITH N-(6-(4-HYDROXYPHENYL)-1H-INDAZOL-3-YL) CYCLOPROPANECARBOXAMIDE
2795, 5vd1A, 0.7717, 2.47, 0.281, 295, 249, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
2796, 5b2lA, 0.7717, 2.47, 0.228, 288, 250, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
2797, 4nfmA, 0.7717, 2.66, 0.191, 293, 256, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
2798, 3vbyA, 0.7717, 2.33, 0.266, 267, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2799, 3eh9A, 0.7717, 2.55, 0.263, 278, 251, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
2800, 2bzhB, 0.7717, 2.40, 0.265, 275, 249, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
2801, 4r3rA, 0.7716, 2.83, 0.195, 309, 256, CRYSTAL STRUCTURES OF EGFR IN COMPLEX WITH MIG6
2802, 3d9vB, 0.7716, 3.01, 0.268, 398, 261, CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI- METHYLATED VARIANT OF FASUDIL
2803, 3bu3A, 0.7716, 2.90, 0.200, 294, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
2804, 2qg5B, 0.7716, 2.63, 0.266, 280, 252, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2805, 2brgA, 0.7716, 2.31, 0.271, 257, 247, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2806, 5opuA, 0.7715, 2.38, 0.270, 261, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
2807, 6cd6B, 0.7714, 2.38, 0.262, 266, 248, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
2808, 5vilD, 0.7714, 2.76, 0.274, 271, 252, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
2809, 4yvcB, 0.7714, 2.81, 0.268, 392, 257, ROCK 1 BOUND TO THIAZOLE INHIBITOR
2810, 3uysC, 0.7714, 2.71, 0.187, 286, 256, CRYSTAL STRUCTURE OF APO HUMAN CK1D
2811, 3eqpB, 0.7714, 2.58, 0.251, 270, 251, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
2812, 1yxsA, 0.7714, 2.45, 0.265, 274, 249, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
2813, 5vioB, 0.7712, 2.86, 0.266, 271, 252, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
2814, 5u7qA, 0.7712, 2.92, 0.274, 388, 259, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2815, 5n7uA, 0.7712, 2.57, 0.258, 350, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-BROMO-35-DIMETHYL-1H-PYRAZOLE
2816, 4wt6A, 0.7712, 2.43, 0.261, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
2817, 3uo4A, 0.7712, 2.35, 0.297, 266, 249, AURORA A IN COMPLEX WITH RPM1680
2818, 3bhhD, 0.7712, 2.69, 0.307, 286, 254, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2819, 2pvfA, 0.7712, 3.00, 0.230, 285, 256, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
2820, 6bkuA, 0.7711, 2.34, 0.287, 267, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
2821, 3zh8B, 0.7711, 2.68, 0.283, 317, 254, A NOVEL SMALL MOLECULE APKC INHIBITOR
2822, 1m17A, 0.7711, 2.77, 0.209, 312, 254, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
2823, 5w4wC, 0.7710, 2.76, 0.172, 284, 256, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2824, 5dgzA, 0.7710, 2.44, 0.265, 273, 249, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
2825, 4xlvA, 0.7710, 2.94, 0.200, 307, 255, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
2826, 4xhhA, 0.7710, 2.77, 0.180, 358, 256, STRUCTURE OF C. GLABRATA HRR25 APO STATE
2827, 4ftrA, 0.7710, 2.39, 0.275, 258, 247, CRYSTAL STRUCTURE OF THE CHK1
2828, 3aglA, 0.7710, 2.68, 0.268, 338, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
2829, 2pvyA, 0.7710, 2.62, 0.239, 288, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
2830, 2itqA, 0.7710, 2.58, 0.206, 300, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
2831, 2bzjA, 0.7710, 2.44, 0.265, 273, 249, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
2832, 5kgdA, 0.7709, 2.30, 0.262, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
2833, 4w7pB, 0.7709, 2.75, 0.273, 387, 256, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
2834, 4jnwB, 0.7709, 2.97, 0.218, 321, 257, BACTERIALLY EXPRESSED TITIN KINASE
2835, 4hokW, 0.7709, 2.81, 0.184, 289, 256, CRYSTAL STRUCTURE OF APO CK1E
2836, 2itwA, 0.7709, 2.57, 0.210, 300, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
2837, 5vilB, 0.7708, 2.94, 0.265, 271, 253, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
2838, 5n3aA, 0.7708, 2.53, 0.259, 349, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-METHYL-5-(1-METHYLIMIDAZOL-2-YL)-13- THIAZOL-2-AMINE
2839, 5jebA, 0.7708, 2.78, 0.200, 299, 255, CRYSTAL STRUCTURE OF EGFR TYROSINE KINASE DOMAIN WITH NOVEL INHIBITOR OF ACTIVE STATE OF HER2
2840, 5autA, 0.7708, 2.49, 0.264, 274, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
2841, 4wa9B, 0.7708, 2.51, 0.223, 276, 251, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
2842, 4mbiA, 0.7708, 2.44, 0.261, 274, 249, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2843, 1ywvA, 0.7708, 2.45, 0.269, 274, 249, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
2844, 1tkiB, 0.7708, 2.86, 0.223, 321, 256, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2845, 1tkiA, 0.7708, 2.86, 0.223, 321, 256, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2846, 6fc8A, 0.7707, 2.72, 0.264, 269, 254, CHK1 KINASE IN COMPLEX WITH COMPOUND 13
2847, 5uzjA, 0.7707, 2.83, 0.268, 387, 257, CRYSTAL STRUCTURE OF ROCK1 BOUND TO AN AMINOPYRIDINE INHIBITOR
2848, 5n4nA, 0.7707, 2.43, 0.265, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 34-DIMETHYL-5-(1H-124-TRIAZOL- 3-YL)THIOPHENE-2-CARBONITRILE
2849, 5l2qA, 0.7707, 2.38, 0.200, 293, 250, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
2850, 4wsyA, 0.7707, 2.43, 0.261, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
2851, 4wihA, 0.7707, 2.55, 0.258, 350, 252, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS
2852, 4ftmA, 0.7707, 2.40, 0.275, 263, 247, CRYSTAL STRUCTURE OF THE CHK1
2853, 3vbxA, 0.7707, 2.32, 0.262, 268, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2854, 3kxxB, 0.7707, 2.80, 0.240, 305, 254, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
2855, 2bilB, 0.7707, 2.42, 0.261, 274, 249, THE HUMAN PROTEIN KINASE PIM1 IN COMPLEX WITH ITS CONSENSUS PEPTIDE PIMTIDE
2856, 5kgeA, 0.7706, 2.31, 0.262, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
2857, 4yveB, 0.7706, 3.01, 0.277, 393, 260, ROCK 1 BOUND TO METHOXYPHENYL THIAZOLE INHIBITOR
2858, 4wrsA, 0.7706, 2.44, 0.261, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
2859, 4wnpB, 0.7706, 2.57, 0.297, 272, 249, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2860, 4wd5A, 0.7706, 2.70, 0.206, 307, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH QL-X138
2861, 4k1bA, 0.7706, 2.45, 0.265, 273, 249, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2862, 3ikaA, 0.7706, 2.94, 0.195, 310, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
2863, 3idcA, 0.7706, 2.63, 0.253, 341, 253, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
2864, 3gubA, 0.7706, 2.60, 0.262, 278, 252, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
2865, 2xynB, 0.7706, 2.47, 0.220, 264, 250, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
2866, 2gqgA, 0.7706, 2.59, 0.227, 277, 251, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
2867, 1yxuB, 0.7706, 2.46, 0.265, 273, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2868, 1yxuA, 0.7706, 2.43, 0.261, 273, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2869, 3tkhA, 0.7705, 2.51, 0.274, 269, 248, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S01
2870, 5kgiA, 0.7704, 2.31, 0.262, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
2871, 4zy4B, 0.7704, 2.76, 0.306, 292, 252, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
2872, 4o0sA, 0.7704, 2.38, 0.302, 265, 248, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2873, 4as0A, 0.7704, 2.30, 0.262, 273, 248, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
2874, 3vbvA, 0.7704, 2.47, 0.261, 268, 249, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2875, 3tv7A, 0.7704, 2.83, 0.272, 394, 257, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
2876, 2yerA, 0.7704, 2.70, 0.261, 268, 253, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2877, 2xeyA, 0.7704, 2.29, 0.272, 252, 246, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2878, 2itpA, 0.7704, 2.71, 0.206, 305, 253, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
2879, 1yxuC, 0.7704, 2.44, 0.261, 272, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2880, 1rqqA, 0.7704, 2.85, 0.205, 294, 254, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
2881, 5n4zA, 0.7703, 2.30, 0.262, 272, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-4-(4-HYDROXYPHENYL)BUT-3-EN-2- ONE
2882, 5n3eA, 0.7703, 2.54, 0.259, 348, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 6-DIMETHYLAMINOPYRIDINE-3-CARBOXYLIC ACID
2883, 5n3cA, 0.7703, 2.60, 0.270, 348, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE THIOPHENE-3-CARBOXIMIDAMIDE
2884, 5dt3A, 0.7703, 2.45, 0.297, 263, 249, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2885, 4xh6A, 0.7703, 2.43, 0.261, 273, 249, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
2886, 4wotC, 0.7703, 2.94, 0.266, 392, 259, ROCK2 IN COMPLEX WITH 1426382-07-1
2887, 4wb6B, 0.7703, 2.46, 0.263, 340, 251, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2888, 4wb6A, 0.7703, 2.53, 0.263, 336, 251, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2889, 3vjnA, 0.7703, 2.52, 0.199, 297, 251, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
2890, 1yxvA, 0.7703, 2.46, 0.261, 274, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
2891, 2o64A, 0.7702, 2.46, 0.261, 274, 249, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
2892, 2bikB, 0.7702, 2.38, 0.266, 272, 248, HUMAN PIM1 PHOSPHORYLATED ON SER261
2893, 5ndtA, 0.7701, 2.31, 0.262, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-3-(2-(THIOPHEN-2-YL)VINYL)-3; 4-DIHYDROQUINOXALIN-2(1H)-ONE 
2894, 5n52A, 0.7701, 2.44, 0.261, 268, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-3-(23-DIMETHOXYPHENYL)ACRYLIC ACID
2895, 5n4yA, 0.7701, 2.45, 0.261, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 25-DIHYDRO-1H-ISOTHIOCHROMENO[3 4-D]PYRAZOL-3-ONE
2896, 5n3fA, 0.7701, 2.54, 0.259, 318, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-[3-(AMINOMETHYL)PHENYL]ACETAMIDE
2897, 5n36A, 0.7701, 2.65, 0.258, 347, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3H-ISOINDOL-2-IUM-1-AMINE
2898, 4jnwA, 0.7701, 2.97, 0.218, 320, 257, BACTERIALLY EXPRESSED TITIN KINASE
2899, 3tv7C, 0.7701, 2.82, 0.272, 394, 257, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
2900, 3ppzB, 0.7701, 2.37, 0.243, 264, 247, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2901, 1xr1A, 0.7701, 2.48, 0.269, 277, 249, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
2902, 5y90A, 0.7700, 2.54, 0.227, 304, 251, MAP2K7 MUTANT -C218S
2903, 5o0yA, 0.7700, 2.66, 0.236, 288, 254, TLK2 KINASE DOMAIN FROM HUMAN 
2904, 5n4rA, 0.7700, 2.34, 0.258, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 2-(AZEPAN-1-YL)-1-(1H-INDOL-3-YL) PROPAN-1-ONE
2905, 5kgkA, 0.7700, 2.44, 0.265, 273, 249, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
2906, 5bmlB, 0.7700, 2.92, 0.264, 395, 258, ROCK 1 BOUND TO A PYRIDINE THIAZOLE INHIBITOR
2907, 4utdA, 0.7700, 2.46, 0.305, 266, 249, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
2908, 4jq8A, 0.7700, 2.62, 0.210, 303, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
2909, 3uytA, 0.7700, 2.59, 0.190, 287, 253, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2910, 3r01A, 0.7700, 2.46, 0.261, 274, 249, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2911, 3kf4B, 0.7700, 2.46, 0.229, 270, 249, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
2912, 3dlsB, 0.7700, 2.36, 0.263, 280, 247, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2913, 2x8eA, 0.7700, 2.50, 0.265, 259, 249, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
2914, 6cd6A, 0.7699, 2.54, 0.265, 264, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
2915, 5v80A, 0.7699, 2.44, 0.261, 273, 249, PIM1 KINASE IN COMPLEX WITH CPD1 (1-METHYL-4-(3-(6-(PIPERAZIN-1-YL) PYRIDIN-2-YL)-1H-PYRAZOLO[3;4-C]PYRIDIN-5-YL)PIPERAZIN-2-ONE) 
2916, 4xhgA, 0.7699, 2.78, 0.164, 357, 256, STRUCTURE OF C. GLABRATA HRR25 BOUND TO ADP (FORMATE CONDITION)
2917, 4hokI, 0.7699, 2.78, 0.184, 291, 256, CRYSTAL STRUCTURE OF APO CK1E
2918, 3we8A, 0.7699, 2.47, 0.265, 273, 249, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
2919, 3kl8G, 0.7699, 2.48, 0.316, 259, 250, CAMKIINTIDE INHIBITOR COMPLEX
2920, 4wotB, 0.7698, 2.76, 0.266, 394, 256, ROCK2 IN COMPLEX WITH 1426382-07-1
2921, 3b2tB, 0.7698, 2.92, 0.240, 287, 254, STRUCTURE OF PHOSPHOTRANSFERASE
2922, 5texA, 0.7697, 2.49, 0.265, 274, 249, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2923, 5n4uA, 0.7697, 2.32, 0.262, 272, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 5-(2-AMINO-13-THIAZOL-4- YL)-13-DIHYDROBENZIMIDAZOL-2-ONE
2924, 4ftkA, 0.7697, 2.41, 0.275, 263, 247, CRYSTAL STRUCTURE OF THE CHK1
2925, 4debA, 0.7697, 2.40, 0.293, 264, 249, AURORA A IN COMPLEX WITH RK2-17-01
2926, 3jyaA, 0.7697, 2.35, 0.262, 274, 248, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2927, 3jxwA, 0.7697, 2.46, 0.261, 274, 249, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2928, 3jpvA, 0.7697, 2.32, 0.262, 273, 248, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
2929, 2psqA, 0.7697, 2.78, 0.237, 287, 253, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
2930, 2g2fB, 0.7697, 2.63, 0.215, 264, 251, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2931, 1yxxA, 0.7697, 2.46, 0.261, 274, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
2932, 1m14A, 0.7697, 2.60, 0.210, 307, 252, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
2933, 5n1mA, 0.7696, 2.66, 0.258, 347, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (5-CHLORO-2-METHOXYPHENYL)METHANAMINE
2934, 4rpvA, 0.7696, 2.44, 0.265, 273, 249, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
2935, 4mblA, 0.7696, 2.46, 0.265, 274, 249, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2936, 2o3pA, 0.7696, 2.47, 0.265, 274, 249, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
2937, 6cmjA, 0.7695, 2.63, 0.295, 285, 251, HUMAN CAMKK2 WITH GSK650393
2938, 5n4xA, 0.7695, 2.33, 0.262, 272, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 45-DIBROMOTHIOPHENE-2- CARBOHYDRAZIDE
2939, 5n4oA, 0.7695, 2.44, 0.261, 271, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE (E)-3-(P-TOLYL)ACRYLIC ACID
2940, 5n1lA, 0.7695, 2.65, 0.258, 347, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 25-DIMETHYL-N-PYRIDIN-4-YLFURAN-3- CARBOXAMIDE
2941, 5kcxA, 0.7695, 2.47, 0.261, 272, 249, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
2942, 5av4A, 0.7695, 2.52, 0.264, 274, 250, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2943, 5auzA, 0.7695, 2.52, 0.264, 274, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
2944, 4ysjB, 0.7695, 2.53, 0.287, 462, 247, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
2945, 4fsuA, 0.7695, 2.49, 0.274, 260, 248, CRYSTAL STRUCTURE OF THE CHK1
2946, 4deeA, 0.7695, 2.45, 0.293, 271, 249, AURORA A IN COMPLEX WITH ADP
2947, 3r04A, 0.7695, 2.35, 0.258, 271, 248, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2948, 2itxA, 0.7695, 2.85, 0.200, 307, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
2949, 1ol5A, 0.7695, 2.31, 0.297, 263, 246, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
2950, 5y9tA, 0.7694, 2.58, 0.207, 300, 251, CRYSTAL STRUCTURE OF EGFR T790M MUTANT IN COMPLEX WITH NAQUOTINIB 
2951, 5hu3A, 0.7694, 2.61, 0.320, 266, 250, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2952, 5auwA, 0.7694, 2.53, 0.264, 274, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
2953, 4ty1A, 0.7694, 2.45, 0.261, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
2954, 4id7A, 0.7694, 2.37, 0.249, 268, 249, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
2955, 4hokO, 0.7694, 2.82, 0.184, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
2956, 4gw8A, 0.7694, 2.32, 0.262, 273, 248, HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND LEUCETTINE L41
2957, 3vbwA, 0.7694, 2.35, 0.262, 264, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2958, 3f9nA, 0.7694, 2.38, 0.271, 253, 247, CRYSTAL STRUCTURE OF CHK1 KINASE IN COMPLEX WITH INHIBITOR 38
2959, 2c47D, 0.7694, 2.70, 0.216, 290, 255, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
2960, 5turA, 0.7693, 2.46, 0.261, 270, 249, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2961, 5n3bA, 0.7693, 2.55, 0.259, 342, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(PYRIDIN-3-YL)ETHANAMINE
2962, 5mhiA, 0.7693, 2.60, 0.258, 348, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (5-CHLORO-2-METHOXYPHENYL)METHANAMINE
2963, 5dlsA, 0.7693, 2.42, 0.271, 257, 247, IDENTIFICATION OF NOVEL IN VIVO ACTIVE CHK1 INHIBITORS UTILIZING STRUCTURE GUIDED DRUG DESIGN
2964, 5auuA, 0.7693, 2.53, 0.264, 274, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
2965, 4medA, 0.7693, 2.42, 0.270, 272, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
2966, 4jq7A, 0.7693, 2.64, 0.210, 303, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
2967, 4ftlA, 0.7693, 2.54, 0.274, 263, 248, CRYSTAL STRUCTURE OF THE CHK1
2968, 2j0lA, 0.7693, 2.51, 0.247, 274, 251, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
2969, 5oq6A, 0.7692, 2.32, 0.268, 257, 246, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
2970, 5ng0B, 0.7692, 2.78, 0.224, 282, 255, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
2971, 5dhjA, 0.7692, 2.45, 0.261, 273, 249, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
2972, 4j8nC, 0.7692, 2.42, 0.293, 266, 249, AURORA A KINASE APO
2973, 3uytB, 0.7692, 2.66, 0.190, 286, 253, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2974, 5t8oA, 0.7691, 2.45, 0.248, 324, 250, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO IMIDAZOBENZOXEPIN COMPOUND 3
2975, 4zy5B, 0.7691, 2.78, 0.306, 287, 252, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
2976, 4tn6B, 0.7691, 2.76, 0.184, 285, 256, CK1D IN COMPLEX WITH INHIBITOR
2977, 4jr3A, 0.7691, 2.65, 0.210, 303, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
2978, 3cxwA, 0.7691, 2.34, 0.266, 272, 248, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A BETA CARBOLINE LIGAND I
2979, 3bkbA, 0.7691, 2.76, 0.233, 373, 253, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)
2980, 2py3B, 0.7691, 2.71, 0.234, 284, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2981, 6bskA, 0.7690, 2.35, 0.258, 273, 248, HUMAN PIM1 KINASE IN COMPLEX WITH COMPOUND 12B
2982, 5n1nA, 0.7690, 2.56, 0.263, 348, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-CHLORO-9-PROPAN-2-YLPURINE
2983, 5mzlA, 0.7690, 2.32, 0.262, 269, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE N-QUINOLIN-5-YLPYRIDINE- 3-CARBOXAMIDE
2984, 5d9kB, 0.7690, 2.44, 0.290, 280, 248, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
2985, 4k18A, 0.7690, 2.45, 0.269, 277, 249, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2986, 4j8nB, 0.7690, 2.42, 0.293, 266, 249, AURORA A KINASE APO
2987, 3ri1A, 0.7690, 2.90, 0.239, 285, 255, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
2988, 3r00A, 0.7690, 2.35, 0.262, 274, 248, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2989, 3jy0A, 0.7690, 2.35, 0.262, 275, 248, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2990, 3bwfA, 0.7690, 2.34, 0.262, 273, 248, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
2991, 5op4A, 0.7689, 2.31, 0.268, 259, 246, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
2992, 4zogA, 0.7689, 2.69, 0.223, 269, 251, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
2993, 4wnpA, 0.7689, 2.60, 0.297, 273, 249, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2994, 4j95C, 0.7689, 2.62, 0.244, 281, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
2995, 4j8nD, 0.7689, 2.43, 0.293, 265, 249, AURORA A KINASE APO
2996, 4aluA, 0.7689, 2.35, 0.262, 274, 248, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2997, 4a7cA, 0.7689, 2.40, 0.266, 273, 248, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
2998, 3eqpA, 0.7689, 2.45, 0.253, 268, 249, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
2999, 2v55C, 0.7689, 3.02, 0.276, 396, 261, MECHANISM OF MULTI-SITE PHOSPHORYLATION FROM A ROCK-I:RHOE COMPLEX STRUCTURE
3000, 2bzkB, 0.7689, 2.34, 0.262, 268, 248, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AMPPNP AND PIMTIDE
3001, 5toeA, 0.7688, 2.50, 0.265, 272, 249, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3002, 5n39A, 0.7688, 2.67, 0.258, 347, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(23-DIHYDROBENZO[B][14]DIOXIN-6-YL) PYRROLIDINE
3003, 4kbkC, 0.7688, 2.77, 0.191, 280, 256, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3004, 4jiaA, 0.7688, 2.77, 0.249, 298, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
3005, 4j8nA, 0.7688, 2.43, 0.293, 266, 249, AURORA A KINASE APO
3006, 3vc4A, 0.7688, 2.35, 0.262, 274, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3007, 3cd3A, 0.7688, 2.40, 0.234, 352, 248, CRYSTAL STRUCTURE OF PHOSPHORYLATED HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V-FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
3008, 2vz6A, 0.7688, 2.88, 0.299, 291, 254, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
3009, 2v55A, 0.7688, 3.02, 0.276, 393, 261, MECHANISM OF MULTI-SITE PHOSPHORYLATION FROM A ROCK-I:RHOE COMPLEX STRUCTURE
3010, 6bqqA, 0.7687, 2.39, 0.279, 271, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
3011, 5l8kA, 0.7687, 2.64, 0.287, 266, 251, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
3012, 5l2qB, 0.7687, 2.66, 0.198, 282, 252, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
3013, 5cavA, 0.7687, 2.62, 0.210, 306, 252, EGFR KINASE DOMAIN WITH COMPOUND 41A
3014, 4obpA, 0.7687, 2.58, 0.251, 285, 251, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
3015, 4jx3A, 0.7687, 2.45, 0.265, 274, 249, CRYSTAL STRUCTURE OF PIM1 KINASE
3016, 4alvA, 0.7687, 2.35, 0.262, 274, 248, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
3017, 3qf9A, 0.7687, 2.34, 0.262, 274, 248, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A FURAN- THIAZOLIDINEDIONE LIGAND
3018, 3qc4A, 0.7687, 2.61, 0.263, 276, 251, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
3019, 3nczD, 0.7687, 2.92, 0.263, 397, 259, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
3020, 6cmjB, 0.7686, 2.67, 0.291, 284, 251, HUMAN CAMKK2 WITH GSK650393
3021, 5n5mA, 0.7686, 2.29, 0.267, 272, 247, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND (R)-3-(2-((ISOQUINOLIN-5-YLMETHYL)(METHYL) CARBAMOYL)PHENYL)PYRROLIDIN-1-IUM
3022, 5n4vA, 0.7686, 2.35, 0.258, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 2-CYCLOPROPYL-45- DIMETHYLTHIENO[54-D]PYRIMIDINE-6-CARBOXYLIC ACID
3023, 5kggA, 0.7686, 2.35, 0.262, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
3024, 4kbkB, 0.7686, 2.80, 0.184, 289, 256, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3025, 2bziB, 0.7686, 2.43, 0.266, 272, 248, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
3026, 1k3aA, 0.7686, 2.87, 0.208, 288, 255, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
3027, 6d8eA, 0.7685, 2.64, 0.203, 304, 251, DISCOVERY OF A HIGHLY POTENT AND BROADLY EFFECTIVE EGFR AND HER2 EXON 20 INSERTION MUTANT INHIBITOR 
3028, 4jx7A, 0.7685, 2.47, 0.261, 274, 249, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
3029, 4fsmA, 0.7685, 2.42, 0.275, 265, 247, CRYSTAL STRUCTURE OF THE CHK1
3030, 3kulB, 0.7685, 2.47, 0.204, 271, 250, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
3031, 2qohA, 0.7685, 2.51, 0.225, 271, 249, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
3032, 2o65A, 0.7685, 2.50, 0.273, 274, 249, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
3033, 2o63A, 0.7685, 2.50, 0.269, 274, 249, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
3034, 5cxhA, 0.7684, 2.65, 0.202, 277, 253, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
3035, 4mtaA, 0.7684, 2.37, 0.258, 273, 248, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
3036, 4kbcA, 0.7684, 2.78, 0.187, 288, 256, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
3037, 3uysD, 0.7684, 2.61, 0.190, 284, 253, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3038, 2j6mA, 0.7684, 2.55, 0.203, 306, 251, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
3039, 2g2iB, 0.7684, 2.52, 0.232, 265, 250, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3040, 5mjbB, 0.7683, 2.64, 0.221, 278, 253, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
3041, 5ipjA, 0.7683, 2.47, 0.261, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
3042, 4umpD, 0.7683, 2.45, 0.308, 321, 247, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3043, 4rc3A, 0.7683, 2.43, 0.266, 271, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3044, 4n6yA, 0.7683, 2.29, 0.267, 273, 247, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
3045, 4lm5A, 0.7683, 2.31, 0.263, 264, 247, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
3046, 4hokU, 0.7683, 2.81, 0.187, 289, 256, CRYSTAL STRUCTURE OF APO CK1E
3047, 3r02A, 0.7683, 2.38, 0.258, 271, 248, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
3048, 2izuA, 0.7683, 2.72, 0.196, 297, 255, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3049, 5oprA, 0.7682, 2.33, 0.268, 258, 246, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
3050, 5n33A, 0.7682, 2.54, 0.259, 347, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINO-5-(TRIFLUOROMETHYL)-1H-PYRIDIN-2- ONE
3051, 5dr2A, 0.7682, 2.58, 0.296, 264, 250, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
3052, 4riyD, 0.7682, 2.65, 0.210, 297, 252, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
3053, 4i41A, 0.7682, 2.31, 0.267, 272, 247, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
3054, 4hnfA, 0.7682, 2.65, 0.186, 289, 253, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
3055, 4dedA, 0.7682, 2.42, 0.293, 265, 249, AURORA A IN COMPLEX WITH YL1-038-21
3056, 3nczA, 0.7682, 2.92, 0.266, 399, 259, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
3057, 3kf4A, 0.7682, 2.57, 0.221, 281, 249, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3058, 2h9vA, 0.7682, 2.92, 0.274, 383, 259, STRUCTURAL BASIS FOR INDUCED-FIT BINDING OF RHO-KINASE TO THE INHIBITOR Y27632
3059, 5v82A, 0.7681, 2.35, 0.266, 273, 248, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
3060, 5n3dA, 0.7681, 2.57, 0.259, 346, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-(TRIFLUOROMETHYL)BENZENECARBOXIMIDAMIDE
3061, 4k0yA, 0.7681, 2.35, 0.266, 274, 248, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
3062, 4fzdB, 0.7681, 2.64, 0.255, 275, 251, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH WSF MOTIF
3063, 4dtkA, 0.7681, 2.37, 0.258, 273, 248, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
3064, 3kl8A, 0.7681, 2.58, 0.311, 256, 251, CAMKIINTIDE INHIBITOR COMPLEX
3065, 2hz4B, 0.7681, 2.60, 0.227, 261, 251, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
3066, 5mjbA, 0.7680, 2.52, 0.219, 276, 251, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
3067, 4idvC, 0.7680, 2.52, 0.247, 335, 251, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
3068, 3up7A, 0.7680, 2.38, 0.294, 264, 248, AURORA A IN COMPLEX WITH YL1-038-09
3069, 3bhhC, 0.7680, 2.70, 0.296, 285, 253, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
3070, 2py3A, 0.7680, 3.00, 0.231, 282, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3071, 1zwsB, 0.7680, 2.60, 0.254, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3072, 5wevA, 0.7679, 2.70, 0.254, 293, 252, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
3073, 5vcyA, 0.7679, 2.58, 0.276, 296, 250, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
3074, 5te0A, 0.7679, 2.41, 0.250, 316, 248, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
3075, 5l3aA, 0.7679, 2.68, 0.250, 290, 252, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
3076, 4ysjA, 0.7679, 2.34, 0.286, 459, 245, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
3077, 4l3lA, 0.7679, 2.59, 0.297, 291, 249, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
3078, 4gmyA, 0.7679, 2.78, 0.253, 298, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
3079, 3a99A, 0.7679, 2.49, 0.261, 273, 249, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
3080, 2yakA, 0.7679, 2.60, 0.266, 277, 252, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
3081, 2iztA, 0.7679, 2.71, 0.192, 296, 255, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3082, 5vd4A, 0.7678, 2.55, 0.219, 261, 247, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 016 A MK1775 ANALOUGUE
3083, 5ugxA, 0.7678, 2.82, 0.237, 297, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
3084, 4hgsA, 0.7678, 2.72, 0.196, 302, 255, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
3085, 3u9nA, 0.7678, 2.42, 0.271, 257, 247, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
3086, 1zwsF, 0.7678, 2.58, 0.254, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3087, 5x18A, 0.7677, 2.80, 0.195, 294, 256, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
3088, 5oryA, 0.7677, 2.40, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3089, 5dn3A, 0.7677, 2.45, 0.294, 264, 248, AURORA A IN COMPLEX WITH ATP AND AA35.
3090, 4rc4A, 0.7677, 2.44, 0.266, 272, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3091, 4hokA, 0.7677, 2.81, 0.184, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
3092, 3c4eD, 0.7677, 2.36, 0.262, 273, 248, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3093, 6brcB, 0.7676, 2.40, 0.289, 260, 246, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
3094, 6babA, 0.7676, 2.83, 0.295, 290, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
3095, 5vczA, 0.7676, 2.44, 0.282, 294, 248, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB ISOMER
3096, 5vcvA, 0.7676, 2.49, 0.282, 287, 248, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH DASATINIB
3097, 5vc5A, 0.7676, 2.53, 0.231, 261, 247, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
3098, 5n5lA, 0.7676, 2.31, 0.267, 271, 247, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND [2-OXO-2-(1H-PYRROL-2-YL)ETHYL] 5-BROMO-1H- INDOLE-3-CARBOXYLATE
3099, 5n51A, 0.7676, 2.30, 0.267, 268, 247, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 34-DIBROMOTHIOPHENE-2-CARBOXYLIC ACID
3100, 5dnrA, 0.7676, 2.54, 0.297, 264, 249, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
3101, 3vjoA, 0.7676, 2.58, 0.204, 298, 250, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
3102, 3sxsA, 0.7676, 2.45, 0.206, 264, 248, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
3103, 3dcvA, 0.7676, 2.45, 0.266, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
3104, 2bujB, 0.7676, 2.63, 0.243, 286, 251, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
3105, 5diaA, 0.7675, 2.37, 0.262, 273, 248, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
3106, 5ax9C, 0.7675, 2.33, 0.246, 282, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
3107, 4bbeD, 0.7675, 2.68, 0.250, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3108, 1zwsG, 0.7675, 2.59, 0.254, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3109, 1oplB, 0.7675, 2.59, 0.220, 365, 250, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3110, 5wneC, 0.7674, 2.84, 0.259, 384, 255, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3111, 5op2A, 0.7674, 2.45, 0.268, 263, 250, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3112, 4w9wA, 0.7674, 2.35, 0.259, 306, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
3113, 4umpB, 0.7674, 2.46, 0.317, 324, 246, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3114, 4tw9A, 0.7674, 2.77, 0.187, 290, 256, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
3115, 4riwD, 0.7674, 2.64, 0.206, 297, 252, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
3116, 3kckA, 0.7674, 2.64, 0.254, 285, 252, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
3117, 3cr0A, 0.7674, 2.50, 0.223, 257, 247, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
3118, 2zm3A, 0.7674, 2.77, 0.216, 300, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
3119, 2xiyA, 0.7674, 2.46, 0.266, 273, 248, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3120, 5n1oA, 0.7673, 2.58, 0.255, 335, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-CHLORO-4-(CHLOROMETHYL)-5- HYDROXYPHENYL)ETHAN-1-ONE
3121, 4wnpD, 0.7673, 2.67, 0.297, 272, 249, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3122, 4idtB, 0.7673, 2.34, 0.251, 335, 247, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
3123, 3wf9A, 0.7673, 2.55, 0.298, 287, 248, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
3124, 3gqiA, 0.7673, 2.79, 0.237, 304, 253, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3125, 2g2hA, 0.7673, 2.66, 0.219, 272, 251, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3126, 5vjaD, 0.7672, 2.45, 0.253, 261, 249, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
3127, 5iisA, 0.7672, 2.46, 0.266, 273, 248, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
3128, 5eolA, 0.7672, 2.49, 0.261, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
3129, 4zk5A, 0.7672, 2.58, 0.255, 286, 251, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
3130, 4txcA, 0.7672, 2.63, 0.266, 276, 252, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3131, 4idvB, 0.7672, 2.52, 0.247, 335, 251, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
3132, 4fswA, 0.7672, 2.53, 0.275, 265, 247, CRYSTAL STRUCTURE OF THE CHK1
3133, 4bbeB, 0.7672, 2.70, 0.254, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3134, 2zm3D, 0.7672, 2.72, 0.209, 293, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
3135, 1zwsD, 0.7672, 2.59, 0.254, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3136, 1xqzA, 0.7672, 2.50, 0.269, 277, 249, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
3137, 1gjoA, 0.7672, 2.74, 0.243, 280, 251, THE FGFR2 TYROSINE KINASE DOMAIN
3138, 5u7rD, 0.7671, 2.75, 0.257, 382, 253, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
3139, 5opsA, 0.7671, 2.30, 0.269, 258, 245, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3140, 5hg8A, 0.7671, 3.05, 0.199, 300, 256, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
3141, 4rc2A, 0.7671, 2.45, 0.266, 272, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3142, 4g16A, 0.7671, 2.73, 0.196, 302, 255, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
3143, 4bbeC, 0.7671, 2.70, 0.254, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3144, 2xj0A, 0.7671, 2.52, 0.261, 274, 249, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3145, 1wvxA, 0.7671, 2.57, 0.263, 275, 251, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3146, 1oecA, 0.7671, 2.72, 0.243, 280, 251, FGFR2 KINASE DOMAIN
3147, 5wnfA, 0.7670, 2.97, 0.273, 395, 260, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3148, 5hg5A, 0.7670, 3.09, 0.202, 302, 257, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
3149, 4w7pC, 0.7670, 2.81, 0.277, 383, 256, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
3150, 4rblA, 0.7670, 2.46, 0.270, 271, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3151, 3c51B, 0.7670, 2.17, 0.260, 461, 242, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 3.55A
3152, 2brhA, 0.7670, 2.46, 0.275, 257, 247, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3153, 1wvwA, 0.7670, 2.54, 0.267, 275, 251, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3154, 5x17A, 0.7669, 2.80, 0.191, 290, 256, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
3155, 5t8oB, 0.7669, 2.54, 0.247, 328, 251, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO IMIDAZOBENZOXEPIN COMPOUND 3
3156, 5d7aB, 0.7669, 2.40, 0.249, 286, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
3157, 3wf8A, 0.7669, 2.62, 0.305, 287, 249, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
3158, 3uytC, 0.7669, 2.76, 0.191, 286, 256, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3159, 2z60A, 0.7669, 2.68, 0.227, 281, 251, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
3160, 2pwlB, 0.7669, 2.74, 0.238, 286, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
3161, 2pwlA, 0.7669, 2.83, 0.241, 284, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
3162, 1yxuD, 0.7669, 2.37, 0.262, 273, 248, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3163, 6g4zB, 0.7668, 2.58, 0.247, 325, 251, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
3164, 6bl8A, 0.7668, 2.69, 0.219, 270, 251, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
3165, 5u7qD, 0.7668, 2.94, 0.253, 383, 257, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
3166, 5l6wL, 0.7668, 2.73, 0.244, 290, 250, STRUCTURE OF THE LIMK1-ATPGAMMAS-CFL1 COMPLEX
3167, 5d9kA, 0.7668, 2.35, 0.297, 280, 246, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
3168, 4uxlA, 0.7668, 2.42, 0.234, 288, 248, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
3169, 5u6bB, 0.7667, 2.69, 0.209, 291, 254, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
3170, 5hvkA, 0.7667, 2.68, 0.237, 297, 249, CRYSTAL STRUCTURE OF LIMK1 MUTANT D460N IN COMPLEX WITH FULL-LENGTH COFILIN-1
3171, 5e8uA, 0.7667, 2.69, 0.210, 306, 252, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
3172, 5d7aA, 0.7667, 2.39, 0.253, 289, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
3173, 4idtA, 0.7667, 2.34, 0.251, 334, 247, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
3174, 3sxrA, 0.7667, 2.54, 0.209, 260, 249, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
3175, 3q4zA, 0.7667, 2.31, 0.280, 282, 246, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
3176, 3cy3A, 0.7667, 2.34, 0.263, 270, 247, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND THE JNK INHIBITOR V
3177, 3cy2A, 0.7667, 2.39, 0.262, 271, 248, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A BETA CARBOLINE LIGAND II
3178, 2of4A, 0.7667, 2.67, 0.220, 271, 250, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
3179, 2izsA, 0.7667, 2.73, 0.192, 298, 255, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3180, 5vd7A, 0.7666, 2.56, 0.219, 261, 247, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 098 A MK1775 ANALOGUE
3181, 5lihB, 0.7666, 2.22, 0.289, 318, 246, STRUCTURE OF A PEPTIDE-SUBSTRATE BOUND TO PKCIOTA CORE KINASE DOMAIN
3182, 4gfgA, 0.7666, 2.65, 0.202, 277, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
3183, 3vbqA, 0.7666, 2.41, 0.258, 271, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3184, 3bgpA, 0.7666, 2.33, 0.267, 272, 247, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
3185, 2xizA, 0.7666, 2.34, 0.267, 273, 247, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3186, 2ckeC, 0.7666, 2.92, 0.239, 300, 255, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
3187, 2c47B, 0.7666, 2.72, 0.209, 289, 254, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3188, 6groA, 0.7665, 2.73, 0.208, 293, 255, HUMAN CSNK1G3 BOUND TO SB-223133 
3189, 5walA, 0.7665, 2.64, 0.219, 286, 251, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
3190, 5e8wA, 0.7665, 2.77, 0.210, 303, 252, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
3191, 5d7aC, 0.7665, 2.34, 0.254, 286, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
3192, 4nfnA, 0.7665, 2.78, 0.191, 293, 257, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
3193, 2pzpA, 0.7665, 2.95, 0.232, 280, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
3194, 1ir3A, 0.7665, 2.97, 0.192, 300, 255, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
3195, 5wngC, 0.7664, 2.87, 0.259, 387, 255, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3196, 4yznA, 0.7664, 2.50, 0.232, 269, 246, HUMANIZED ROCO4 BOUND TO COMPOUND 19
3197, 4rixD, 0.7664, 2.66, 0.210, 297, 252, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
3198, 4ckiA, 0.7664, 2.81, 0.238, 293, 252, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
3199, 3jvsA, 0.7664, 2.36, 0.273, 256, 245, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
3200, 2ivtA, 0.7664, 2.81, 0.238, 288, 252, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
3201, 1gagA, 0.7664, 2.96, 0.192, 300, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
3202, 5y5tA, 0.7663, 2.35, 0.206, 263, 248, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
3203, 5oktC, 0.7663, 2.58, 0.187, 285, 251, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
3204, 5f4nA, 0.7663, 2.47, 0.275, 258, 247, MULTI-PARAMETER LEAD OPTIMIZATION TO GIVE AN ORAL CHK1 INHIBITOR CLINICAL CANDIDATE: (R)-5-((4-((MORPHOLIN-2-YLMETHYL)AMINO)-5- (TRIFLUOROMETHYL)PYRIDIN-2-YL)AMINO)PYRAZINE-2-CARBONITRILE (CCT245737)
3205, 4tl0A, 0.7663, 2.88, 0.251, 300, 255, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
3206, 4lg4C, 0.7663, 2.62, 0.270, 288, 252, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3207, 4jajA, 0.7663, 2.54, 0.301, 265, 249, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
3208, 4ftaA, 0.7663, 2.53, 0.275, 264, 247, CRYSTAL STRUCTURE OF THE CHK1
3209, 4btjB, 0.7663, 2.80, 0.187, 293, 257, TTBK1 IN COMPLEX WITH ATP
3210, 6b16B, 0.7662, 2.50, 0.296, 281, 247, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
3211, 5vcwA, 0.7662, 2.63, 0.285, 285, 249, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PELITINIB
3212, 5u6bD, 0.7662, 2.70, 0.209, 291, 254, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
3213, 5orzA, 0.7662, 2.42, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3214, 5j9yA, 0.7662, 2.59, 0.199, 300, 251, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
3215, 4iaaA, 0.7662, 2.45, 0.270, 272, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
3216, 2pz5B, 0.7662, 2.70, 0.235, 280, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3217, 2pz5A, 0.7662, 2.96, 0.232, 280, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3218, 5oseA, 0.7661, 2.43, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3219, 5osdA, 0.7661, 2.43, 0.294, 266, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3220, 5orpA, 0.7661, 2.43, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3221, 3ug2A, 0.7661, 2.68, 0.195, 299, 251, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
3222, 2of2A, 0.7661, 2.68, 0.220, 271, 250, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
3223, 6g4yB, 0.7660, 2.58, 0.247, 328, 251, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 1A 
3224, 5fqdF, 0.7660, 2.85, 0.199, 294, 256, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
3225, 4lg4A, 0.7660, 2.63, 0.277, 289, 253, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3226, 4jrvA, 0.7660, 2.51, 0.205, 300, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
3227, 4hglA, 0.7660, 2.74, 0.196, 302, 255, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
3228, 4bbeA, 0.7660, 2.86, 0.255, 288, 255, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3229, 3t9iA, 0.7660, 2.44, 0.270, 273, 248, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
3230, 2x2mA, 0.7660, 2.72, 0.240, 286, 250, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
3231, 2chlA, 0.7660, 2.74, 0.192, 298, 255, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
3232, 1opkA, 0.7660, 2.76, 0.215, 449, 251, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3233, 5osfA, 0.7659, 2.43, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3234, 5orrA, 0.7659, 2.42, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3235, 5oq7B, 0.7659, 2.33, 0.271, 256, 247, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3236, 4idvA, 0.7659, 2.55, 0.247, 335, 251, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
3237, 4ckjA, 0.7659, 2.83, 0.238, 292, 252, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
3238, 4bznA, 0.7659, 2.36, 0.263, 272, 247, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
3239, 3kl8C, 0.7659, 2.45, 0.319, 256, 248, CAMKIINTIDE INHIBITOR COMPLEX
3240, 3bgzA, 0.7659, 2.37, 0.263, 267, 247, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
3241, 2q0bA, 0.7659, 2.87, 0.237, 280, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3242, 2psqB, 0.7659, 2.89, 0.236, 286, 254, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
3243, 2c47A, 0.7659, 2.67, 0.206, 288, 253, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3244, 5os3A, 0.7658, 2.43, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3245, 5orwA, 0.7658, 2.43, 0.298, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3246, 4xhkB, 0.7658, 2.34, 0.267, 269, 247, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
3247, 4gh2A, 0.7658, 2.33, 0.278, 266, 245, CRYSTAL STRUCTURE OF THE CHK1
3248, 4bbfC, 0.7658, 2.87, 0.251, 288, 255, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3249, 4bbfB, 0.7658, 2.86, 0.255, 288, 255, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3250, 2x2kA, 0.7658, 2.83, 0.238, 289, 252, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
3251, 2q0bB, 0.7658, 2.77, 0.234, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3252, 2pzpB, 0.7658, 2.71, 0.239, 282, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
3253, 2objA, 0.7658, 2.37, 0.263, 272, 247, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
3254, 2izrA, 0.7658, 2.75, 0.192, 298, 255, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3255, 2csnA, 0.7658, 2.80, 0.180, 293, 256, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
3256, 5wnhA, 0.7657, 2.95, 0.263, 394, 259, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3257, 5vuaB, 0.7657, 2.37, 0.259, 270, 247, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3258, 5ih5A, 0.7657, 2.78, 0.199, 286, 256, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
3259, 5dwrA, 0.7657, 2.47, 0.266, 273, 248, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
3260, 4uv0A, 0.7657, 2.78, 0.252, 300, 254, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
3261, 3lm5A, 0.7657, 2.39, 0.248, 274, 246, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
3262, 3f2aA, 0.7657, 2.34, 0.263, 276, 247, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
3263, 2pzrA, 0.7657, 2.95, 0.228, 280, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3264, 1yrpB, 0.7657, 2.58, 0.255, 275, 251, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
3265, 1yrpA, 0.7657, 2.58, 0.255, 275, 251, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
3266, 5orvA, 0.7656, 2.44, 0.298, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3267, 5oktB, 0.7656, 2.74, 0.185, 281, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
3268, 5ih6A, 0.7656, 2.77, 0.187, 286, 256, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
3269, 4btmB, 0.7656, 2.79, 0.187, 293, 257, TTBK1 IN COMPLEX WITH INHIBITOR
3270, 2jiuA, 0.7656, 2.83, 0.200, 303, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
3271, 2ckeD, 0.7656, 2.91, 0.239, 300, 255, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
3272, 1yhsA, 0.7656, 2.30, 0.268, 267, 246, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
3273, 5wnfC, 0.7655, 2.86, 0.267, 386, 255, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3274, 5vd5A, 0.7655, 2.39, 0.224, 260, 245, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 050 A MK1775 ANALOUGUE
3275, 5u8lA, 0.7655, 3.05, 0.203, 289, 256, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH A SULFONYL FLUORIDE PROBE XO44
3276, 4n70A, 0.7655, 2.37, 0.263, 274, 247, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
3277, 4lmuA, 0.7655, 2.39, 0.267, 265, 247, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
3278, 3bymA, 0.7655, 2.69, 0.220, 271, 250, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
3279, 3bhyA, 0.7655, 2.46, 0.259, 268, 247, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
3280, 3bgqA, 0.7655, 2.50, 0.266, 272, 248, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
3281, 2qg5A, 0.7655, 2.73, 0.266, 284, 252, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3282, 1zwsH, 0.7655, 2.63, 0.254, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3283, 1oplA, 0.7655, 2.77, 0.215, 451, 251, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3284, 5os0A, 0.7654, 2.44, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3285, 5oroA, 0.7654, 2.44, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3286, 5ornA, 0.7654, 2.44, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3287, 5lihA, 0.7654, 2.42, 0.289, 324, 249, STRUCTURE OF A PEPTIDE-SUBSTRATE BOUND TO PKCIOTA CORE KINASE DOMAIN
3288, 4ftjA, 0.7654, 2.43, 0.276, 266, 246, CRYSTAL STRUCTURE OF THE CHK1
3289, 4alwA, 0.7654, 2.58, 0.261, 273, 249, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
3290, 2x2lA, 0.7654, 2.85, 0.238, 287, 252, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
3291, 1yi4A, 0.7654, 2.31, 0.272, 267, 246, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
3292, 1jktA, 0.7654, 2.71, 0.261, 276, 253, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
3293, 6fdyU, 0.7653, 2.83, 0.313, 261, 252, UNC-51-LIKE KINASE 3 (ULK3) IN COMPLEX WITH BOSUTINIB 
3294, 5os5A, 0.7653, 2.44, 0.294, 267, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3295, 5os1A, 0.7653, 2.44, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3296, 5e90A, 0.7653, 2.69, 0.212, 303, 250, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
3297, 4x2kA, 0.7653, 2.77, 0.210, 303, 252, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3298, 4x2jA, 0.7653, 2.77, 0.210, 303, 252, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3299, 4gihA, 0.7653, 2.78, 0.222, 288, 252, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
3300, 4g3dA, 0.7653, 2.56, 0.247, 324, 251, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
3301, 4g17A, 0.7653, 2.75, 0.196, 302, 255, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
3302, 2yabB, 0.7653, 2.86, 0.256, 299, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
3303, 2x2mB, 0.7653, 2.67, 0.241, 279, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
3304, 2dq7X, 0.7653, 2.46, 0.235, 262, 247, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
3305, 2ckeB, 0.7653, 2.94, 0.239, 300, 255, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
3306, 1yxtA, 0.7653, 2.56, 0.261, 274, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
3307, 5x2kA, 0.7652, 2.79, 0.198, 314, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH WZ4003
3308, 5uglA, 0.7652, 2.87, 0.241, 285, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
3309, 5orxA, 0.7652, 2.44, 0.298, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3310, 4fsqA, 0.7652, 2.44, 0.276, 263, 246, CRYSTAL STRUCTURE OF THE CHK1
3311, 3nrmA, 0.7652, 2.53, 0.289, 263, 249, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
3312, 6b8yA, 0.7651, 2.78, 0.210, 304, 252, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-(3- FLUOROPYRIDIN-4-YL)-2-[6-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-7H-PYRROLO[2 3-D]PYRIMIDIN-4-AMINE
3313, 5x18B, 0.7651, 2.86, 0.195, 294, 256, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
3314, 5uhnA, 0.7651, 2.92, 0.237, 282, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
3315, 5hvkC, 0.7651, 2.80, 0.236, 291, 250, CRYSTAL STRUCTURE OF LIMK1 MUTANT D460N IN COMPLEX WITH FULL-LENGTH COFILIN-1
3316, 4j95A, 0.7651, 2.71, 0.244, 279, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
3317, 4d2pD, 0.7651, 2.64, 0.315, 317, 248, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3318, 4bzoA, 0.7651, 2.49, 0.266, 272, 248, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
3319, 3pa4A, 0.7651, 2.54, 0.274, 257, 248, X-RAY CRYSTAL STRUCTURE OF COMPOUND 2A BOUND TO HUMAN CHK1 KINASE DOMAIN
3320, 1zwsC, 0.7651, 2.66, 0.254, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3321, 5wnhC, 0.7650, 2.87, 0.255, 388, 255, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3322, 5e8yA, 0.7650, 2.68, 0.232, 298, 250, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
3323, 4x2nA, 0.7650, 2.77, 0.210, 303, 252, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3324, 4n6zA, 0.7650, 2.51, 0.266, 272, 248, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
3325, 4hokE, 0.7650, 2.86, 0.184, 291, 256, CRYSTAL STRUCTURE OF APO CK1E
3326, 2qohB, 0.7650, 2.70, 0.223, 281, 251, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
3327, 5orsA, 0.7649, 2.44, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3328, 3pa3A, 0.7649, 2.54, 0.274, 259, 248, X-RAY CRYSTAL STRUCTURE OF COMPOUND 70 BOUND TO HUMAN CHK1 KINASE DOMAIN
3329, 3kmmA, 0.7649, 2.58, 0.221, 270, 249, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
3330, 6ccfB, 0.7648, 2.57, 0.266, 262, 248, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH HESPERADIN
3331, 4zs0A, 0.7648, 2.24, 0.303, 257, 244, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
3332, 4x2gA, 0.7648, 2.78, 0.210, 303, 252, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3333, 4li5A, 0.7648, 2.79, 0.210, 306, 252, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
3334, 4k33A, 0.7648, 2.83, 0.241, 293, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
3335, 3r7oA, 0.7648, 2.97, 0.212, 299, 255, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
3336, 2z2wA, 0.7648, 2.49, 0.224, 260, 246, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
3337, 2xj1A, 0.7648, 2.49, 0.266, 273, 248, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
3338, 4twcA, 0.7647, 2.80, 0.191, 293, 256, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
3339, 4hokG, 0.7647, 2.85, 0.184, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
3340, 4gj3A, 0.7647, 2.79, 0.218, 288, 252, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
3341, 4f1oA, 0.7647, 2.61, 0.230, 276, 248, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
3342, 3twjC, 0.7647, 2.94, 0.276, 396, 257, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
3343, 3kl8E, 0.7647, 2.47, 0.319, 256, 248, CAMKIINTIDE INHIBITOR COMPLEX
3344, 2xj2A, 0.7647, 2.38, 0.263, 273, 247, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3345, 1pkgA, 0.7647, 2.75, 0.223, 290, 251, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
3346, 6bleA, 0.7646, 2.56, 0.286, 265, 248, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
3347, 5fqdC, 0.7646, 2.87, 0.199, 294, 256, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
3348, 5e8zA, 0.7646, 2.71, 0.216, 303, 250, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
3349, 5amnA, 0.7646, 2.84, 0.238, 287, 252, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
3350, 4x2fA, 0.7646, 2.78, 0.210, 303, 252, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3351, 4iwdA, 0.7646, 2.92, 0.212, 299, 255, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
3352, 4gj2A, 0.7646, 2.79, 0.222, 288, 252, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
3353, 4btjA, 0.7646, 2.87, 0.191, 292, 257, TTBK1 IN COMPLEX WITH ATP
3354, 3ppzA, 0.7646, 2.21, 0.255, 264, 243, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3355, 2wotA, 0.7646, 2.72, 0.216, 303, 250, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
3356, 2w4kA, 0.7646, 2.83, 0.252, 301, 254, X-RAY STRUCTURE OF A DAP-KINASE 2-302
3357, 5vd8A, 0.7645, 2.61, 0.219, 260, 247, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 099 A MK1775 ANALOGUE
3358, 5o12A, 0.7645, 2.34, 0.272, 264, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3359, 5ax9A, 0.7645, 2.28, 0.252, 282, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
3360, 4giiA, 0.7645, 2.80, 0.222, 289, 252, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
3361, 3ri1B, 0.7645, 2.75, 0.238, 283, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
3362, 2zm3C, 0.7645, 2.84, 0.216, 296, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
3363, 6gttA, 0.7644, 2.22, 0.324, 282, 244, HUMAN STK10 BOUND TO BIRB-796 
3364, 4x0mA, 0.7644, 2.78, 0.210, 303, 252, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3365, 4hokS, 0.7644, 2.87, 0.195, 286, 256, CRYSTAL STRUCTURE OF APO CK1E
3366, 4hokK, 0.7644, 2.88, 0.187, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
3367, 4dinA, 0.7644, 2.70, 0.257, 340, 253, NOVEL LOCALIZATION AND QUATERNARY STRUCTURE OF THE PKA RI BETA HOLOENZYME
3368, 4btmA, 0.7644, 2.83, 0.187, 292, 257, TTBK1 IN COMPLEX WITH INHIBITOR
3369, 3sxrB, 0.7644, 2.51, 0.206, 258, 248, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
3370, 2yabA, 0.7644, 2.86, 0.260, 299, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
3371, 2x0gA, 0.7644, 2.94, 0.250, 318, 256, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
3372, 1ol7A, 0.7644, 2.40, 0.296, 261, 247, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
3373, 5mjaB, 0.7643, 2.56, 0.223, 274, 251, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
3374, 4j99A, 0.7643, 2.82, 0.243, 280, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
3375, 3ug1A, 0.7643, 2.43, 0.202, 296, 247, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
3376, 2xf0A, 0.7643, 2.30, 0.270, 251, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3377, 2a2aD, 0.7643, 2.92, 0.239, 303, 255, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3378, 5c26A, 0.7642, 2.78, 0.202, 272, 253, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
3379, 4ytfA, 0.7642, 2.69, 0.258, 283, 252, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
3380, 4cegA, 0.7642, 2.47, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
3381, 4bn1A, 0.7642, 2.33, 0.285, 261, 246, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
3382, 3lm0A, 0.7642, 2.47, 0.243, 278, 247, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
3383, 2ckeA, 0.7642, 2.94, 0.239, 301, 255, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
3384, 5w4wD, 0.7641, 2.65, 0.187, 287, 252, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3385, 5ortA, 0.7641, 2.45, 0.298, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3386, 5ar2B, 0.7641, 2.88, 0.224, 285, 255, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
3387, 4l46A, 0.7641, 2.52, 0.308, 317, 247, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
3388, 4d2tD, 0.7641, 2.60, 0.308, 319, 247, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3389, 3byoA, 0.7641, 2.69, 0.220, 270, 250, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
3390, 2xezA, 0.7641, 2.31, 0.270, 249, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3391, 1yi3A, 0.7641, 2.31, 0.268, 267, 246, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
3392, 5o13A, 0.7640, 2.33, 0.268, 270, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3393, 4wotD, 0.7640, 2.93, 0.265, 389, 257, ROCK2 IN COMPLEX WITH 1426382-07-1
3394, 4twpA, 0.7640, 2.43, 0.231, 266, 247, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
3395, 4trlA, 0.7640, 2.46, 0.210, 268, 248, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
3396, 4lgdB, 0.7640, 2.62, 0.266, 350, 252, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3397, 3q6wA, 0.7640, 2.94, 0.216, 297, 255, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
3398, 3nczC, 0.7640, 2.88, 0.258, 389, 256, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
3399, 2g2fA, 0.7640, 2.61, 0.228, 275, 250, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3400, 1zwsA, 0.7640, 2.66, 0.250, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3401, 5oq8A, 0.7639, 2.50, 0.265, 261, 249, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3402, 4hokC, 0.7639, 2.84, 0.184, 289, 256, CRYSTAL STRUCTURE OF APO CK1E
3403, 4gvjA, 0.7639, 2.85, 0.222, 290, 252, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
3404, 3iokA, 0.7639, 2.70, 0.258, 285, 252, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
3405, 6bqlA, 0.7638, 2.49, 0.271, 278, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH TAE-226
3406, 5kziA, 0.7638, 2.43, 0.258, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
3407, 5gtzA, 0.7638, 2.83, 0.202, 317, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
3408, 4iw0A, 0.7638, 3.21, 0.238, 647, 261, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
3409, 4f0fA, 0.7638, 2.58, 0.226, 276, 248, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
3410, 2yaaB, 0.7638, 2.89, 0.260, 299, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
3411, 5os6A, 0.7637, 2.46, 0.298, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3412, 5os4A, 0.7637, 2.46, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3413, 4ythA, 0.7637, 2.68, 0.254, 287, 252, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
3414, 4f1mA, 0.7637, 2.62, 0.226, 278, 248, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
3415, 5es1A, 0.7636, 2.20, 0.333, 304, 240, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3416, 4wsqA, 0.7636, 2.39, 0.247, 317, 247, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3417, 3bi6A, 0.7636, 2.51, 0.224, 258, 246, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
3418, 3ac5A, 0.7636, 2.71, 0.220, 270, 250, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3419, 2a2aC, 0.7636, 2.95, 0.239, 303, 255, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3420, 1csnA, 0.7636, 2.86, 0.180, 293, 256, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
3421, 5l8lA, 0.7635, 2.56, 0.297, 263, 249, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
3422, 4wnoA, 0.7635, 2.70, 0.297, 272, 249, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
3423, 3lvpC, 0.7635, 2.83, 0.209, 293, 254, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3424, 3dqwB, 0.7635, 2.64, 0.244, 278, 250, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
3425, 2xixA, 0.7635, 2.47, 0.267, 272, 247, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3426, 5vc4A, 0.7634, 2.55, 0.215, 261, 247, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
3427, 5tt7A, 0.7634, 2.42, 0.206, 274, 248, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
3428, 4zy6B, 0.7634, 2.55, 0.300, 280, 247, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
3429, 4i5mA, 0.7634, 2.49, 0.242, 273, 248, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3430, 4hokM, 0.7634, 2.90, 0.184, 291, 256, CRYSTAL STRUCTURE OF APO CK1E
3431, 4d2pB, 0.7634, 2.48, 0.314, 323, 245, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3432, 3uixA, 0.7634, 2.33, 0.264, 266, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3433, 3cqeA, 0.7634, 2.51, 0.224, 258, 246, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
3434, 2zm1A, 0.7634, 2.72, 0.220, 270, 250, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3435, 2wmrA, 0.7634, 2.32, 0.270, 254, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3436, 2hziA, 0.7634, 2.68, 0.220, 268, 250, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
3437, 2c3iB, 0.7634, 2.45, 0.263, 266, 247, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH IMIDAZOPYRIDAZIN I
3438, 1zwsE, 0.7634, 2.65, 0.250, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3439, 1qpdA, 0.7634, 2.62, 0.221, 270, 249, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
3440, 5opbA, 0.7633, 2.51, 0.268, 262, 250, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
3441, 4kb8D, 0.7633, 2.64, 0.187, 278, 251, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3442, 4hokQ, 0.7633, 2.88, 0.184, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
3443, 5oktD, 0.7632, 2.66, 0.183, 282, 251, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
3444, 5ih4A, 0.7632, 2.82, 0.199, 286, 256, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
3445, 4xeyB, 0.7632, 2.45, 0.211, 359, 247, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
3446, 4hzrA, 0.7632, 2.30, 0.257, 261, 245, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
3447, 4gfmA, 0.7632, 2.71, 0.254, 289, 252, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
3448, 3we4A, 0.7632, 2.63, 0.306, 286, 248, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
3449, 2wmxA, 0.7632, 2.25, 0.272, 248, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3450, 2ivuA, 0.7632, 2.81, 0.239, 288, 251, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
3451, 3ac2A, 0.7631, 2.73, 0.220, 270, 250, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3452, 2pvyC, 0.7631, 2.72, 0.237, 285, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
3453, 2ofuA, 0.7631, 2.71, 0.220, 272, 250, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
3454, 4w7pD, 0.7630, 3.01, 0.278, 387, 259, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
3455, 4l42A, 0.7630, 2.67, 0.297, 299, 249, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
3456, 3lckA, 0.7630, 2.62, 0.221, 270, 249, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
3457, 3dqwA, 0.7630, 2.65, 0.244, 278, 250, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
3458, 2kulA, 0.7630, 3.00, 0.142, 360, 261, SOLUTION STRUCTURE OF HUMAN VACCINIA RELATED KINASE 1(VRK1)
3459, 1qpcA, 0.7630, 2.62, 0.221, 270, 249, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
3460, 6g4zA, 0.7629, 2.56, 0.245, 322, 249, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
3461, 5vd9A, 0.7629, 2.54, 0.220, 261, 246, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 097 A MK1775 ANALOGUE
3462, 5vd3A, 0.7629, 2.55, 0.278, 293, 248, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (DE-PHOSPHORYLATED) IN COMPLEX WITH SARACATINIB
3463, 4nt4A, 0.7629, 2.80, 0.195, 300, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
3464, 4dhfA, 0.7629, 2.52, 0.296, 258, 247, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3465, 3ac1A, 0.7629, 2.62, 0.221, 270, 249, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3466, 2zybA, 0.7629, 2.61, 0.221, 270, 249, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3467, 2ym5A, 0.7629, 2.27, 0.272, 248, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3468, 2hziB, 0.7629, 2.52, 0.219, 264, 247, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
3469, 1y57A, 0.7629, 2.59, 0.241, 452, 249, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
3470, 5vubB, 0.7628, 2.47, 0.263, 269, 247, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3471, 5tvtA, 0.7628, 2.19, 0.328, 321, 241, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
3472, 6bqpA, 0.7627, 2.47, 0.287, 263, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
3473, 5cwzB, 0.7627, 2.47, 0.249, 284, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
3474, 4wotA, 0.7627, 2.91, 0.273, 389, 256, ROCK2 IN COMPLEX WITH 1426382-07-1
3475, 4kbaD, 0.7627, 2.66, 0.195, 274, 251, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3476, 4d0wA, 0.7627, 2.71, 0.258, 289, 252, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
3477, 3f5pD, 0.7627, 2.80, 0.208, 297, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3478, 2x7fA, 0.7627, 2.18, 0.259, 276, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
3479, 2a2aA, 0.7627, 2.96, 0.239, 304, 255, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3480, 1u54B, 0.7627, 2.31, 0.261, 261, 245, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
3481, 4xhlA, 0.7626, 2.87, 0.168, 330, 256, STRUCTURE OF S. CEREVISIAE HRR25 1-394 (K38R MUTANT)
3482, 4l45A, 0.7626, 2.50, 0.306, 317, 245, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
3483, 3f5pH, 0.7626, 2.80, 0.208, 299, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3484, 3f5pC, 0.7626, 2.80, 0.208, 301, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3485, 3f5pA, 0.7626, 2.81, 0.208, 299, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3486, 2zm4A, 0.7626, 2.72, 0.220, 270, 250, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
3487, 2qg5D, 0.7626, 2.60, 0.264, 283, 250, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3488, 1z9xB, 0.7626, 2.95, 0.239, 303, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
3489, 6g4yA, 0.7625, 2.55, 0.245, 322, 249, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 1A 
3490, 5t8qB, 0.7625, 2.63, 0.247, 328, 251, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO ARYL PYRROLE FRAGMENT 17
3491, 4l3jA, 0.7625, 2.70, 0.297, 291, 249, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
3492, 4ftnA, 0.7625, 2.45, 0.278, 253, 245, CRYSTAL STRUCTURE OF THE CHK1
3493, 3clyA, 0.7625, 2.96, 0.236, 289, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
3494, 2ydkA, 0.7625, 2.65, 0.268, 263, 250, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3495, 4z16B, 0.7624, 2.63, 0.253, 276, 249, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3496, 3s95A, 0.7624, 2.68, 0.247, 290, 247, CRYSTAL STRUCTURE OF THE HUMAN LIMK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3497, 3acjA, 0.7624, 2.62, 0.221, 270, 249, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3498, 3ac3A, 0.7624, 2.62, 0.221, 270, 249, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3499, 2pzrB, 0.7624, 2.79, 0.234, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3500, 2c47C, 0.7624, 2.61, 0.207, 282, 251, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3501, 1z9xA, 0.7624, 2.96, 0.239, 303, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
3502, 1qpjA, 0.7624, 2.63, 0.221, 265, 249, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
3503, 5vd0A, 0.7623, 2.65, 0.277, 293, 249, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH MK1775
3504, 5vc6A, 0.7623, 2.50, 0.220, 259, 245, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
3505, 5ebzE, 0.7623, 3.51, 0.253, 655, 265, CRYSTAL STRUCTURE OF HUMAN IKK1
3506, 4lgdD, 0.7623, 2.63, 0.262, 338, 252, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3507, 3kulA, 0.7623, 2.47, 0.206, 267, 248, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
3508, 3e63A, 0.7623, 2.72, 0.258, 290, 252, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
3509, 3ackA, 0.7623, 2.62, 0.221, 270, 249, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3510, 2hk5A, 0.7623, 2.59, 0.242, 269, 248, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
3511, 5vcxA, 0.7622, 2.54, 0.283, 287, 247, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (UNTREATED) IN COMPLEX WITH SARACATINIB
3512, 5v5yA, 0.7622, 2.47, 0.234, 259, 244, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
3513, 5usqA, 0.7622, 2.63, 0.217, 299, 249, ALK-5 KINASE INHIBITOR COMPLEX
3514, 4rx7A, 0.7622, 2.57, 0.204, 272, 250, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
3515, 4g3eB, 0.7622, 2.64, 0.247, 325, 251, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 6-ALKYNYLINDOLINE (CMP1)
3516, 4fl1A, 0.7622, 2.46, 0.206, 268, 248, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
3517, 4d0xA, 0.7622, 2.71, 0.258, 291, 252, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
3518, 3ad5A, 0.7622, 2.63, 0.221, 270, 249, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3519, 2yaaA, 0.7622, 2.90, 0.260, 300, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
3520, 5imeA, 0.7621, 2.12, 0.293, 280, 242, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
3521, 5e8sA, 0.7621, 2.63, 0.217, 301, 249, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
3522, 4ytcA, 0.7621, 2.72, 0.254, 284, 252, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
3523, 4y85A, 0.7621, 2.08, 0.237, 307, 241, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
3524, 4kbkD, 0.7621, 2.66, 0.187, 281, 251, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3525, 3f5pT, 0.7621, 2.78, 0.209, 295, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3526, 2ivvA, 0.7621, 2.72, 0.241, 282, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
3527, 2fo0A, 0.7621, 2.73, 0.223, 465, 251, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
3528, 5uzjB, 0.7620, 2.98, 0.280, 386, 257, CRYSTAL STRUCTURE OF ROCK1 BOUND TO AN AMINOPYRIDINE INHIBITOR
3529, 5o11A, 0.7620, 2.34, 0.268, 268, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3530, 5l2qD, 0.7620, 2.75, 0.199, 294, 251, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
3531, 3f5pG, 0.7620, 2.81, 0.208, 299, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3532, 2x4fB, 0.7620, 2.77, 0.253, 288, 253, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
3533, 3op5A, 0.7619, 2.95, 0.138, 320, 260, HUMAN VACCINIA-RELATED KINASE 1
3534, 3eyhA, 0.7619, 2.72, 0.240, 285, 250, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3535, 3bceC, 0.7619, 2.71, 0.212, 286, 250, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
3536, 3ad4A, 0.7619, 2.62, 0.221, 270, 249, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3537, 1x8bA, 0.7619, 2.48, 0.224, 259, 245, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
3538, 5vucB, 0.7618, 2.50, 0.263, 269, 247, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3539, 5i3oB, 0.7618, 2.49, 0.258, 302, 248, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3540, 4w7pA, 0.7618, 2.87, 0.272, 388, 257, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
3541, 4g3dB, 0.7618, 2.57, 0.248, 318, 250, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
3542, 4enyA, 0.7618, 2.37, 0.260, 261, 246, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
3543, 4enxA, 0.7618, 2.37, 0.260, 266, 246, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
3544, 3op5B, 0.7618, 2.95, 0.138, 319, 260, HUMAN VACCINIA-RELATED KINASE 1
3545, 3f5pB, 0.7618, 2.81, 0.208, 298, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3546, 3ad6A, 0.7618, 2.62, 0.221, 272, 249, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3547, 3ac4A, 0.7618, 2.62, 0.221, 270, 249, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3548, 2clqA, 0.7618, 2.50, 0.273, 263, 245, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
3549, 1qpeA, 0.7618, 2.63, 0.221, 270, 249, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
3550, 6cnxA, 0.7617, 2.97, 0.146, 322, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 (VRK1) BOUND TO AN N-PROPYNYL-N-ISOPENTYL-DIHYDROPTERIDIN INHIBITOR
3551, 4idvD, 0.7617, 2.61, 0.247, 335, 251, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
3552, 3nz0A, 0.7617, 2.72, 0.224, 285, 250, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
3553, 3ac8A, 0.7617, 2.63, 0.221, 270, 249, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3554, 2xzsA, 0.7617, 2.92, 0.252, 301, 254, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
3555, 2x4fA, 0.7617, 2.78, 0.253, 289, 253, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
3556, 1mq4A, 0.7617, 2.47, 0.291, 261, 247, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
3557, 1ckiA, 0.7617, 2.85, 0.191, 292, 256, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
3558, 6bu6A, 0.7616, 2.96, 0.142, 322, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3559, 5ci7A, 0.7616, 2.69, 0.298, 276, 248, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
3560, 5aepA, 0.7616, 2.72, 0.254, 287, 252, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
3561, 4tn6A, 0.7616, 2.91, 0.187, 292, 256, CK1D IN COMPLEX WITH INHIBITOR
3562, 4dhfB, 0.7616, 2.43, 0.297, 258, 246, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3563, 3uysA, 0.7616, 2.67, 0.183, 281, 251, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3564, 2y0aA, 0.7616, 2.84, 0.252, 300, 254, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
3565, 1u4dB, 0.7616, 2.22, 0.259, 262, 243, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
3566, 4wnpC, 0.7615, 2.68, 0.298, 271, 248, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3567, 4fstA, 0.7615, 2.41, 0.275, 253, 244, CRYSTAL STRUCTURE OF THE CHK1
3568, 3naxA, 0.7615, 2.67, 0.255, 278, 251, PDK1 IN COMPLEX WITH INHIBITOR MP7
3569, 4py1A, 0.7614, 2.87, 0.230, 289, 252, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
3570, 4j99D, 0.7614, 2.76, 0.245, 281, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
3571, 3f5pF, 0.7614, 2.82, 0.208, 299, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3572, 3e62A, 0.7614, 2.81, 0.249, 291, 253, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
3573, 2bvaA, 0.7614, 2.20, 0.258, 272, 244, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
3574, 1xbcA, 0.7614, 2.41, 0.206, 268, 247, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
3575, 4xg6A, 0.7613, 2.59, 0.204, 271, 250, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3576, 3e64A, 0.7613, 2.73, 0.258, 291, 252, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
3577, 5ukfA, 0.7612, 2.96, 0.142, 322, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
3578, 5u94A, 0.7612, 2.39, 0.265, 263, 245, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
3579, 5deyB, 0.7612, 2.53, 0.300, 281, 247, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
3580, 3ma3A, 0.7612, 2.32, 0.269, 266, 245, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND
3581, 6drwA, 0.7611, 2.81, 0.251, 289, 251, JAK2 JH1 IN COMPLEX WITH JNJ-7706621 (CRYSTAL FORM 2) 
3582, 5uoxA, 0.7611, 2.58, 0.278, 263, 245, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3583, 5tozA, 0.7611, 2.62, 0.248, 278, 250, JAK3 WITH COVALENT INHIBITOR PF-06651600
3584, 5orlA, 0.7611, 2.49, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3585, 5objA, 0.7611, 2.46, 0.305, 260, 246, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
3586, 4zimB, 0.7611, 2.85, 0.253, 294, 253, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
3587, 4lgdA, 0.7611, 2.64, 0.262, 350, 252, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3588, 4e4mD, 0.7611, 2.79, 0.258, 296, 252, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3589, 3jy9A, 0.7611, 2.68, 0.259, 282, 251, JANUS KINASE 2 INHIBITORS
3590, 2ym6A, 0.7611, 2.31, 0.272, 253, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3591, 5v24B, 0.7610, 2.59, 0.278, 263, 245, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3592, 4xg7A, 0.7610, 2.64, 0.203, 266, 251, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3593, 4jikA, 0.7610, 2.37, 0.270, 256, 244, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22A (R)-2-(4-CHLOROPHENYL)-8- (PIPERIDIN-3-YLAMINO)IMIDAZO[12-C]PYRIMIDINE-5-CARBOXAMIDE BOUND TO HUMAN CHK1 KINASE DOMAIN
3594, 3f5pE, 0.7610, 2.82, 0.208, 299, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3595, 4jboA, 0.7609, 2.64, 0.297, 266, 249, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3596, 4e4mB, 0.7609, 2.80, 0.258, 296, 252, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3597, 5nk5A, 0.7608, 2.70, 0.206, 287, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
3598, 5i3rB, 0.7608, 2.50, 0.258, 302, 248, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3599, 5ebzJ, 0.7608, 3.54, 0.254, 655, 264, CRYSTAL STRUCTURE OF HUMAN IKK1
3600, 4yc8A, 0.7608, 2.72, 0.209, 259, 249, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
3601, 4kbaB, 0.7608, 2.62, 0.184, 285, 250, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3602, 2vz6B, 0.7608, 2.86, 0.292, 294, 253, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
3603, 2a2aB, 0.7608, 3.01, 0.239, 303, 255, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3604, 5nkeA, 0.7607, 2.70, 0.206, 292, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
3605, 5cy3A, 0.7607, 2.68, 0.203, 276, 251, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
3606, 4ytiA, 0.7607, 2.69, 0.255, 284, 251, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
3607, 4d2tB, 0.7607, 2.55, 0.314, 323, 245, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3608, 4bbfD, 0.7607, 2.78, 0.250, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3609, 3umwA, 0.7607, 2.41, 0.268, 264, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
3610, 3lxlA, 0.7607, 2.66, 0.248, 281, 250, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3611, 5lmaA, 0.7606, 2.50, 0.190, 267, 248, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
3612, 5c27A, 0.7606, 2.77, 0.202, 272, 252, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
3613, 4wnmA, 0.7606, 2.52, 0.209, 273, 249, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
3614, 2wouA, 0.7606, 2.60, 0.218, 299, 248, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
3615, 2b4sB, 0.7606, 3.06, 0.197, 294, 254, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
3616, 5twuA, 0.7605, 2.17, 0.315, 318, 241, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
3617, 1ckjA, 0.7605, 2.86, 0.195, 296, 256, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
3618, 5usyB, 0.7604, 2.70, 0.260, 287, 250, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
3619, 5t8qA, 0.7604, 2.63, 0.248, 323, 250, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO ARYL PYRROLE FRAGMENT 17
3620, 5j95A, 0.7604, 2.51, 0.250, 284, 248, MAP4K4 IN COMPLEX WITH INHIBITOR
3621, 4kbaC, 0.7604, 2.71, 0.190, 277, 252, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3622, 4euuB, 0.7604, 3.11, 0.243, 307, 259, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
3623, 4d2vD, 0.7604, 2.53, 0.313, 318, 246, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3624, 4bbfA, 0.7604, 2.79, 0.250, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3625, 2wmtA, 0.7604, 2.31, 0.267, 248, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3626, 6ccfA, 0.7603, 2.43, 0.272, 260, 246, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH HESPERADIN
3627, 5ugaA, 0.7603, 2.85, 0.207, 283, 251, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH 4-(4-{[2-{[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9- (PROPAN-2-YL)-9H-PURIN-6-YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
3628, 5ebzD, 0.7603, 3.40, 0.242, 655, 264, CRYSTAL STRUCTURE OF HUMAN IKK1
3629, 4hzrB, 0.7603, 2.35, 0.261, 258, 245, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
3630, 3p1aA, 0.7603, 2.34, 0.275, 281, 244, STRUCTURE OF HUMAN MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE- SPECIFIC CDC2-INHIBITORY KINASE MYT1 (PKMYT1)
3631, 3kxxD, 0.7603, 2.79, 0.245, 288, 249, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
3632, 2ya9A, 0.7603, 3.02, 0.247, 299, 255, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
3633, 5x28A, 0.7602, 2.77, 0.199, 310, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(6)
3634, 5nkhA, 0.7602, 2.71, 0.206, 295, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
3635, 5ghvB, 0.7602, 2.32, 0.200, 265, 245, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3636, 5e91A, 0.7602, 2.74, 0.233, 297, 249, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
3637, 4rixB, 0.7602, 2.63, 0.217, 293, 249, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
3638, 4kb8B, 0.7602, 2.64, 0.184, 285, 250, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3639, 4e4mA, 0.7602, 2.92, 0.249, 296, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3640, 4dflA, 0.7602, 2.41, 0.206, 263, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
3641, 4xg3A, 0.7601, 2.45, 0.206, 262, 248, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3642, 2ym3A, 0.7601, 2.27, 0.269, 247, 242, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3643, 2auhA, 0.7601, 3.09, 0.196, 297, 255, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
3644, 6cmmA, 0.7600, 2.98, 0.147, 318, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
3645, 6bruA, 0.7600, 2.99, 0.146, 322, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3646, 5ghvA, 0.7600, 2.32, 0.200, 265, 245, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3647, 4u42A, 0.7600, 2.47, 0.255, 282, 247, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
3648, 4rioA, 0.7600, 2.67, 0.247, 285, 251, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
3649, 4lrmB, 0.7600, 2.70, 0.207, 293, 251, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
3650, 4e4mE, 0.7600, 2.92, 0.249, 296, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3651, 4e20A, 0.7600, 2.80, 0.220, 282, 250, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
3652, 3dk3B, 0.7600, 2.74, 0.217, 269, 249, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3653, 2b4sD, 0.7600, 3.03, 0.198, 294, 253, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
3654, 1wmkF, 0.7600, 2.98, 0.239, 303, 255, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3655, 5t8pA, 0.7599, 2.68, 0.247, 327, 251, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO BENZOXEPIN COMPOUND 2
3656, 5ebzK, 0.7599, 3.57, 0.253, 655, 265, CRYSTAL STRUCTURE OF HUMAN IKK1
3657, 5cxzA, 0.7599, 2.42, 0.206, 269, 247, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
3658, 4y85B, 0.7599, 2.11, 0.232, 306, 241, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
3659, 4kb8C, 0.7599, 2.72, 0.190, 277, 252, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3660, 3sv0A, 0.7599, 2.91, 0.180, 294, 256, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
3661, 3kxzA, 0.7599, 2.80, 0.220, 263, 250, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
3662, 6gl9A, 0.7598, 2.97, 0.239, 292, 255, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
3663, 5dosA, 0.7598, 2.43, 0.302, 259, 245, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
3664, 4y83B, 0.7598, 2.13, 0.237, 302, 241, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
3665, 4riwB, 0.7598, 2.59, 0.206, 293, 248, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
3666, 3io7A, 0.7598, 2.70, 0.259, 282, 251, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
3667, 5friA, 0.7597, 2.66, 0.213, 301, 249, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
3668, 5e8tA, 0.7597, 2.76, 0.212, 302, 250, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
3669, 4w9xA, 0.7597, 2.42, 0.260, 300, 246, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
3670, 4hvgA, 0.7597, 2.64, 0.248, 281, 250, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
3671, 3zewA, 0.7597, 2.37, 0.216, 269, 245, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
3672, 3s95B, 0.7597, 2.61, 0.240, 290, 246, CRYSTAL STRUCTURE OF THE HUMAN LIMK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3673, 2a27D, 0.7597, 2.97, 0.251, 304, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3674, 1wmkH, 0.7597, 2.99, 0.239, 304, 255, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3675, 1wmkG, 0.7597, 2.99, 0.239, 313, 255, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3676, 1bi8C, 0.7597, 2.37, 0.483, 264, 242, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
3677, 1bi8A, 0.7597, 2.37, 0.483, 264, 242, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
3678, 5cf5B, 0.7596, 2.86, 0.253, 294, 253, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3679, 4xg3B, 0.7596, 2.54, 0.198, 267, 248, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3680, 3kxxC, 0.7596, 2.73, 0.246, 286, 248, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
3681, 3fqhA, 0.7596, 2.48, 0.206, 262, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
3682, 3f5pI, 0.7596, 2.80, 0.209, 294, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3683, 2x7oA, 0.7596, 2.77, 0.212, 330, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
3684, 2x6dA, 0.7596, 2.36, 0.291, 255, 244, AURORA-A BOUND TO AN INHIBITOR
3685, 2wmwA, 0.7596, 2.25, 0.273, 247, 242, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3686, 5usyA, 0.7595, 2.76, 0.252, 287, 250, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
3687, 5lwmA, 0.7595, 2.80, 0.245, 290, 253, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
3688, 4u6rA, 0.7595, 2.46, 0.285, 403, 246, CRYSTAL STRUCTURE OF HUMAN IRE1 CYTOPLASMIC DOMAINS IN COMPLEX WITH A SULFONAMIDE INHIBITOR.
3689, 2bdwA, 0.7595, 2.82, 0.297, 309, 256, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
3690, 5x17B, 0.7594, 2.90, 0.191, 289, 256, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
3691, 5ebzA, 0.7594, 3.57, 0.253, 655, 265, CRYSTAL STRUCTURE OF HUMAN IKK1
3692, 4pv0A, 0.7594, 2.48, 0.206, 268, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
3693, 3dk7B, 0.7594, 2.71, 0.225, 268, 249, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3694, 1u54A, 0.7594, 2.44, 0.252, 262, 246, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
3695, 5lwnA, 0.7593, 2.80, 0.245, 290, 253, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
3696, 5cf4B, 0.7593, 2.88, 0.253, 291, 253, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3697, 4wkqA, 0.7593, 2.52, 0.206, 296, 247, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
3698, 3f5pS, 0.7593, 2.80, 0.209, 295, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3699, 3f5pM, 0.7593, 2.83, 0.208, 295, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3700, 2w1iB, 0.7593, 2.88, 0.250, 284, 252, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3701, 1wmkC, 0.7593, 2.89, 0.240, 303, 254, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3702, 5cwzA, 0.7592, 2.52, 0.253, 284, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
3703, 5ar3A, 0.7592, 2.53, 0.222, 279, 248, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP
3704, 1wmkE, 0.7592, 2.89, 0.240, 313, 254, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3705, 1wmkD, 0.7592, 2.90, 0.240, 314, 254, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3706, 1wmkA, 0.7592, 2.89, 0.240, 303, 254, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3707, 6cqhB, 0.7591, 3.01, 0.147, 316, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
3708, 5vdaA, 0.7591, 2.59, 0.215, 259, 246, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 101 A MK1775 ANALOGUE
3709, 5tr6A, 0.7591, 2.44, 0.206, 272, 247, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
3710, 4riyB, 0.7591, 2.62, 0.206, 293, 248, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
3711, 4f1tA, 0.7591, 2.63, 0.231, 269, 247, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
3712, 3dqwC, 0.7591, 2.60, 0.234, 275, 248, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
3713, 1wmkB, 0.7591, 2.89, 0.240, 314, 254, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3714, 6gl9B, 0.7590, 2.99, 0.239, 291, 255, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
3715, 5dt4A, 0.7590, 2.43, 0.302, 259, 245, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
3716, 4dfnA, 0.7590, 2.49, 0.206, 269, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
3717, 2ya9B, 0.7590, 3.02, 0.247, 299, 255, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
3718, 2itoA, 0.7590, 2.88, 0.199, 303, 251, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH IRESSA
3719, 5oq7A, 0.7589, 2.49, 0.274, 259, 248, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3720, 4euuA, 0.7589, 3.13, 0.239, 307, 259, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
3721, 2a27H, 0.7589, 2.89, 0.252, 304, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3722, 2a27F, 0.7589, 2.89, 0.252, 303, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3723, 5x26A, 0.7588, 2.84, 0.203, 302, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(3)
3724, 5mqvC, 0.7588, 2.88, 0.191, 288, 256, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3725, 2a27A, 0.7588, 3.03, 0.239, 304, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3726, 5ebzB, 0.7587, 3.42, 0.247, 655, 263, CRYSTAL STRUCTURE OF HUMAN IKK1
3727, 3dqwD, 0.7587, 2.59, 0.234, 276, 248, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
3728, 2w1iA, 0.7587, 2.79, 0.247, 284, 251, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3729, 2a27B, 0.7587, 2.90, 0.252, 303, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3730, 5tiuA, 0.7586, 2.44, 0.206, 266, 247, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
3731, 5gmpA, 0.7586, 2.75, 0.205, 305, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
3732, 4d2vB, 0.7586, 2.44, 0.307, 322, 244, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3733, 3krrA, 0.7586, 2.78, 0.258, 291, 252, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
3734, 2x7oD, 0.7586, 2.78, 0.212, 330, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
3735, 5ebzG, 0.7585, 3.52, 0.246, 655, 264, CRYSTAL STRUCTURE OF HUMAN IKK1
3736, 4d2wD, 0.7585, 2.66, 0.304, 326, 247, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3737, 2a27C, 0.7585, 2.93, 0.240, 303, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3738, 5y5uA, 0.7584, 2.50, 0.206, 266, 248, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
3739, 5ebzC, 0.7584, 3.56, 0.245, 655, 265, CRYSTAL STRUCTURE OF HUMAN IKK1
3740, 5ax9B, 0.7584, 2.22, 0.251, 274, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
3741, 5ar5A, 0.7584, 2.72, 0.227, 284, 251, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
3742, 4rx9A, 0.7584, 2.46, 0.202, 268, 247, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
3743, 4rssA, 0.7584, 2.64, 0.196, 269, 250, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
3744, 4l44A, 0.7584, 2.68, 0.302, 321, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
3745, 4kbkA, 0.7584, 2.66, 0.184, 283, 250, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3746, 2a27G, 0.7584, 2.98, 0.251, 303, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3747, 5x27A, 0.7582, 2.83, 0.199, 302, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(5)
3748, 4jjrB, 0.7582, 2.84, 0.180, 283, 256, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
3749, 3kl8I, 0.7582, 2.33, 0.320, 254, 244, CAMKIINTIDE INHIBITOR COMPLEX
3750, 2x7oE, 0.7582, 2.79, 0.212, 330, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
3751, 2pvyB, 0.7582, 2.63, 0.239, 286, 247, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
3752, 1iasB, 0.7582, 2.81, 0.208, 324, 250, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3753, 5t8pB, 0.7581, 2.70, 0.247, 328, 251, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO BENZOXEPIN COMPOUND 2
3754, 3vf8A, 0.7581, 2.46, 0.206, 265, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
3755, 3bceA, 0.7581, 2.68, 0.213, 285, 249, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
3756, 2ym7A, 0.7581, 2.38, 0.276, 248, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3757, 4d1sA, 0.7580, 2.59, 0.259, 280, 247, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
3758, 2wtwA, 0.7580, 2.46, 0.310, 256, 245, AURORA-A INHIBITOR STRUCTURE (2ND CRYSTAL FORM)
3759, 1xbaA, 0.7580, 2.46, 0.206, 266, 247, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
3760, 1ckiB, 0.7580, 2.87, 0.191, 286, 256, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
3761, 5eakA, 0.7579, 2.61, 0.322, 305, 242, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
3762, 3nyxA, 0.7579, 2.86, 0.206, 287, 253, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
3763, 2a27E, 0.7579, 2.91, 0.252, 303, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3764, 3uysB, 0.7578, 2.62, 0.181, 279, 249, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3765, 3ndmA, 0.7578, 2.69, 0.260, 383, 250, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
3766, 1ckjB, 0.7578, 2.86, 0.187, 293, 256, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
3767, 6cpfA, 0.7577, 2.34, 0.305, 259, 243, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION 
3768, 5fedA, 0.7577, 2.49, 0.203, 288, 246, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
3769, 5e92A, 0.7576, 2.84, 0.232, 298, 250, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
3770, 3vf9A, 0.7576, 2.47, 0.206, 265, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
3771, 3q32A, 0.7576, 2.82, 0.254, 291, 252, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
3772, 5j79A, 0.7575, 2.56, 0.226, 283, 248, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
3773, 4yjoA, 0.7575, 2.47, 0.190, 267, 247, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
3774, 2io6A, 0.7575, 2.38, 0.227, 252, 242, WEE1 KINASE COMPLEXED WITH INHIBITOR PD330961
3775, 5ebzL, 0.7574, 3.48, 0.242, 655, 264, CRYSTAL STRUCTURE OF HUMAN IKK1
3776, 3f5pK, 0.7574, 2.79, 0.209, 293, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3777, 5u6yK, 0.7573, 2.95, 0.292, 459, 253, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3778, 5hvuB, 0.7573, 2.88, 0.264, 394, 254, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH A PYRIDINE THIAZOLE PIPERIDINE INHIBITOR
3779, 4g3cB, 0.7573, 2.71, 0.247, 327, 251, CRYSTAL STRUCTURE OF APO MURINE NF-KAPPAB INDUCING KINASE (NIK)
3780, 2ym8A, 0.7573, 2.26, 0.270, 246, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3781, 2wtkF, 0.7573, 2.53, 0.266, 268, 244, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3782, 5u6yC, 0.7572, 2.95, 0.292, 459, 253, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3783, 2x7oC, 0.7572, 2.81, 0.212, 330, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
3784, 5u6yI, 0.7571, 2.97, 0.292, 459, 253, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3785, 5kz8A, 0.7571, 2.36, 0.326, 302, 239, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
3786, 5ebzI, 0.7571, 3.59, 0.246, 655, 264, CRYSTAL STRUCTURE OF HUMAN IKK1
3787, 4r5sA, 0.7571, 2.80, 0.203, 299, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
3788, 4ftqA, 0.7571, 2.42, 0.276, 254, 243, CRYSTAL STRUCTURE OF THE CHK1
3789, 4asxA, 0.7571, 2.78, 0.229, 310, 249, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
3790, 3pa5A, 0.7571, 2.49, 0.275, 255, 244, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
3791, 2dylA, 0.7571, 2.34, 0.230, 272, 243, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 ACTIVATED MUTANT (S287D T291D)
3792, 2dwbA, 0.7571, 2.35, 0.307, 259, 244, AURORA-A KINASE COMPLEXED WITH AMPPNP
3793, 5uorB, 0.7570, 2.62, 0.279, 262, 244, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3794, 4wsqB, 0.7570, 2.48, 0.247, 310, 247, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3795, 2x8iA, 0.7570, 2.53, 0.267, 261, 247, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3796, 2ituA, 0.7570, 2.76, 0.200, 304, 250, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
3797, 1u46B, 0.7570, 2.23, 0.264, 257, 242, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
3798, 5os2A, 0.7569, 2.41, 0.298, 261, 245, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3799, 5drdA, 0.7569, 2.47, 0.306, 259, 245, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
3800, 3ot8A, 0.7569, 2.43, 0.276, 251, 243, X-RAY CRYSTAL STRUCTURE OF COMPOUND 17R BOUND TO HUMAN CHK1 KINASE DOMAIN
3801, 3f5pL, 0.7569, 2.80, 0.209, 293, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3802, 3bceB, 0.7569, 2.61, 0.211, 286, 247, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
3803, 2x7oB, 0.7569, 2.81, 0.212, 330, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
3804, 6btwA, 0.7568, 2.99, 0.151, 317, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
3805, 4lrmA, 0.7568, 2.99, 0.199, 307, 256, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
3806, 3dk6A, 0.7568, 2.74, 0.218, 262, 248, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3807, 4l43A, 0.7567, 2.51, 0.307, 316, 244, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
3808, 3pjcA, 0.7567, 2.71, 0.252, 286, 250, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
3809, 3faaC, 0.7567, 2.96, 0.206, 330, 252, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
3810, 2ktyA, 0.7567, 3.01, 0.154, 360, 260, SOLUTION STRUCTURE OF HUMAN VACCINIA RELATED KINASE-1
3811, 2in6A, 0.7567, 2.39, 0.227, 256, 242, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
3812, 5ikwA, 0.7566, 2.51, 0.259, 297, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3813, 5ebzF, 0.7566, 3.49, 0.246, 655, 264, CRYSTAL STRUCTURE OF HUMAN IKK1
3814, 3srvB, 0.7566, 2.44, 0.199, 263, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
3815, 3qc4B, 0.7566, 2.40, 0.287, 278, 244, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
3816, 3lxnA, 0.7566, 2.85, 0.224, 287, 250, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3817, 3lvpB, 0.7566, 3.12, 0.211, 295, 256, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3818, 3f5pR, 0.7566, 2.84, 0.209, 294, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3819, 2ittA, 0.7566, 2.82, 0.200, 302, 250, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
3820, 2itnA, 0.7566, 2.82, 0.200, 304, 250, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
3821, 1k2pA, 0.7566, 2.54, 0.186, 258, 247, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
3822, 5uvfB, 0.7565, 2.96, 0.155, 316, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
3823, 5ukfC, 0.7565, 3.04, 0.150, 317, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
3824, 5tq3B, 0.7565, 2.86, 0.258, 285, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3825, 5dt0A, 0.7565, 2.49, 0.306, 259, 245, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
3826, 2ydjA, 0.7565, 2.31, 0.273, 252, 242, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3827, 6cqhA, 0.7564, 3.02, 0.147, 316, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
3828, 5d9lA, 0.7564, 2.54, 0.298, 299, 245, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
3829, 4lgdC, 0.7564, 2.62, 0.264, 349, 250, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3830, 3q32B, 0.7564, 2.93, 0.253, 294, 253, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
3831, 1rw8A, 0.7564, 2.94, 0.216, 301, 250, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
3832, 5u6yL, 0.7563, 2.88, 0.294, 459, 252, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3833, 5u6yJ, 0.7563, 2.88, 0.294, 459, 252, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3834, 5u6yH, 0.7563, 2.88, 0.294, 459, 252, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3835, 5u6yG, 0.7563, 2.88, 0.294, 459, 252, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3836, 5u6yF, 0.7563, 2.88, 0.294, 459, 252, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3837, 5u6yE, 0.7563, 2.88, 0.294, 459, 252, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3838, 5u6yD, 0.7563, 2.88, 0.294, 459, 252, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3839, 5u6yB, 0.7563, 2.88, 0.294, 459, 252, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3840, 5u6yA, 0.7563, 2.88, 0.294, 459, 252, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3841, 4y85C, 0.7563, 2.18, 0.232, 303, 241, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
3842, 4mneB, 0.7563, 2.69, 0.196, 270, 250, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3843, 3lxpA, 0.7563, 2.80, 0.226, 285, 248, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3844, 6glbA, 0.7562, 2.74, 0.247, 288, 251, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
3845, 5uvfA, 0.7562, 3.01, 0.147, 317, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
3846, 5ttvA, 0.7562, 2.68, 0.249, 280, 249, JAK3 WITH COVALENT INHIBITOR 6
3847, 5hznG, 0.7562, 2.96, 0.206, 296, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3848, 5ar2A, 0.7562, 2.57, 0.226, 277, 248, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
3849, 6glbB, 0.7561, 2.74, 0.247, 288, 251, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
3850, 5hznC, 0.7561, 2.96, 0.206, 296, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3851, 4xg4A, 0.7561, 2.34, 0.201, 264, 244, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3852, 3faaB, 0.7561, 2.86, 0.208, 324, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
3853, 3bizA, 0.7561, 2.41, 0.223, 250, 242, WEE1 KINASE COMPLEX WITH INHIBITOR PD331618
3854, 1iasD, 0.7561, 2.95, 0.206, 330, 252, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3855, 6cpeA, 0.7560, 2.28, 0.306, 256, 242, STRUCTURE OF APO; DEPHOSPHORYLATED AURORA A (122-403) IN AN ACTIVE CONFORMATION 
3856, 5di1A, 0.7560, 2.61, 0.254, 285, 248, MAP4K4 IN COMPLEX WITH AN INHIBITOR
3857, 4rx8A, 0.7560, 2.51, 0.202, 269, 247, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
3858, 4bicB, 0.7560, 2.39, 0.278, 259, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3859, 3tzmA, 0.7560, 2.67, 0.219, 295, 247, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
3860, 3pp0B, 0.7560, 2.84, 0.194, 296, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
3861, 3faaA, 0.7560, 2.96, 0.207, 328, 251, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
3862, 2xzsB, 0.7560, 2.86, 0.254, 293, 252, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
3863, 6eqiC, 0.7559, 2.91, 0.238, 392, 252, STRUCTURE OF PINK1 BOUND TO UBIQUITIN
3864, 5uu1A, 0.7559, 3.08, 0.146, 315, 260, CRYSTAL STRUCTURE OF HUMAN VACCINIA-RELATED KINASE 2 (VRK-2) BOUND TO BI-D1870
3865, 5ttuA, 0.7559, 2.56, 0.251, 271, 247, JAK3 WITH COVALENT INHIBITOR 7
3866, 5ng2B, 0.7559, 2.68, 0.221, 278, 249, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
3867, 5hvjA, 0.7559, 2.71, 0.237, 283, 245, CRYSTAL STRUCTURE OF LIMK1 D460N MUTANT IN COMPLEX WITH AMP-PNP
3868, 5cf6A, 0.7559, 2.80, 0.255, 285, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3869, 4gl9B, 0.7559, 2.73, 0.248, 280, 250, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
3870, 3dk7A, 0.7559, 2.79, 0.217, 265, 249, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3871, 3dk3A, 0.7559, 2.55, 0.227, 266, 247, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3872, 3lxkA, 0.7558, 2.72, 0.248, 279, 250, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3873, 3faaE, 0.7558, 2.86, 0.216, 330, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
3874, 6glaB, 0.7557, 2.75, 0.243, 286, 251, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
3875, 6cmmB, 0.7557, 3.02, 0.143, 310, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
3876, 6cfmA, 0.7557, 3.00, 0.147, 316, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PROPYNYL-PTERIDINONE INHIBITOR
3877, 5vdkA, 0.7557, 2.55, 0.254, 260, 244, CRYSTAL STRUCTURE OF HUMAN WEE2 KINASE DOMAIN IN COMPLEX WITH MK1775
3878, 5lmbA, 0.7557, 2.49, 0.206, 264, 247, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
3879, 5cf5A, 0.7557, 2.82, 0.259, 287, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3880, 4e6qA, 0.7557, 2.92, 0.249, 296, 253, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
3881, 3dk6B, 0.7557, 2.69, 0.220, 259, 246, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3882, 5tkxA, 0.7556, 3.08, 0.146, 315, 260, CRYSTAL STRUCTURE OF HUMAN VACCINIA-RELATED KINASE 2 (VRK-2) BOUND TO BI-D1870
3883, 5hznD, 0.7556, 2.94, 0.206, 304, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3884, 1yvjA, 0.7556, 2.71, 0.247, 288, 251, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
3885, 5hznH, 0.7555, 2.94, 0.206, 303, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3886, 5e8vA, 0.7555, 2.72, 0.238, 296, 248, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
3887, 4y83A, 0.7555, 2.18, 0.237, 299, 240, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
3888, 3f5pJ, 0.7555, 2.82, 0.209, 293, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3889, 6glaA, 0.7554, 2.76, 0.247, 288, 251, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
3890, 6cmmC, 0.7554, 2.97, 0.155, 316, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
3891, 4xg9B, 0.7554, 2.44, 0.211, 265, 246, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3892, 2wmuA, 0.7554, 2.30, 0.270, 246, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3893, 2itvA, 0.7554, 2.83, 0.200, 303, 250, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
3894, 6cmmD, 0.7553, 3.04, 0.151, 315, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
3895, 6bp0A, 0.7553, 3.02, 0.147, 317, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3896, 4ivaA, 0.7553, 2.91, 0.245, 290, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
3897, 4d2wB, 0.7553, 2.56, 0.299, 323, 244, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3898, 3zbfA, 0.7553, 2.45, 0.238, 281, 244, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
3899, 1vjyA, 0.7553, 2.86, 0.216, 299, 250, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
3900, 5mqvF, 0.7552, 2.86, 0.201, 286, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3901, 5hznE, 0.7552, 3.04, 0.206, 296, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3902, 4kbcB, 0.7552, 2.82, 0.194, 277, 252, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
3903, 4at3A, 0.7552, 2.71, 0.225, 289, 249, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
3904, 4aqcB, 0.7552, 2.96, 0.253, 295, 253, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
3905, 3umxA, 0.7552, 2.51, 0.273, 261, 245, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDOL-3-YL)METHYLENE]-7-(AZEPAN-1-YLMETHYL)-6-HYDROXYBENZOFURAN- 3(2H)-ONE
3906, 3socB, 0.7552, 2.75, 0.226, 309, 248, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
3907, 3faaD, 0.7552, 2.98, 0.206, 330, 252, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
3908, 1py5A, 0.7552, 2.97, 0.216, 301, 250, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
3909, 5m57A, 0.7551, 2.30, 0.278, 261, 241, NEK2 BOUND TO ARYLAMINOPURINE 6
3910, 5hznA, 0.7551, 3.05, 0.202, 296, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3911, 3zepA, 0.7551, 2.72, 0.255, 274, 247, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3912, 3eygA, 0.7551, 2.64, 0.243, 280, 247, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3913, 6dd4B, 0.7550, 3.06, 0.147, 309, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
3914, 4xg2A, 0.7550, 2.34, 0.201, 259, 244, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
3915, 4f09A, 0.7550, 2.90, 0.249, 288, 253, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3916, 5t68B, 0.7549, 2.36, 0.201, 264, 244, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
3917, 5dewB, 0.7549, 2.63, 0.291, 281, 247, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
3918, 4lg4F, 0.7549, 2.22, 0.278, 276, 241, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3919, 6cswC, 0.7548, 3.08, 0.154, 319, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
3920, 6bu6D, 0.7548, 3.05, 0.150, 318, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3921, 4gl9A, 0.7548, 2.75, 0.248, 282, 250, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
3922, 4g5jA, 0.7548, 2.52, 0.204, 307, 245, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
3923, 5dpvA, 0.7547, 2.35, 0.305, 257, 243, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
3924, 3zepC, 0.7547, 2.75, 0.254, 276, 248, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3925, 2ityA, 0.7547, 2.73, 0.198, 300, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
3926, 5oatF, 0.7546, 2.88, 0.231, 359, 251, PINK1 STRUCTURE
3927, 4qt1A, 0.7546, 2.61, 0.250, 277, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
3928, 4hvhA, 0.7546, 2.62, 0.250, 278, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
3929, 4hvdA, 0.7546, 2.62, 0.250, 276, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
3930, 4gl9C, 0.7546, 2.75, 0.248, 282, 250, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
3931, 4g5pA, 0.7546, 2.77, 0.202, 299, 252, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
3932, 5oatB, 0.7545, 2.93, 0.226, 359, 252, PINK1 STRUCTURE
3933, 5czoB, 0.7544, 2.88, 0.159, 365, 252, STRUCTURE OF S. CEREVISIAE HRR25:MAM1 COMPLEX FORM 2
3934, 2clqB, 0.7544, 2.39, 0.282, 259, 241, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
3935, 5kz8B, 0.7543, 2.21, 0.329, 300, 237, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
3936, 3kcfE, 0.7543, 2.98, 0.206, 330, 252, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3937, 6bp0B, 0.7542, 2.99, 0.152, 304, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3938, 5i9vA, 0.7542, 2.33, 0.214, 279, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
3939, 4yjqA, 0.7542, 2.90, 0.195, 264, 251, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000224
3940, 4bicA, 0.7542, 2.49, 0.281, 260, 242, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3941, 6dd4C, 0.7541, 3.06, 0.154, 317, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
3942, 6dd4A, 0.7541, 3.03, 0.151, 317, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
3943, 5hznF, 0.7541, 2.97, 0.206, 296, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3944, 5hznB, 0.7541, 2.97, 0.206, 296, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3945, 5cf6B, 0.7541, 2.85, 0.255, 290, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3946, 4yjtA, 0.7541, 2.71, 0.197, 268, 249, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
3947, 4lqmA, 0.7541, 2.83, 0.192, 305, 250, EGFR L858R IN COMPLEX WITH PD168393
3948, 6bu6C, 0.7540, 2.95, 0.152, 315, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3949, 5t68A, 0.7540, 2.44, 0.200, 266, 245, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
3950, 5oatE, 0.7540, 2.90, 0.231, 359, 251, PINK1 STRUCTURE
3951, 5oatC, 0.7540, 2.89, 0.231, 359, 251, PINK1 STRUCTURE
3952, 5feqA, 0.7540, 2.50, 0.208, 290, 245, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE
3953, 5ebzH, 0.7540, 3.52, 0.247, 655, 263, CRYSTAL STRUCTURE OF HUMAN IKK1
3954, 5eakB, 0.7540, 2.40, 0.326, 300, 239, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
3955, 5v19B, 0.7539, 2.46, 0.277, 260, 242, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3956, 5k00A, 0.7539, 2.32, 0.329, 311, 240, MELK IN COMPLEX WITH NVS-MELK5
3957, 5feeA, 0.7539, 2.49, 0.204, 287, 245, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
3958, 1iasC, 0.7539, 2.87, 0.212, 330, 250, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3959, 6babC, 0.7538, 2.75, 0.298, 284, 248, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
3960, 5twlA, 0.7538, 2.39, 0.329, 319, 240, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
3961, 5oatD, 0.7538, 2.94, 0.226, 359, 252, PINK1 STRUCTURE
3962, 5i9uA, 0.7538, 2.43, 0.213, 281, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
3963, 4yjrA, 0.7538, 2.91, 0.195, 263, 251, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000225
3964, 2j5fA, 0.7538, 2.91, 0.202, 308, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
3965, 1iasE, 0.7538, 2.96, 0.215, 330, 251, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3966, 3q4tB, 0.7537, 2.77, 0.226, 308, 248, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
3967, 3kcfB, 0.7537, 2.89, 0.208, 324, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3968, 6bruC, 0.7536, 2.98, 0.147, 315, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3969, 2qnjA, 0.7536, 2.66, 0.322, 318, 245, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
3970, 2j4zB, 0.7536, 2.45, 0.310, 269, 242, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3971, 5i3oA, 0.7535, 2.59, 0.258, 302, 248, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3972, 4yjvA, 0.7535, 2.91, 0.195, 263, 251, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
3973, 4mneC, 0.7535, 2.60, 0.202, 260, 247, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3974, 4i6qA, 0.7535, 2.65, 0.250, 277, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
3975, 5hg7A, 0.7534, 2.84, 0.209, 280, 249, EGFR (L858R T790M V948R) IN COMPLEX WITH 1-{(3R4R)-3-[5-CHLORO-2- (1-METHYL-1H-PYRAZOL-4-YLAMINO)-7H-PYRROLO[23-D]PYRIMIDIN-4- YLOXYMETHYL]-4-METHOXY-PYRROLIDIN-1-YL}PROPENONE (PF-06459988)
3976, 4e6qB, 0.7534, 2.94, 0.257, 296, 253, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
3977, 4bibB, 0.7534, 2.39, 0.279, 258, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3978, 4asxB, 0.7534, 2.92, 0.224, 307, 250, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
3979, 3srvA, 0.7534, 2.56, 0.206, 262, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
3980, 1p4fA, 0.7534, 2.57, 0.260, 269, 246, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
3981, 6cqhD, 0.7533, 3.08, 0.158, 315, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
3982, 6bp0C, 0.7533, 2.96, 0.152, 315, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3983, 4aqcA, 0.7533, 2.90, 0.254, 289, 252, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
3984, 3kcfC, 0.7533, 3.02, 0.206, 330, 252, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3985, 2wzjA, 0.7533, 2.48, 0.314, 310, 242, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3986, 6cswB, 0.7532, 3.13, 0.142, 308, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
3987, 5oatA, 0.7532, 2.91, 0.227, 359, 251, PINK1 STRUCTURE
3988, 4lrmC, 0.7532, 2.82, 0.206, 293, 252, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
3989, 2fumA, 0.7532, 2.49, 0.261, 263, 245, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3990, 4ftoA, 0.7531, 2.50, 0.276, 252, 243, CRYSTAL STRUCTURE OF THE CHK1
3991, 6fcfA, 0.7530, 2.32, 0.274, 251, 241, CHK1 KINASE IN COMPLEX WITH COMPOUND 44
3992, 5ng0A, 0.7530, 2.70, 0.222, 274, 248, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
3993, 5mjaA, 0.7530, 2.52, 0.224, 271, 246, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
3994, 5dr9A, 0.7530, 2.43, 0.309, 257, 243, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
3995, 4dn5A, 0.7530, 2.36, 0.251, 331, 243, CRYSTAL STRUCTURE OF NF-KB-INDUCING KINASE (NIK)
3996, 3zepD, 0.7530, 2.68, 0.256, 272, 246, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3997, 3fqsA, 0.7530, 2.40, 0.201, 268, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
3998, 1u46A, 0.7530, 2.35, 0.256, 255, 242, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
3999, 4ixpA, 0.7529, 3.13, 0.316, 334, 253, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
4000, 6cfmC, 0.7528, 2.97, 0.152, 316, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PROPYNYL-PTERIDINONE INHIBITOR
4001, 5tq8A, 0.7528, 2.88, 0.254, 291, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4002, 5tq5A, 0.7528, 2.87, 0.258, 291, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4003, 4f08A, 0.7528, 2.96, 0.253, 288, 253, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
4004, 1iasA, 0.7528, 3.08, 0.209, 330, 253, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
4005, 5up3A, 0.7527, 2.40, 0.283, 258, 240, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4006, 5lmbB, 0.7527, 2.56, 0.191, 261, 246, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
4007, 4zimA, 0.7527, 2.87, 0.255, 285, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
4008, 2zv2A, 0.7527, 2.30, 0.288, 256, 243, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
4009, 2jitA, 0.7527, 2.86, 0.182, 299, 253, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
4010, 6btwC, 0.7526, 2.99, 0.147, 315, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4011, 4mneG, 0.7526, 2.77, 0.198, 259, 248, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4012, 5m51A, 0.7525, 2.37, 0.274, 260, 241, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
4013, 4gl9D, 0.7525, 2.79, 0.248, 282, 250, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
4014, 1z9xC, 0.7525, 2.96, 0.259, 303, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
4015, 1o6yA, 0.7525, 2.36, 0.260, 260, 242, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
4016, 5ar5B, 0.7524, 2.54, 0.228, 279, 246, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
4017, 4z16A, 0.7524, 2.54, 0.254, 271, 244, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
4018, 4f08B, 0.7524, 2.98, 0.253, 288, 253, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
4019, 3fxxA, 0.7524, 2.64, 0.214, 288, 248, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BOUND TO SUBSTRATE KQWDNYE[PTYR]IW
4020, 4lrmE, 0.7523, 2.76, 0.199, 290, 251, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
4021, 4dn5B, 0.7523, 2.36, 0.247, 330, 243, CRYSTAL STRUCTURE OF NF-KB-INDUCING KINASE (NIK)
4022, 4bidB, 0.7522, 2.39, 0.279, 258, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4023, 5mqvA, 0.7521, 2.85, 0.198, 286, 253, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4024, 4z16C, 0.7521, 2.55, 0.254, 271, 244, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
4025, 2itzA, 0.7521, 2.88, 0.200, 302, 250, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
4026, 5ttsA, 0.7520, 2.56, 0.252, 274, 246, JAK3 WITH COVALENT INHIBITOR 4
4027, 5imeB, 0.7520, 2.49, 0.298, 280, 242, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
4028, 4lg4B, 0.7520, 2.58, 0.270, 284, 244, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4029, 4fynA, 0.7520, 2.40, 0.201, 267, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
4030, 6cswA, 0.7519, 3.00, 0.152, 316, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
4031, 5vd2A, 0.7519, 2.67, 0.233, 258, 245, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PF- 03814735
4032, 5tq3A, 0.7519, 2.84, 0.260, 282, 250, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4033, 5dr6A, 0.7519, 2.46, 0.309, 257, 243, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
4034, 6bu6B, 0.7518, 3.00, 0.140, 307, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4035, 2fumB, 0.7518, 2.50, 0.262, 262, 244, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4036, 4zp5A, 0.7517, 2.67, 0.254, 284, 248, MAP4K4 IN COMPLEX WITH INHIBITOR
4037, 4puzA, 0.7517, 2.62, 0.191, 263, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
4038, 2wzjC, 0.7517, 2.52, 0.314, 310, 242, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4039, 5i3rA, 0.7515, 2.62, 0.258, 302, 248, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
4040, 2wzjF, 0.7515, 2.52, 0.314, 310, 242, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4041, 4z16D, 0.7514, 2.59, 0.258, 271, 244, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
4042, 3tjcB, 0.7514, 2.90, 0.255, 287, 251, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
4043, 2w1gA, 0.7514, 2.37, 0.303, 254, 241, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4044, 1u4dA, 0.7514, 2.37, 0.256, 258, 242, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
4045, 5vc3A, 0.7513, 2.73, 0.232, 260, 246, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
4046, 4wrgA, 0.7513, 2.44, 0.210, 289, 243, 1.9 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN
4047, 4o0rB, 0.7513, 2.59, 0.317, 282, 243, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
4048, 3zosA, 0.7513, 2.91, 0.216, 301, 250, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
4049, 3lctA, 0.7513, 3.01, 0.178, 308, 253, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4050, 3kcfA, 0.7513, 2.94, 0.208, 328, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
4051, 2np8A, 0.7513, 2.40, 0.305, 256, 243, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
4052, 4lg4E, 0.7512, 2.53, 0.289, 275, 246, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4053, 4d2tA, 0.7512, 2.20, 0.328, 316, 238, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4054, 5nkgA, 0.7511, 2.73, 0.211, 292, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
4055, 5ng2A, 0.7511, 2.59, 0.215, 274, 246, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
4056, 4bieB, 0.7511, 2.37, 0.280, 257, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4057, 5ug8A, 0.7510, 2.77, 0.206, 280, 248, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(1- METHYL-1H-PYRAZOL-4-YL)AMINO]-9-(PROPAN-2-YL)-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
4058, 5nkfA, 0.7510, 2.74, 0.211, 291, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
4059, 5mqvB, 0.7510, 2.92, 0.193, 287, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4060, 5hg9A, 0.7510, 2.78, 0.206, 280, 248, EGFR (L858R T790M V948R) IN COMPLEX WITH 1-[(3R4R)-3-[({2-[(1- METHYL-1H-PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY) METHYL]-4-(TRIFLUOROMETHYL)PYRROLIDIN-1-YL]PROP-2-EN-1-ONE
4061, 3kcfD, 0.7510, 3.03, 0.206, 330, 252, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
4062, 6cnxD, 0.7509, 3.02, 0.152, 312, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 (VRK1) BOUND TO AN N-PROPYNYL-N-ISOPENTYL-DIHYDROPTERIDIN INHIBITOR
4063, 5cf8B, 0.7509, 2.86, 0.256, 288, 250, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
4064, 3fy2A, 0.7509, 2.52, 0.203, 285, 246, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BOUND TO SUBSTRATE KQWDNYEFIW
4065, 6fnhB, 0.7508, 2.76, 0.201, 271, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
4066, 5ug9A, 0.7508, 2.81, 0.209, 280, 249, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(3- METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO]-9-(PROPAN-2-YL)-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
4067, 5cf4A, 0.7508, 2.86, 0.256, 283, 250, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
4068, 2zvaA, 0.7508, 2.81, 0.235, 261, 247, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
4069, 1xbbA, 0.7508, 2.44, 0.201, 268, 244, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
4070, 5fm3A, 0.7507, 3.01, 0.234, 276, 248, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
4071, 5ar3B, 0.7507, 2.54, 0.224, 276, 245, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP
4072, 4ji9A, 0.7507, 2.85, 0.260, 284, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
4073, 4jjrA, 0.7506, 2.76, 0.196, 284, 250, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
4074, 3uzsA, 0.7506, 2.31, 0.266, 609, 241, STRUCTURE OF THE C13.28 RNA APTAMER BOUND TO THE G PROTEIN-COUPLED RECEPTOR KINASE 2-HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNIT COMPLEX
4075, 5ugcA, 0.7505, 2.81, 0.209, 280, 249, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(3- METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO]-9-METHYL-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
4076, 4px6A, 0.7505, 2.44, 0.201, 262, 244, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
4077, 4ji9B, 0.7505, 2.97, 0.251, 288, 251, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
4078, 4e26A, 0.7505, 2.61, 0.203, 270, 246, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
4079, 2qnjB, 0.7505, 2.54, 0.321, 322, 243, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
4080, 6eimA, 0.7504, 2.59, 0.317, 286, 243, HUMAN STK10 BOUND TO GW683134A
4081, 5ia2A, 0.7504, 2.66, 0.211, 287, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
4082, 4yjpA, 0.7504, 2.57, 0.195, 263, 246, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
4083, 5w5qA, 0.7503, 2.84, 0.255, 291, 251, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
4084, 4o0tB, 0.7503, 2.70, 0.297, 280, 246, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
4085, 4nzwB, 0.7503, 2.37, 0.270, 266, 241, CRYSTAL STRUCTURE OF STK25-MO25 COMPLEX
4086, 3fqeA, 0.7502, 2.50, 0.200, 269, 245, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
4087, 2cmwA, 0.7502, 2.83, 0.195, 294, 251, STRUCTURE OF HUMAN CASEIN KINASE 1 GAMMA-1 IN COMPLEX WITH 2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9- ISOPROPYLPURINE (CASP TARGET)
4088, 5vt1A, 0.7501, 2.66, 0.287, 265, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO A BENZAMIDE INHIBITOR
4089, 4i0sA, 0.7501, 2.45, 0.201, 267, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
4090, 3lvpA, 0.7501, 2.94, 0.215, 289, 251, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
4091, 6bruD, 0.7499, 3.07, 0.147, 311, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4092, 3l9pA, 0.7499, 3.02, 0.178, 303, 253, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4093, 2wzjB, 0.7499, 2.58, 0.314, 310, 242, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4094, 2b7aA, 0.7499, 2.89, 0.256, 284, 250, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
4095, 3hmiA, 0.7498, 2.86, 0.216, 268, 250, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
4096, 3fqhB, 0.7498, 2.49, 0.193, 258, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
4097, 3fe3B, 0.7498, 2.41, 0.322, 317, 242, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
4098, 1yi6B, 0.7498, 2.76, 0.246, 274, 248, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
4099, 1mruA, 0.7498, 2.66, 0.266, 269, 244, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
4100, 4hviA, 0.7496, 2.62, 0.252, 274, 246, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
4101, 3uzpB, 0.7496, 2.80, 0.187, 284, 251, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
4102, 3eknA, 0.7496, 3.01, 0.194, 297, 252, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
4103, 1wvyA, 0.7496, 2.92, 0.254, 273, 252, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
4104, 1k2pB, 0.7496, 2.60, 0.190, 258, 247, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
4105, 6dd4D, 0.7495, 3.16, 0.146, 311, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
4106, 6cnxC, 0.7495, 3.08, 0.147, 311, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 (VRK1) BOUND TO AN N-PROPYNYL-N-ISOPENTYL-DIHYDROPTERIDIN INHIBITOR
4107, 5mqvD, 0.7495, 2.94, 0.193, 287, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4108, 5hgiA, 0.7495, 2.48, 0.296, 395, 243, CRYSTAL STRUCTURE OF APO HUMAN IRE1 ALPHA
4109, 5fm2A, 0.7495, 2.97, 0.239, 273, 247, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
4110, 4mkcA, 0.7495, 3.17, 0.185, 303, 254, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
4111, 3lcsA, 0.7495, 3.05, 0.182, 304, 253, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4112, 2qluA, 0.7495, 2.88, 0.222, 297, 248, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
4113, 1jktB, 0.7495, 2.96, 0.261, 276, 253, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
4114, 5j79B, 0.7494, 2.55, 0.220, 277, 245, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
4115, 4xg8A, 0.7494, 2.49, 0.212, 258, 245, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4116, 3rvgA, 0.7494, 2.71, 0.263, 285, 247, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
4117, 1b6cF, 0.7494, 3.10, 0.215, 326, 251, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4118, 5nk6A, 0.7493, 2.67, 0.212, 284, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
4119, 5cf8A, 0.7493, 2.84, 0.257, 285, 249, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
4120, 3socA, 0.7493, 2.89, 0.229, 307, 249, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
4121, 2w5bA, 0.7493, 2.87, 0.275, 271, 247, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
4122, 4p7eB, 0.7492, 2.95, 0.255, 285, 251, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
4123, 6cnxB, 0.7491, 3.04, 0.148, 311, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 (VRK1) BOUND TO AN N-PROPYNYL-N-ISOPENTYL-DIHYDROPTERIDIN INHIBITOR
4124, 2j4zA, 0.7491, 2.50, 0.306, 263, 242, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
4125, 4ix4A, 0.7490, 3.48, 0.207, 346, 256, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH ADP
4126, 4d2vC, 0.7490, 2.07, 0.329, 316, 237, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4127, 3zfxA, 0.7490, 2.52, 0.230, 267, 244, CRYSTAL STRUCTURE OF EPHB1
4128, 2ydjB, 0.7490, 2.38, 0.274, 251, 241, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4129, 4jbqA, 0.7489, 2.39, 0.303, 257, 241, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
4130, 4ix5A, 0.7489, 3.47, 0.207, 346, 256, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH AMP-PNP
4131, 4fyoA, 0.7489, 2.41, 0.202, 267, 243, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
4132, 4rvtA, 0.7488, 2.58, 0.257, 281, 245, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
4133, 3zfxD, 0.7488, 2.53, 0.230, 265, 244, CRYSTAL STRUCTURE OF EPHB1
4134, 5mqvE, 0.7487, 2.91, 0.198, 287, 253, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4135, 4yjuA, 0.7487, 2.62, 0.191, 262, 246, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
4136, 4u40A, 0.7487, 2.87, 0.255, 295, 251, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
4137, 4fz6A, 0.7487, 2.46, 0.201, 266, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
4138, 5nkbA, 0.7486, 2.76, 0.207, 285, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
4139, 4lrmD, 0.7486, 2.90, 0.206, 289, 252, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
4140, 5ih8A, 0.7485, 2.30, 0.332, 306, 238, MELK IN COMPLEX WITH NVS-MELK1
4141, 4i0rA, 0.7485, 2.47, 0.201, 264, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
4142, 4bc6A, 0.7485, 2.79, 0.320, 285, 244, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
4143, 3q4tA, 0.7485, 2.91, 0.229, 305, 249, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
4144, 2r0iB, 0.7485, 2.33, 0.325, 300, 237, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
4145, 2r0iA, 0.7485, 2.31, 0.325, 300, 237, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
4146, 2b7aB, 0.7485, 2.94, 0.255, 287, 251, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
4147, 4puzB, 0.7484, 2.52, 0.200, 265, 245, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
4148, 4j8mA, 0.7484, 2.47, 0.308, 265, 240, AURORA A IN COMPLEX WITH CD532
4149, 4hgtA, 0.7484, 2.76, 0.192, 283, 250, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
4150, 4byiA, 0.7484, 2.39, 0.299, 254, 241, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
4151, 4b9dB, 0.7484, 2.85, 0.275, 295, 251, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
4152, 3zosB, 0.7484, 3.02, 0.215, 303, 251, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
4153, 3zhpD, 0.7484, 2.62, 0.255, 264, 247, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
4154, 4y83C, 0.7483, 2.11, 0.241, 293, 237, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
4155, 4ix6A, 0.7483, 3.47, 0.207, 346, 256, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE SOAKED WITH ATP
4156, 4c62A, 0.7483, 2.71, 0.268, 273, 246, INHIBITORS OF JAK2 KINASE DOMAIN
4157, 6cfmD, 0.7482, 3.17, 0.154, 313, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PROPYNYL-PTERIDINONE INHIBITOR
4158, 3d15A, 0.7482, 2.41, 0.289, 256, 242, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
4159, 6bp0D, 0.7481, 3.14, 0.155, 311, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4160, 5nk9A, 0.7481, 2.77, 0.207, 285, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
4161, 4bieA, 0.7481, 2.45, 0.280, 257, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4162, 4bhnB, 0.7481, 2.43, 0.285, 257, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4163, 3zmmA, 0.7481, 2.71, 0.268, 273, 246, INHIBITORS OF JAK2 KINASE DOMAIN
4164, 3uytD, 0.7481, 2.64, 0.194, 268, 247, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4165, 5nk1A, 0.7480, 2.80, 0.211, 284, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
4166, 4p90A, 0.7480, 2.17, 0.273, 272, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
4167, 4apcB, 0.7480, 2.85, 0.275, 296, 251, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
4168, 3zepB, 0.7480, 2.72, 0.257, 268, 245, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
4169, 2wzjE, 0.7480, 2.56, 0.314, 310, 242, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4170, 1fvrB, 0.7480, 2.58, 0.216, 300, 245, TIE2 KINASE DOMAIN
4171, 4e1zA, 0.7479, 2.86, 0.221, 288, 249, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
4172, 1b6cD, 0.7479, 3.06, 0.216, 326, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4173, 5ih9A, 0.7478, 2.22, 0.329, 308, 237, MELK IN COMPLEX WITH NVS-MELK8A
4174, 5ar4B, 0.7478, 2.61, 0.220, 279, 246, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
4175, 4hgeA, 0.7478, 2.90, 0.256, 284, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
4176, 4f4pA, 0.7478, 2.46, 0.209, 262, 244, SYK IN COMPLEX WITH LIGAND LASW836
4177, 4d2pC, 0.7478, 2.20, 0.316, 316, 237, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4178, 1fvrA, 0.7478, 2.42, 0.218, 299, 243, TIE2 KINASE DOMAIN
4179, 5kbqB, 0.7477, 2.66, 0.295, 273, 244, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
4180, 5ei8A, 0.7477, 2.42, 0.312, 261, 240, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4181, 3wf7A, 0.7477, 2.83, 0.312, 288, 247, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
4182, 4p7eA, 0.7476, 2.92, 0.256, 281, 250, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
4183, 3zhpC, 0.7476, 2.64, 0.255, 272, 247, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
4184, 5khwA, 0.7475, 2.62, 0.245, 276, 245, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
4185, 3lpbA, 0.7475, 2.85, 0.257, 278, 249, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
4186, 2w5aA, 0.7475, 2.90, 0.271, 267, 247, HUMAN NEK2 KINASE ADP-BOUND
4187, 6bruB, 0.7474, 2.92, 0.150, 301, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4188, 5nk2A, 0.7474, 2.61, 0.213, 290, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
4189, 4g3eA, 0.7474, 2.46, 0.251, 314, 243, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 6-ALKYNYLINDOLINE (CMP1)
4190, 3fupA, 0.7474, 2.92, 0.256, 284, 250, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
4191, 5i9xA, 0.7473, 2.80, 0.215, 284, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
4192, 5am7A, 0.7473, 2.86, 0.241, 294, 249, FGFR1 MUTANT WITH AN INHIBITOR
4193, 3dj7A, 0.7473, 2.47, 0.288, 257, 243, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
4194, 2qocA, 0.7473, 2.53, 0.204, 283, 245, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
4195, 2jiiB, 0.7473, 3.23, 0.143, 326, 259, STRUCTURE OF VACCINIA RELATED KINASE 3
4196, 5ugxB, 0.7472, 2.75, 0.245, 282, 245, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
4197, 4useA, 0.7472, 2.78, 0.311, 286, 244, HUMAN STK10 (LOK) WITH SB-633825
4198, 5wfjA, 0.7470, 2.58, 0.253, 265, 245, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
4199, 5nk7A, 0.7470, 2.83, 0.211, 284, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
4200, 4u5jB, 0.7470, 2.48, 0.245, 267, 241, C-SRC IN COMPLEX WITH RUXOLITINIB
4201, 4o0wA, 0.7470, 2.38, 0.299, 259, 241, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
4202, 4mneF, 0.7470, 2.70, 0.192, 258, 245, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4203, 1mruB, 0.7470, 2.68, 0.266, 271, 244, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
4204, 5xp5B, 0.7469, 2.59, 0.251, 267, 243, C-SRC IN COMPLEX WITH ATP-CHF
4205, 4yjsA, 0.7469, 2.57, 0.200, 257, 245, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
4206, 4ix5B, 0.7469, 3.57, 0.206, 350, 257, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH AMP-PNP
4207, 3r21A, 0.7469, 2.44, 0.303, 254, 241, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
4208, 3d14A, 0.7469, 2.47, 0.288, 262, 243, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
4209, 4ix3A, 0.7468, 3.49, 0.207, 346, 256, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE
4210, 3tjcA, 0.7468, 2.93, 0.256, 284, 250, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
4211, 6eimB, 0.7467, 2.72, 0.318, 295, 245, HUMAN STK10 BOUND TO GW683134A
4212, 5j5tA, 0.7467, 3.02, 0.275, 297, 247, GLK CO-CRYSTAL STRUCTURE WITH AMINOPYRROLOPYRIMIDINE INHIBITOR
4213, 5ei6A, 0.7467, 2.34, 0.310, 264, 239, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4214, 2ym4A, 0.7467, 2.39, 0.276, 251, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4215, 5uvfC, 0.7466, 2.97, 0.150, 301, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4216, 2w1fA, 0.7466, 2.39, 0.304, 253, 240, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4217, 5ek7B, 0.7465, 2.62, 0.212, 286, 245, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
4218, 2jiiA, 0.7465, 3.21, 0.143, 321, 258, STRUCTURE OF VACCINIA RELATED KINASE 3
4219, 4zauA, 0.7464, 2.41, 0.207, 283, 241, AZD9291 COMPLEX WITH WILD TYPE EGFR
4220, 3tt0A, 0.7464, 3.04, 0.235, 305, 251, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
4221, 3c4fA, 0.7464, 2.86, 0.241, 290, 249, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
4222, 1mqbB, 0.7464, 2.48, 0.214, 265, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
4223, 5am6A, 0.7463, 2.88, 0.241, 295, 249, NATIVE FGFR1 WITH AN INHIBITOR
4224, 4v0gA, 0.7463, 2.69, 0.262, 267, 244, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
4225, 3d2iA, 0.7463, 2.42, 0.289, 255, 242, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
4226, 5ew8A, 0.7462, 2.86, 0.237, 291, 249, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
4227, 4kikA, 0.7462, 3.39, 0.261, 618, 253, HUMAN IKB KINASE BETA
4228, 4hgeB, 0.7462, 2.97, 0.256, 288, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
4229, 3r22A, 0.7462, 2.55, 0.293, 255, 242, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
4230, 5nk4A, 0.7461, 2.72, 0.208, 290, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
4231, 5f1zA, 0.7461, 2.48, 0.223, 281, 242, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
4232, 4z55A, 0.7461, 3.05, 0.187, 294, 251, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
4233, 4hgtB, 0.7461, 2.78, 0.180, 280, 250, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
4234, 4fz7A, 0.7461, 2.46, 0.202, 265, 243, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
4235, 2wzjD, 0.7461, 2.48, 0.315, 313, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4236, 5oneA, 0.7460, 2.57, 0.312, 257, 240, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
4237, 2xngA, 0.7460, 2.31, 0.305, 253, 239, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
4238, 4u43A, 0.7459, 2.73, 0.253, 287, 249, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
4239, 4d55A, 0.7459, 2.43, 0.257, 260, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4240, 3cekA, 0.7459, 2.43, 0.312, 256, 240, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
4241, 2j0jA, 0.7459, 2.67, 0.254, 611, 244, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
4242, 5o49A, 0.7458, 2.85, 0.237, 289, 249, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4243, 5nkcA, 0.7458, 2.58, 0.214, 286, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
4244, 5ajqB, 0.7458, 2.36, 0.325, 267, 240, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
4245, 4ix6B, 0.7458, 3.58, 0.206, 350, 257, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE SOAKED WITH ATP
4246, 4i0tA, 0.7458, 2.45, 0.202, 266, 243, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
4247, 3zfxH, 0.7458, 2.53, 0.226, 266, 243, CRYSTAL STRUCTURE OF EPHB1
4248, 3js2A, 0.7458, 2.85, 0.237, 295, 249, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
4249, 3c4fB, 0.7458, 2.87, 0.237, 290, 249, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
4250, 4d2wC, 0.7457, 2.11, 0.328, 313, 235, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4251, 2wtvC, 0.7457, 2.64, 0.306, 261, 242, AURORA-A INHIBITOR STRUCTURE
4252, 1fgkA, 0.7457, 2.85, 0.241, 278, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
4253, 5cyzA, 0.7456, 2.99, 0.139, 353, 252, STRUCTURE OF S. CEREVISIAE HRR25:MAM1 COMPLEX FORM 1
4254, 4umqA, 0.7456, 2.42, 0.335, 314, 239, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4255, 2xa4A, 0.7456, 2.73, 0.272, 276, 246, INHIBITORS OF JAK2 KINASE DOMAIN
4256, 4f63A, 0.7455, 2.86, 0.241, 278, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
4257, 4b9dA, 0.7455, 2.92, 0.255, 290, 251, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
4258, 4aotA, 0.7455, 2.42, 0.336, 278, 241, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
4259, 3qd2B, 0.7455, 2.73, 0.270, 271, 244, CRSYTAL STRUCTURE OF MOUSE PERK KINASE DOMAIN
4260, 5w86C, 0.7454, 2.58, 0.260, 273, 242, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4261, 5mahA, 0.7454, 2.41, 0.332, 316, 238, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4262, 5c8mA, 0.7454, 2.66, 0.197, 302, 244, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
4263, 4umpC, 0.7454, 2.21, 0.331, 311, 236, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4264, 4jrnA, 0.7454, 2.69, 0.212, 349, 245, ROP18 KINASE DOMAIN IN COMPLEX WITH AMP-PNP AND SUCROSE
4265, 2hz0A, 0.7454, 2.97, 0.209, 265, 249, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
4266, 2eb3A, 0.7454, 2.80, 0.203, 294, 246, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
4267, 1fgiA, 0.7454, 2.87, 0.237, 283, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
4268, 6cswD, 0.7453, 3.13, 0.152, 312, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
4269, 4ueuA, 0.7453, 2.56, 0.244, 256, 242, TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL
4270, 4c61A, 0.7453, 2.80, 0.268, 272, 246, INHIBITORS OF JAK2 KINASE DOMAIN
4271, 3kfaA, 0.7453, 2.75, 0.238, 284, 244, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
4272, 1yi6A, 0.7453, 2.74, 0.235, 274, 247, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
4273, 1bi7A, 0.7453, 2.65, 0.467, 269, 242, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURE OF THE CDK6-P16INK4A TUMOR SUPPRESSOR COMPLEX
4274, 5magA, 0.7452, 2.33, 0.333, 314, 237, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4275, 4rwiA, 0.7452, 2.93, 0.237, 305, 249, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
4276, 4qqjA, 0.7452, 2.91, 0.241, 282, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
4277, 4f64A, 0.7452, 2.88, 0.241, 278, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
4278, 4d2tC, 0.7452, 2.16, 0.328, 313, 235, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4279, 3kfaB, 0.7452, 2.74, 0.230, 284, 244, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
4280, 3fe3A, 0.7452, 2.67, 0.324, 317, 244, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
4281, 1agwA, 0.7452, 2.86, 0.241, 278, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
4282, 3rhxA, 0.7451, 2.86, 0.241, 289, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
4283, 5vndB, 0.7450, 3.09, 0.234, 295, 252, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
4284, 4ix4B, 0.7450, 3.64, 0.205, 350, 258, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH ADP
4285, 3tjdB, 0.7450, 3.02, 0.251, 287, 251, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
4286, 3fupB, 0.7450, 3.02, 0.255, 287, 251, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
4287, 3emgA, 0.7450, 2.35, 0.195, 255, 241, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
4288, 5obrA, 0.7449, 2.54, 0.307, 255, 241, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
4289, 5nk3A, 0.7449, 2.74, 0.211, 281, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
4290, 5n84A, 0.7449, 2.55, 0.304, 256, 240, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
4291, 4qrcA, 0.7449, 2.88, 0.242, 297, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
4292, 4e26B, 0.7449, 2.56, 0.202, 264, 243, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
4293, 2c6eA, 0.7449, 2.43, 0.312, 251, 240, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
4294, 1zmwA, 0.7449, 2.58, 0.315, 302, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4295, 5i9zA, 0.7448, 2.73, 0.213, 273, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
4296, 4cqgA, 0.7448, 2.46, 0.324, 313, 238, THE CRYSTAL STRUCTURE OF MPK38 IN COMPLEX WITH OTSSP167 AN ORALLY-ADMINISTRATIVE MELK SELECTIVE INHIBITOR
4297, 3ky2A, 0.7448, 2.93, 0.237, 307, 249, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
4298, 5hvjB, 0.7447, 2.65, 0.240, 284, 242, CRYSTAL STRUCTURE OF LIMK1 D460N MUTANT IN COMPLEX WITH AMP-PNP
4299, 5ehlA, 0.7447, 2.36, 0.310, 258, 239, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4300, 4rwkA, 0.7447, 3.02, 0.236, 308, 250, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
4301, 4e6dA, 0.7447, 2.89, 0.261, 286, 249, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
4302, 3lvpD, 0.7447, 2.60, 0.213, 282, 244, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
4303, 3fbvA, 0.7447, 2.89, 0.296, 415, 247, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4304, 5owrA, 0.7446, 2.75, 0.318, 282, 242, HUMAN STK10 BOUND TO DASATINIB
4305, 5iu2B, 0.7446, 2.27, 0.233, 313, 240, DISCOVERY OF IMIDAZOQUINOLINES AS A NOVEL CLASS OF POTENT SELECTIVE AND IN VIVO EFFICACIOUS COT KINASE INHIBITORS
4306, 5caqA, 0.7446, 2.69, 0.197, 301, 244, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
4307, 4rwjA, 0.7446, 2.93, 0.237, 307, 249, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
4308, 3ohtA, 0.7446, 3.08, 0.319, 331, 254, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
4309, 6btwB, 0.7445, 2.99, 0.154, 301, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4310, 5vo6A, 0.7445, 2.68, 0.248, 271, 246, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
4311, 5j7bA, 0.7445, 2.60, 0.220, 277, 245, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
4312, 5ftoA, 0.7445, 2.99, 0.184, 298, 250, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
4313, 4uwyA, 0.7445, 3.02, 0.236, 296, 250, FGFR1 APO STRUCTURE
4314, 4ix3B, 0.7445, 3.61, 0.206, 350, 257, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE
4315, 4gk4A, 0.7445, 2.49, 0.206, 275, 243, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
4316, 3fbvC, 0.7445, 2.82, 0.297, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4317, 2wtvB, 0.7445, 2.43, 0.308, 261, 240, AURORA-A INHIBITOR STRUCTURE
4318, 2w1eA, 0.7445, 2.38, 0.310, 252, 239, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4319, 1b6cB, 0.7445, 3.12, 0.216, 326, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4320, 5nkdA, 0.7444, 2.61, 0.214, 287, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
4321, 5aafA, 0.7444, 2.36, 0.300, 254, 240, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
4322, 3hmmA, 0.7444, 2.75, 0.212, 293, 245, STRUCTURE OF ALK5 + GW855857
4323, 5iu2A, 0.7443, 2.28, 0.233, 312, 240, DISCOVERY OF IMIDAZOQUINOLINES AS A NOVEL CLASS OF POTENT SELECTIVE AND IN VIVO EFFICACIOUS COT KINASE INHIBITORS
4324, 5canA, 0.7443, 2.69, 0.197, 301, 244, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
4325, 4c8bB, 0.7443, 2.69, 0.216, 281, 245, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
4326, 3ohtB, 0.7443, 3.08, 0.319, 331, 254, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
4327, 3js2B, 0.7443, 2.87, 0.241, 291, 249, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
4328, 2zmcA, 0.7443, 2.33, 0.310, 260, 239, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
4329, 5ek7A, 0.7442, 2.64, 0.212, 286, 245, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
4330, 3zfxE, 0.7442, 2.52, 0.227, 262, 242, CRYSTAL STRUCTURE OF EPHB1
4331, 3sdmG, 0.7442, 2.83, 0.297, 415, 246, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4332, 3sdmF, 0.7442, 2.83, 0.297, 415, 246, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4333, 3sdmE, 0.7442, 2.83, 0.297, 415, 246, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4334, 3sdmD, 0.7442, 2.82, 0.297, 415, 246, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4335, 3sdmC, 0.7442, 2.83, 0.297, 415, 246, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4336, 3sdmB, 0.7442, 2.83, 0.297, 415, 246, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4337, 3sdmA, 0.7442, 2.82, 0.297, 415, 246, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4338, 3fbvN, 0.7442, 2.83, 0.297, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4339, 3fbvG, 0.7442, 2.83, 0.297, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4340, 3fbvF, 0.7442, 2.83, 0.297, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4341, 3fbvB, 0.7442, 2.83, 0.297, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4342, 2fgiA, 0.7442, 2.84, 0.234, 274, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
4343, 5m5aA, 0.7441, 2.29, 0.329, 315, 237, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4344, 5a46B, 0.7441, 2.89, 0.237, 297, 249, FGFR1 IN COMPLEX WITH DOVITINIB
4345, 4zsaA, 0.7441, 2.91, 0.241, 289, 249, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
4346, 4u5jA, 0.7441, 2.63, 0.251, 267, 243, C-SRC IN COMPLEX WITH RUXOLITINIB
4347, 4j95D, 0.7441, 2.66, 0.248, 271, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
4348, 3fbvL, 0.7441, 2.83, 0.297, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4349, 3fbvK, 0.7441, 2.83, 0.297, 422, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4350, 5nttA, 0.7440, 2.47, 0.312, 276, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
4351, 4uwcB, 0.7440, 2.89, 0.241, 301, 249, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
4352, 4c02A, 0.7440, 2.89, 0.231, 313, 247, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
4353, 4bfmA, 0.7440, 2.35, 0.325, 313, 237, THE CRYSTAL STRUCTURE OF MOUSE PK38
4354, 4aszA, 0.7440, 2.88, 0.225, 289, 249, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
4355, 3tjdA, 0.7440, 2.97, 0.256, 284, 250, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
4356, 3fbvD, 0.7440, 2.90, 0.296, 422, 247, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4357, 6cqhC, 0.7439, 3.03, 0.149, 308, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
4358, 5ei2A, 0.7439, 2.34, 0.311, 256, 238, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4359, 4v0gB, 0.7439, 2.67, 0.263, 272, 243, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
4360, 4uwcA, 0.7439, 2.90, 0.237, 300, 249, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
4361, 4gk3A, 0.7439, 2.46, 0.207, 275, 242, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
4362, 3hgkA, 0.7439, 3.28, 0.202, 286, 253, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
4363, 3fbvM, 0.7439, 2.83, 0.297, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4364, 3fbvH, 0.7439, 2.83, 0.297, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4365, 2wmsA, 0.7439, 2.33, 0.277, 243, 238, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4366, 2ivsB, 0.7439, 2.75, 0.247, 277, 243, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
4367, 5ihaA, 0.7438, 2.25, 0.335, 303, 236, MELK IN COMPLEX WITH NVS-MELK8F
4368, 3oy3A, 0.7438, 2.76, 0.238, 284, 244, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
4369, 3fbvE, 0.7438, 2.83, 0.297, 415, 246, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4370, 3ckwA, 0.7438, 2.20, 0.282, 255, 238, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
4371, 5j7bB, 0.7437, 2.64, 0.220, 281, 245, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
4372, 4xg9A, 0.7437, 2.40, 0.195, 259, 241, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4373, 4d2wA, 0.7437, 2.09, 0.332, 314, 235, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4374, 3lpbB, 0.7437, 2.77, 0.264, 284, 246, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
4375, 3hmpA, 0.7437, 2.33, 0.311, 258, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
4376, 2rsvA, 0.7437, 3.28, 0.146, 403, 260, SOLUTION STRUCTURE OF HUMAN FULL-LENGTH VACCINIA RELATED KINASE 1 (VRK1)
4377, 5hcyA, 0.7436, 2.75, 0.196, 302, 245, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
4378, 4qpsA, 0.7436, 2.35, 0.264, 270, 239, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
4379, 5n87A, 0.7435, 2.48, 0.301, 255, 239, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
4380, 5kz7B, 0.7435, 2.23, 0.322, 296, 233, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
4381, 4d2pA, 0.7435, 2.00, 0.333, 313, 234, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4382, 3sdjC, 0.7435, 2.91, 0.296, 415, 247, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4383, 3oy3B, 0.7435, 2.75, 0.238, 284, 244, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
4384, 4xcuA, 0.7434, 2.92, 0.242, 288, 248, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
4385, 3wf5A, 0.7434, 2.36, 0.318, 277, 239, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
4386, 3sdjF, 0.7434, 2.92, 0.296, 415, 247, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4387, 3sdjB, 0.7434, 2.92, 0.296, 415, 247, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4388, 3sdjA, 0.7434, 2.91, 0.296, 415, 247, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4389, 3k5uA, 0.7434, 2.38, 0.300, 260, 240, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
4390, 5o4aA, 0.7433, 2.90, 0.241, 290, 249, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4391, 5czoA, 0.7433, 2.94, 0.160, 365, 250, STRUCTURE OF S. CEREVISIAE HRR25:MAM1 COMPLEX FORM 2
4392, 5cwzC, 0.7433, 2.28, 0.255, 271, 239, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
4393, 3sdjN, 0.7433, 2.92, 0.296, 415, 247, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4394, 3sdjM, 0.7433, 2.92, 0.296, 415, 247, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4395, 3sdjL, 0.7433, 2.92, 0.296, 415, 247, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4396, 3sdjK, 0.7433, 2.92, 0.296, 422, 247, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4397, 3sdjH, 0.7433, 2.92, 0.296, 415, 247, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4398, 3sdjG, 0.7433, 2.92, 0.296, 415, 247, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4399, 3sdjE, 0.7433, 2.92, 0.296, 415, 247, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4400, 3pp0A, 0.7433, 2.82, 0.197, 286, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
4401, 3dqxA, 0.7433, 2.64, 0.251, 267, 243, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
4402, 5ew8B, 0.7432, 3.04, 0.232, 290, 250, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
4403, 4g3cA, 0.7432, 2.50, 0.251, 315, 243, CRYSTAL STRUCTURE OF APO MURINE NF-KAPPAB INDUCING KINASE (NIK)
4404, 4apcA, 0.7432, 2.94, 0.255, 293, 251, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
4405, 3hgkC, 0.7432, 3.27, 0.202, 284, 253, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
4406, 3h10A, 0.7432, 2.64, 0.306, 268, 242, AURORA A INHIBITOR COMPLEX
4407, 3gfwA, 0.7432, 2.25, 0.304, 253, 237, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYROLO-PYRIDIN LIGAND
4408, 5y5uB, 0.7431, 2.42, 0.195, 257, 241, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
4409, 5ar7B, 0.7431, 2.61, 0.224, 278, 245, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
4410, 4qqtA, 0.7431, 2.80, 0.240, 283, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
4411, 4at4A, 0.7431, 2.86, 0.225, 292, 249, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
4412, 3sdjD, 0.7431, 2.92, 0.296, 422, 247, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4413, 3f69B, 0.7431, 2.85, 0.233, 282, 249, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
4414, 4tt7A, 0.7430, 3.13, 0.192, 291, 250, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
4415, 3wf6A, 0.7430, 2.38, 0.318, 277, 239, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
4416, 5o91A, 0.7429, 2.51, 0.317, 266, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604W MUTANT IN COMPLEX WITH CPD-5
4417, 4uwbA, 0.7429, 2.93, 0.237, 299, 249, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
4418, 3zfxI, 0.7429, 2.48, 0.228, 263, 241, CRYSTAL STRUCTURE OF EPHB1
4419, 3op5D, 0.7429, 3.11, 0.144, 302, 257, HUMAN VACCINIA-RELATED KINASE 1
4420, 3ik3A, 0.7429, 2.77, 0.234, 280, 244, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
4421, 5w86D, 0.7428, 2.53, 0.261, 272, 241, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4422, 5w5oM, 0.7428, 2.50, 0.226, 276, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4423, 5odtA, 0.7428, 2.58, 0.303, 258, 241, AURORA-A IN COMPLEX WITH TACC3
4424, 5kz7A, 0.7428, 2.23, 0.322, 296, 233, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
4425, 4cnhB, 0.7428, 2.92, 0.202, 293, 248, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
4426, 5xdlA, 0.7427, 2.70, 0.193, 292, 243, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
4427, 5oy6D, 0.7427, 3.00, 0.234, 292, 248, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4428, 4zjiB, 0.7427, 2.52, 0.309, 276, 243, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4429, 4zegA, 0.7427, 2.25, 0.308, 260, 237, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
4430, 4an2A, 0.7427, 3.17, 0.257, 282, 253, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
4431, 2qo9A, 0.7427, 2.51, 0.206, 277, 243, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
4432, 6fu5B, 0.7426, 2.72, 0.224, 286, 246, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
4433, 5w86B, 0.7426, 2.56, 0.261, 267, 241, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4434, 5em7A, 0.7426, 2.68, 0.198, 300, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
4435, 5e1eA, 0.7426, 2.76, 0.244, 279, 246, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
4436, 5casA, 0.7426, 2.68, 0.198, 299, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
4437, 4cd0A, 0.7426, 2.83, 0.186, 295, 247, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
4438, 3hgkD, 0.7426, 3.22, 0.202, 286, 252, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
4439, 1ol6A, 0.7426, 2.22, 0.301, 245, 236, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
4440, 5tq4A, 0.7425, 2.98, 0.254, 290, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4441, 5iuiA, 0.7425, 3.13, 0.187, 303, 252, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
4442, 4zjiA, 0.7425, 2.55, 0.309, 278, 243, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4443, 4qpsC, 0.7425, 2.71, 0.256, 276, 246, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
4444, 1zmwB, 0.7425, 2.62, 0.315, 302, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4445, 6fu5A, 0.7424, 2.75, 0.215, 282, 246, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
4446, 5aagA, 0.7424, 2.39, 0.304, 253, 240, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
4447, 4u0iA, 0.7424, 2.65, 0.221, 297, 244, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
4448, 5eh0A, 0.7423, 2.28, 0.304, 258, 237, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4449, 5c8nA, 0.7423, 2.67, 0.198, 300, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
4450, 4bhnA, 0.7423, 2.49, 0.290, 256, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4451, 3wyxA, 0.7423, 2.61, 0.312, 258, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
4452, 3vw6A, 0.7423, 2.38, 0.283, 255, 237, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
4453, 3f6xD, 0.7423, 2.50, 0.250, 267, 240, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4454, 5v19A, 0.7422, 2.20, 0.289, 250, 235, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
4455, 1zmvB, 0.7422, 2.30, 0.315, 296, 235, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
4456, 4fobA, 0.7421, 2.98, 0.185, 295, 249, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
4457, 3hgkB, 0.7421, 3.27, 0.202, 286, 253, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
4458, 3fdnA, 0.7421, 2.46, 0.299, 261, 241, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
4459, 1zmuB, 0.7421, 2.33, 0.319, 296, 235, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
4460, 6fnhA, 0.7420, 2.77, 0.203, 277, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
4461, 4uzdB, 0.7420, 2.52, 0.280, 258, 243, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4462, 4hvsA, 0.7419, 2.69, 0.225, 326, 244, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
4463, 4uwbB, 0.7418, 3.06, 0.232, 299, 250, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
4464, 3psdB, 0.7418, 2.49, 0.203, 264, 241, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
4465, 3ik3B, 0.7418, 2.79, 0.234, 286, 244, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
4466, 2vx0A, 0.7418, 2.78, 0.206, 273, 247, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4467, 5i9yA, 0.7417, 2.57, 0.215, 287, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
4468, 5capA, 0.7417, 2.80, 0.204, 303, 245, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
4469, 3dbqA, 0.7417, 2.45, 0.305, 259, 239, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
4470, 2v62A, 0.7417, 3.13, 0.160, 309, 256, STRUCTURE OF VACCINIA-RELATED KINASE 2
4471, 5ehyA, 0.7416, 2.44, 0.307, 255, 238, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4472, 4xg8C, 0.7416, 2.36, 0.196, 254, 240, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4473, 4at5A, 0.7416, 2.85, 0.225, 294, 249, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
4474, 2vwyA, 0.7416, 2.89, 0.214, 274, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4475, 1lufA, 0.7416, 2.52, 0.228, 275, 241, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
4476, 5ap6A, 0.7415, 2.23, 0.316, 262, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4477, 4h58B, 0.7415, 2.57, 0.203, 262, 241, BRAF IN COMPLEX WITH COMPOUND 3
4478, 4dfyE, 0.7415, 2.55, 0.268, 312, 246, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
4479, 4c4jA, 0.7415, 2.37, 0.311, 261, 238, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4480, 5mafA, 0.7414, 2.24, 0.331, 315, 236, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4481, 5khxA, 0.7414, 2.84, 0.246, 276, 248, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
4482, 3nczB, 0.7414, 2.78, 0.259, 379, 247, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
4483, 2vx1A, 0.7414, 2.78, 0.202, 274, 247, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4484, 5khwB, 0.7413, 2.71, 0.245, 276, 245, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
4485, 5aadA, 0.7413, 2.38, 0.293, 252, 239, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
4486, 4zloB, 0.7413, 2.12, 0.294, 263, 235, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
4487, 4rj4A, 0.7413, 2.69, 0.198, 299, 243, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
4488, 4equB, 0.7413, 2.38, 0.322, 282, 236, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
4489, 4bi0A, 0.7413, 2.37, 0.308, 254, 237, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4490, 5hx8A, 0.7412, 2.86, 0.242, 291, 248, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
4491, 5c8kA, 0.7412, 2.69, 0.198, 300, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
4492, 4umrA, 0.7412, 2.40, 0.332, 313, 238, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4493, 4umpA, 0.7412, 2.08, 0.325, 313, 234, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4494, 4bi1A, 0.7412, 2.39, 0.308, 252, 237, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4495, 4bf2B, 0.7412, 2.28, 0.289, 252, 235, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4496, 3hmnA, 0.7412, 2.46, 0.303, 255, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
4497, 2z7rA, 0.7412, 2.21, 0.314, 265, 236, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
4498, 2xruA, 0.7412, 2.40, 0.305, 253, 239, AURORA-A T288E COMPLEXED WITH PHA-828300
4499, 2vwzA, 0.7412, 2.78, 0.202, 274, 247, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4500, 6fnmA, 0.7411, 2.68, 0.207, 270, 246, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH DASATINIB 
4501, 5ia3A, 0.7411, 2.41, 0.212, 275, 240, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
4502, 4yhtB, 0.7411, 2.50, 0.203, 258, 241, BRAF COMPLEXED WITH AN INHIBITOR
4503, 3a4oX, 0.7411, 2.65, 0.236, 259, 242, LYN KINASE DOMAIN
4504, 2wmqA, 0.7411, 2.25, 0.275, 246, 236, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4505, 2vwxA, 0.7411, 2.78, 0.202, 274, 247, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4506, 2hakF, 0.7411, 2.64, 0.326, 318, 242, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4507, 1b6cH, 0.7411, 3.17, 0.216, 326, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4508, 5w5oE, 0.7410, 2.57, 0.222, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4509, 4oliA, 0.7410, 2.55, 0.236, 539, 242, THE PSEUDOKINASE/KINASE PROTEIN FROM JAK-FAMILY MEMBER TYK2
4510, 3q4zB, 0.7410, 2.65, 0.289, 279, 242, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
4511, 3fbvJ, 0.7410, 2.85, 0.294, 413, 245, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4512, 2lavA, 0.7410, 3.23, 0.150, 361, 260, NMR SOLUTION STRUCTURE OF HUMAN VACCINIA-RELATED KINASE 1
4513, 1zmuA, 0.7410, 2.46, 0.305, 293, 236, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
4514, 5xp5A, 0.7409, 2.67, 0.252, 267, 242, C-SRC IN COMPLEX WITH ATP-CHF
4515, 5twuB, 0.7409, 1.94, 0.313, 315, 233, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
4516, 5hicA, 0.7409, 2.74, 0.197, 302, 244, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
4517, 4kb8A, 0.7409, 2.64, 0.201, 265, 244, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4518, 3psbB, 0.7409, 2.50, 0.203, 264, 241, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
4519, 3m11A, 0.7409, 2.38, 0.305, 256, 239, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
4520, 3fbvI, 0.7409, 2.85, 0.294, 413, 245, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4521, 2zv8A, 0.7409, 2.71, 0.231, 257, 242, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
4522, 5ia0B, 0.7408, 2.49, 0.215, 266, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
4523, 5ajqA, 0.7408, 2.67, 0.328, 280, 244, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
4524, 4usfB, 0.7408, 2.83, 0.283, 285, 247, HUMAN SLK WITH SB-440719
4525, 3priA, 0.7408, 2.60, 0.203, 264, 241, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
4526, 3f6xB, 0.7408, 2.46, 0.251, 267, 239, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4527, 6fnkA, 0.7407, 2.71, 0.207, 274, 246, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
4528, 5lpzA, 0.7407, 2.82, 0.220, 283, 245, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1196) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
4529, 4e6dB, 0.7407, 2.95, 0.257, 286, 249, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
4530, 4bhzA, 0.7407, 2.38, 0.308, 251, 237, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4531, 3priB, 0.7407, 2.60, 0.203, 264, 241, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
4532, 3ppjB, 0.7407, 2.51, 0.203, 264, 241, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
4533, 5am7B, 0.7406, 2.88, 0.243, 287, 247, FGFR1 MUTANT WITH AN INHIBITOR
4534, 4bi2A, 0.7406, 2.38, 0.308, 253, 237, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4535, 3hmoA, 0.7406, 2.35, 0.304, 257, 237, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
4536, 3dqxB, 0.7406, 2.67, 0.251, 268, 243, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
4537, 2wtvD, 0.7406, 2.60, 0.311, 262, 241, AURORA-A INHIBITOR STRUCTURE
4538, 6es0B, 0.7405, 2.83, 0.231, 287, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
4539, 6bbvA, 0.7405, 3.10, 0.253, 289, 253, CRYSTAL STRUCTURE OF JAK2 IN COMPLEX WITH COMPOUND 25
4540, 5vamA, 0.7405, 2.64, 0.197, 269, 244, BRAF IN COMPLEX WITH RAF709
4541, 5f20A, 0.7405, 2.43, 0.221, 274, 240, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
4542, 5ehoA, 0.7405, 2.37, 0.312, 258, 237, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4543, 5ap0A, 0.7405, 2.38, 0.304, 254, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4544, 4prjA, 0.7405, 2.49, 0.300, 251, 240, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
4545, 4cljA, 0.7405, 2.94, 0.181, 295, 248, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
4546, 4anbA, 0.7405, 3.15, 0.254, 282, 252, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
4547, 1zmvA, 0.7405, 2.32, 0.302, 293, 235, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
4548, 1t45A, 0.7405, 2.78, 0.229, 331, 245, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
4549, 5n7vA, 0.7404, 2.42, 0.311, 260, 238, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
4550, 5grnA, 0.7404, 2.96, 0.206, 285, 247, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
4551, 5calA, 0.7404, 2.70, 0.198, 300, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
4552, 4c4fA, 0.7404, 2.43, 0.304, 254, 237, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4553, 2j7tA, 0.7404, 2.74, 0.321, 285, 240, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO SU11274
4554, 1t46A, 0.7404, 2.68, 0.221, 297, 244, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
4555, 6bbuA, 0.7403, 2.87, 0.242, 279, 248, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH COMPOUND 25
4556, 5hcxA, 0.7403, 2.71, 0.198, 298, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
4557, 5gjdA, 0.7403, 2.58, 0.292, 292, 240, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 2
4558, 3h10B, 0.7403, 2.68, 0.306, 267, 242, AURORA A INHIBITOR COMPLEX
4559, 2wtvA, 0.7403, 2.61, 0.311, 262, 241, AURORA-A INHIBITOR STRUCTURE
4560, 2w5hA, 0.7403, 2.87, 0.279, 265, 244, HUMAN NEK2 KINASE APO
4561, 5n9sA, 0.7402, 2.43, 0.311, 259, 238, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
4562, 4hniA, 0.7402, 2.83, 0.193, 284, 249, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
4563, 4g2fA, 0.7402, 2.46, 0.207, 275, 241, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
4564, 4cvaA, 0.7402, 2.33, 0.300, 254, 237, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4565, 4c4iA, 0.7402, 2.31, 0.312, 253, 237, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4566, 3g6hA, 0.7402, 2.58, 0.253, 266, 241, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
4567, 2zmdA, 0.7402, 2.40, 0.311, 259, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
4568, 5njzA, 0.7401, 2.57, 0.212, 273, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
4569, 4rj8A, 0.7401, 2.67, 0.198, 298, 242, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
4570, 3sdjJ, 0.7401, 2.94, 0.293, 413, 246, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4571, 3sdjI, 0.7401, 2.94, 0.293, 413, 246, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4572, 5w5oO, 0.7400, 2.65, 0.230, 276, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4573, 4ymjA, 0.7400, 2.68, 0.231, 270, 242, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4574, 3h9fA, 0.7400, 2.35, 0.315, 260, 238, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYRIMIDO-DIAZEPIN LIGAND
4575, 5tq6A, 0.7399, 2.96, 0.254, 274, 248, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4576, 5ihcA, 0.7399, 2.48, 0.329, 305, 237, MELK IN COMPLEX WITH NVS-MELK12B
4577, 4f0iB, 0.7399, 2.71, 0.214, 294, 243, CRYSTAL STRUCTURE OF APO TRKA
4578, 3op5C, 0.7399, 3.13, 0.148, 308, 257, HUMAN VACCINIA-RELATED KINASE 1
4579, 2j0kB, 0.7399, 2.45, 0.258, 612, 240, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
4580, 5zv2A, 0.7398, 2.89, 0.227, 284, 247, FGFR-1 IN COMPLEX WITH LIGAND LENVATINIB 
4581, 4mxxA, 0.7398, 2.46, 0.243, 266, 239, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4582, 4k77A, 0.7398, 2.91, 0.242, 282, 248, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
4583, 3eqhA, 0.7398, 3.16, 0.254, 314, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
4584, 5w5oA, 0.7397, 2.60, 0.222, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4585, 5e1eB, 0.7397, 2.84, 0.243, 280, 247, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
4586, 3zc6A, 0.7397, 2.91, 0.256, 277, 246, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
4587, 3vw6B, 0.7397, 2.35, 0.292, 253, 236, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
4588, 6es0A, 0.7396, 3.05, 0.220, 288, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
4589, 5wo4A, 0.7396, 2.90, 0.242, 292, 248, JAK1 COMPLEXED WITH COMPOUND 28
4590, 5w86A, 0.7396, 2.62, 0.261, 269, 241, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4591, 5a4eC, 0.7396, 1.71, 0.357, 262, 227, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
4592, 4pdpB, 0.7396, 2.32, 0.331, 265, 236, CRYSTAL STRUCTURE OF RAD53 KINASE DOMAIN AND SCD2
4593, 3q4uB, 0.7396, 3.04, 0.230, 300, 248, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4594, 3mdyC, 0.7396, 2.80, 0.211, 320, 246, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
4595, 1k9aE, 0.7396, 2.51, 0.233, 440, 240, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4596, 5k5xA, 0.7395, 2.87, 0.206, 345, 247, CRYSTAL STRUCTURE OF HUMAN PDGFRA
4597, 4pdpA, 0.7395, 2.42, 0.321, 261, 237, CRYSTAL STRUCTURE OF RAD53 KINASE DOMAIN AND SCD2
4598, 3eqfA, 0.7395, 2.89, 0.258, 314, 248, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
4599, 3d4qA, 0.7395, 2.59, 0.203, 264, 241, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
4600, 5uhnB, 0.7394, 2.76, 0.244, 269, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
4601, 5em6A, 0.7394, 2.71, 0.198, 301, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
4602, 3ppkB, 0.7394, 2.53, 0.203, 264, 241, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
4603, 2v62B, 0.7394, 3.19, 0.163, 310, 257, STRUCTURE OF VACCINIA-RELATED KINASE 2
4604, 5vndA, 0.7393, 2.90, 0.226, 302, 248, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
4605, 5cauA, 0.7393, 2.69, 0.198, 297, 242, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
4606, 4fodA, 0.7393, 2.97, 0.185, 308, 248, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
4607, 4bl1A, 0.7393, 2.12, 0.333, 312, 234, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH AMP-PNP
4608, 6d22A, 0.7392, 2.78, 0.217, 299, 244, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR 
4609, 5w5oJ, 0.7392, 2.61, 0.226, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4610, 4i5cA, 0.7392, 2.85, 0.243, 279, 247, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4611, 4focA, 0.7392, 3.01, 0.185, 296, 248, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
4612, 3wyyA, 0.7392, 2.57, 0.314, 258, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
4613, 2i1mA, 0.7392, 3.06, 0.206, 311, 247, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
4614, 5jgaA, 0.7391, 2.55, 0.293, 296, 239, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 11C
4615, 4fk6A, 0.7391, 3.04, 0.240, 285, 250, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
4616, 4ckrA, 0.7391, 3.02, 0.221, 295, 249, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
4617, 4c4eA, 0.7391, 2.30, 0.314, 256, 236, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4618, 5twzA, 0.7390, 2.39, 0.325, 313, 237, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
4619, 4uzdA, 0.7390, 2.43, 0.282, 254, 241, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4620, 3prfA, 0.7390, 2.44, 0.197, 262, 239, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
4621, 3g0fB, 0.7390, 2.75, 0.230, 293, 244, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
4622, 5j7hA, 0.7389, 2.72, 0.193, 291, 244, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
4623, 3g0eA, 0.7389, 2.84, 0.229, 332, 245, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
4624, 2qkwB, 0.7389, 3.30, 0.202, 290, 252, STRUCTURAL BASIS FOR ACTIVATION OF PLANT IMMUNITY BY BACTERIAL EFFECTOR PROTEIN AVRPTO
4625, 5mrbA, 0.7388, 2.51, 0.319, 264, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
4626, 5ap1A, 0.7388, 2.60, 0.317, 268, 240, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4627, 4mxzB, 0.7388, 2.44, 0.252, 264, 238, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4628, 4mxyB, 0.7388, 2.44, 0.252, 264, 238, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4629, 4e4nB, 0.7388, 2.86, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
4630, 3zc6B, 0.7388, 2.93, 0.256, 276, 246, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
4631, 3vquA, 0.7388, 2.57, 0.314, 258, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
4632, 3gxlA, 0.7388, 2.51, 0.208, 285, 240, ALK-5 KINASE COMPLEX WITH GW857175
4633, 2w1dA, 0.7388, 2.31, 0.312, 251, 237, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4634, 2j0kA, 0.7388, 2.39, 0.255, 598, 239, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
4635, 5y25A, 0.7387, 2.60, 0.199, 292, 241, EGFR KINASE DOMAIN MUTANT (T790M/L858R) WITH COVALENT LIGAND NS-062 
4636, 5w5oK, 0.7387, 2.62, 0.226, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4637, 5hhwA, 0.7387, 2.94, 0.190, 306, 247, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
4638, 5ap3A, 0.7387, 2.47, 0.304, 253, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4639, 5a46A, 0.7387, 2.89, 0.239, 289, 247, FGFR1 IN COMPLEX WITH DOVITINIB
4640, 4rwlA, 0.7387, 2.87, 0.243, 282, 247, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
4641, 4o6lA, 0.7387, 2.45, 0.312, 257, 237, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4642, 4e93A, 0.7387, 2.59, 0.245, 361, 241, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)IN COMPLEX WITH TAE684
4643, 4c3rA, 0.7387, 2.39, 0.297, 252, 239, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
4644, 3q4cB, 0.7387, 2.60, 0.202, 264, 242, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
4645, 3mdyA, 0.7387, 2.94, 0.230, 320, 248, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
4646, 3d4qB, 0.7387, 2.60, 0.203, 264, 241, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
4647, 2helA, 0.7387, 2.35, 0.192, 256, 239, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
4648, 5w5oD, 0.7386, 2.62, 0.226, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4649, 4g3fA, 0.7386, 2.60, 0.250, 312, 244, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 2-(AMINOTHIAZOLY)PHENOL (CMP2)
4650, 3g0fA, 0.7386, 2.76, 0.230, 291, 244, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
4651, 2bdfB, 0.7386, 2.67, 0.252, 265, 242, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
4652, 5b7vA, 0.7385, 2.91, 0.239, 282, 247, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
4653, 4v05B, 0.7385, 2.76, 0.233, 286, 245, FGFR1 IN COMPLEX WITH AZD4547.
4654, 4e5wB, 0.7385, 2.77, 0.244, 278, 246, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
4655, 3g2fA, 0.7385, 3.01, 0.235, 302, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE II (BMPR2) AT 2.35 A RESOLUTION
4656, 6b2qB, 0.7384, 2.56, 0.266, 266, 241, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
4657, 5uglB, 0.7384, 2.76, 0.248, 271, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
4658, 5m53A, 0.7384, 2.55, 0.285, 255, 239, NEK2 BOUND TO ARYLAMINOPURINE INHIBITOR 11
4659, 4fnwA, 0.7384, 3.02, 0.190, 304, 248, CRYSTAL STRUCTURE OF THE APO F1174L ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4660, 4b8lA, 0.7384, 2.43, 0.304, 249, 237, AURORA B KINASE P353G MUTANT
4661, 2etmB, 0.7384, 2.47, 0.254, 263, 240, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
4662, 5edpA, 0.7383, 2.69, 0.198, 295, 243, EGFR KINASE (T790M/L858R) APO
4663, 4zjjA, 0.7383, 2.82, 0.305, 280, 246, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4664, 4ivdB, 0.7383, 2.86, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
4665, 4fk6B, 0.7383, 2.99, 0.244, 284, 250, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
4666, 2jitB, 0.7383, 3.21, 0.171, 312, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
4667, 6dkiA, 0.7382, 2.49, 0.221, 279, 240, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 19. 
4668, 4k77B, 0.7382, 2.86, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
4669, 4g3gA, 0.7382, 2.61, 0.250, 312, 244, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) V408L BOUND TO A 2-(AMINOTHIAZOLYL)PHENOL (CMP3)
4670, 3mygA, 0.7382, 2.38, 0.307, 252, 238, AURORA A KINASE COMPLEXED WITH SCH 1473759
4671, 6gwrA, 0.7381, 3.19, 0.221, 300, 253, STRUCTURE OF THE KINASE DOMAIN OF HUMAN DDR1 IN COMPLEX WITH A POTENT AND SELECTIVE INHIBITOR OF DDR1 AND DDR2 
4672, 5v5nA, 0.7381, 2.52, 0.294, 294, 238, CRYSTAL STRUCTURE OF TAKINIB BOUND TO TAK1
4673, 5uorA, 0.7381, 2.35, 0.289, 249, 235, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4674, 4rj7A, 0.7381, 2.64, 0.199, 295, 241, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
4675, 2zv9A, 0.7381, 2.74, 0.231, 256, 242, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
4676, 6d20A, 0.7380, 2.74, 0.218, 296, 243, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE AND 5-{[2;4- DICHLORO-5-(PYRIDIN-2-YL)BENZENE-1-CARBONYL]AMINO}-N-(2-HYDROXY-2- METHYLPROPYL)-1-PHENYL-1H-PYRAZOLE-3-CARBOXAMIDE INHIBITORS 
4677, 5wr7A, 0.7380, 2.77, 0.222, 301, 243, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
4678, 5w5oI, 0.7380, 2.53, 0.223, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4679, 5w5oH, 0.7380, 2.53, 0.223, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4680, 5w5oG, 0.7380, 2.64, 0.226, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4681, 4cv9A, 0.7380, 2.48, 0.303, 254, 238, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4682, 3psbA, 0.7380, 2.45, 0.205, 262, 239, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
4683, 3lw0A, 0.7380, 2.93, 0.212, 292, 245, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
4684, 4rj6A, 0.7379, 2.69, 0.198, 297, 242, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
4685, 3lw0C, 0.7379, 2.94, 0.212, 292, 245, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
4686, 3b2wA, 0.7379, 2.80, 0.230, 261, 244, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
4687, 5hx8B, 0.7378, 2.88, 0.243, 279, 247, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
4688, 5hczA, 0.7378, 2.74, 0.198, 300, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
4689, 4js8A, 0.7378, 2.51, 0.311, 259, 238, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
4690, 3lw0D, 0.7378, 2.94, 0.212, 292, 245, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
4691, 3aoxA, 0.7378, 2.94, 0.190, 298, 247, X-RAY CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CH5424802
4692, 2hyyC, 0.7378, 2.57, 0.225, 262, 240, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4693, 5o49B, 0.7377, 3.05, 0.226, 286, 248, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4694, 4o6lB, 0.7377, 2.38, 0.314, 256, 236, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4695, 4e5wA, 0.7377, 2.87, 0.243, 292, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
4696, 6gipA, 0.7376, 3.17, 0.229, 296, 249, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH A QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 2; 5-DIMETHYL CORE. 
4697, 6dkbA, 0.7376, 2.64, 0.220, 272, 241, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 10B. 
4698, 6c7yA, 0.7376, 2.79, 0.245, 273, 245, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS1 IN COMPLEX WITH JAK1 KINASE DOMAIN 
4699, 4neuA, 0.7376, 3.03, 0.216, 286, 250, X-RAY STRUCTURE OF RECEPTOR INTERACTING PROTEIN 1 (RIP1)KINASE DOMAIN WITH A 1-AMINOISOQUINOLINE INHIBITOR
4700, 4mxoA, 0.7376, 2.50, 0.247, 266, 239, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
4701, 4c4gA, 0.7376, 2.23, 0.306, 251, 235, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4702, 3etaB, 0.7376, 2.98, 0.199, 292, 246, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
4703, 5uoxB, 0.7375, 2.37, 0.285, 252, 235, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4704, 5tq7A, 0.7375, 2.92, 0.251, 275, 247, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4705, 5bvkA, 0.7375, 3.20, 0.220, 278, 250, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4706, 5ap5A, 0.7375, 2.28, 0.305, 252, 236, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4707, 4bkyA, 0.7375, 2.22, 0.338, 311, 234, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH PYRROLOPYRAZOLE INHIBITOR
4708, 3lw0B, 0.7375, 2.94, 0.212, 292, 245, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
4709, 3d7uC, 0.7375, 2.49, 0.238, 257, 239, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4710, 3d7uA, 0.7375, 2.49, 0.238, 257, 239, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4711, 1k9aA, 0.7375, 2.49, 0.234, 439, 239, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4712, 6dkgA, 0.7374, 2.50, 0.221, 276, 240, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 13B. 
4713, 6b2qC, 0.7374, 2.36, 0.265, 264, 238, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
4714, 4ivcB, 0.7374, 2.87, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
4715, 4h58A, 0.7374, 2.47, 0.204, 263, 240, BRAF IN COMPLEX WITH COMPOUND 3
4716, 3zzeA, 0.7374, 3.04, 0.215, 286, 247, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
4717, 6d1yA, 0.7373, 2.69, 0.219, 300, 242, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 2;4-DICHLORO-N-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)BENZAMIDE INHIBITOR 
4718, 5lpvA, 0.7373, 2.87, 0.220, 282, 246, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH AMPPNP AND MN FROM ARABIDOPSIS THALIANA
4719, 5ljjA, 0.7373, 2.51, 0.308, 264, 237, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
4720, 5kmnA, 0.7373, 2.62, 0.216, 296, 241, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
4721, 4uynA, 0.7373, 2.28, 0.315, 249, 235, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4722, 4cmuA, 0.7373, 3.05, 0.185, 294, 248, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
4723, 4ccuA, 0.7373, 2.99, 0.202, 292, 247, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
4724, 4c62B, 0.7373, 2.60, 0.266, 271, 241, INHIBITORS OF JAK2 KINASE DOMAIN
4725, 2fb8A, 0.7373, 2.54, 0.203, 259, 241, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
4726, 2bdjA, 0.7373, 2.53, 0.251, 254, 239, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
4727, 5nkaA, 0.7372, 2.34, 0.210, 271, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
4728, 5jgdA, 0.7372, 2.58, 0.293, 295, 239, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 12
4729, 3psdA, 0.7372, 2.47, 0.205, 262, 239, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
4730, 6gwrB, 0.7371, 3.02, 0.217, 285, 249, STRUCTURE OF THE KINASE DOMAIN OF HUMAN DDR1 IN COMPLEX WITH A POTENT AND SELECTIVE INHIBITOR OF DDR1 AND DDR2 
4731, 6d1zA, 0.7371, 2.60, 0.216, 290, 241, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE INHIBITOR 
4732, 6b2pA, 0.7371, 2.37, 0.252, 255, 238, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
4733, 5kvtA, 0.7371, 2.72, 0.213, 287, 244, THE STRUCTURE OF TRKA KINASE DOMAIN BOUND TO THE INHIBITOR ENTRECTINIB
4734, 5aaeA, 0.7371, 2.37, 0.307, 252, 238, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
4735, 5aabA, 0.7371, 2.96, 0.190, 293, 247, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4736, 4usdB, 0.7371, 2.58, 0.329, 267, 243, HUMAN STK10 (LOK) WITH SB-633825
4737, 4cmoA, 0.7371, 2.86, 0.187, 295, 246, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
4738, 2xneA, 0.7371, 2.22, 0.297, 246, 236, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
4739, 2xa4B, 0.7371, 2.66, 0.269, 275, 242, INHIBITORS OF JAK2 KINASE DOMAIN
4740, 2oiqB, 0.7371, 2.58, 0.258, 265, 240, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
4741, 5t0pB, 0.7370, 2.48, 0.253, 263, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4742, 5bvoA, 0.7370, 3.15, 0.219, 276, 251, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4743, 4k8aB, 0.7370, 2.50, 0.254, 258, 240, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
4744, 4gu6A, 0.7370, 2.86, 0.250, 271, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
4745, 3uqgA, 0.7370, 2.42, 0.253, 263, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
4746, 5w5oL, 0.7369, 2.65, 0.226, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4747, 5n93A, 0.7369, 2.40, 0.291, 259, 237, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
4748, 5lpwA, 0.7369, 2.83, 0.230, 280, 244, CRYSTAL STRUCTURE OF THE APO-BRI1 KINASE DOMAIN (865-1160)
4749, 4o0uA, 0.7369, 2.60, 0.302, 259, 242, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
4750, 4kbaA, 0.7369, 2.60, 0.198, 263, 242, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4751, 4jbpA, 0.7369, 2.49, 0.301, 255, 239, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
4752, 3ppkA, 0.7369, 2.48, 0.205, 262, 239, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
4753, 3fzrA, 0.7369, 2.64, 0.207, 261, 242, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
4754, 2j0mB, 0.7369, 2.30, 0.253, 257, 237, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
4755, 6btwD, 0.7368, 3.30, 0.154, 307, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4756, 5tq6B, 0.7368, 2.96, 0.263, 271, 247, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4757, 5ar7A, 0.7368, 2.77, 0.224, 278, 245, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
4758, 5aaaA, 0.7368, 2.87, 0.191, 294, 246, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4759, 4ztsA, 0.7368, 2.43, 0.303, 249, 238, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
4760, 4bkzA, 0.7368, 2.19, 0.330, 309, 233, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH A BENZODIPYRAZOLE INHIBITOR
4761, 3omvA, 0.7368, 2.60, 0.191, 264, 241, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
4762, 3et7A, 0.7368, 2.63, 0.202, 261, 242, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
4763, 1muoA, 0.7368, 2.45, 0.308, 251, 237, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
4764, 5ap7A, 0.7367, 2.36, 0.309, 263, 236, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4765, 4ymjB, 0.7367, 2.68, 0.232, 275, 241, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4766, 2xvdA, 0.7367, 2.66, 0.222, 270, 243, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4767, 5a4cB, 0.7366, 3.13, 0.229, 286, 249, FGFR1 LIGAND COMPLEX
4768, 3w1fA, 0.7366, 2.40, 0.295, 259, 237, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
4769, 3q4uC, 0.7366, 2.97, 0.220, 296, 246, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4770, 1jqhA, 0.7366, 2.99, 0.201, 291, 249, IGF-1 RECEPTOR KINASE DOMAIN
4771, 5kmlA, 0.7365, 2.62, 0.216, 296, 241, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
4772, 5aa9A, 0.7365, 2.88, 0.191, 295, 246, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
4773, 4v05A, 0.7365, 2.87, 0.236, 287, 246, FGFR1 IN COMPLEX WITH AZD4547.
4774, 4ivbB, 0.7365, 2.89, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
4775, 4c61B, 0.7365, 2.61, 0.270, 274, 241, INHIBITORS OF JAK2 KINASE DOMAIN
4776, 4anqA, 0.7365, 2.97, 0.190, 293, 247, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4777, 3cjgA, 0.7365, 2.65, 0.219, 280, 242, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
4778, 2fb8B, 0.7365, 2.41, 0.205, 259, 239, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
4779, 1p4oA, 0.7365, 3.02, 0.206, 308, 247, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
4780, 6eixA, 0.7364, 3.33, 0.231, 312, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
4781, 5edqA, 0.7364, 2.79, 0.201, 298, 244, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
4782, 4cliA, 0.7364, 2.98, 0.186, 294, 247, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
4783, 4aotB, 0.7364, 2.73, 0.333, 279, 243, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
4784, 3zlsA, 0.7364, 3.12, 0.255, 315, 251, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
4785, 5w5oP, 0.7363, 2.65, 0.222, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4786, 5w5oF, 0.7363, 2.55, 0.223, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4787, 5ia4A, 0.7363, 2.84, 0.204, 269, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
4788, 5caoA, 0.7363, 2.65, 0.199, 300, 241, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
4789, 4ehzA, 0.7363, 2.93, 0.246, 290, 248, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4790, 4bf2A, 0.7363, 2.45, 0.288, 253, 236, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4791, 4ansA, 0.7363, 2.97, 0.194, 293, 247, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4792, 3h0zA, 0.7363, 2.45, 0.308, 248, 237, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4793, 3e8nA, 0.7363, 3.27, 0.261, 291, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
4794, 5w5oC, 0.7362, 2.66, 0.222, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4795, 4mxoB, 0.7362, 2.49, 0.244, 264, 238, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
4796, 4lmnA, 0.7362, 3.32, 0.257, 292, 253, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
4797, 3uojB, 0.7362, 2.45, 0.312, 263, 237, AURORA A IN COMPLEX WITH RPM1715
4798, 3q4cA, 0.7362, 2.54, 0.203, 264, 241, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
4799, 3ppjA, 0.7362, 2.49, 0.205, 262, 239, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
4800, 5oxgD, 0.7361, 3.17, 0.229, 293, 249, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4801, 4e4nA, 0.7361, 2.86, 0.244, 291, 246, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
4802, 3zmmB, 0.7361, 2.63, 0.266, 274, 241, INHIBITORS OF JAK2 KINASE DOMAIN
4803, 3uojA, 0.7361, 2.53, 0.315, 263, 238, AURORA A IN COMPLEX WITH RPM1715
4804, 2xkfA, 0.7361, 2.68, 0.276, 250, 239, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 2
4805, 2qobA, 0.7361, 2.63, 0.198, 279, 243, HUMAN EPHA3 KINASE DOMAIN BASE STRUCTURE
4806, 2hyyB, 0.7361, 2.58, 0.225, 265, 240, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4807, 5xy1A, 0.7360, 2.58, 0.238, 253, 239, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
4808, 5o4aB, 0.7360, 3.09, 0.218, 291, 248, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4809, 5ar4A, 0.7360, 2.60, 0.219, 274, 242, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
4810, 5ap2A, 0.7360, 2.33, 0.318, 256, 236, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4811, 4yhtA, 0.7360, 2.45, 0.205, 256, 239, BRAF COMPLEXED WITH AN INHIBITOR
4812, 4usdA, 0.7360, 2.54, 0.326, 268, 242, HUMAN STK10 (LOK) WITH SB-633825
4813, 4dfyA, 0.7360, 2.54, 0.270, 310, 244, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
4814, 3d94A, 0.7360, 2.89, 0.205, 288, 244, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
4815, 2zv7A, 0.7360, 2.66, 0.228, 257, 241, LYN TYROSINE KINASE DOMAIN APO FORM
4816, 2wkmA, 0.7360, 3.05, 0.215, 286, 247, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
4817, 1jqhC, 0.7360, 3.00, 0.201, 291, 249, IGF-1 RECEPTOR KINASE DOMAIN
4818, 5wo4B, 0.7359, 2.91, 0.243, 280, 247, JAK1 COMPLEXED WITH COMPOUND 28
4819, 5a9uA, 0.7359, 3.01, 0.186, 292, 247, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
4820, 4p2kA, 0.7359, 2.61, 0.202, 259, 242, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4821, 4ctbA, 0.7359, 2.87, 0.191, 292, 246, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (5R)-8-AMINO-3-FLUORO-519-DIMETHYL-20-OXO-5181920- TETRAHYDRO-711-(AZENO)PYRIDO(2 1 :23)IMIDAZO(45-H)(2511) BENZOXADIAZACYCLOTETRADECINE-14-CARBONITRILE
4822, 4an9A, 0.7359, 3.28, 0.253, 281, 253, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
4823, 3lauA, 0.7359, 2.26, 0.312, 251, 234, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
4824, 4c4hA, 0.7358, 2.17, 0.308, 248, 234, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4825, 2xkdA, 0.7358, 2.69, 0.267, 251, 240, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 12
4826, 2wgjA, 0.7358, 3.02, 0.220, 289, 246, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
4827, 2etmA, 0.7358, 2.77, 0.259, 262, 243, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
4828, 5bvwA, 0.7357, 3.07, 0.222, 274, 248, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4829, 5aa8A, 0.7357, 3.01, 0.190, 292, 247, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
4830, 4u43B, 0.7357, 3.32, 0.236, 302, 254, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
4831, 4twoA, 0.7357, 2.52, 0.207, 278, 241, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 164
4832, 4cv8A, 0.7357, 2.38, 0.304, 255, 237, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4833, 3q4uD, 0.7357, 3.16, 0.229, 299, 249, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4834, 2hakE, 0.7357, 2.59, 0.328, 318, 241, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4835, 5kz0A, 0.7356, 2.94, 0.187, 293, 246, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
4836, 5edrA, 0.7356, 2.70, 0.198, 299, 242, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
4837, 5bvnA, 0.7356, 3.24, 0.214, 278, 252, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4838, 4ibmA, 0.7356, 2.87, 0.196, 301, 245, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
4839, 4c7tA, 0.7356, 2.74, 0.260, 259, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
4840, 2jkmA, 0.7356, 2.54, 0.259, 260, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4841, 2hiwA, 0.7356, 2.77, 0.231, 274, 242, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
4842, 5ftqA, 0.7355, 2.95, 0.187, 293, 246, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
4843, 4k6zA, 0.7355, 2.86, 0.244, 279, 246, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
4844, 4ivcA, 0.7355, 2.88, 0.244, 291, 246, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
4845, 2qokA, 0.7355, 2.52, 0.212, 281, 241, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:S768A TRIPLE MUTANT
4846, 1p4oB, 0.7355, 2.94, 0.207, 314, 246, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
4847, 5w5oB, 0.7354, 2.66, 0.222, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4848, 5oxgC, 0.7354, 3.18, 0.229, 301, 249, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4849, 4p5qA, 0.7354, 2.48, 0.208, 275, 240, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
4850, 4nkaB, 0.7354, 3.06, 0.219, 287, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
4851, 4c8bA, 0.7354, 2.73, 0.218, 279, 243, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
4852, 4bggB, 0.7354, 3.11, 0.230, 293, 248, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4853, 4an3A, 0.7354, 3.26, 0.258, 280, 252, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
4854, 2x9fA, 0.7354, 2.64, 0.219, 265, 242, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4855, 1m7nB, 0.7354, 2.92, 0.207, 299, 246, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
4856, 5b7vB, 0.7353, 2.75, 0.238, 277, 244, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
4857, 4u41A, 0.7353, 2.76, 0.259, 275, 243, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
4858, 4d2vA, 0.7353, 2.11, 0.326, 313, 233, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4859, 3unzB, 0.7353, 2.55, 0.315, 263, 238, AURORA A IN COMPLEX WITH RPM1679
4860, 3unzA, 0.7353, 2.55, 0.315, 263, 238, AURORA A IN COMPLEX WITH RPM1679
4861, 3eqgA, 0.7353, 3.23, 0.254, 314, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
4862, 3beaA, 0.7353, 2.79, 0.205, 310, 244, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
4863, 2jiuB, 0.7353, 3.43, 0.162, 309, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
4864, 5jgbA, 0.7352, 2.53, 0.282, 295, 238, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 10
4865, 5aacA, 0.7352, 3.01, 0.186, 292, 247, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4866, 4oh4A, 0.7352, 2.90, 0.224, 299, 245, CRYSTAL STRUCTURE OF BRI1 IN COMPLEX WITH BKI1
4867, 4fk3B, 0.7352, 2.41, 0.214, 257, 238, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
4868, 4bggA, 0.7352, 3.12, 0.230, 296, 248, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4869, 4arkA, 0.7352, 3.33, 0.257, 291, 253, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
4870, 4ap7A, 0.7352, 3.03, 0.220, 289, 246, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
4871, 4gu9B, 0.7351, 2.61, 0.253, 255, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
4872, 3uo6B, 0.7351, 2.43, 0.316, 264, 237, AURORA A IN COMPLEX WITH YL5-083
4873, 3uo6A, 0.7351, 2.43, 0.316, 264, 237, AURORA A IN COMPLEX WITH YL5-083
4874, 3k5vA, 0.7351, 2.75, 0.232, 286, 241, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
4875, 3a62A, 0.7351, 2.23, 0.319, 263, 235, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
4876, 5ap4A, 0.7350, 2.37, 0.314, 257, 236, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4877, 4ei4B, 0.7350, 2.92, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
4878, 4aojA, 0.7350, 2.36, 0.210, 260, 238, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
4879, 3cohB, 0.7350, 2.52, 0.304, 247, 237, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
4880, 2evaA, 0.7350, 2.51, 0.282, 295, 238, STRUCTURAL BASIS FOR THE INTERACTION OF TAK1 KINASE WITH ITS ACTIVATING PROTEIN TAB1
4881, 1iepA, 0.7350, 2.71, 0.231, 274, 242, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
4882, 5xp7A, 0.7349, 2.55, 0.255, 265, 239, C-SRC IN COMPLEX WITH ATP-CHCL
4883, 4aojC, 0.7349, 2.34, 0.218, 261, 238, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
4884, 4anlA, 0.7349, 2.98, 0.190, 292, 247, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE
4885, 3prfB, 0.7349, 2.51, 0.197, 262, 239, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
4886, 3eqcA, 0.7349, 3.15, 0.255, 312, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
4887, 5na0A, 0.7348, 2.40, 0.301, 253, 236, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
4888, 4zjjB, 0.7348, 2.56, 0.311, 277, 241, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4889, 3eqdA, 0.7348, 2.94, 0.258, 315, 248, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
4890, 2y4iC, 0.7348, 3.19, 0.251, 313, 251, KSR2-MEK1 HETERODIMER
4891, 2xirA, 0.7348, 2.94, 0.216, 296, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH PF-00337210 (N2-DIMETHYL-6-(7-(2-MORPHOLINOETHOXY) QUINOLIN-4-YLOXY)BENZOFURAN-3-CARBOXAMIDE)
4892, 2uv2A, 0.7348, 2.51, 0.282, 286, 238, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 4-(4-( 5-CYCLOPROPYL-1H-PYRAZOL-3-YLAMINO)-QUINAZOLIN-2-YLAMINO)- PHENYL)-ACETONITRILE
4893, 2hakD, 0.7348, 2.36, 0.332, 309, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4894, 5iuhA, 0.7347, 2.73, 0.186, 285, 242, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
4895, 5ia5A, 0.7347, 2.76, 0.201, 273, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH GOLVATINIB (E7050)
4896, 4uzhA, 0.7347, 2.31, 0.312, 251, 234, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4897, 4rwlB, 0.7347, 3.13, 0.230, 285, 248, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
4898, 3zclA, 0.7347, 3.04, 0.220, 289, 246, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
4899, 1fpuA, 0.7347, 2.66, 0.232, 275, 241, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
4900, 5nadA, 0.7346, 2.26, 0.302, 256, 235, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
4901, 4mnfA, 0.7346, 2.48, 0.206, 257, 238, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
4902, 3zlxA, 0.7346, 3.03, 0.253, 312, 249, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
4903, 5oxgB, 0.7345, 3.13, 0.230, 296, 248, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4904, 4mxzA, 0.7345, 2.58, 0.251, 266, 239, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4905, 4mxyA, 0.7345, 2.58, 0.251, 266, 239, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4906, 3cohA, 0.7345, 2.52, 0.304, 247, 237, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
4907, 1opjB, 0.7345, 2.86, 0.239, 288, 243, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
4908, 5zv2B, 0.7344, 2.82, 0.230, 282, 244, FGFR-1 IN COMPLEX WITH LIGAND LENVATINIB 
4909, 4nk9B, 0.7344, 3.18, 0.219, 282, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
4910, 4ivbA, 0.7344, 2.88, 0.244, 291, 246, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
4911, 3uohB, 0.7344, 2.56, 0.315, 264, 238, AURORA A IN COMPLEX WITH RPM1722
4912, 3uohA, 0.7344, 2.56, 0.315, 264, 238, AURORA A IN COMPLEX WITH RPM1722
4913, 3eqiA, 0.7344, 2.94, 0.254, 315, 248, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
4914, 3en4B, 0.7344, 2.59, 0.255, 266, 239, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
4915, 3dv3A, 0.7344, 3.22, 0.259, 288, 251, MEK1 WITH PF-04622664 BOUND
4916, 2c6dA, 0.7344, 2.51, 0.315, 254, 238, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
4917, 5nk0A, 0.7343, 2.34, 0.215, 273, 237, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
4918, 4o2pB, 0.7343, 2.58, 0.255, 265, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
4919, 4i5cB, 0.7343, 2.90, 0.244, 291, 246, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4920, 4ag8A, 0.7343, 2.95, 0.216, 296, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
4921, 3txoA, 0.7343, 2.82, 0.271, 317, 240, PKC ETA KINASE IN COMPLEX WITH A NAPHTHYRIDINE
4922, 1iepB, 0.7343, 2.67, 0.232, 274, 241, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
4923, 5l4qB, 0.7342, 2.34, 0.253, 287, 237, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
4924, 4bkjB, 0.7342, 3.09, 0.225, 297, 249, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
4925, 3og7B, 0.7342, 2.48, 0.214, 254, 238, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
4926, 3l8vA, 0.7342, 2.93, 0.216, 293, 245, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
4927, 2j51A, 0.7342, 2.50, 0.277, 288, 238, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-124-TRIAZOLE-1-CARBOTHIOAMIDE
4928, 1m7nA, 0.7342, 2.96, 0.207, 299, 246, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
4929, 4jaiA, 0.7341, 2.41, 0.318, 249, 236, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH N-{4-[(6-OXO-56- DIHYDROBENZO[C][18]NAPHTHYRIDIN-1-YL)AMINO]PHENYL}BENZAMIDE
4930, 3zlwA, 0.7341, 3.04, 0.253, 312, 249, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
4931, 3v5qB, 0.7341, 2.59, 0.230, 265, 239, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
4932, 3pp1A, 0.7341, 3.28, 0.249, 291, 253, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
4933, 3krjA, 0.7341, 2.80, 0.206, 304, 243, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
4934, 5v24A, 0.7340, 2.37, 0.286, 249, 234, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
4935, 4u7zA, 0.7340, 3.32, 0.261, 291, 253, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
4936, 4tyiA, 0.7340, 2.71, 0.240, 277, 242, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4
4937, 4o91A, 0.7340, 2.44, 0.300, 293, 237, CRYSTAL STRUCTURE OF TYPE II INHIBITOR NG25 BOUND TO TAK1-TAB1
4938, 2hiwB, 0.7340, 2.65, 0.232, 274, 241, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
4939, 3my0N, 0.7339, 3.07, 0.228, 300, 246, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4940, 2hyyA, 0.7339, 2.67, 0.224, 263, 241, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4941, 1jqhB, 0.7339, 3.00, 0.202, 287, 248, IGF-1 RECEPTOR KINASE DOMAIN
4942, 5wnjA, 0.7338, 2.68, 0.212, 264, 240, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN KINASE 4 (RIPK4) D143N IN COMPLEX WITH LESTAURTINIB 
4943, 4r7hA, 0.7338, 2.86, 0.213, 308, 244, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
4944, 4gt5A, 0.7338, 2.75, 0.215, 290, 242, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
4945, 3h3cA, 0.7338, 2.47, 0.209, 263, 239, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
4946, 2yhvA, 0.7338, 3.02, 0.190, 291, 247, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE
4947, 4y95A, 0.7337, 2.80, 0.182, 266, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
4948, 3wzkA, 0.7337, 2.52, 0.311, 258, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
4949, 3omvB, 0.7337, 2.68, 0.191, 264, 241, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
4950, 3my0M, 0.7337, 3.31, 0.220, 298, 250, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4951, 1pkgB, 0.7336, 2.78, 0.232, 277, 241, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
4952, 5oy6B, 0.7335, 3.07, 0.235, 292, 247, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4953, 5kmjA, 0.7335, 2.66, 0.217, 300, 240, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
4954, 4ztrA, 0.7335, 2.40, 0.300, 249, 237, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
4955, 3wzeA, 0.7335, 2.79, 0.222, 298, 243, KDR IN COMPLEX WITH LIGAND SORAFENIB
4956, 3my0L, 0.7335, 3.28, 0.221, 296, 249, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4957, 5twyA, 0.7334, 2.29, 0.325, 313, 234, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
4958, 5lpyA, 0.7334, 2.90, 0.221, 282, 244, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ATP FROM ARABIDOPSIS THALIANA
4959, 3zlyA, 0.7334, 3.04, 0.257, 310, 249, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
4960, 3mblA, 0.7334, 3.31, 0.245, 290, 253, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
4961, 5l8jA, 0.7333, 2.51, 0.277, 253, 238, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 S93R
4962, 4obqA, 0.7333, 2.56, 0.264, 275, 239, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
4963, 4kabB, 0.7333, 2.64, 0.253, 258, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
4964, 4bidA, 0.7333, 2.53, 0.280, 254, 236, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4965, 3zfxB, 0.7333, 2.31, 0.225, 254, 236, CRYSTAL STRUCTURE OF EPHB1
4966, 3qriA, 0.7333, 2.77, 0.232, 275, 241, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
4967, 2jfmA, 0.7333, 2.44, 0.283, 287, 237, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
4968, 2j50B, 0.7333, 2.62, 0.303, 249, 238, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4969, 2j50A, 0.7333, 2.62, 0.303, 249, 238, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4970, 1k9aD, 0.7333, 2.67, 0.224, 433, 241, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4971, 5wnlA, 0.7332, 2.50, 0.211, 262, 237, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO STAUROSPORINE 
4972, 5uvfD, 0.7332, 3.21, 0.152, 296, 256, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4973, 5ia1A, 0.7332, 2.46, 0.210, 261, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
4974, 5i9wA, 0.7332, 2.40, 0.207, 267, 237, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
4975, 3zfxF, 0.7332, 2.32, 0.225, 254, 236, CRYSTAL STRUCTURE OF EPHB1
4976, 2ijmB, 0.7332, 2.48, 0.255, 261, 239, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
4977, 5vamB, 0.7331, 2.54, 0.197, 260, 239, BRAF IN COMPLEX WITH RAF709
4978, 4nkaA, 0.7331, 2.86, 0.230, 279, 244, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
4979, 4b0gA, 0.7331, 2.11, 0.306, 247, 232, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
4980, 3zxzA, 0.7331, 3.02, 0.220, 289, 245, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
4981, 3zbxA, 0.7331, 3.05, 0.220, 282, 246, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
4982, 1fpuB, 0.7331, 2.69, 0.224, 270, 241, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
4983, 4y95D, 0.7330, 2.77, 0.174, 265, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
4984, 4pmmA, 0.7330, 2.74, 0.220, 285, 241, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
4985, 4nk9A, 0.7330, 2.82, 0.226, 281, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
4986, 4ctcA, 0.7330, 2.88, 0.192, 288, 245, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
4987, 3vo3A, 0.7330, 2.96, 0.216, 303, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
4988, 3o23A, 0.7330, 2.88, 0.197, 293, 244, HUMAN UNPHOSPHORYLATED IGF1-R KINASE DOMAIN IN COMPLEX WITH AN HYDANTOIN INHIBITOR
4989, 3g2fB, 0.7330, 2.89, 0.226, 300, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE II (BMPR2) AT 2.35 A RESOLUTION
4990, 3d7tB, 0.7330, 2.60, 0.234, 265, 239, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4991, 2yfxA, 0.7330, 2.94, 0.187, 292, 246, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4992, 5j9zA, 0.7329, 2.70, 0.216, 291, 241, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
4993, 5fdxA, 0.7329, 3.11, 0.220, 280, 250, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
4994, 4ivdA, 0.7329, 2.86, 0.245, 290, 245, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
4995, 4gs6A, 0.7329, 2.51, 0.287, 294, 237, IRREVERSIBLE INHIBITION OF TAK1 KINASE BY 5Z-7-OXOZEAENOL
4996, 4aoiA, 0.7329, 3.06, 0.220, 289, 246, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
4997, 3uokB, 0.7329, 2.46, 0.316, 265, 237, AURORA A IN COMPLEX WITH YL5-81-1
4998, 3uokA, 0.7329, 2.46, 0.316, 265, 237, AURORA A IN COMPLEX WITH YL5-81-1
4999, 3my0B, 0.7329, 3.25, 0.221, 295, 249, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
5000, 3fzpA, 0.7329, 2.42, 0.210, 259, 238, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
